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*Corresponding author
Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-
related events (SREs) in patients with bone metastases from solid tumours.
Objectives: The aim of this review was to assess the clinical effectiveness and cost-effectiveness of 
denosumab, within its licensed indication, for the prevention of SREs in patients with bone metastases 
from solid tumours.
Data sources: Databases searched were MEDLINE (1948 to April 2011), EMBASE (1980 to March 2011), 
The Cochrane Library (all sections; Issue 1, 2011) and Web of Science with Conference Proceedings (1970 
to May 2011).
Review methods: Only randomised controlled trials (RCTs) assessing denosumab, bisphosphonates (BPs) 
or best supportive care (BSC) in patients with bone metastases were included. Systematic reviews and 
observational studies were used for safety and quality-of-life assessments. Study quality was assessed using 
the Cochrane risk of bias tool. Studies suitable for meta-analysis were synthesised using network meta-
analysis (NMA). A systematic review was conducted for cost, quality-of-life and cost-effectiveness studies. 
The results of this informed the cost–utility modelling. This principally estimated the cost-effectiveness of 
denosumab relative to zoledronic acid for when BPs are currently recommended and relative to BSC when 
BPs are not recommended or are contraindicated.
Results: A literature search identified 39 studies (eight suitable for NMA). Denosumab was effective in 
delaying time to first SRE and reducing the risk of multiple SREs compared with zoledronic acid. Generally 
speaking, denosumab was similar to zoledronic acid for quality of life, pain, overall survival and safety. The 
NMA demonstrated that denosumab was more effective in delaying SREs than placebo, but was limited by 
numerous uncertainties. Cost–utility modelling results for denosumab relative to zoledronic acid were 
driven by the availability of the patient access scheme (PAS) for denosumab. Without this, denosumab was 
not estimated to be cost-effective compared with zoledronic acid. With it, the cost-effectiveness ranged 
between dominance for breast and prostate cancer, to between £5400 and £15,300 per quality-adjusted 
life-year (QALY) for other solid tumours (OSTs) including non-small cell lung cancer (NSCLC) and £12,700 
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per QALY for NSCLC. Owing to small patient gains estimated, the cost-effectiveness of denosumab was 
very sensitive to the zoledronic acid price. Denosumab was not estimated to be cost-effective compared 
with BSC.
Limitations: Only subgroup data were available for denosumab for NSCLC, and OSTs excluding NSCLC. 
The NMA was subject to numerous uncertainties. Owing to small patient gains estimated, the cost-
effectiveness of denosumab was very sensitive to the zoledronic acid price.
Conclusion: Denosumab, compared with zoledronic acid and placebo, is effective in delaying SREs, but is 
similar with regard to quality of life and pain. Cost-effectiveness showed that without the PAS denosumab 
was not estimated to be cost-effective relative to either zoledronic acid or BSC. With the PAS, denosumab 
was estimated to be cost-effective relative to zoledronic acid but not BSC.
Study registration: PROSPERO number CRD42011001418.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Scientific summary
Background
Bone metastases are associated with a poor prognosis, reduced quality of life and increased risk of 
complications. The term ‘skeletal-related event’ (SRE) is used to group the following complications 
together: pathological fracture, spinal cord compression (SCC) and radiotherapy or surgery to bone. 
Bisphosphonates (BPs) can be used to prevent SREs or to treat bone pain in cases where conventional 
analgesics have failed. Patients who are not treated with BPs receive best supportive care (BSC), which 
can vary depending on the type of primary cancer but may include chemotherapy, palliative radiotherapy, 
antibiotics, steroids, analgesics or surgery. The specific place of BPs in the care pathway varies. Denosumab 
(Xgeva®, Amgen Inc.), administered by subcutaneous injection every 4 weeks, offers an alternative therapy 
to BPs and/or BSC for the prevention of SREs in patients with bone metastases from solid tumours.
Objectives
The aim of this review was to assess the clinical effectiveness and cost-effectiveness of denosumab, within 
its licensed indication, for the treatment of bone metastases from breast cancer, prostate cancer, non-small 
cell lung cancer (NSCLC) or other solid tumours (OSTs).
Methods
Electronic searches were undertaken to identify published and unpublished reports. The databases 
searched included MEDLINE, EMBASE, The Cochrane Library and Web of Science with Conference 
Proceedings. Other sources including the 2010 and 2011 meeting abstracts of the American Society of 
Clinical Oncology (ASCO), American Urological Association and San Antonio Breast Cancer symposium 
were also searched. The date of the last searches was July 2011. The types of studies considered were 
systematic reviews or randomised controlled trials (RCTs); observational studies were also considered for 
data on safety. Participants had breast cancer, prostate cancer, lung cancer or OSTs and at least one bone 
metastasis. Outcome measures included time to first on-study SRE, risk of first and subsequent SREs, 
incidence of SREs, hypercalcaemia, overall survival, pain, health-related quality of life (HRQoL) and adverse 
events related to treatment.
Two reviewers screened the titles and abstracts of all reports identified by the search strategy. Data 
extraction and quality assessment were undertaken by one reviewer and checked by a second reviewer. 
The quality of the RCTs was assessed using the Cochrane risk-of-bias tool. As scoping searches had 
indicated that there were no direct comparisons of denosumab with BPs (other than zoledronic acid) 
or BSC we planned to undertake a network meta-analysis (NMA), pooling direct and indirect evidence 
in a single analysis to obtain an indirect estimate of the relative effectiveness of denosumab against 
these comparators.
The economic modelling approach adopted was to amend the inputs to the manufacturer’s model to 
revise the base-case estimates, coupled with some additional sensitivity analyses around clinical inputs and 
costs. The impact of the results from the assessment group (AG)’s NMA were then applied and contrasted 
with those of the manufacturer. The AG then rebuilt the manufacturer’s model as a cross check and to 
enable the introduction of the structural model elements of (1) SCC having a sustained impact on quality 
of life beyond 5 months from diagnosis, and (2) a decay in quality of life in the final year. This was coupled 
with additional sensitivity analyses.
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Results
Description of studies
Thirty-nine studies met the inclusion criteria for the review of clinical effectiveness. Of these, 31 did not 
contribute data to the NMA and none reported denosumab. Eight studies were included in the NMA, 
of which four studies, involving more than 3700 patients, reported breast cancer; two studies, involving 
more than 2300 patients, reported prostate cancer; and two studies, involving more than 2100 patients, 
reported OSTs, both of which included subgroups of (1) NSCLC (n = 946) and (2) OSTs excluding NSCLC 
(n = 1164).
Quality of studies
All studies were generally of good quality. Three of the breast cancer studies were multicentre and 
international, while the fourth was multicentre and set in Japan.
Summary of risk/benefits
In terms of the direct evidence, for breast cancer, there was a statistically significant difference in favour of 
denosumab compared with zoledronic acid for the time to first on-study SRE for all patients [hazard ratio 
(HR) 0.82; 95% confidence interval (CI) 0.71 to 0.95; not reached vs median 26.4 months (academic-in-
confidence information has been removed)].
For prostate cancer, there was a statistically significant difference in favour of denosumab compared with 
zoledronic acid for the time to first on-study SRE for all patients (HR 0.82; 95% CI 0.71 to 0.95; median 
20.7 vs 17.1 months) and for those with no previous SRE (HR 0.80; 95% CI 0.67 to 0.95). (Academic-in-
confidence information has been removed.) There was also a statistically significant difference in favour of 
denosumab for reducing the risk of developing first and subsequent SREs for all patients [relative risk (RR) 
0.82; 95% CI 0.71 to 0.94] (academic-in-confidence information has been removed).
For the subgroup of patients with NSCLC, the time to first on-study SRE for all patients favoured 
denosumab without being statistically significant (HR 0.84; 95% CI 0.64 to 1.10; academic-in-confidence 
information has been removed). For the subgroup of patients with OSTs excluding NSCLC, there was a 
statistically significant difference in favour of denosumab for median time to first on-study SRE for all 
patients (HR 0.79; 95% CI 0.62 to 0.99; academic-in-confidence information has been removed). 
For OSTs including NSCLC, there was a statistically significant difference in favour of denosumab for time 
to first on-study SRE for all patients (HR 0.81; 95% CI 0.68 to 0.96; 21.4 vs 15.4 months). (Academic-
in-confidence information has been removed.) For risk of developing first and subsequent SREs, for all 
patients, the difference was borderline significant in favour of denosumab (RR 0.8; 95% CI 0.72 to 1.00), 
(academic-in-confidence information has been removed).
In the denosumab studies the vast majority of SREs consisted of pathological fracture and radiation to 
bone, whereas there were few occurrences of SCC or surgery to bone. Overall survival was similar between 
the treatment groups in the three studies apart from an ad hoc analysis of the subgroup with NSCLC, 
which reported a statistically significant difference in favour of denosumab (HR 0.79; 95% CI 0.65 to 
0.95). However, this was a subgroup of a study that was not powered to detect differences in overall 
survival and until further evidence becomes available this result should be interpreted with caution.
Denosumab delayed the time to development of moderate or severe worst pain (worst pain score of > 4 
points) compared with zoledronic acid (breast cancer: median 9.7 vs 5.8 months, p = 0.0024; prostate 
cancer: HR 0.89; 95% CI 0.77 to 1.04; median 5.8 vs 4.9 months; OSTs including NSCLC: HR 0.81; 
95% CI 0.66 to 0.99; median 3.7 vs 2.8 months; p = 0.038). In all three studies, in terms of quality of life, 
overall mean Functional Assessment of Cancer Therapy (FACT) scores remained similar between the groups. 
(Academic-in-confidence information has been removed.)
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In terms of adverse events, for breast cancer, prostate cancer and OSTs respectively, there were more 
occurrences of hypocalcaemia in the denosumab group compared with the zoledronic acid group (5.5% 
vs 3.4%; 12.8% vs 5.8%; 10.8% vs 5.8%), rates of osteonecrosis of the jaw were slightly higher (2.0% 
vs 1.4%; 2.3% vs 1.3%; 1.3% vs 1.1%), while there were lower rates of events associated with renal 
impairment (4.9% vs 8.5%; 14.7% vs 16.2%; 8.3% vs 10.9%) and acute-phase reactions (10.4% vs 27.3%; 
8.4% vs 17.8%; 6.9% vs 14.5%).
In terms of the NMAs, for breast cancer, prostate cancer and OSTs including NSCLC, the AG’s NMA 
reported a statistically significant difference in favour of denosumab compared with placebo for both 
time to first on-study SRE (HR 0.46; 95% CI 0.29 to 0.72; HR 0.56; 95% CI 0.40 to 0.77; and HR 0.49; 
95% CI 0.30 to 0.78, respectively) and risk of first and subsequent SREs (RR 0.45; 95% CI 0.28 to 0.72; 
RR 0.53; 95% CI 0.39 to 0.72; and RR 0.62; 95% CI 0.46 to 0.85, respectively). (Academic-in-confidence 
information has been removed.) For NSCLC, the AG’s NMA comparison of denosumab with placebo 
favoured denosumab without being statistically significant for time to first on-study SRE (HR 0.68; 
95% CI 0.45 to 1.03), whereas there was a statistically significant difference in favour of denosumab for 
risk of first and subsequent SREs (RR 0.63; 95% CI 0.42 to 0.97). For OSTs excluding NSCLC, the AG’s NMA 
reported a statistically significant difference in favour of denosumab compared with placebo for both time 
to first on-study SRE (HR 0.30; 95% CI 0.11 to 0.82) and risk of first and subsequent SREs (RR 0.61; 95% 
CI 0.39 to 0.97). The manufacturer’s NMA did not report these last two outcomes.
Summary of costs
The manufacturer’s estimates through a survey of oncology nurses and pharmacists are that denosumab 
will result in staff time savings compared with zoledronic acid of around (academic-in-confidence 
information has been removed) minutes per administration.
This time saving coupled with consumables and fixed costs estimated within the micro-costing study yields 
the following total annual direct drug and administration costs as per the manufacturer: denosumab 
£4466.80 without a patient access scheme (PAS), (commercial-in-confidence information has been 
removed); zoledronic acid £3364.66 [British National Formulary (BNF) 62 states £3245.97]; disodium 
pamidronate £4117.23 (BNF62 states £4081.74); ibandronic acid (intravenous) £3369.73; and ibandronic 
acid (oral) £2464.80. These costs do not include withheld doses due to poor renal function, or any patient 
management costs due to poor renal function. Without the PAS the annual denosumab cost is around 
£1102 more expensive than zoledronic acid.
The PAS proposed by the manufacturer has recently been approved. (Commercial-in-confidence 
information has been removed.)
Among those receiving 3-weekly intravenous chemotherapy the likelihood is that any intravenous BPs 
would also be administered 3-weekly. Whether or not denosumab would be administered on a 3-weekly 
basis in this situation is a moot point. Four-weekly dosing would seem a possibility and be likely to result in 
denosumab being cost saving.
Summary of cost-effectiveness
The manufacturer’s case is broadly that while the average patient benefits from the reduced number of 
SREs is not large. (Commercial-in-confidence information has been removed.)
(Commercial-in-confidence information has been removed.) The manufacturer’s cost-effectiveness 
estimates for denosumab compared with BSC are typically in excess of £100,000 per quality-adjusted 
life-year (QALY), and even with the PAS are closer to £100,000 per QALY than £50,000 per QALY.
Assessment group within-trial analyses suggest that for breast cancer patients denosumab results in a 
slightly lower average number of SREs compared with zoledronic acid, and that this will translate into 
a small average annual gain of perhaps 0.003 to 0.006 QALYs. Without the PAS the additional cost of 
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denosumab does not justify these relatively minor gains but with it denosumab is estimated to be broadly 
cost neutral to slightly cost saving compared with zoledronic acid, but this is sensitive to the price of 
zoledronic acid.
The within-trial analyses for prostate cancer again suggest a lower average number of SREs from 
denosumab compared with zoledronic acid and a slightly larger additional average annual gain of 
perhaps 0.008 to 0.016 QALYs owing to the greater proportion of SCCs within the overall number of 
SREs in prostate cancer. But there may be slightly fewer zoledronic acid administrations than denosumab 
administrations, and this triangulates with the higher proportion of zoledronic acid patients having doses 
withheld for creatinine clearance. This aspect is not considered in either the manufacturer’s model or the 
AG’s economic model.
Without the PAS, the additional cost of denosumab does not justify the small estimated gains. With the 
PAS (commercial-in-confidence information has been removed) annual costs are estimated to increase by 
around £100, which translates into cost-effectiveness estimates of between £6545 per QALY and £15,272 
per QALY. Again, this result is sensitive to the price of zoledronic acid.
For the cost–utility modelling within breast cancer, the lifetime gains across all patients are estimated 
to be around 0.007 QALYs compared with zoledronic acid, which does not justify the additional cost of 
£1707 per patient. With the PAS (commercial-in-confidence information has been removed) denosumab is 
estimated to dominate zoledronic acid. But for those contraindicated to BPs the cost-effectiveness is poor: 
even with the PAS the cost-effectiveness is £157,829 per QALY.
For the cost–utility modelling within prostate cancer, across all patients the gain from denosumab over 
zoledronic acid is around 0.009 QALYs whereas compared with BSC it is 0.035 QALYs, at net costs without 
the PAS of £1059 and £3951, respectively.
With the PAS, denosumab is estimated to be cost saving compared with zoledronic acid and so dominate 
it. For those contraindicated to BPs, denosumab is again not estimated to be cost-effective compared 
with BSC.
Applying the SRE-naive and -experienced subgroup-specific clinical effectiveness has a reasonably large 
impact on the results. The impact of this on the modelling is not symmetric because more patients fall into 
the SRE-experienced group over time. As a consequence the estimated cost-effectiveness of denosumab 
worsens. But the PAS is still sufficient for (commercial-in-confidence information has been removed) 
denosumab to be estimated to remain dominant over zoledronic acid.
Within the cost–utility modelling of OSTs including lung, the gains from denosumab over zoledronic acid 
are estimated to be less than 0.01 QALYs. Without the PAS denosumab is not cost-effective, but with it 
the small additional overall costs of around £50 result in cost-effectiveness estimates of between £5400 
per QALY and £15,300 per QALY. The impact of applying the SRE subgroup-specific estimates within this 
group is quite large; even with the PAS it is not sufficient to render it cost-effective. Owing to the lower 
SRE-experienced RR for SREs (academic-in-confidence information has been removed) compared with 
zoledronic acid, the cost-effectiveness estimate for denosumab worsens dramatically to £155,285 per 
QALY compared with zoledronic acid among these patients.
For lung cancer, possibly because of the short life expectancy, the patient gains from denosumab over 
zoledronic acid among SRE-experienced patients are estimated to be small: 0.003 QALYs. With the PAS, the 
additional cost of £43 results in a cost-effectiveness of £12,743 per QALY.
Sensitivity analysis
A concern within the modelling is BSC being assumed to have a zero incidence of the modelled 
serious adverse events (SAEs). Sensitivity analyses that exclude SAEs from the analysis improve the 
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cost-effectiveness of denosumab compared with BSC, but are not sufficient to render denosumab cost-
effective. Even with the PAS, all but one of the cost-effectiveness estimates remain above £50,000 per 
QALY with most being above £100,000 per QALY.
A range of additional univariate sensitivity analyses explored the effects of applying the manufacturer’s 
clinical estimates and cost estimates within the model; the rates of discontinuations assumed for active 
treatments; the assumed step change in utility for a SRE-naive patient experiencing a SRE; applying utility 
multipliers for those nearing death; limiting or excluding the effects of SAEs; altering the time horizon to 
5 years and to 2 years; excluding general mortality; and extending the effect of SCC to beyond 5 months 
from diagnosis.
Excluding the step change in utility estimated between SRE-naive patients and SRE-experienced patients 
has quite a large impact on the results for SRE-naive patients. This is not to say that there is no effect, 
only that aspects of the cancers other than just SREs may be contributing to this, particularly if SRE-naive 
patients tend to be earlier in the disease pathway than SRE-experienced patients.
Another aspect that may have an impact is the treatment of SCCs. Extending the average quality-of-life 
decrement measured during the trial through to death improves the estimated cost-effectiveness. Applying 
the average (maximum) decrement through to death improves the cost-effectiveness of denosumab 
among SRE-naive prostate cancer patients from £72,269 per QALY to £56,420 (£49,032) per QALY 
compared with BSC.
Cost estimates from averaging reference costs for SCC may be too low. Clinical guideline (CG) 75 suggests 
an average therapy cost of £14,173 (£13,705). Adding this to the average rehabilitation costs and 
applying the maximum decrement through to death results in a cost-effectiveness estimate for SRE-naive 
prostate patients of (commercial-in-confidence information has been removed) of £38,553 per QALY 
compared with BSC.
Probabilistic modelling suggests central estimates that are in line with deterministic estimates.
Discussion
Strengths, limitations of the analyses and uncertainties
In terms of strengths, our review focused on RCTs, resulting in a high level of evidence. We undertook a 
NMA to provide an indirect estimate of the effectiveness of denosumab against relevant comparators. In 
terms of limitations, non-English-language studies were excluded. Only subgroup data were available for 
denosumab for NSCLC, and for OSTs excluding NSCLC. The NMAs are not randomised comparisons but 
rather observational findings across studies and therefore subject to considerable uncertainty and should 
be interpreted with caution.
In terms of uncertainties:
 z SREs are composite end points. Therefore, higher event rates and larger treatment effects that are 
associated with the less important components of a composite end point could result in a misleading 
impression of the treatment’s effectiveness in relation to components that are clinically more 
important but occur less frequently.
 z Pathological fractures vary from unnoticeable, asymptomatic fractures to vertebral fractures associated 
with SCC that result in paraplegia.
 z The AG’s economic analysis is in part framed by the manufacturer’s analysis in terms of outlook 
and approach. The cost–utility modelling relies on it for the greater part of its input, because of the 
paucity of other data sources for elements such as quality-of-life values. But the broad conclusions of 
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the assessment appear relatively insensitive to the approach adopted, as shown by the much simpler 
within-trial analyses.
Several questions remain concerning the underlying assumptions:
 z The base-case cost-effectiveness results apply the clinical effectiveness estimates pooled across all 
patients for denosumab versus zoledronic acid. SRE-naive and -experienced clinical effectiveness 
estimates are available. Applying these considerably worsens the estimated number of SREs avoided 
and the QALY gain for denosumab compared with zoledronic acid among SRE-experienced patients 
for prostate cancer and OSTs. Should the base case apply to the SRE subgroup-specific clinical 
effectiveness estimates?
 z To what extent do the available data on SRE-naive patients and SRE-experienced patients reflect the 
likely patient groups for whom zoledronic acid is used? Is the manufacturer’s case review sufficient to 
conclude that most SRE-experienced patients within the cancers reviewed are typically receiving BPs, 
leading to zoledronic acid being the appropriate comparator?
 z To what extent should zoledronic acid coming off patent in 2013 be considered? The anticipated 
patient benefits from denosumab over zoledronic acid are small. Only a relatively small drop in the 
price of zoledronic acid would be sufficient to make denosumab not cost-effective when judged by 
conventional thresholds.
Generalisability of the findings
The three RCTs comparing denosumab with zoledronic acid were large, international, multicentre 
trials. The participants all had advanced cancer (breast, prostate, lung or OSTs) with one or more bone 
metastases, European Cooperative Oncology Group status ≤ 2 and a life expectancy of ≥ 6 months. 
Therefore, it is reasonable to expect that the results of the trials would be generalisable to patients meeting 
the above criteria, although not to patients with a life expectancy of < 6 months. (Academic-in-confidence 
information has been removed.) Patients with poor renal function (creatinine clearance < 30 ml/minute) 
were excluded from the trials on the basis that they could not be randomised to zoledronic acid, as the 
drug would be contraindicated. Therefore, the effects of denosumab on patients with advanced cancer 
with bone metastases and poor renal function are unknown. The RCT for OSTs (excluding breast or 
prostate cancer) included a number of different types of solid tumour. This makes it difficult to assess 
whether denosumab is more effective in one type of tumour than another.
Conclusions
Implications for service provision
Compared with zoledronic acid and BSC, denosumab is effective in delaying time to first on-study SRE and 
reducing the risk of multiple SREs. These results are mostly statistically significant and met the minimal 
clinically significant change described by clinical experts (HR reduction of more than 20%). However, the 
importance of the composite SRE outcome, and the spectrum of corresponding possible health states, to 
an individual patient is not clear. Evidence for the effectiveness of denosumab compared with zoledronic 
acid in reducing pain and improving relative quality of life is less evident. The NMA results indirectly 
comparing denosumab with BSC are subject to considerable uncertainty and should be interpreted 
with caution.
The impact on service provision of denosumab depends on whether the patient would alternatively 
have received an intravenous or oral BP, or BSC. Compared with intravenous delivery, subcutaneous 
injections would require a shorter time to administer and could potentially be given to some patients in 
an outpatient setting, general practitioner surgery or even at home. However, such a shift may require 
additional resources and training in the community. For patients who would have previously been treated 
with BSC alone, the addition of denosumab would usually mean additional health-care appointments.
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The manufacturer’s model, the AG’s within-trials analyses and the AG’s cost–utility model all estimate 
denosumab to result in patient benefits from reduced SREs compared with zoledronic acid, and larger 
benefits compared with BSC. But the estimates of the numbers of SREs avoided per patient are small: 
when compared with zoledronic acid typically less than 0.3 SREs over the patient lifetime and often a 
lot less than this. SCC is relatively rare. The QALY gains from the number of SREs avoided compared with 
zoledronic acid are small: typically less than 0.02 QALYs over the patient lifetime and again often quite a lot 
less than this.
(Commercial-in-confidence information has been removed.) Given this and the small QALY gains, 
denosumab is in the main estimated to dominate or be cost-effective compared with zoledronic acid. But 
zoledronic acid comes off patent soon. Only a relatively minor price reduction (commercial-in-confidence 
has been removed) for zoledronic acid is required to result in the additional net costs from denosumab 
rendering it not cost-effective at current thresholds.
For those patients for whom BPs are not currently recommended or are not used, possibly owing to 
contraindications, both the manufacturer and the AG conclude that denosumab is not cost-effective 
compared with BSC.
Suggested research priorities
Further research would be helpful in the following areas:
 z The effectiveness of denosumab compared with zoledronic acid in delaying time to first SRE and 
reducing the risk of first and subsequent SREs in patients with hormone-refractory prostate cancer and 
painful bone metastases for whom other treatments have failed.
 z Whether or not there is an identifiable subgroup of patients at higher risk of SCC for whom 
denosumab might result in larger QALY gains.
 z The safety and efficacy of denosumab in (1) patients with severe renal impairment and advanced 
cancer (breast, prostate, NSCLC and OSTs) and (2) patients with advanced cancer who have previously 
been exposed to a BP.
 z The role of bone markers in identifying subgroups of patients with advanced cancer and bone 
metastases who may be likely to benefit from bone-targeting therapies.
 z Given the NSCLC subgroup result, further exploration of the effectiveness of denosumab compared 
with zoledronic acid for overall survival in patients with NSCLC and bone metastases.
Trial registration
The systematic review is registered as PROSPERO CRD42011001418.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National 
Institute for Health Research.
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Chapter 1 Background
Description of health problem
Brief statement describing health problem
Cancer is the leading cause of death in women and the second commonest cause of death in men; almost 
30% of all deaths in England and Wales are caused by cancer.1 Breast, prostate, lung and colorectal 
cancers are the commonest causes of cancer death in the UK.2 In most cases, death is caused not by 
the primary tumour but by metastases or their complications. Almost any cancer can metastasise to 
bone, but cancers of the breast, prostate, lung, bladder, thyroid and kidney spread to bone most often. 
Cancer disrupts the architecture of bone, causing structural weakness. Subsequently, patients may suffer 
severe bone pain, pathological fractures or spinal cord compression (SCC), further reducing quality of life 
and adding to the burden of disease. Treatments that alleviate, prevent or delay these events offer the 
possibility of improving a patient’s quality of life.
Overview of types of cancer commonly spreading to bone
Breast cancer
Bone metastases and their consequences depend on the type of primary tumour. Breast cancer is the 
commonest cancer in women. In the UK, approximately 124 women per 100,000 are diagnosed with 
breast cancer each year.2 Approximately 0.5% of women have bone metastases at diagnosis, with 4.7% 
developing bone metastases in 5 years.3 Bone metastases are associated with reduced median survival of 
approximately 24 months and 5-year survival of 20%.4 However, survival is more heavily dependent on 
the presence of visceral organ metastases. Breast cancer commonly spreads to bone, liver, lung and brain. 
It has been estimated that breast cancer patients with metastatic disease only to bone survive 6 months 
longer than those with bone metastases and metastases outside a bone (1.6 years compared with 
2.1 years).5
Breast cancer most commonly originates from cells lining ducts or lobules (namely ductal carcinoma 
or lobular carcinoma). The natural history of the tumour is dependent on a range of different variables 
which, in turn, contribute to classification. Tumour–node–metastasis (TNM) is the most important 
prognostic classification and refers to the size of the tumour (T), spread to lymph nodes (N) and presence 
of metastases (M). Low-grade or precancerous cells are referred to as in situ carcinoma and do not 
cause metastases, unless the tumour progresses to an invasive carcinoma. Tumour aggressiveness can 
be predicted by the degree to which tumour cells are differentiated; poorly differentiated cells tend to 
be more aggressive, whereas well-differentiated cells are less so. Treatment and prognosis depend on 
receptors expressed by tumour cells. The three most important are oestrogen receptor (ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (HER-2). Generally tumours that are receptor 
negative are less responsive to treatment and have a worse prognosis.
Prostate cancer
In men the most common cancer is prostate cancer. Approximately 98 men per 100,000 are diagnosed 
with prostate cancer in the UK each year. Almost 24 men per 100,000 each year die because of prostate 
cancer.2 Prostate cancer often progresses to involve bone. At diagnosis 22% of patients have stage IV 
disease and a further 25% will develop clinically detectable metastases over the course of the disease.6 One 
study found that 90% of patients with prostate cancer had some evidence of bone involvement at death.7 
Survival is reduced considerably in the presence of bone metastases, and 5-year survival drops from 56% in 
patients without bone metastases to 3% in patients with bone metastases.8 However, this does not imply 
that bone metastases cause death per se, but rather, they occur in more aggressive cancers.
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Prostate cancer originates in glandular cells and is therefore categorised as an adenocarcinoma. Similar 
to breast cancer, the TNM classification is the most important prognostic indicator. A worse prognosis is 
associated with the presence of disease in lymph nodes, or beyond. The grade of tumour cells is measured 
using the Gleason score. A high Gleason score suggests a poorly differentiated tumour and therefore 
poorer prognosis. Prostate-specific antigen (PSA) is a protein released by the prostate and can be a marker 
for cancer. However, there has been much debate around PSA testing. High levels of PSA can be found 
in patients without cancer and normal levels can be found in patients with cancer.9 Prostate tumours 
are dependent on androgens to progress. Therefore, antiandrogen treatment can delay progression by 
either chemical or surgical castration. When tumours respond to castration therapy they are classified as 
castration-sensitive prostate cancer (CSPC), and when tumours no longer respond to castration treatment 
they are classified as castration-resistant prostate cancer (CRPC). Hormone-sensitive and hormone-
refractory nomenclature has been used. However, some tumours remain dependent on androgens (and 
amenable to further androgen deprivation)10 to progress irrespective of castration therapy; here, the term 
castration resistant is more accurate.
Lung cancer
Lung cancer is the second commonest cancer, after breast (in women) and prostate (in men), and has 
an incidence of 48 per 100,000 per year. Lung cancer prognosis is very poor. More people die from lung 
cancer each year than from any other cancer (40 patients per 100,000).2 One-year survival is 25% (in men) 
and 26% (in women). Five-year survival is only 7.8% (in men) and 8.7% (in women) and reflects cancers 
that are detected early, at a surgically resectable stage.11 Spread of tumour to bone is common in lung 
cancer. Up to 36% of patients with lung cancer have evidence of bone metastases at death.12 Other organs 
to which lung cancer often metastasises include the adrenal glands and the brain.
Classification of lung cancer is histological. Non-small cell lung cancer (NSCLC) and small cell lung 
cancer (SCLC) constitute more than 95% of all lung cancers. NSCLC includes squamous cell carcinoma, 
adenocarcinoma and large cell carcinoma. SCLC carries a worse prognosis and metastases are usually 
present at diagnosis. Both SCLC and NSCLC are staged using the TNM classification, or categorised as 
stage IA (better prognosis) to IV (worse prognosis).
Other solid tumours
Almost any cancer can metastasise to bone. At autopsy, 35–42% of thyroid, renal and bladder tumours 
have evidence of bone metastases.13 Colorectal cancer mainly spreads to the liver, but in 6–10% of cases 
metastasises to bone.14,15 Since colorectal cancer is the third commonest cancer, after breast (in women), 
prostate (in men) and lung, the actual number of patients with bone involvement is considerable. Each 
cancer has different subclassifications, each with its own pathophysiology, treatment and prognosis. 
For example, papillary thyroid cancer has a very good prognosis compared with anaplastic thyroid 
cancer. Bladder tumours may be superficial, requiring only local ablation therapy, or may be muscle 
invasive, requiring surgical resection or radical radiotherapy to the bladder. Therefore, the pathway 
to bone metastases in each cancer type varies according to primary site, cell type, classification and 
antineoplastic treatment.
Pathophysiology of bone metastasis
Bone provides an ideal environment for adhesive tumour cells, illustrated by the ‘seed and soil 
hypothesis’.16 Blood flow through bone marrow provides ample opportunity for transportation of ‘seeds’ 
(tumour cells). A range of growth factors provides suitable ‘soil’. Once tumour cells have been established 
in bone marrow, the normal physiology of bone remodelling is disrupted.
Normal bone remodelling is dependent on the balance between osteoblasts and osteoclasts on the 
trabecular surfaces. Osteoblasts arise from mesenchymal stem cells and are responsible for bone 
formation. A cascade of bone proteins and growth factors drive and halt the bone formation process.
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Osteoclasts resorb bone. They derive from the monocyte–macrophage lineage and rely on various 
cytokines and osteoblastic products to develop. One such cytokine is a tumour necrosis factor called 
receptor activator of nuclear factor k-B ligand (RANKL). Through increased expression of RANKL, 
osteoclasts are induced and therefore bone resorption increases. Bone resorption results in calcium release. 
When combined with increased calcium reabsorption in the kidneys, this can lead to hypercalcaemia of 
malignancy (HCM).
Bone metastases result in an imbalance of osteoclast and osteoblast activity. If osteoclasts are primarily 
activated, bone resorption increases and metastases are more lytic in nature. Osteolytic lesions are thin 
lesions owing to the active resorption of bone and can be detected on plain radiograph. Appearance can 
be from a single well-defined lesion to multiple ill-defined lesions.
If osteoblasts are activated, bone formation increases and bone metastases are more sclerotic in nature. 
Sclerotic lesions are caused by increased bone formation so these lesions tend to be denser. The fact that 
these lesions are denser results not in normal/increased bone strength, but rather in weakness because of 
disruption of the bone matrix. Therefore, any imbalance of osteoblasts or osteoclasts causes disruption of 
the essential bone architecture and results in bone weakness.
Traditionally it was thought that bone metastases could be osteolytic, osteoblastic or mixed. Prostate 
cancer generally results in predominantly osteoblastic lesions and breast cancer predominantly osteolytic 
lesions.17 However, current opinion is that a spectrum exists, with no metastasis being purely osteolytic 
or osteoblastic.18
Clinical sequelae of bone metastases
The impact of bone metastases on patients is considerable. Bone metastases are associated with a worse 
prognosis, reduced quality of life and increased risk of complications. Quality of life is decreased by 
bone pain, reduced mobility and complications such as pathological fracture, SCC and HCM. Metastatic 
bone pain can be of a constant or intermittent nature, and it is not unusual for strong opioid analgesics 
to provide little relief. Alternatives to first-line analgesics include radiotherapy, bisphosphonates 
(BPs), corticosteroids or radionucleotides. Mobility may be reduced because of bone pain and other 
complications. Immobility places individuals at risk of other complications such as thromboembolism and 
lower respiratory tract infection, further increasing morbidity.
Complications are caused by weakness in the bone or disrupted calcium homoeostasis. Either osteoblastic 
or osteolytic lesions can cause pathological fractures, defined as pathological because minimal or no 
force is required. The commonest sites for fractures are the axial skeleton and long bones. Vertebral body 
collapse is common and can cause deformity of the spine. Saad and colleagues19 demonstrated that 
pathological fractures were correlated with reduced survival. Surgical fixation or radiotherapy can be used 
to prevent or treat pathological fractures.
The most serious complication of bone metastasis is SCC. Impingement of the spinal cord (i.e. SCC) 
is caused by either vertebral body collapse or direct tumour growth into the spinal canal. Even with 
emergency treatment, SCC can cause irreversible neurological damage, paraplegia and death. Neurological 
damage can range from mild sensory loss to complete paraplegia with loss of bowel and bladder function.
A further serious complication of bone metastases is hypercalcaemia (i.e. HCM). High circulating levels of 
calcium are caused by release of calcium from metastases and dysregulation in the kidney. HCM causes a 
typical pattern of unpleasant, non-specific symptoms. Untreated it can lead to coma, cardiac arrhythmias 
and death.
The term ‘skeletal-related event’ (SRE) is used to group the following complications together for research 
purposes: pathological fracture, SCC, and radiotherapy or surgery to bone. Some definitions include 
hypercalcaemia or change in antineoplastic therapies. The marketing authorisation for denosumab 
NIHR Journals Library www.journalslibrary.nihr.ac.uk
backgrOunD
4
defines the term SRE as pathological fracture, SCC, and radiation to bone or surgery to bone. SREs should 
be considered as a spectrum of conditions, from unnoticed asymptomatic fractures to SCC resulting 
in paralysis.
Brown and colleagues,20 using randomised controlled trial (RCT) data, investigated baseline prognostic 
factors for patients experiencing a SRE. They found that significant factors included age, pain score, 
prior history of SRE, lesion type (osteolytic, osteoblastic or mixed) and elevated bone-specific alkaline 
phosphatase (BSAP) or lactate dehydrogenase (LDH). Bone pain at diagnosis has also been associated with 
increased SRE risk.21 The incidence of SREs in patients with bone metastases without previous BP treatment 
was 3.5 events per year.22 Sathiakumar and colleagues,23 using Medicar-linked data, found increased risk 
of death in patients with bone metastases from prostate cancer plus a SRE compared with patients with 
bone metastases plus no SRE. Yong and colleagues24 found a similar result in breast cancer. However, the 
majority of trials of bone-modifying agents aimed at delaying SREs in patients with bone metastases have 
not been shown to affect overall survival.
In addition, bone metastases have wider implications for patients. Aside from the symptoms and 
complications, the diagnosis of bone metastases substantially increases health-care contact. Patients may 
require a change in antineoplastic medications, careful titration of analgesics, radiotherapy, intravenous 
BPs, radiological imaging or frequent blood tests. More frequent health-care appointments can be 
especially difficult for patients who live in rural locations or do not have ready access to transport. Bone 
pain, decreased mobility and SREs undoubtedly have a further impact on patients and their families. Bone 
pain is characteristically severe and can be difficult to control. SREs can result in lengthy hospital stays and 
reduced mobility, especially in the case of communicated pathological fractures or SCC. The combination 
of increased contact with health care, reduced mobility and increased pain inevitably restricts daily 
activities and results in patients requiring a higher level of care. Increased care has a subsequent impact on 
carers and social services.
Measurement of disease
Investigations for bone metastases and skeletal-related events
Bone metastases and SREs can be measured in several different ways.25 At the time of cancer diagnosis 
clinicians may screen for metastases. The decision to screen depends on stage of tumour and patients’ 
symptoms. Skeletal scintigraphy (bone scan) uses injected radioactive material, which is then scanned with 
a gamma camera. Areas of increased bone metabolism are shown. This test shows the whole skeleton 
and is advantageous for a broad examination of the skeleton in asymptomatic patients. Plain radiographs 
(X-rays) are used for investigation of specific bones where metastases are suspected. Other investigations 
can then be used to investigate bone lesions, such as computerised tomography (CT), magnetic resonance 
imaging (MRI), positron emission tomography (PET) and single-photon emission CT (SPECT).
Bone markers, measured in blood or urine, have been used to monitor bone turnover in clinical trials. 
Patients with bone metastases and elevated bone markers are at increased risk of SREs.26 It has been 
suggested that bone markers could be used to stratify risk of SRE in individuals with bone metastases, 
assisting in the choice of bone-modifying agents and monitoring treatment response.27,28 There are several 
different bone markers, including BSAP, osteocalcin and N-terminal type 1 procollagen peptides (PINPs) 
markers for monitoring bone formation, and urinary or serum collagen type 1 cross-linked C telopeptide 
(CTX) and urinary collagen type 1 cross-linked N-telopeptide (NTX) for monitoring bone resorption. 
Denosumab trials have included measures of NTX and BSAP as secondary outcomes.29–31 NTX increases in 
response to osteoclast-mediated bone resorption and can be measured in the blood or urine. During BP 
treatment, normalised levels of NTX appear to be associated with a reduced risk of SREs.32,33 BSAP reflects 
osteoblastic activity by measuring bone formation. BP and denosumab treatment have been found to 
reduce BSAP. Conversely, persistent elevation of BSAP despite BP treatment is associated with increased 
SREs.32 American Society of Clinical Oncology (ASCO) guidelines do not recommend the use of bone 
markers outside the trial setting.34
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In routine clinical practice acute uncomplicated pathological fractures are generally investigated by 
plain radiography. In the trial setting, regular skeletal surveys have been used to screen and diagnose 
pathological fractures. A skeletal survey is performed by taking plain radiographs of the skull, chest, 
spine, pelvis and long bones of the arms and legs. Therefore, both asymptomatic (lesions demonstrated 
radiologically but the patient does not complain of any symptoms) and symptomatic fractures will be 
observed. For pathological fractures of the spine, plain radiographs may not be sufficient. There may be 
uncertainty about the presence of a fracture and plain radiographs do not assess the integrity of the spinal 
canal. In this scenario, imaging with a MRI or CT scan may be necessary. In the case of suspected SCC, MRI 
is the investigation of choice.
Hypercalcaemia often presents with non-specific symptoms and is easily diagnosed on blood test. Signs 
and symptoms worsen as serum calcium increases. A serum calcium of more than 2.6 mmol/l is suggestive 
of hypercalcaemia.
Measuring skeletal-related events
There are several ways of recording SRE data in clinical trials:
 z time to first SRE
 z time to first and subsequent SREs (multiple event analysis)
 z SRE incidence
 z proportion of patients with at least one on-study SRE
 z skeletal morbidity rate (SMR) – number of events per year
 z skeletal morbidity period rate (SMPR) – the number of 12-week periods with new SREs divided by the 
total observational time.
It is important to note that SRE as a composite end point includes both complications of bone 
metastases (pathological fracture and SCC) and therapeutic or preventative measures (radiotherapy and 
surgery). Caution is needed because radiotherapy and surgery would be considered best supportive care 
(BSC).35,36 Therefore, measures of radiotherapy and surgery contribute to both the treatment and the 
outcome measure.
Trinkaus and colleagues37 compared observational SRE frequency in ‘real life’ with SRE frequency in the 
intravenous BP trials. They found that the rate of SREs was higher in the trial setting than in ‘real life’. This 
may reflect the fact that bone scans are undertaken fequently in trials.
The various methods of assessing SRE data have evolved to overcome specific problems.
Some outcomes, such as proportion of patients with at least one on-study SRE or SMR, fail to consider 
time delays in SREs. For example, an individual who suffers SCC on day 1 of a trial is considered equivalent 
to an individual who suffers SCC after a year. To overcome this issue, time to first SRE can be measured. 
This outcome does not distinguish the number or timing of subsequent SREs. Consequently, the multiple-
event analysis was developed.38 The Andersen–Gill system is the commonest method used for multiple-
event analysis. It includes a measure of both time and number of events. This method has been criticised 
because it fails to differentiate between individuals who have died and individuals who have left the 
trial for another reason.39 Other methods have been described that also attempt to take mortality into 
account.40,41
The choice of SRE measure depends on what is considered the most important outcome. To measure SRE 
prevention, the proportion of patients experiencing a SRE would be more suitable. To measure a reduction 
in rate, SMR/SMPR would be most appropriate. However, to measure delay, time to first or time to first and 
subsequent SRE would be more appropriate.
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The situation is made more complex because more than one SRE may occur in relation to a single 
event and therefore the second SRE is dependent on the first. For example, an individual may suffer a 
pathological fracture, which is treated by radiotherapy or surgery (two SREs). In the pivotal denosumab 
and BP trials, a subsequent SRE is counted only after a 21-day period. This is not the case for SMR, which 
assumes independence for each event and can therefore lead to multiple counting of events. In an attempt 
to address this issue the SMPR outcome has been used.
The incidence of SREs is generally not considered appropriate because of underestimation of time 
variability within the data (similar criticism could be made of SMR).42 A patient who suffers several SREs 
within the first 6 months is considered equivalent to a patient who suffers the same number of events over 
several years. The former patient is likely to have a reduced quality of life compared with the latter.
Trials have consistently used SRE as a composite outcome. This undoubtedly increases efficiency and 
power, but some caution is needed. However, the impact on health-care resources and a patient’s quality 
of life is vastly different for SCC compared with an asymptomatic rib fracture. Nor does this SRE composite 
outcome directly measure factors that are important to patients such as mobility or pain (these are 
measured indirectly through need for radiotherapy or surgery).43
Burden of bone metastases and skeletal-related events on health care and society
Undoubtedly, bone metastases and SREs require considerable health-care resources. In 2010, Pockett 
and colleagues44 reported the hospital burden associated with bone metastases and SREs from breast, 
prostate and lung cancer in Spain. They collected data on over 28,000 patients over 1 year. The incidence 
of hospital admission was greatly increased when a SRE occurred. Among patients with breast cancer, the 
hospital admission incidence rate was 95 per 1000 patients over 3 years for non-SRE-related metastatic 
bone disease and 211 per 1000 for SRE-related admissions. Among those with lung and prostate cancer, 
the incidence was 156 (lung) and 163 per 1000 patients (prostate) over 3 years for non-SRE-related 
metastatic bone disease and 260 and 150 for a SRE-related admission, respectively.
Current service provision
Current management of bone metastases and skeletal-related events
There are four National Institute for Health and Care Excellence (NICE) clinical guidelines (CGs) relevant to 
this appraisal:
 z Breast cancer – CG81.45
 z Prostate cancer – CG58.46
 z Metastatic SCC – CG75.47
 z Lung cancer – CG121.48
These guidelines recommend the use of BPs in:
1. all patients with advanced breast cancer and newly diagnosed bone metastases45
2. patients with ‘hormone-resistant’ prostate cancer and painful bone metastases when other treatments 
(including analgesics and palliative radiotherapy) have failed46 
3. patients with breast cancer or multiple myeloma, plus vertebral involvement to reduce pain and 
prevent complications.47
Bisphosphonates are not currently recommended to prevent skeletal complications in prostate cancer46 or 
tumours with vertebral involvement, excluding breast and multiple myeloma.47 The lung cancer guideline48 
states ‘methods of treating bone metastases include radiotherapy, BPs and nerve blocks’49 and ‘the effect 
of BPs . . . needs more research’.50
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ASCO has recently published guidelines concerning the use of bone-modifying agents in metastatic breast 
cancer.34 Based on clinical efficacy, not cost-effectiveness, ASCO has recommended the use of zoledronic 
acid, disodium pamidronate or denosumab in patients with bone metastases from breast cancer.
The Scottish Intercollegiate Guidelines Network (SIGN) suggests that there is insufficient evidence to 
recommend BPs for first-line treatment of cancer-related pain, but it does recommend that BPs should be 
considered.51 The SIGN breast cancer guideline52 recommends BPs in patients with metastatic breast cancer 
and symptomatic bone metastases.
An expert panel of European clinical oncologists has published recommendations.53 Based on clinical 
effectiveness, but without economic evaluation, they recommended that all patients with bone metastases 
from lung cancer should be prescribed a BP.
Bisphosphonates
Bisphosphonates reduce bone resorption by inhibiting osteoclasts.54 Clinical effectiveness starts 
after 6–12 months of treatment.55 There are first-, second- and third-generation BPs. Early non-
aminobisphosphonates include clodronate and etidronate. The addition of a nitrogen group to the 
BP structure was found to increase potency by inhibition of the 5-hydroxy-3-methylglutaryl-coenzyme 
A (HMG-CoA) reductase pathway. These aminobisphosphonates include ibandronic acid, disodium 
pamidronate and zoledronic acid.
During the early studies of oral nitrogen-containing BPs, an association with oesophagitis was frequently 
reported.56 Therefore, zoledronic acid and disodium pamidronate are available only as intravenous 
preparations. Ibandronic acid is available as an oral or intravenous preparation. Intravenous BPs are 
excreted rapidly from the kidneys and are typically associated with a higher incidence of hypocalcaemia 
and renal impairment than oral BPs.57 Administration time varies from 15 minutes for zoledronic acid to 
120 minutes for disodium pamidronate.
Oral BPs are absorbed by passive diffusion in the gastrointestinal tract. As a result, less than 6% of the 
active compound is absorbed, and this is further reduced with the presence of food. In addition, oral BPs 
increase the risk of oesophageal erosions, inflammation and neoplasm.58 It is therefore recommended that 
patients remain upright for 30–60 minutes after ingestion. Consequently, oral BPs become burdensome 
for patients.59 Location of treatment is important to patients. One study found that patients prefer 
administration at home, but this is not often possible with intravenous treatments.60
Bisphosphonates are considered to be relatively safe drugs. Possible adverse reactions include renal failure, 
osteonecrosis of the jaw (ONJ), hypocalcaemia and acute-phase reaction. To avoid renal impairment, 
renal function is checked before administration, dose is adjusted if necessary and the intravenous infusion 
is given slowly. McDermott and colleagues61 assessed predictors of renal impairment in patients given 
zoledronic acid. The following predictive factors were found on multivariate analysis: age, myeloma or 
renal cell cancer, number of doses, concomitant non-steroidal anti-inflammatory drug therapy and current 
or prior treatment with cisplatin. ONJ has only recently been associated with BPs;62 ONJ leads to oral or 
periodontal lesions, which are usually associated with previous dental procedures. Hypocalcaemia can 
be rectified with oral calcium. Acute-phase reaction usually presents with transient pyrexia following 
first administration.
Four BPs are currently licensed in the UK for bone metastases:
(a) Zoledronic acid (Zometa™, Novartis, Basel, Switzerland) is licensed for the reduction of bone damage 
in advanced malignancies involving bone. It is administered by intravenous infusion over at least 
15 minutes at a dose of 4 mg every 3–4 weeks.
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(b) Disodium pamidronate (Aredia®, Novartis) is licensed for osteolytic lesions and bone pain in bone 
metastases associated with breast cancer or multiple myeloma. It is administered by slow intravenous 
infusion (over at least 2 hours) at a dose of 90 mg every 4 weeks.
(c) Sodium clodronate (Bonefos™, Bayer Schering, Berlin, Germany; Clasteon™, Beacon, Tunbridge Wells, 
UK; Loron 520™, Roche, Basel, Switzerland) is licensed for osteolytic lesions, hypercalcaemia and 
bone pain associated with skeletal metastases in patients with breast cancer or multiple myeloma. It is 
administered by mouth at a dose of 1.6–3.2 g daily.
(d) Ibandronic acid (Bondronate™, Roche) is licensed for the reduction of bone damage in bone 
metastases in breast cancer. It is administered either by mouth (50 mg daily) or by intravenous infusion 
(6 mg every 3–4 weeks).
Therefore, zoledronic acid is the only drug licensed for cancer involving bone, other than breast or multiple 
myeloma. Zoledronic acid has been the most studied BP and, according to expert opinion, is the most 
widely used BP. The patent for zoledronic acid is expected to expire in 2013. There are currently no firm 
criteria to advise when BPs should be stopped.
Best supportive care
Best supportive care varies between each primary cancer type.
In patients with breast cancer and bone metastases, BSC encompasses the use of BPs to prevent SRE 
and reduce pain. However, for the purpose of this report, the definition of BSC does not include BPs. 
Pain is also managed by the use of both simple and opioid analgesics, corticosteroids and non-steroidal 
anti-inflammatory agents. External beam radiotherapy is used to control pain at specific sites and, less 
commonly now, systemic radiopharmaceuticals may be used to alleviate widespread pain at multiple sites 
not controlled by other means. All patients with metastases in a long bone should be assessed for the risk 
of pathological fracture and referred to an orthopaedic surgeon for consideration of prophylactic fixation. 
Not all patients will require treatment with all modalities discussed above. The NICE guidelines currently 
recommend that all patients with bone metastases receive a BP, while ASCO guidelines recommend the use 
of a bone-modifying agent in patients with bone metastases and evidence of bone destruction. There is 
variation in the use of the other interventions mentioned, dependent on local practice and patient factors.
In patients with bone metastases, current BSC encompasses the use of systemic anticancer therapies 
including chemotherapy and further hormone therapies. Palliative external beam radiotherapy and systemic 
radionucleotides, such as strontium-89, are widely used and may be used on multiple occasions to treat 
metastatic bone pain. Despite these measures, pain may continue to be burdensome, and analgesics, often 
requiring specialist pain services, are frequently required. Attitudes to systemic anticancer therapies used 
in this context vary across the UK; in particular, there remains widespread controversy about the optimal 
timing of docetaxel-based chemotherapy, some clinicians opting to use it to prevent symptoms such as 
bone pain, whereas others save it until symptoms become burdensome. Two new drugs, cabazitaxel and 
abiraterone acetate, which are licensed for this indication, may change BSC patterns in this population, 
but neither drug has been the subject of published NICE review and access outside of clinical trials remains 
limited in the UK. The treatment of SRE is similar to that of other solid tumours (OSTs). Pathological 
fractures can be treated or prevented with surgery, radiotherapy or analgesics. Current practice is that 
BPs are not given to prevent complications of bone metastases, such as pathological fractures and SCC. 
However, BPs are used to treat pain when first-line analgesics have not alleviated pain.
In patients with lung cancer with bone metastases, BSC may include chemotherapy, palliative radiotherapy, 
antibiotics, steroids, surgery, analgesics and antiemetics.63 Certain treatments are aimed at slowing disease 
progress (chemotherapy), while others are aimed at alleviating (analgesics and antiemetics) or preventing 
(surgery to prevent pathological fracture) symptoms. BSC may vary according to the location or primary 
tumour and presence of distal metastases. BPs are generally not used to prevent SREs. However, clinicians 
may consider BPs as a second-line analgesic option for painful bone metastases. BSC for pathological 
fracture and SCC in lung cancer is similar to that for OSTs.
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Current treatments of skeletal-related events
Treatment of pathological fractures depends on the severity of injury, the bones involved and the degree of 
destruction. Management options include analgesics, immobilisation, surgical fixation, radiotherapy or a 
combination of the above. The impact of pathological fractures varies widely; some may be unnoticed and 
asymptomatic while more severe fractures may be associated with SCC and paraplegia.
Management of metastatic SCC has been described.47 The guidelines highlight the need for early diagnosis 
and imaging with MRI. Acute treatment recommendations include good nursing care, corticosteroids and 
appropriate case selection for surgery or radiotherapy. Moreover, the guidelines make recommendations 
for long-term care, including management of pressure ulcers, bladder or bowel incontinence, postural 
hypotension and lung secretions, prevention of thromboprophylaxis and planning for rehabilitation or 
long-term care.
Hypercalcaemia of malignancy can present with various different signs and symptoms. If untreated, 
HCM can lead to confusion, drowsiness or coma. Rehydration and BP treatment are the cornerstone of 
management. Loop diuretics and steroids can also be used. Older agents such as plicamycin, calcitonin 
and gallium nitrate are not commonly administered.
Variation in service
There is variation among oncologists in the choice of BPs and more so in breast cancer, for which four BPs 
are licensed. With no clear guidelines about which BP to use, the decision is often made by the individual 
clinician. Based on expert opinion, zoledronic acid is the most widely used BP.
Bisphosphonates are used consistently in breast cancer; however, the use of BPs in other cancers varies. 
Among patients with metastatic tumours other than breast cancer, some clinicians use BPs routinely, 
wherease others reserve BPs only for uncontrolled pain and still others rarely use BPs. With the imminent 
patent expiry of zoledronic acid and the anticipated reduction in price, patterns of use may change 
significantly in the near future.
Fallowfield and colleagues64 conducted a UK survey to evaluate BP prescribing habits among oncologists. 
They found that 53% of oncologists gave intravenous and oral drugs, 40% gave only intravenous 
drugs and 7% gave only oral drugs. Zoledronic acid (56–85%) and disodium pamidronate (23–42%) 
were the commonest intravenous drugs, and ibandronic acid (66%) was the commonest oral BP used. 
Reasons reported for using oral preparations included ‘health authority/primary care trust only funds 
oral preparation’, ‘local guidelines dictate which patients receive oral/intravenous’ and ‘intravenous 
preparations are not listed on the local formulary’.
Variation in BSC exists between treatment centres. Local policy, available resources and clinician 
prescribing habits all affect the likelihood of patients being offered certain BPs, analgesics or 
antineoplastic medications.
Current service cost
Bisphosphonates are an adjuvant to BSC. British National Formulary (BNF) 62 gives a list price for 
zoledronic acid of £174.17, which can be administered as a 15-minute intravenous infusion. Disodium 
pamidronate is given a list cost of £165.00 in BNF62 and is administered as a slow intravenous injection 
over at least 2 hours every 4 weeks. Additional costs include staff time to administer BPs, monitoring costs, 
in particular monitoring of renal function, and capital costs.
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The technology
Summary of intervention and important subgroups
Denosumab is a fully human monoclonal antibody. It has been designed to reduce osteoclast-mediated 
bone destruction through the inhibition of the RANKL. Its mechanism of action therefore varies from that 
of current BPs.
Tumour cells appear to increase the release of RANKL through activation of osteoblasts. RANKL, in turn, 
promotes osteoclast activity. Therefore, inhibition of RANKL reduces bone destruction. Denosumab is the 
first monoclonal antibody developed with this mode of activity.
Denosumab (Prolia®, Amgen, Thousand Oaks, CA, USA) is currently licensed for treatment of osteoporosis 
and bone loss caused by hormone ablation treatment in prostate cancer. Prolia is given in a dose of 60 mg 
every 6 months. Denosumab (Xgeva®, Amgen) for the prevention of SREs in bone metastases from solid 
tumours was granted marketing authorisation in July 2011. Multiple myeloma was not included within the 
marketing authorisation and therefore has been removed from the decision problem chapter of this report. 
Denosumab is administered as a 120 mg subcutaneous injection every 4 weeks. Xgeva is administered in a 
higher dose and more frequently than Prolia.
The Food and Drug Administration in the USA, on 18 November 2010, granted approval for a new 
indication for denosumab, to include the prevention of SREs in patients with bone metastases from solid 
tumours, to be marketed under a new proprietary name, Xgeva.
Current usage in the National Health Service
Denosumab has only recently been granted licensing authorisation in the UK. The assessment group (AG) 
is unaware of any current use in clinical practice.
Anticipated costs associated with intervention
Denosumab is admistered by 4-weekly subcutaneous injection in hospital while patients receive other 
therapy such as chemotherapy, at an outpatient appointment or potentially in primary care or through 
a dedicated health visitor domestic visit. The direct drug cost is £309.86 per dose. (Commercial-in-
confidence information has been removed.)
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Chapter 2 Definition of the decision problem
This section specifies the decision problem, outlines the key issues and provides an explanation of changes made between the scope and protocol or subsequent to the protocol.
Decision problem
The purpose of this report is to assess the clinical effectiveness and cost-effectiveness of denosumab within 
its licensed indication for the prevention of SREs in patients with bone metastases from solid tumours. 
Denosumab offers an alternative treatment to BPs, or an addition to BSC, for the prevention of SREs.
Interventions
Scope: Denosumab
Protocol: Denosumab
The intervention is denosumab (Xgeva), administered every 4 weeks at a dose of 120 mg as a 
subcutaneous injection.
Population including subgroups
Scope Adults with bone metastases from solid tumours and adults with multiple myeloma
Protocol Adults with bone metastases from solid tumours and bone disease in multiple myeloma
The population assessed is adults with bone metastases from solid tumours. The scope requested that each 
tumour type be presented separately. Breast, prostate and NSCLC are the tumours that most commonly 
metastasise to bone. This grouping is reflected in the published literature. Therefore, the population is 
divided into those with breast cancer, prostate cancer, NSCLC and OSTs.
As far as the evidence allows, a subgroup based on prior history of SRE is considered.
Multiple myeloma is not included in the marketing authorisation for denosumab and has therefore been 
withdrawn from the decision problem.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DefInItIOn Of tHe DecIsIOn prOblem
12
Relevant comparators
Scope
Bisphosphonates such as sodium clodronate, disodium pamidronate, ibandronic acid and zoledronic acid
 z Best supportive care
Protocol
 z Breast cancer – BPs
 z Prostate cancer, lung cancer and OSTs – BPs and BSC
Denosumab is compared with BPs and BSC.
The comparator of BSC is not mutually exclusive with denosumab or BP treatment. Both on-study and 
in ‘real life’ patients receive BSC, irrespective of denosumab or BP treatment. Therefore, a more accurate 
description of the comparators would be denosumab plus BSC compared with BPs plus BSC or BSC alone. 
However, for the purpose of this report the terms denosumab, BPs and BSC are used.
In breast cancer, denosumab is compared with BPs. Denosumab is compared with zoledronic acid, 
disodium pamidronate, ibandronic acid and sodium clodronate, depending on available literature.
In prostate cancer the NICE guideline46 recommends the use of BPs when conventional analgesics fail. 
Zoledronic acid is the only BP licensed and is the most commonly used. Therefore, denosumab is compared 
with BSC and zoledronic acid.
In NSCLC the NICE guideline48 states that ‘methods of treating bone metastases include radiotherapy, BPs 
and nerve blocks’. No clear guidance exists about when BPs should be administered. Zoledronic acid is the 
only BP licensed. Therefore, in NSCLC denosumab is compared with BSC and zoledronic acid.
In OSTs, excluding breast, prostate and NSCLC, no clear guidance exists about the circumstances under 
which BPs should be administered. Zoledronic acid is the only BP licensed. Therefore, denosumab is 
compared with BSC and zoledronic acid.
In patients with bone metastases from solid tumours who are eligible for a BP but are contraindicated (e.g. 
due to renal impairment), denosumab is compared with BSC.
The metastatic SCC NICE guideline47 recommends the use of BPs in (1) breast cancer to reduce pain and 
the risk of vertebral fracture/collapse and (2) prostate cancer to reduce pain if conventional analgesics 
fail to control pain. The guideline recommends that BPs are not used to treat pain, or with the intention 
of preventing metastatic SCC, in patients with vertebral involvement from solid tumour types other than 
breast and prostate cancer.
There is wide variation in the use of BPs for the management of patients with bone metastases in the UK. 
Patterns of use depend on local and national guidelines, and physician and patient preferences. Expert 
opinion is used to assess the use of unlicensed BPs in solid tumours other than breast cancer.
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Outcomes 
Scope
The outcome measures to be considered include:
 z Time to first SRE (pathological fracture, SCC, radiation or surgery to the bone)
 z Time to first and subsequent SRE
 z Incidence of SREs
 z SMR
 z Hypercalcaemia
 z Survival
 z Pain
 z Health-related quality of life (HRQoL)
 z Adverse effects of treatment
Protocol
 z As per scope
The above outcomes are assessed according to available literature and suitability for network meta-analysis 
(NMA). In addition, the proportion of patients experiencing an on-study SRE is included. This outcome is 
synonymous with crude incidence of patients experiencing an on-study SRE.
Where the evidence allows, each type of SRE is presented separately. SRE is defined as pathological 
fracture, radiotherapy to bone, surgery to bone or SCC.
The use of SRE as a composite end point is discussed in Chapter 1 and Chapter 11. The term SRE is used 
in trials but not in clinical practice. The main criticism is that SRE encompasses a wide spectrum of possible 
health states, from asymptomatic fractures to SCC resulting in paraplegia, and does not directly measure 
pain or mobility. Including treatments (radiotherapy and surgery) in addition to complications (fracture and 
SCC) can make results difficult to interpret.
According to clinical advisors, the minimal clinically significant change in time to first SRE would be a 20% 
reduction in hazard ratio (HR) (R Jones). Mathias and colleagues65 correlated Brief Pain Inventory (BPI) 
scores and quality-of-life scores [European Quality of Life-5 dimensions (EQ-5D) and Function Assessment 
of Cancer Therapy (FACT)] using data from the trial by Stopeck and colleagues31 comparing denosumab 
and zoledronic acid in breast cancer with bone metastases. The authors concluded that a two-point 
change, or more, in BPI score should be considered as clinically meaningful.
Key issues
The place of denosumab within the treatment pathway is a crucial issue. The following possible places in 
the treatment pathway are considered:
 z Bone metastases from breast cancer.
 | An alternative to BPs as a first-line treatment in the prevention of SREs.
 | Second-line treatment for patients who have a SRE on a BP.
 z Bone metastases from prostate, NSCLC and OSTs, excluding breast cancer.
 | An alternative to BSC as a first-line treatment in the prevention of SREs.
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 | As a first-line therapy for the secondary prevention of SREs in patients who have already suffered 
a SRE.
 | An alternative to BPs as a second-line therapy for prevention of SREs in patients for whom BSC has 
not proved adequate.
 z Bone metastases from breast cancer, prostate cancer, NSCLC and OSTs.
 | As a second-line treatment in patients unable to tolerate intravenous BPs, or for whom they 
are contraindicated.
The three main challenges with this appraisal are (1) a population that includes all solid tumours, (2) 
widespread variation in the use of comparators and (3) limited evidence suitable for inclusion in a NMA.
Three Phase III clinical trials have evaluated denosumab compared with zoledronic acid in breast cancer,31 
prostate cancer,29 and OSTs (excluding breast and prostate) and multiple myeloma.30 Breast, prostate and 
lung cancer are the tumours that most commonly metastasise to bone, although almost any tumour has 
the potential to do so. Treatment effect could be influenced if tumour types are combined or considered 
separately. In this appraisal, breast cancer, prostate cancer and NSCLC are considered separately; all OSTs 
are combined. Furthermore, at diagnosis of bone metastases patients may have been exposed to a variety 
of therapies. These include chemotherapy, hormonal therapy, radiotherapy or surgery. Therefore, the 
evidence of a treatment, which is given in addition to these therapies, and in a variety of tumour types, 
requires careful interpretation.
Comparators include BPs and BSC. There has been no NICE technology appraisal for the use of BPs in bone 
metastases. Four NICE guidelines give recommendations on the use of BPs in advanced breast cancer,45 
prostate cancer,46 lung cancer48 and metastatic SCC.47 Variation in practice exists in the use of BPs between 
tumour types and the choice of BP. Although zoledronic acid is the only licensed BP for solid tumours 
other than breast cancer, other BPs may be used off licence. Not only does BP use vary, but also BSC varies 
between geographical region and tumour type. Therefore, BSC is defined by clinical experts. There is no 
direct evidence comparing denosumab with current BSC. Placebo or no active treatment is used as a proxy 
for BSC. To compare denosumab with BSC several network meta-analyses are required. Only data that 
are sufficiently homogeneous, in terms of population, intervention, comparators, outcomes assessed, SRE 
definition and timeframe, can be included.
Other treatment-effect and cost-effect modifiers include:
 z symptomatic versus asymptomatic fractures (pivotal denosumab studies report combined 
symptomatic and asymptomatic fractures; the inclusion of asymptomatic fractures may overestimate 
treatment effects)
 z overall survival (tumours with extended survival may benefit more from denosumab)
 z place of administration of denosumab (community versus hospital).
Overall aims and objectives of assessment
Scope
To appraise the clinical effectiveness and cost-effectiveness of denosumab within its licensed indication for 
the treatment of bone metastases from solid tumours and multiple myeloma
Protocol
To appraise the clinical effectiveness and cost-effectiveness of denosumab within its licensed indication for 
the treatment of bone metastases from solid tumours and bone disease in multiple myeloma
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The purpose of this review is to appraise the clinical effectiveness and cost-effectiveness of denosumab, 
within its licensed indication, for the treatment of bone metastases from solid tumours. Multiple myeloma 
is not included in the marketing authorisation for denosumab and has therefore been withdrawn from 
the decision problem. As stated above, results are presented separately based on the type of primary 
cancer: (1) breast cancer, (2) prostate cancer, (3) NSCLC and (4) OSTs excluding breast, prostate or NSCLC. 
Where evidence allows, data for each type of SRE (pathological fracture, requirement for radiation therapy 
to bone, surgery to bone, or SCC) are presented separately. In addition, where evidence allows, data on 
patients with a history of SREs are presented separately.
The following aspects are not included in the aim of this report:
 z denosumab for the prevention of bone metastases
 z the clinical effectiveness and cost-effectiveness of BPs relative to BSC.
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Chapter 3 Methods for reviewing effectiveness
Identification of studies
Studies were identified by searching electronic databases and relevant websites, contact with clinical 
experts and the scrutiny of bibliographies of retrieved papers.
The databases searched were MEDLINE (1948 to April 2011), EMBASE (1980 to March 2011), The 
Cochrane Library (all sections; Issue 1, 2011) and Web of Science with Conference Proceedings (1970 to 
May 2011). Auto-alerts were set-up in MEDLINE and EMBASE to identify any studies indexed after the 
above searches were done. Other sources, including the 2010 and 2011 meeting abstracts of ASCO and 
the American Urological Association, and the San Antonio Breast Cancer symposium were also searched. 
Searches were limited to English-language studies only.
Full details of all searches are shown, see Appendix 1.
Inclusion and exclusion criteria
Types of studies
The following studies were considered for inclusion:
 z Systematic reviews and RCTs.
There was no restriction on the number of patients in trials, because those with inadequate numbers, and 
hence power, would have been useful when combined in a meta-analysis.
If there were any high-quality existing systematic reviews that met the inclusion criteria, we would have 
considered updating them; however, no relevant systematic reviews were identified.
 z Observational studies were used, in addition to RCTs, for data on quality of life and safety.
Only studies published in full and published abstracts that reported additional outcomes or analyses from 
studies already published in full were included.
Meeting abstracts were tabulated for use in the discussion to indicate ongoing research (for recent 
abstracts), or possible sources of publication bias (for older abstracts not subsequently published in full).
Types of participants
The population considered were adults with confirmed carcinoma of the following:
 z breast
 z prostate
 z NSCLC or
 z OSTs
plus, evidence of at least one bone metastasis.
We considered separately patient groups based on location or type of primary cancer, where 
data permitted.
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Types of interventions
Denosumab (trade name Xgeva), manufactured by Amgen, was given as a subcutaneous injection at dose 
of 120 mg every 4 weeks. The approved indication for denosumab is the prevention of SREs (pathological 
fracture, radiation to bone, SCC or surgery to bone) in adults with bone metastases resulting from 
solid tumours.
We excluded studies (such as pharmacokinetic or drug tolerability studies) in which patients were given 
only a single dose of a drug and where studies compared different routes of administration of the same 
BP. In studies that have arms with more than one dose of a licensed comparator drug, only arms of studies 
that used the UK-licensed doses of the drug were included.
Types of comparators
The relevant comparators are (1) BPs and (2) BSC.
Bisphosphonates
Bisphosphonates considered as a comparator included:
 z sodium clodronate
 z disodium pamidronate
 z ibandronic acid 
 z zoledronic acid.
Etidronate was initially considered as an unlicensed (for this purpose) comparator, because of its much 
lower cost. However, clinical advice suggests that it should be used infrequently because it may cause 
gastrointestinal toxicity.
Currently, zoledronic acid has UK marketing authorisation for the reduction of bone damage in all 
advanced malignancies involving bone. Disodium pamidronate and sodium clodronate are licensed for 
breast cancer and multiple myeloma, and ibandronic acid is licensed only for breast cancer. However, we 
also considered inclusion of trials of these BPs when used outside their licensed indications.
Clinical experts and NICE guidelines were consulted to determine the place of BPs in the care pathway. For 
patient groups in which BPs are considered the current standard of care, denosumab was compared with 
BPs only.
A BP class effect was not assumed. As data allowed, all BPs would be included within a NMA.
Best supportive care (excluding bisphosphonates)
Best supportive care was considered a comparator where BPs were not recommended. This varied 
depending on the type of cancer. The relevant NICE CGs are CG81 for advanced breast cancer,45 CG58 
for prostate cancer,46 CG121 for lung cancer48 and CG75 for metastatic SCC.47 All of these guidelines 
recommend radiotherapy and analgesics within BSC. Other recommended supportive care for bone 
metastasis includes surgical fixation in breast cancer and multiple myeloma, strontium-89 in prostate 
cancer and nerve blocks in lung cancer.
Breast cancer
NICE CG81 on breast cancer recommends offering BPs to patients with newly diagnosed bone metastases 
to prevent SREs and to reduce pain.45 Therefore, BSC was not used as a comparator in patients with 
advanced breast cancer and bone metastases. The planned NMA is shown in Figure 1.
Prostate cancer
The NICE guidance, CG58, on prostate cancer recommends that ‘the use of BPs to prevent or reduce the 
complications of bone metastases in men with hormone-refractory prostate cancer is not recommended. 
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Bisphosphonates for pain relief may be considered for men with hormone-refractory prostate cancer when 
other treatments (including analgesics and palliative radiotherapy) have failed’.46 Therefore, in prostate 
cancer denosumab is compared with both BPs and BSC.
Lung cancer
No guideline recommendation for the use of BPs exists for bone metastases from lung cancer. NICE 
CG121 suggested that there was insufficient evidence to recommend BPs as a first-line treatment in bone 
metastases from lung cancer.66 However, the standard treatments such as analgesics, or single-fraction 
radiotherapy, are recommended for the relief of symptoms from bone metastasis.
As the NICE guidelines for prostate and lung cancer recommend BSC before giving a BP, for these patient 
groups we plan to include BSC as a comparator, where data exist. The planned NMA for prostate cancer, 
lung cancer and OSTs is shown in Figure 2.
Other solid tumours
In the protocol we stated that if we obtained enough data on OSTs for which no relevant NICE guidelines 
existed, we would seek expert opinion as to the place of BPs in the clinical pathway.
Denosumab
BPs other than
zoledronic acid
Placebo Zoledronic
acid
Denosumab
Zoledronic
acid
BPs other
than
zoledronic
acid
BSC
Placebo/no
treatment
FIGURE 1 Network meta-analysis for those with bone metastases from breast cancer.
FIGURE 2 Network meta-analysis for those with bone metastases from prostate cancer, lung cancer or OST.
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Expert opinion suggested that BPs, mainly zoledronic acid, were used in OSTs. Therefore, the network 
diagram will be as in Figure 2 and denosumab is compared with both BPs and BSC.
Types of outcomes
These included:
 z time to first on-study SREs (SRE defined as pathological fracture, requirement for radiation therapy to 
bone, surgery to bone, or SCC)
 z time to first and subsequent on-study SRE
 z SMR
 z incidence of SREs
 z prevention of hypercalcaemia
 z overall survival rate
 z pain
 z HRQoL
 z adverse events related to treatment (including hypocalcaemia, ONJ, renal toxicity, 
acute-phase reactions).
Data extraction strategy
Selection of studies
Study selection was made independently by two reviewers (PR, JF) by screening titles, abstracts and full-
text papers. Discrepancies were resolved by discussion. There was no requirement for a third reviewer.
Data extraction and management
Data were extracted from the included studies by one reviewer, using a standardised data extraction form 
(see Appendix 2), and checked by a second. Discrepancies were resolved by discussion. There was no 
need for a third reviewer. Any study data received from the manufacturer’s submission (MS) that met the 
inclusion criteria were extracted and quality was assessed in accordance with the procedures outlined in 
the protocol for the assessment.
Critical appraisal strategy
The quality of the individual studies was assessed by one reviewer, and independently checked for 
agreement by a second reviewer.
The quality of the RCTs was assessed using the Cochrane risk-of-bias tool67 (see Appendix 3), which 
includes the following components:
 z adequate sequence generation
 z allocation concealment
 z blinding
 z incomplete outcome data addressed
 z free of selective reporting.
Any sponsorship or conflict of interests mentioned was recorded.
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Methods of data synthesis
Initially we looked for head-to-head trials of denosumab versus BPs or BSC. Our initial scoping searches 
indicated that at present there were only three published Phase III trials of denosumab that included our 
relevant population. All three use zoledronic acid as a comparator. The three patient groups included in 
the three trials are (1) patients with advanced breast cancer, (2) patients with CRPC and (3) patients with 
advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Therefore, to be able to 
compare denosumab with BPs other than zoledronic acid, or with BSC, the search was widened to allow 
for NMA. This included head-to-head BP trials, placebo-controlled BP trials or BSC-controlled trials.
Assessment of heterogeneity
Trials meeting the inclusion criteria were assessed for heterogeneity. The studies were examined for 
similarity with respect to population, intervention, comparators, outcomes, SRE definition and time frame. 
If trials were sufficiently homogeneous, a NMA of denosumab versus BP and BSC was carried out to pool 
direct and indirect evidence from randomised trials in a single analysis.
Patient groups were analysed separately based on location or type of primary cancer. When sufficient data 
were available, subgroup analyses were performed to examine the effect of treatment depending on the 
type of SRE, history of SREs, prior use of BP, prior type of BSC, different adjuvant therapies, different routes 
of administration of the BPs, and the location of the metastases.
An indirect comparison/NMA was performed as shown in Figure 1 and Figure 2.
Statistical technique of network meta-analysis
The NMAs were carried out using methods for mixed treatment comparisons described by Lu and Ades.68 
The Bayesian software package WinBUGS (MRC Biostatistics Unit, Cambridge, UK), which employs Markov 
chain Monte Carlo methods, was used for the analyses.
Network meta-analyses were conducted for all the cancer types included in this appraisal. Outcomes 
analysed were time to first SRE (HRs), time to first and subsequent SRE (rate ratios from Anderson–Gill38 
multiple event analyses reported in primary studies), SMR ratios (for breast and prostate cancer only) and 
the proportion of patients with at least one on-study SRE. The proportions of patients with a SRE were 
also analysed by SRE type for breast and prostate cancer and by SRE history (SRE naive/experienced) for 
breast cancer.
Fixed effects models were used for time to first SRE, adopting an approach recommended by the NICE 
Decision Support Unit69 for modelling trial-based summary measures, which can be applied to modelling 
HRs on the log hazard scale. The trial-level data included in the models comprised log HRs and their 
standard error. Where HRs were not reported or derivable in the primary study, Kaplan–Meier estimates 
and numbers at risk (if available) were used, applying the methods of Tierney and colleagues70 to estimate 
the HR. Pairwise HRs were estimated from the median of the posterior distribution with credible intervals 
taken from the 2.5% and 97.5% percentiles. Two chains were used in the Markov chain Monte Carlo 
analyses, each with 10,000 simulations following a burn-in of 10,000. The same approach was taken for 
modelling rate ratios in the analysis of time to first and subsequent SREs.
For SMR and proportions of patients with a SRE, random effects models were adopted using arm-based 
data. The data included in the SMR models were mean SMR and standard deviation (SD) along with 
the number of patients. Where SDs were not reported, values were imputed by taking the mean of 
reported SDs from other studies but for the same treatment. The robustness of the imputation was 
tested by comparing results with those obtained by treating missing data as an uncertain parameter. For 
the proportions with a SRE, the numbers of patients and the numbers with a SRE were used. Posterior 
distributions for relative treatment effects were estimated from the absolute risks of outcome from the 
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relevant individual treatments. Median estimates and credible intervals were taken from 10,000 Markov 
chain Monte Carlo simulations after a burn-in of 10,000.
To estimate the absolute risk of outcome in the analyses of arm-based data, it was necessary to include 
an estimate of the baseline risk of the control treatment in the models. Zoledronic acid was treated as the 
reference treatment in each analysis as it is the treatment common to the largest number of trials and 
is present in multiple included studies for each NMA. Single-arm meta-analyses of zoledronic acid were 
conducted to estimate baseline risk, from studies included in the NMA that had zoledronic acid as one of 
its comparators. The data in the time-to-event analyses, however, were trial-based and baseline risk could 
not be estimated, and so the absolute effect of the reference treatment was set to zero in these models.
The quality of the models was examined by inspecting convergence using Gelman–Rubin–Brooks plots, 
assessing autocorrelation between iterations of the Markov chain and checking whether or not the Monte 
Carlo error was less than 5% of the posterior SD.
Methods for estimating quality of life
Quality-of-life data for patients who had experienced bone metastases and SREs were obtained from the 
studies identified from the clinical effectiveness searches, the MS, and the denosumab clinical study reports 
(CSRs). A further systematic review of the effects on quality of life of SREs arising from metastatic bone 
disease and from myeloma bone disease was undertaken (see Chapter 9, Systematic reviews of cost-
effectiveness studies and quality-of-life studies).
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Chapter 4 Results: breast cancer
The clinical effectiveness chapters (see Chapter 4 on breast cancer; Chapter 5 on prostate cancer; Chapter 6 on NSCLC; Chapter 7 on OST excluding NSCLC; and Chapter 8 on OST including NSCLC) 
follow the same structure. Information is provided on the quantity of research available, followed by the 
results and then a summary of the chapter. For the outcomes of time to first on-study SRE, risk of first and 
subsequent on-study SRE, SMR and incidence of SREs, information is also reported, where available, for 
SRE by type, and history of SRE. Towards the end of each chapter there is a separate section reporting the 
results of the NMA. Chapter 6 (on NSCLC) and Chapter 7 (on OST excluding NSCLC) are subgroups of one 
trial. Therefore, Chapter 8 (on OST including NSCLC) has been included to present the outcomes for which 
the trial was powered and outcomes which are not presented within the aforementioned subgroups.
Quantity of research available: overall review of clinical effectiveness
As a single search strategy was designed to identify all potentially relevant studies for the clinical 
effectiveness review, information on the overall numbers of studies is given in the first three sections, as 
well as information specifically relating to breast cancer. The remaining sections focus on breast cancer.
Number and type of studies included
Overall
A flow diagram outlining the screening process for the overall review of clinical effectiveness is shown in 
Figure 3.
The searches identified 989 records, of which 585 were unique studies (after removing duplicates). 
Following screening of titles and abstracts, the full text of 352 articles was obtained for further assessment. 
With the addition of four reports received from the manufacturer, this resulted in 39 studies (74 reports) 
meeting the inclusion criteria for the review of clinical effectiveness (see Appendix 4). However, of these 
39 studies, 31 were not able to contribute data to the AG’s NMA and none reported denosumab, and 
therefore these studies were not reported further in the results chapters. The reasons why they were not 
able to contribute data to the NMA included:
1. studies did not report uniform definition of SREs
2. studies did not report standardised SRE rates
3. studies did not report outcomes separately for different cancer types
4. studies included patient groups where some patients were not diagnosed with bone metastases.
Of these 31 studies, 6 reported on bone metastases from breast cancer,71–76 13 reported on bone 
metastases from prostate cancer77–89 and 12 reported on bone metastases from OSTs.90–101
Of the remaining eight studies that did contribute data to the network meta-analyses, four reported 
breast cancer31,102–104 [18 reports22,31,102–116; and Amgen Ltd. Multiple Technology Appraisal: Denosumab 
for the treatment of bone metastases from solid tumours (unpublished report). London: National Institute 
for Health and Care Evidence; 2011], two reported prostate cancer29,117 (15 reports19,29,117–129) and two 
reported OSTs, excluding breast and prostate cancer30,130 (seven reports30,130–135). Therefore, across the 
review of clinical effectiveness, eight studies (40 reports) contributed data to the NMAs.
All of the included studies were RCTs. No systematic reviews were identified that exactly met our inclusion 
criteria. The ASCO clinical practice guideline update on the role of bone-modifying agents in metastatic 
breast cancer was the most relevant systematic review identified. This review included denosumab, 
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disodium pamidronate and zoledronic acid but did not include ibandronate or clodronate (because they 
are not licensed for this indication in the USA), which, therefore, were not considered further.34
A search of safety-related articles identified 28 additional studies.61,62,136–161
Breast cancer
The primary comparator for denosumab was considered to be BPs (zoledronic acid, disodium pamidronate, 
ibandronic acid or sodium clodronate) as recommended in NICE guideline CG81 for all patients with 
advanced breast cancer and newly diagnosed bone metastases.45
One RCT (10 reports,31,105,106,110–114,116 including CSR 20050136) was identified comparing denosumab with 
zoledronic acid, with the primary published report considered to be that by Stopeck and colleagues.31 An 
additional three studies contributed data to the NMA. One study, by Kohno and colleagues,102 compared 
zoledronic acid with placebo. One study (four reports22,103,107,115) compared disodium pamidronate with 
placebo, with the primary published report considered to be that by Lipton and colleagues.103 One study 
(three reports104,108,109) compared zoledronic acid with disodium pamidronate, with the primary published 
report considered to be the 2003 paper by Rosen and colleagues.104
Additional records identified
through other sources
(n = 9 ASCO abstracts)
Eight studies (40 reports) included
in NMA
39 studies (74 reports) included
Full-text articles assessed for
eligibility
(n = 351)
Records screened
(n = 564)
Records after duplicates removed
(n = 585)
Records identified through
database searching
(n = 980)
Records excluded on
basis of title and abstract
(n = 213)
Full-text articles excluded
(n = 281)
Three clinical study
reports
One EMA 
Full-text articles
excluded from NMA
[n = 31 studies
(34 reports)] 
FIGURE 3 Flow diagram of the searches and screening process.
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Number and type of studies excluded
A list of the 281 potentially relevant studies identified by the search strategy for which full-text papers 
were obtained but which subsequently failed to meet the inclusion criteria is given in Appendix 5. These 
studies were excluded because they failed to meet one or more of the inclusion criteria in terms of the type 
of study, participants, intervention or outcomes reported. Three trials of denosumab, one in patients with 
breast cancer,162 one in patients with prostate cancer163 and one in patients with OSTs,164 were excluded 
because they used mixtures of BPs as a comparator and did not report the outcomes separately for each 
type of BP. Table 1 shows the numbers of studies excluded along with the reasons for their exclusion.
Characteristics of the included studies
Overall
All 31 studies that were excluded from the NMA included comparisons of BPs with placebo or another BP, 
and some compared BSC with placebo or another BSC. Table 2 provides a summary of the interventions 
and comparators included in the trials and a list of studies included or excluded from the NMA. Studies 
meeting the inclusion criteria but not contributing data to the NMA were not reported on in the 
chapters on clinical effectiveness because none provided direct evidence on denosumab compared with 
BPs, placebo or BSC. However, the results from these studies have been presented in appendices; see 
Appendix 6 for the characteristics of the participants and description of the interventions/comparators 
with the reasons for exclusions from the NMA and Appendix 7 for the results of these studies. Appendix 8 
shows the characteristics of the included studies.
Breast cancer
Table 3 shows summary information for the four studies that provided direct evidence for denosumab or 
were included in the NMA. The study by Kohno and colleagues102 was undertaken between May 2000 
and May 2003 and enrolled adults with at least one osteolytic bone metastasis from breast cancer from 
51 centres in Japan. Patients received 4 mg zoledronic acid or placebo every 4 weeks for 12 months. The 
TABLE 1 Studies excluded from the review after full-text screening
Reasons for exclusion Number of studies 
Not a RCT 93
Reviews 69
Other study design 24
Comparing doses of radiotherapy 23
Not a relevant patient group 26
Dose-ranging study 21
Not a required dose used 17
No relevant outcomes 30
Economic study 10
Adjuvant use of drug 20
No relevant comparators 7
No relevant interventions 18
Multiple myeloma patient group 14
Treatment of hypercalcaemia 2
Total 281
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TABLE 2 Summary of interventions and comparators in the included RCTs
Comparison
No. of 
studies
Primary 
tumour Intervention Comparator Study ID
Included in NMA (n = 8)
Denosumab vs 
zoledronic acid 
3 Breast Denosumab (s.c.) Zoledronic acid (i.v.) Stopeck 201031
Prostate Denosumab (s.c.) Zoledronic acid (i.v.) Fizazi 201129
NSCLC 
(subgroup)
Denosumab (s.c.) Zoledronic acid (i.v.) Henry 201130
OST Denosumab (s.c.) Zoledronic acid (i.v.) Henry 201130
BPs vs placebo/another 
BP 
5 Breast Zoledronic acid (i.v.) Placebo Kohno 2005102
Breast Zoledronic acid (i.v.) Disodium 
pamidronate (i.v.)
Rosen 2003a104
Breast Disodium pamidronate (i.v.) Placebo Lipton 2000103
Prostate Zoledronic acid (i.v.) Placebo Saad 2002117
NSCLC 
(subgroup)
Zoledronic acid (i.v.) Placebo Rosen 2003b130
OST Zoledronic acid (i.v.) Placebo Rosen 2003b130
Excluded from NMA (n = 31)
BP vs placebo/another 
BP
27 Breast Ibandronate (oral) Placebo Body 200472
Ibandronate (i.v.) Placebo Body 200371
Ibandronate (i.v.) Placebo Heras 200974
Clodronate (oral) Placebo Elomaa 198873
Clodronate (oral) Placebo Paterson 199376
Clodronate (oral) Open Kristensen 199975
Clodronate (oral) Placebo Dearnaley 200379 
Prostate Clodronate (i.v.) Placebo Elomaa 199280
Clodronate (i.v.) Open Kylmala 199382
Clodronate (i.v.) Placebo Ernst 200381
Clodronate 
(i.v. + i.m. + oral)
Placebo Adami 198977
Clodronate (i.v. + oral) Placebo Kylmala 199783
Clodronate (i.v.) Placebo Strang 199789
Disodium pamidronate (i.v.) Placebo Small 200387
Etidronate (i.v. + oral) Placebo Smith 198988
Clodronate (oral) Placebo Arican 199990
OST Clodronate (oral) Placebo Brown 200792
Clodronate (oral) Placebo O’Rourke 199596
Clodronate (oral) Placebo Piga 199897
Clodronate (oral) Placebo Robertson 199598
Clodronate (oral) Disodium 
pamidronate (i.v.)
Jagdev 200194
Ibandronate (oral) Ibandronate (i.v.) Mystakidou 200895
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Comparison
No. of 
studies
Primary 
tumour Intervention Comparator Study ID
Ibandronate (i.v.) Placebo Heras 200793
Zoledronic acid (i.v.) Placebo Lipton 2003101
Zoledronic acid (i.v.) Disodium 
pamidronate (i.v.)
Berenson 200191
Zoledronic acid (i.v.) Placebo Zaghloul 201099
Zoledronic acid (i.v.) Open Zhao 2011100
BSC vs placebo/another 
BSC
4 Prostate Strontium chloride (i.v.) Placebo Buchali 198878
 Strontium chloride (i.v.) FEM Nilsson 200584
Strontium chloride (i.v.) Placebo Porter 199385
Strontium chloride (i.v.) Radiotherapy Quilty 199486
FEM, 5-fluorouracil, epirubicin and mitomycin C; i.m., intramuscular; i.v., intravenous; s.c., subcutaneous.
TABLE 2 Summary of interventions and comparators in the included RCTs (continued)
primary outcome was the ratio of the SRE rate (defined as the total number of SREs divided by the total 
years on study) for patients treated with zoledronic acid divided by the SRE rate for the placebo group. 
Follow-up was 52 weeks. The study was funded by Novartis.
The study by Lipton and colleagues103 reports results of two similarly conducted RCTs.22,115 The studies 
were undertaken between 1990 and 1996 and enrolled women with stage IV breast cancer and at least 
one predominantly lytic metastatic bone lesion measuring ≥ 1 cm from 106 centres in the USA, Canada, 
Australia and New Zealand. Patients received 90 mg disodium pamidronate every 3–4 weeks or placebo 
every 4 weeks for 24 cycles. The primary outcome was the SMR, defined as the ratio of the number of 
skeletal complications experienced by a patient divided by the time on the trial for that patient (expressed 
as the number of events per year). Follow-up was 24 months. The study was funded by Novartis.
The study by Rosen and colleagues104 was undertaken between October 1998 and January 2000 and 
enrolled women with at least one bone metastasis (osteolytic, osteoblastic, or mixed) secondary to stage 
IV breast cancer. The primary analysis of this study included advanced multiple myeloma, but a subgroup 
of those patients with breast cancer is presented separately.110 The study was described as multicentre and 
international. Patients received 4 mg zoledronic acid or 90 mg disodium pamidronate every 3–4 weeks for 
24 months. Zoledronic acid was initially infused over 5 minutes in 50 ml of hydration solution. However, 
because of concerns over renal safety a protocol amendment in June 1999 changed the infusion time to 
15 minutes and increased the volume of the infusion to 100 ml. The primary outcome was the proportion 
of patients who experienced at least one SRE during the study period. Follow-up was 25 months. The 
study was funded by Novartis.
The study by Stopeck and colleagues31 was undertaken between April 2006 and December 2007 and 
enrolled women with confirmed breast cancer and at least one bone metastasis from 322 centres in 
Europe, North America, South America, Japan, Australia, India and South Africa. However, few (academic-
in-confidence information has been removed) of patients were from the UK (MS). Patients with creatinine 
clearance < 30 ml/minute, prior intravenous BP treatment, current or prior oral BPs for the treatment of 
bone metastases, non-healed dental/oral surgery and prior malignancy within 3 years before random 
assignment were excluded. Patients received a subcutaneous injection of 120 mg denosumab and an 
intravenous infusion of placebo or an intravenous infusion of 4 mg zoledronic acid and a subcutaneous 
injection of placebo every 4 weeks. The study was powered to detect both non-inferiority and superiority 
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with respect to time to first on-study SRE (primary outcome), and risk of first and subsequent on-study 
SREs. Follow-up was around 34 months. The study was funded by Amgen and Daiichi Sankyo.
Quality of the included studies
Table 4 shows the results of the risk of bias assessment for the four studies that were included in the NMA. 
See Appendix 9 for risk of bias assessment for other included studies.
The study by Lipton and colleagues103 used computer-generated randomisation, whereas the study 
by Rosen and colleagues104 reported an automated system and the study by Kohno and colleagues102 
employed a dynamic balancing method. Although the study by Stopeck and colleagues31 was described 
as randomised, no further details were given of the sequence generation or allocation concealment. In 
the study by Lipton and colleagues103 patients, investigators and other study personnel were blinded, 
the study by Kohno and colleagues102 involved blinded radiographic assessment and the studies by 
Stopeck and colleagues31 and Rosen and colleagues104 were described as double blind. The study by 
Kohno and colleagues102 did not provide an explanation as to the reasons why around 33% of patients 
in the zoledronic acid group and 36% in the placebo group did not complete the study. It was unclear 
in the study by Lipton and colleagues103 whether or not the issue of incomplete outcome data had been 
addressed (reasons for discontinuation stated but number discontinued not given for one trial; Hortobagyi 
and colleagues 199622) or whether or not the study was free of selective reporting of outcomes (the 
stated primary end point and end point for power calculation were different for one trial; Theriault and 
colleagues 1999115).
Assessment of effectiveness
This section reports the clinical effectiveness and safety of denosumab for the treatment of bone 
metastases from breast cancer compared with BPs or placebo for those comparative studies included in the 
NMA. See Appendix 7 for the results for the following outcomes reported by those studies comparing BPs 
with placebo that were not included in the NMA.
Time to first on-study skeletal-related event
Table 5 shows the results for time to first on-study SRE as reported in the studies by Lipton and 
colleagues,103 Kohno and colleagues,102 Stopeck and colleagues31 and Rosen and colleagues.104
In the study by Stopeck and colleagues,31 median time to first on-study SRE was not reached in the 
denosumab group compared with a median of 26.4 months in the zoledronic acid group during 
approximately 34 months of follow-up [HR 0.82; 95% confidence interval (95% CI) 0.71 to 0.95; 
p ≤ 0.0001]. Figure 4 shows the Kaplan–Meier estimates of the time to first on-study SRE. The MS reported 
that denosumab reduced the risk of a symptomatic SRE (academic-in-confidence information has been 
removed) and reduced the proportion of patients with symptomatic SREs (academic-in-confidence 
information has been removed). After an extended 4 months of blinded follow-up, Stopeck and 
TABLE 4 Results of the risk of bias assessment
Risk of bias criteria Kohno 2005102 Lipton 2000103 Rosen 2003a104 Stopeck 2010a31
Adequate sequence generation Yes Yes Yes Unclear
Adequate allocation concealment Yes Yes Yes Unclear
Blinding Yes Yes Yes Yes 
Incomplete outcome data 
addressed
No Unclear Yes Yes 
Free of selective reporting Yes Unclear Yes Yes
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colleagues31 reported that the median time to first on-study SRE was longer in the denosumab group 
compared with the zoledronic acid group by 5 months (32.4 vs 27.4 months).
The median time to first on-study SRE was significantly longer in the BPs group compared with the placebo 
group in the study by Kohno and colleagues102 (not reached vs approximately 12 months; p = 0.007) and 
Lipton and colleagues103 [12.7 (95% CI 9.6 to 17.2) vs 7.0 (95% CI 6.2 to 8.5) months; p < 0.001]. The 
median time to first SRE was similar in the BPs groups as reported in trials by Lipton and colleagues103 
(12.7 months) and Rosen and colleagues104 (~ 11.6 to 13.8 months). There was no difference in the time 
to first SRE including or excluding hypercalcaemia as reported in the trial by Kohno and colleagues.102
TABLE 5 Results for time to first on-study SRE
Study 
ID Outcomes Measures 
Values
p-valueIntervention Comparator
Denosumab 
(n = 1026)
Zoledronic acid 
(n = 1020)
aStopeck 
201031
Time to first SRE (~ 34 months’ 
study duration)
Median months Not reached 26.4 NA
Time to first SRE (from 4 months’ 
extended treatment phase) 
Median months 32.4 27.4 NA
Delay to first on-study SRE HR (95% CI) 0.82 (0.71 to 0.95) p < 0.01 
(superiority 
analysis)
Zoledronic 
acid (n = 114)
Placebo (n = 113)
bKohno 
2005102 
Time to first SRE (excluding HCM) Median days Not reached 364 
(~12.1 months)
0.007
Time to first SRE (including HCM) Median days Not reached 360 (~12 months) 0.004
Disodium 
pamidronate 
(n = 367)
Placebo (n = 387)
Lipton 
2000103
Time to any first SRE Median months 
(95% CI)
12.7 (9.6 to 
17.2)
7.0 (6.2 to 8.5) < 0.001
Time to first pathological fracture Median months 25.2 12.8 0.003
Time before requiring bone radiation Median months Not reached 16.0 < 0.001
Zoledronic 
acid (n = 378)
Disodium 
pamidronate 
(n = 388)
Rosen 
2003a104 
Time to first SRE (chemotherapy 
treated)
Median days 349 
(~ 11.6 months)
366 
(~ 12.2 months)
0.826
Time to first SRE (hormone therapy 
treated)
Median days 415 
(~ 13.8 months)
370 
(~ 12.3 months) 
0.047
Time to first SRE (lytic) Median days 310 
(~ 10.3 months)
174 
(~ 5.8 months)
0.013
Time to first SRE (non-lytic) Median days NR NR NR
NA, not applicable; NR, not reported; NS, not significant.
a Cox proportional hazards model with treatment group as the independent variable and stratified by the 
randomisation factors. 
b Cox regression (Wald test of the regression coefficient) stratified by prior fracture. 
One month = 30 days.
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Skeletal-related events by type
In the denosumab RCT Stopeck and colleagues31 did not report SRE by type. The MS reported that 
denosumab reduced the risk for time to radiation in bone by (academic-in-confidence information has 
been removed) compared with zoledronic acid. Table 6 shows the distribution of first on-study SRE by type 
of SRE in the denosumab study. The distribution of type of SRE was similar across the treatment groups, 
with radiation to bone and pathological fracture being the most commonly occurring.
In the study by Lipton and colleagues,103 the median time to first pathological fracture was significantly 
longer in the disodium pamidronate group compared with the placebo group (by almost 12 months). The 
time before requiring bone radiation was not reached in the disodium pamidronate group compared with 
a median of 16 months in the placebo group (p < 0.001).103
History of skeletal-related events
The MS reported time to first on-study SRE by history of SRE for the denosumab study 136 (Table 7). 
This showed that for those without a prior SRE (academic-in-confidence information has been removed). 
Covariate analysis showed that patients with a prior SRE history had an increased risk (academic-in-
confidence information has been removed) compared with those without a SRE history.
The study by Rosen and colleagues,104 comparing zoledronic acid with disodium pamidronate, reported 
time to first on-study SRE by lytic and non-lytic subgroup. There was no significant difference between the 
non-lytic treatment groups. For those lytic cases, the time to first SRE was much longer in the zoledronic 
acid (~ 10.3 months) group compared with the disodium pamidronate group (~ 5.8 months).
Risk of first and subsequent on-study skeletal-related events
Table 8 shows the results for risk of first and subsequent on-study SREs.
Stopeck and colleagues31 reported a risk reduction of 23% [relative risk (RR) 0.77; 95% CI 0.66 to 0.89; 
p = 0.001] for the denosumab group compared with the zoledronic acid group over 34 months, with the 
risk remaining similar when the duration of treatment was extended by another 4 months (RR 0.78; 95% 
CI 0.68 to 0.90; p = 0.002). Figure 5 shows the cumulative mean number of SREs (multiple-event analysis).
Kohno and colleagues102 and Rosen and colleagues104 reported the risk for developing multiple SREs 
for zoledronic acid compared with placebo and disodium pamidronate, respectively. In both studies, 
zoledronic acid significantly reduced the risk of developing multiple SREs when HCM was included in the 
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Stopeck et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with 
advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132–39.30
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SRE analysis (44% reduction compared with placebo102 and approximately 20% reduction compared with 
disodium pamidronate).104 Similar results were reported when HCM was excluded from the SRE analysis 
(the risk of developing multiple SREs was 41% lower in the zoledronic group compared with the placebo 
group and 20% lower compared with the disodium pamidronate group).
Skeletal-related events by type
None of the studies reported risk of first and subsequent SREs by individual SRE type.
The MS reported the distribution of first and subsequent on-study SRE by type of SRE in the denosumab 
RCT (study 136) (Table 9). As for first on-study SRE by type, the distribution of type of SRE was 
TABLE 6 Patients with first on-study SRE by type
SRE
Denosumab (n = 1026 randomised) Zoledronic acid (n = 1020 randomised)
Number of events (%) Number of events (%)
Overall 315 (100%) 372 (100%)
Radiation to bone AiC information has been removed AiC information has been removed
Pathological fracture AiC information has been removed AiC information has been removed
SCC AiC information has been removed AiC information has been removed
Surgery to bone AiC information has been removed AiC information has been removed
AiC, academic-in-confidence.
Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
TABLE 7 Time to first on-study SRE by prior history of SRE
SRE history Denosumab Zoledronic acid
Overall
Number 1026 1020
HRa (95% CI) 0.82 (0.71 to 0.95)
p-value 0.0101
No prior SRE
Number 648 647
HR (95% CI) AiC information has been removed
p-value AiC information has been removed
Prior SRE
Number 378 373
HR (95% CI) AiC information has been removed
p-value AiC information has been removed
Covariate effect
Point estimate (95% CI) AiC information has been removed
p-value AiC information has been removed
AiC, academic-in-confidence.
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similar across the treatment groups, with radiation to bone and pathological fracture again the most 
commonly occurring.
Prior history of skeletal-related events
The MS reported risk of first and subsequent on-study SRE by history of SRE for study 136 (Table 10). 
(Academic-in confidence information has been removed.) Covariate analysis as presented in the 
manufacturer’s table showed that patients with a history of SRE had an increased risk (academic-in 
confidence information has been removed) compared with those without a SRE history.
TABLE 8 Results for risk of first and subsequent on-study SRE
Study 
ID
Treatment 
duration Outcomes Measures 
Values, variance
p-valueIntervention Comparator
Denosumab 
(n = 1026)
Zoledronic 
acid (n = 1020)
Stopeck 
201031
~ 34 months Risk of developing multiple 
SREs
Rate ratio 
(95% CI)
0.77 (0.66 to 0.89) 0.001
From 4 months’ 
extended 
treatment phase
Risk of first and subsequent 
on-study SRE 
Rate ratio 
(95% CI)
0.78 (0.68 to 0.90) 0.002
Zoledronic 
acid (n = 114)
Placebo 
(n = 113)
Kohno 
2005102
12 months Risk for developing SREs 
(multiple-event analysis)
Excluding HCM
Risk ratio 
(95% CI)
0.59 (0.375 to 0.914) 0.019a
Risk for developing SREs 
(multiple-event analysis)
Including HCM
Risk ratio 
(95% CI)
0.56 (0.363 to 0.867) 0.009a
Zoledronic 
acid (n = 378)
Disodium 
pamidronate 
(n = 388)
Rosen 
2003a104 
25 months Risk of developing any SRE 
(multiple-event analysis)
Including HCM
Risk ratio 
(95% CI)
0.799 (0.657 to 0.972) 0.025
25 months Risk of developing a SRE
Including HCM; hormone 
therapy treated
Risk ratio 
(95% CI)
0.693 (0.527 to 0.911) 0.009
13 months Risk for multiple skeletal 
events (total)
Excluding HCM
HR (95% 
CI)
0.801 (Not reported) 0.037
13 months Risk for multiple skeletal 
events (lytic) excluding HCM
HR (95% 
CI)
0.704 (Not reported) 0.010
13 months Risk for multiple skeletal 
events (non-lytic) excluding 
HCM
Not 
reported
Not reported 0.760
a Wald test of the regression coefficient, stratified by prior fracture.
FIGURE 5 Cumulative mean number of SREs (multiple-event analysis). (Academic-in-confidence information has been 
removed.) Source: MS.
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Skeletal morbidity rate
Table 11 shows the results for SMR. The SMR is defined as the ratio of the number of SREs per patient 
divided by the patient’s time at risk. The MS stated that for the SMR calculations a 21-day event window 
was used for counting on-study SREs, so that any event occurring within 21 days of a previous event was 
not counted as a separate on-study SRE.
Stopeck and colleagues31 reported that the mean SMR (ratio of the number of SREs per patient divided 
by the patient’s time at risk) was significantly lower in the denosumab group (0.45 events per patient per 
year) compared with the zoledronic acid group (0.58 events per patient per year) (p = 0.004). The studies 
by Kohno and colleagues102 and Lipton and colleagues103 comparing BPs with placebo reported that SRE 
TABLE 9 Distribution of first and subsequent SRE by type: with 21-day window
SRE
Denosumab (n = 1026 randomised) Zoledronic acid (n = 1020 randomised)
Number of events (%) Number of events (%)
Total confirmed events AiC information has been removed AiC information has been removed
Radiation to bone AiC information has been removed AiC information has been removed
Pathological fracture AiC information has been removed AiC information has been removed
SCC AiC information has been removed AiC information has been removed
Surgery to bone AiC information has been removed AiC information has been removed
AiC, academic-in-confidence.
Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
TABLE 10 Risk of first and subsequent on-study SRE by history of SRE
SRE history Denosumab Zoledronic acid
Overall
Number 1026 1020
Rate ratio (95% CI) AiC information has been removed
p-value AiC information has been removed
No prior SRE
Number 648 647
Rate ratio (95% CI) AiC information has been removed
p-value AiC information has been removed
Prior SRE
Number 378 373
Rate ratio (95% CI) AiC information has been removed
p-value AiC information has been removed
Covariate effect
Point estimate (95% CI) AiC information has been removed
p-value AiC information has been removed
AiC, academic-in-confidence.
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events occurred less frequently in the BPs group (0.63 to 2.4 events per year) than in the placebo group 
(1.1 to 3.7 events per year). In the study by Rosen and colleagues104 the SMR rate was lower for zoledronic 
acid compared with disodium pamidronate (0.9 events per year vs 1.49 events per year), although the 
difference was not statistically significant (p = 0.125). In the study by Kohno and colleagues102 the rate 
of SREs was reduced by 39% (0.61; p = 0.027) in the zoledronic acid group compared with the placebo 
group when adjusted for whether or not patients had experienced prior pathological fracture before study 
entry. A similar SMR was reported when HCM was included or excluded from the analysis in the studies by 
Lipton and colleagues103 and Rosen and colleagues.104
Skeletal-related events by type
The MS did not report SMR by type of SRE.
The study by Lipton and colleagues103 comparing disodium pamidronate with placebo reported SMR for 
different types of SREs including radiation to bone, radiation to bone for pain relief, pathological fracture, 
surgery to bone, SCC and hypercalcaemia. A statistically significant difference was reported between 
disodium pamidronate and placebo for all types of SRE other than SCC. Among all the SREs, the highest 
rate (events per year) was reported for pathological fracture (1.6 vs 2.2) and the lowest rate was reported 
for SCC (0.07 vs 0.37).
Prior history of skeletal-related events
The MS did not report SMR by prior history of SREs.
In the study by Kohno and colleagues102 the SRE rate reduction for zoledronic acid was more than 30% 
higher in patients without a prior fracture (unadjusted SRE rate ratio 0.43) than in patients with a prior 
fracture (unadjusted SRE rate ratio 0.81).
In the subgroup analysis of patients with lytic lesions, Rosen and colleagues104 reported SRE rates in the 
zoledronic acid arm (1.16 events per year) that were almost half of those in the disodium pamidronate 
arm (2.36 events per year; p = 0.008). In those with non-lytic lesions, the difference between the 
treatment groups for SRE rate was reported to be non-significant (0.81 vs 0.97; p = 0.904).
Incidence of skeletal-related events
Table 12 shows the results for the crude incidence of SREs.
Stopeck and colleagues31 reported that at approximately 34 months of treatment, 30.7% of those receiving 
denosumab compared with 36.5% receiving zoledronic acid experienced any on-study SRE. The MS 
reported an annualised SRE rate based on the number of SREs observed in each treatment arm divided by 
the number of patient-years for each treatment arm and reported this outcome both with and without a 
21-day event window.
Table 13 shows the annualised SRE rate both with and without the 21-day window for study 136. The 
MS reported that the primary analysis of annualised SRE rates was based on all SREs reported in each arm 
of the study (calculated without a 21-day window). Subsequently, a post-hoc analysis of the annualised 
SRE rate applying the trial-defined 21-day window for SREs was conducted. Both analyses show that 
the annualised SRE rate was lower in patients receiving denosumab compared with those receiving 
zoledronic acid.
A statistically significant difference in favour of BPs compared with placebo for patients experiencing 
an on-study SRE was reported in the studies by Kohno and colleagues102 and Lipton and colleagues.103 
The proportion of patients experiencing at least one on-study SRE at 1 year was significantly lower by 
20% in the zoledronic acid group compared with the placebo group (29.8% vs 49.6%) in the study by 
Kohno and colleagues.102 In the study by Lipton and colleagues,103 at 2 years, the disodium pamidronate 
group experienced a lower rate of SREs compared with the placebo group (51% vs 64%). Rosen and 
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colleagues,104 comparing zoledronic acid with disodium pamidronate, reported a non-significant difference 
between the groups for the crude incidence of SREs at 13 or 25 months. Rosen and colleagues104 further 
reported non-significant difference in the crude incidence of SREs between zoledronic acid and disodium 
pamidronate for those with lytic lesion. For those with non-lytic lesion a similar crude incidence was 
reported between the groups.
TABLE 12 Crude incidence of on-study SREs
Study ID Outcomes Measures 
Values, variance
p-valueIntervention Comparator
Denosumab 
(n = 1026)
Zoledronic 
acid (n = 1020)
Stopeck 
201031
Proportion of patients who experienced any 
on-study SRE 
At 34 months 30.7% 36.5% NR
Zoledronic 
acid (n = 114)
Placebo 
(n = 113)
Kohno 
2005102
Proportion of patients with at least one SRE 
(excluding HCM)
At 1 year 29.8% 49.6% 0.003
Proportion of patients with at least one SRE 
(including HCM)
30.7% 52.2% 0.001
Proportion with fractures At 1 year 25.4% 38.9% NR
Proportion with radiation to bone At 1 year 8.8% 17.7% NR
Proportion with surgery to bone At 1 year 0.0% 0.9% NR
Proportion with SCC At 1 year 3.5% 11.5% NR
Proportion with hypercalcaemia At 1 year 2.6% 8.8% NR
Disodium 
pamidronate 
(n = 367)
Placebo 
(n = 387) 
Lipton 
2000103
Proportion with any SRE (excluding HCM) At 2 years 51% 64% < 0.001
Proportion with any SRE (including HCM) At 2 years 53% 68% < 0.001
Proportion with radiation to bone At 2 years 29% 43% < 0.001
Proportion with radiation to bone for pain 
relief
At 2 years 25% 37% < 0.001
Proportion with pathological fracture At 2 years 40% 52% 0.002
Proportion with surgery to bone At 2 years 6% 11% 0.008
Proportion with SCC At 2 years 3% 3% 0.762
Proportion with hypercalcaemia At 2 years 6% 13% 0.001
Zoledronic 
acid (n = 378) 
Disodium 
pamidronate 
(n = 388)
Rosen 
2003a104 
Proportion with any SRE (excluding HCM) At 25 months 46% 49% NR
At 13 months 43% 45% NS
Proportion with any SRE: lytic subgroup At 13 months 48% 58% 0.58
Proportion with any SRE: non-lytic subgroup At 13 months 38% 36% NR
NR, not reported; NS, not significant.
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Skeletal-related events by type
The MS did not report this outcome.
The studies by Kohno and colleagues102 and Lipton and colleagues103 reported the proportions of patients 
experiencing types of SRE at 1 year and 2 years, respectively. For each type of SRE reported (other than 
for SCC in the study by Lipton and colleagues103), the BP group experienced lower rates compared with 
placebo. In the study by Lipton and colleagues,103 the difference between the treatment groups for each 
type of SRE was statistically significant other than for SCC. In both studies the most frequently occurring 
type of SRE was fractures (25.4% vs 39.8% at 1 year in the study by Kohno and colleagues102 and 40% vs 
52% at 2 years in the study by Lipton and colleagues103), followed by radiation to the bone.
In a subgroup analysis comparing patients with lytic and non-lytic lesions, Rosen and colleagues104 
reported a non-significant difference for the proportion experiencing a SRE between zoledronic acid and 
disodium pamidronate in each subgroup at 13 months.
Prior history of skeletal-related events
None of the studies reported incidence of SRE by prior history of SREs.
Prevention of hypercalcaemia
In study 136, (academic-in-confidence information has been removed) (CSR 136).
Kohno and colleagues102 reported that 2.6% (3/114) of the zoledronic acid group and 8.8% (10/113) of 
the placebo group experienced hypercalcaemia.
Overall survival
A non-significant difference in overall survival was reported for denosumab compared with zoledronic acid 
in the study by Stopeck and colleagues31 (HR 0.95; 95% CI 0.81 to 1.11; p = 0.49). The MS reported this 
(academic-in-confidence information has been removed) for denosumab versus (academic-in-confidence 
information has been removed) for zoledronic acid (MS). In the study by Lipton and colleagues103 overall 
median survival was slightly longer in the disodium pamidronate group (19.8 months) compared with 
the placebo group (17.8 months) although the difference was not statistically significant (p = 0.976). 
In a subgroup analysis of women < 50 years Lipton and colleagues103 reported a significantly longer 
median overall survival in the disodium pamidronate group compared with the placebo group (24.6 vs 
15.7 months; p = 0.009).
TABLE 13 Annualised SRE rate in study 136
Annualised SRE rate per 
patient Denosumab (n = 1026) Zoledronic acid (n = 1020)
Subject years AiC information has been removed AiC information has been removed
Without 21-day window
Number of events AiC information has been removed AiC information has been removed
Annualised rate AiC information has been removed AiC information has been removed
With 21-day window
Number of events AiC information has been removed AiC information has been removed
Annualised rate AiC information has been removed AiC information has been removed
AiC, academic-in-confidence.
Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
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Prior history of skeletal-related events
None of the studies reported overall survival by prior history of SREs.
Pain
Stopeck and colleagues31 reported the proportion of patients with no/mild pain at baseline (n = 1042) 
developing moderate/severe pain at study visits for up to 73 weeks. The severity of pain and interference 
with daily functioning were assessed using the Brief Pain Inventory-Short Form (BPI-SF) instrument, 
completed by patients at baseline, day 8 and before each monthly visit through to the end of the study. In 
each study visit week, the proportion of patients with no/mild pain at baseline, reporting moderate/severe 
pain was lower in the denosumab group (range 14.8% at 73 weeks to 19.9% at 25 weeks) compared 
with the zoledronic acid group (range 22.1% at 13 weeks to 27.4% at 37 weeks). The median time to 
developing moderate/severe pain in patients with no/mild pain at baseline was reported to be significantly 
longer in the denosumab group compared with the zoledronic acid group (295 vs 176 days; HR 0.78; 95% 
CI 0.67 to 0.92; p = 0.0024).
The median time to worsening pain (≥ 2-point increase from baseline in BPI-SF worst pain score) non-
significantly favoured denosumab compared with zoledronic acid (8.5 vs 7.4 months, p = 0.822) and was 
similar between groups for time to pain improvement (median 82 days vs 85 days; HR 1.02; 95% CI 0.91 
to 1.15; p = 0.7245).
(Academic-in-confidence information has been removed) (MS).
There was no statistical difference at study end point in the use of strong analgesics in breast cancer 
(academic-in-confidence information has been removed) (MS).
(Academic-in-confidence information has been removed) (CSR 136).
Lipton and colleagues103 reported, for disodium pamidronate compared with placebo, mean change in 
pain scores and analgesic scores from baseline to 24 months. Bone pain was evaluated using a scoring 
system that quantified both severity and frequency of bone pain.103 The bone pain score was determined 
by multiplying the bone pain severity score by the bone pain frequency score. The mean pain score 
decreased significantly in the disodium pamidronate group (–0.07; SD 3.07) compared with the placebo 
group (1.14; SD 3.42) over the 24 months (p = 0.015). Similarly, the mean analgesic score decreased 
significantly in the disodium pamidronate group (–0.06; SD 3.28) compared with the placebo group (1.84; 
SD 3.73). At the last visit mean pain score and analgesic score were increased in both groups, but was 
significantly lower in the disodium pamidronate group compared with the placebo group (p < 0.001).
Health-related quality of life
Functional Assessment of Cancer Therapy
The Functional Assessment of Cancer Therapy – Breast (FACT-B) questionnaire consists of the Functional 
Assessment of Cancer Therapy -General (FACT-G) questionnaire plus additional questions specific to breast 
cancer. For each component of the FACT-B [FACT-G total score, FACT-B total score, physical well-being 
domain, functional well-being domain and trial outcome index (TOI): a composite of the functional 
well-being domain, physical well-being domain, and the prostate cancer subscale], a higher score indicates 
better HRQoL.
Stopeck and colleagues31 reported quality of life using the FACT-G questionnaire completed by patients at 
baseline, day 8, and before each monthly visit through to the end of the study (73 weeks). At 73 weeks 
30% of patients had discontinued the study (academic-in-confidence information has been removed) 
(CSR 136).
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Patients were divided into two subgroups at baseline: no/mild pain or moderate/severe pain, based on 
BPI. For those with no/mild pain at baseline, an average of 4.1% more patients (range –0.6% to 9.3%) 
treated with denosumab had a ≥ 5-point increase in the FACT-G score and an average of 2.4% fewer 
patients (range –4.4% to 6.3%) had a ≥ 5-point decrease in the FACT-G score at 18 months compared 
with those patients treated with zoledronic acid. For those with moderate/severe pain at baseline, a similar 
proportion of patients treated with denosumab had either a ≥ 5-point increase (average 3% more; range 
–1.7% to 7.9%) or a ≥ 5-point decrease (average 3.5% fewer; range –1.1% to 11.5%) in the FACT-G score 
at 18 months compared with those treated with zoledronic acid.106 An average of 3.2% (range 1% to 7%) 
more patients in the denosumab group experienced a clinically meaningful improvement in quality of life 
(≥ 5-point increase in FACT-G total score) from week 5 through to week 73.105
European Quality of Life-5 Dimensions
For both components of EQ-5D [the health index and the visual analogue scale (VAS)], a higher score 
indicates a more preferred health status. For the health index questions of the EQ-5D, a three-level 
response was used to assess quality of life (academic-in-confidence information has been removed) 
(CSR 136).
(Academic-in-confidence information has been removed) (CSR 136).
Lipton and colleagues,103 comparing disodium pamidronate with placebo, reported mean change in the 
quality-of-life scores from baseline to 24 months and to the last visit. Quality of life was evaluated using 
the Spitzer quality-of-life index. From baseline to the last visit quality of life worsened in both the disodium 
pamidronate group (–1.80; SD 2.81) and the placebo group (–2.13; SD 2.63) (p = 0.088).
Adverse events related to treatment
Hypocalcaemia
The MS reported that hypocalcaemia events were mainly non-serious and transient and resolved either 
spontaneously or with calcium supplementation (MS). More hypocalcaemia adverse events occurred in the 
denosumab group than in the zoledronic acid group [5.5% (56/1020) vs 3.4% (34/1013) respectively].
Kohno and colleagues102 reported that 39% of the zoledronic acid group and 7% of the placebo 
group experienced grade 1 hypocalcaemia. There were no grade 2 or 3 hypocalcaemia events in the 
zoledronic acid group, while one patient in each group experienced grade 4 hypocalcaemia.102 Lipton 
and colleagues,103 comparing disodium pamidronate with placebo, reported that one patient (1/367) 
discontinued disodium pamidronate after a symptomatic hypocalcaemia episode. Rosen and colleagues104 
did not report this outcome in their study comparing zoledronic acid with disodium pamidronate.
An observational study165 reported on 177 patients receiving BPs over 13 months. They found the 
incidence of hypocalcaemia to be 15.8% in patients treated with zoledronic acid over this period. However, 
this study included all grades of hypocalcaemia.
Osteonecrosis of the jaw
The rates of ONJ in the denosumab RCT were low and similar between the denosumab group and the 
zoledronic acid group [2.0% (20/1020) vs 1.4% (14/1013); p = 0.39].31 The cumulative incidence of ONJ 
in the denosumab and zoledronic acid groups, respectively, was 0.8% and 0.5% at 1 year, 1.9% and 1.2% 
at 2 years, and 2.0% and 1.4% at 3 years.31 Stopeck and colleagues31 reported that, as of February 2010, 
10 (50%) denosumab-treated patients and six (43%) zoledronic acid-treated patients had resolution of 
the ONJ event; 10 (50%) denosumab-treated patients and nine (64%) zoledronic acid-treated patients 
reported local infection; and seven patients in each group (35%, denosumab; 50%, zoledronic acid) 
reported undergoing limited surgical procedures such as debridement and sequestrectomy.
None of the other RCTs or observational studies reported ONJ.
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Renal toxicity
In the denosumab RCT, a statistically significant lower rate of adverse events potentially associated with 
renal impairment occurred in the denosumab group compared with the zoledronic acid group [4.9% 
(50/1020) vs 8.5% (86/1013), respectively; p = 0.001].31 Stopeck and colleagues31 also reported that the 
rates of severe and serious adverse events (SAEs) associated with renal impairment were also lower for 
denosumab than for zoledronic acid (0.4% vs 2.2%, and 0.2% vs 1.5%, respectively). The incidence of 
renal adverse events among patients with baseline renal clearance ≤ 60 ml/minute was also lower in the 
denosumab group (5.9%) than in the zoledronic acid group (20.0%), and a greater proportion of patients 
had decreases in their baseline creatinine clearance from ≥ 60 ml/minute to < 60 ml/minute with zoledronic 
acid (16.1%) compared with denosumab (12.7%).31
It should be noted that, as zoledronic acid is contraindicated in patients with poor renal function, 
such patients were excluded from the denosumab study. The manufacturer stated that the incidence 
of renal toxicity observed in the denosumab group represented a background rate for patients with 
advanced cancer, as such patients were predisposed to renal dysfunction, for example through the use of 
nephrotoxic drugs (MS).
Rosen and colleagues130 reported that there was no significant difference in renal safety profiles between 
the 4 mg zoledronic acid group and the 90 mg disodium pamidronate group. After 25 months, a change 
in the creatinine level of more than 0.5 mg/dl from baseline had occurred in 7.7% of patients in the 
zoledronic acid group and 6.0% of patients in the disodium pamidronate group.130
Kohno and colleagues102 stated that there was no evidence of decreased renal function among patients 
in either group. In the zoledronic acid group, mean serum creatinine was 0.79 mg/dl at baseline and 
0.78 mg/dl at the end of study while in the placebo group it was 0.79 mg/dl at baseline and 0.85 mg/dl at 
the end. In one patient in the zoledronic acid group, serum creatinine increased notably from a baseline of 
1.3 mg/dl to 2.0 mg/dl, compared with seven patients in the placebo group. No patient in the zoledronic 
acid group developed a Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4 serum 
creatinine increase, while one patient in the placebo experienced such an event.102
Acute-phase reactions
Acute-phase reactions encompass flu-like symptoms including pyrexia, chills, flushing, bone pain, 
arthralgias and myalgias.31 Stopeck and colleagues31 reported that acute-phase reactions in the first 3 days 
after treatment were 2.7 times more common in the zoledronic acid group than in the denosumab group 
[27.3% (277/1013) vs 10.4% (106/1020), respectively]. In the MS, SAEs of acute-phase reactions within 
3 days of first dose were reported. (Academic-in-confidence information has been removed.)
Other adverse events
Table 14 shows, for the denosumab RCT, rates of a number of selected other adverse events, including 
those leading to treatment discontinuation, CTCAE grade 3 or 4 events, serious and fatal adverse events. 
The rates for both groups were broadly similar.
For details of all other adverse events extracted from the RCTs meeting the review’s inclusion criteria and 
also adverse events extracted from a number of observational studies identified, see Appendix 10.
Network meta-analysis
A NMA was undertaken by the AG. A NMA was also presented within the MS. The AG included four 
studies30,31,103,104 and the MS’s NMA included 11 studies. Table 15 shows the comparisons and outcomes 
reported by the AG’s and MS’s NMAs.
To convert time to event analysis, the statistical technique outlined by Tierney and colleagues70 was used. 
Although this is an accepted method of converting to HRs, assumptions are made, and this adds a further 
layer to the uncertainties of the NMA. This was performed for time to first SRE for Kohno and colleagues102 
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(zoledronic acid vs placebo HR 0.56; 95% CI 0.36 to 0.85) and Rosen and colleagues104 (zoledronic acid 
vs disodium pamidronate: HR 0.97; 95% CI 0.78 to 1.20). Conversion of Kohno and colleagues102 was 
straightforward using the number of observed events and p-value between groups. Conversion of Rosen 
and colleagues104 involved combining the lytic and non-lytic Kaplan–Meier curves.109 The number of 
patients without a SRE at each time point and number at risk were then used to produce a HR. The HRs 
calculated by the AG and manufacturer were the same for Kohno and colleagues,102 but different for 
Rosen and colleagues.104 It is unclear what the precise method was that was used by the manufacturer to 
calculate the HR for the Rosen study.
The manufacturer included 11 studies in the NMA. Five studies were considered too heterogeneous by 
the AG for the reasons outlined in Table 16. One study was not included in the AG’s NMA because it was 
non-English language (French). The AG used pooled results of two studies,103 while the MS used unpooled 
studies.107,115
Time to first on-study skeletal-related event
The results from the AG’s and MS’s NMAs are shown below in Table 17.
In both the AG’s NMA and the MS’s NMA, time to first SRE favoured denosumab compared with 
zoledronic acid, disodium pamidronate and placebo. In the AG’s NMA, the difference was statistically 
significant for denosumab versus zoledronic acid and denosumab versus placebo (academic-in-confidence 
information has been removed). The AG did not compare denosumab with ibandronic acid because 
they considered the studies too heterogeneous to provide meaningful results. (Academic-in-confidence 
information has been removed.) Risk of first and subsequent on-study SREs (academic-in-confidence 
information has been removed).
The results for risk of developing first and subsequent on-study SREs are provided below in Table 18.
TABLE 14 Selected other adverse events
Adverse event Denosumab (n = 1020) Zoledronic acid (n = 1013)
AE leading to treatment discontinuation 98 (10%) 125 (12%)
CTCAE ≥ grade 3 AE 609 (60%) 635 (63%)
Serious AE 453 (44%) 471 (47%)
AE, adverse event.
CTCAE version 3.0 was used.
Source: Stopeck 2010.31 
TABLE 15 Assessment group’s NMA compared with the manufacturer’s NMA
Comparisons Time to first SRE
Time to first and 
subsequent SRE SMR/SMPR
Proportion of patients 
with on-study SRE
Denosumab vs zoledronic acid AG + MS AG + MS AG + MS AG
Denosumab vs placebo AG + MS AG + MS AG + MS AG
Denosumab vs disodium 
pamidronate
AG + MS AG + MS AG + MS Neither
Zoledronic acid vs placebo AG + MS AG + MS AG + MS AG
Denosumab vs ibandronic acid MS MS Neither Neither
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Risk of first and subsequent SREs favoured denosumab compared with zoledronic acid, disodium 
pamidronate or placebo in both the AG’s NMA and the MS’s NMA. In the AG’s NMA the difference 
was statistically significant. (Academic-in-confidence information has been removed.) SMR and SMPR 
(academic-in-confidence information has been removed).
The AG did not have access to SMPR for denosumab compared with zoledronic acid and were therefore 
unable to perform this comparison (Table 19).
The SMRs in both the AG’s NMA and the MS’s NMA favour denosumab. There was a statistically 
significant difference for denosumab compared with placebo (AG’s NMA), zoledronic acid compared with 
placebo (AG’s NMA). (Academic-in-confidence information has been removed.) Proportion of patients with 
on-study SRE (academic-in-confidence information has been removed).
The AG undertook a NMA comparing the proportion of patients with an on-study SRE (Table 20). This is 
a less informative outcome as it does not differentiate between lengths of study. However, the AG judged 
the study lengths to be similar enough to be included within the NMA. It also provided an opportunity to 
compare interventions by individual SRE.
TABLE 16 Reasons for exclusion of studies from the AG’s NMA
Study Reason that AG considered study too heterogeneous
Heras 200974 Different definition of SRE (includes change in antineoplastic medications)
Body 200371 Different definition of SRE (excludes SCC)
Paterson 199376 Different definition of SRE (excludes surgery and SCC)
Kristensen 199975 Different definition of SRE (includes HCM, excludes need for surgery and SCC)
Body 200472 (Tripathy 2003166) Different definition of SRE (excludes SCC)
TABLE 17 Time to first on-study SRE
Comparison AG’s NMA HR (95% CI) MS’s NMA HR (95% CI)
Denosumab vs zoledronic acid 0.82 (0.71 to 0.95) AiC information has been removed
Denosumab vs disodium pamidronate 0.79 (0.61 to 1.03) AiC information has been removed
Denosumab vs placebo 0.46 (0.29 to 0.72) AiC information has been removed
Zoledronic acid vs placebo 0.56 (0.36 to 0.86) AiC information has been removed
Denosumab vs ibandronic acid Not performed AiC information has been removed
AiC, academic-in-confidence.
TABLE 18 Risk of first and subsequent on-study SRE
Comparison AG’s NMA RR (95% CI) MS’s NMA RR (95% CI)
Denosumab vs zoledronic acid 0.77 (0.66 to 0.89) AiC information has been removed
Denosumab vs disodium pamidronate 0.62 (0.48 to 0.80) AiC information has been removed
Denosumab vs placebo 0.45 (0.28 to 0.72) AiC information has been removed
Zoledronic acid vs placebo 0.59 (0.37 to 0.91) AiC information has been removed
Denosumab vs ibandronic acid Not performed AiC information has been removed
AiC, academic-in-confidence.
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Compared with zoledronic acid denosumab non-significantly reduced the risk of any SRE, pathological 
fracture and radiation to bone. There was a non-significant increase in SCC compared with zoledronic acid. 
Compared with placebo both denosumab and zoledronic acid non-significantly reduced the risk of each 
individual SRE. It should be noted that none of the above results was statistically significant and the NMA 
is not sufficiently powered to detect differences. Individual SREs should not be compared with each other, 
for example comparing the effectiveness of an intervention to prevent pathological fractures compared 
with SCC, because of the low numbers of events.
Summary
Only one study, by Stopeck and colleagues,31 was identified comparing denosumab with the primary 
comparator zoledronic acid. Three other studies contributed data to the indirect comparisons of 
denosumab versus BSC undertaken by the AG (these three studies were also included in the MS’s NMA) 
and are therefore also reported in this chapter. Kohno and colleagues102 compared zoledronic acid with 
placebo, Rosen and colleagues104 compared zoledronic acid with disodium pamidronate, and Lipton and 
colleagues103 compared disodium pamidronate with placebo. All studies were generally of good quality. 
In terms of generalisability, all studies were multicentre and the first two were international. In the Kohno 
and colleagues study102 the patients were all Japanese and all had osteolytic lesions. The Stopeck and 
colleagues study31 was the largest, randomising 2046 patients, although few (academic-in-confidence 
information has been removed) were from the UK. All participants in this study had advanced breast 
TABLE 19 Skeletal morbidity rate and SMPR
Comparison
SMR SMPR
AG’s NMA rate ratio 
(95% CI)
MS’s NMA rate ratio 
(95% CrI)
MS’s NMA rate ratio 
(95% CrI)
Denosumab vs zoledronic acid 0.90 (0.67 to 1.09) AiC information has been 
removed
AiC information has been 
removed
Denosumab vs disodium 
pamidronate
0.73 (0.41 to 1.06) AiC information has been 
removed
AiC information has been 
removed
Denosumab vs placebo 0.47 (0.25 to 0.67) AiC information has been 
removed
AiC information has been 
removed
Zoledronic acid vs placebo 0.52 (0.32 to 0.70) AiC information has been 
removed
AiC information has been 
removed
Denosumab vs ibandronic acid Not performed AiC information has been 
removed
AiC information has been 
removed
AiC, academic-in-confidence; CrI, credible interval.
TABLE 20 Proportion of patients with an on-study SRE
Comparison
Any SRE OR 
(95% CI)
Pathological 
fracture OR (95% CI)
Radiation to 
bone OR (95% CI) 
Surgery to bone 
OR (95% CI)
SCC OR 
(95% CI)
Denosumab vs 
zoledronic acid
0.77 (0.11 to 
4.86)
0.80 (0.06 to 10.11) 0.72 (0.06 to 8.62) 1.03 (0.08 to 
13.15)
1.30 (0.10 
to 17.94)
Denosumab vs 
placebo
0.36 (0.03 to 
3.96)
0.42 (0.01 to 15.96) 0.31 (0.01 to 
12.48)
0.38 (0.00 to 
30.47)
0.34 (0.01 
to 14.73
Zoledronic acid vs 
placebo
0.47 (0.09 to 
2.23)
0.53 (0.04 to 6.89) 0.43 (0.03 to 6.28) 0.37 (0.01 to 
12.97)
0.26 (0.02 
to 3.89)
OR, odds ratio.
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cancer with one or more bone metastases, Eastern Cooperative Oncology Group (ECOG) status ≤ 2 and 
a life expectancy of ≥ 6 months. Patients with severe renal impairment, current or prior BP treatment, 
non-healed dental/oral surgery or prior malignancy within 3 years before randomisation were excluded. 
The study was powered to detect both non-inferiority and superiority with respect to time to first and risk 
of first and subsequent on-study SREs.
The study by Stopeck and colleagues31 reported a statistically significant difference in favour of denosumab 
compared with zoledronic acid in both the median time to first on-study SRE (not yet reached vs 
26.4 months), most of which were radiation to bone or pathological fractures, and the risk of developing 
first and subsequent on-study SREs.
In the study by Kohno and colleagues,102 the median time to first on-study SRE was significantly longer in 
the zoledronic acid group than in the placebo group (not reached vs around 12 months), whereas the risk 
of developing multiple SREs was 41% lower in the zoledronic acid group. Likewise, in the study by Lipton 
and colleagues,103 the time to first on-study SRE was significantly longer in the disodium pamidronate 
group than in the placebo group (12.7 vs 7 months). In the study by Rosen and colleagues,104 comparing 
zoledronic acid with disodium pamidronate, the median time to first on-study SRE was broadly similar 
(around 11.6 vs 12.2 months) while the risk of developing multiple SREs was 20% lower in the zoledronic 
acid group.
Kohno and colleagues, in the denosumab RCT (academic-in-confidence information has been 
removed), reported that 2.6% of the zoledronic acid group and 8.8% of the placebo group 
experienced hypercalcaemia.
Stopeck and colleagues reported no difference in overall survival between denosumab and zoledronic acid 
(HR 0.95; 95% CI 0.81 to 1.11). Lipton and colleagues103 reported that median overall survival was slightly 
longer in the disodium pamidronate group than in the placebo group (19.8 vs 17.8 months).
Denosumab delayed the time to development of moderate or severe pain by more than 4 months 
compared with zoledronic acid (around 10.5 vs 6.3 months). Lipton and colleagues103 reported that the 
mean pain score decreased significantly in the disodium pamidronate group (–0.07) compared with the 
placebo group (1.14). The FACT quality-of-life scores were similar in the denosumab and zoledronic acid 
groups, and likewise there were no notable differences between the groups in terms of EQ-5D. Lipton and 
colleagues,103 using the Spitzer quality-of-life index, noted that from baseline to the last visit quality of life 
worsened in both the disodium pamidronate group (–1.80) and the placebo group (–2.13).
In terms of adverse events, slightly more hypocalcaemia events occurred in the denosumab group than 
in the zoledronic acid group (5.5% vs 3.4%), likewise for ONJ (2.0% vs 1.4%). There was a statistically 
significant lower rate of adverse events potentially associated with renal impairment (4.9% vs 8.5%), while 
fewer patients in the denosumab group experienced acute-phase reactions (10.4% vs 27.3%). The rates 
for adverse events leading to treatment discontinuation, CTCAE grade 3 or 4, or SAEs were broadly similar 
between the denosumab and zoledronic acid groups.
In the study by Kohno and colleagues,102 39% of the zoledronic acid group and 7% of the placebo group 
experienced grade 1 hypocalcaemia. Rosen and colleagues104 reported that there was no significant 
difference in renal safety profiles between the zoledronic acid and disodium pamidronate groups, whereas 
in the study by Kohno and colleagues102 there was no evidence of decreased renal function in either the 
zoledronic acid or placebo groups.
The AG’s NMA included fewer trials than the MS’s NMA, improving homogeneity; however, this reduced 
the number of outcomes and available comparisons. The MS’s NMA included six more studies. It is the 
opinion of the AG that inclusion of these six additional studies introduced significant methodological 
heterogeneity to the NMA. All treatment effects were in the same direction in both AG’s NMA and MS’s 
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NMA. The results from the AG’s NMA show that denosumab, compared with zoledronic acid or placebo, 
significantly delayed the time to first SRE. For these comparisons and denosumab versus disodium 
pamidronate, denosumab significantly reduced the risk of first and subsequent SRE, and denosumab 
compared with placebo significantly reduced the SMR. (Academic-in-confidence information has been 
removed.) The proportion of SREs was non-significantly reduced in all SRE types, except for SCC. However, 
these results are subject to considerable uncertainty and should be interpreted with caution.
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Chapter 5 Results: prostate cancer
Quantity of research available
Number and type of studies included
The flow diagram outlining the screening process for the overall review is shown in Figure 3 (see 
Chapter 4).
The primary comparator for denosumab was considered to be BSC, as in the NICE guideline on the 
diagnosis and treatment of prostate cancer the use of BPs to prevent or reduce the complications of bone 
metastases in men with hormone-refractory prostate cancer is not recommended.46 BSC was defined as 
including palliative radiotherapy and analgesics. As the guideline states that BPs for pain relief may be 
considered when other treatments (including analgesics and palliative radiotherapy) have failed, BPs were 
considered as a secondary comparator in relation to this group of patients.
No RCTs were identified comparing denosumab with BSC. One RCT (six reports29,122,124,125,127,129) was 
identified comparing denosumab with the BP zoledronic acid. The primary published report for this study 
was considered to be that by Fizazi and colleagues.29 One study (nine reports19,117–121,123,126,128) comparing 
zoledronic acid with placebo was identified and this study also contributed data to the indirect comparison 
of denosumab versus BSC. The primary report for this study was considered to be the 2002 paper by Saad 
and colleagues.117
Number and type of studies excluded
For information on studies that were excluded from the review see Chapter 4, Number and type of studies 
excluded, and see Appendix 5 for a list of these studies along with the reasons for their exclusion. These 
studies were excluded because they failed to meet one or more of the inclusion criteria in terms of types of 
study, participants, intervention or outcomes reported.
Characteristics of the included studies
Appendix 8 shows the characteristics of the included studies. Table 21 shows summary information for the 
two studies that provided direct evidence for denosumab or were included in the NMA.
The study by Fizazi and colleagues29 was undertaken between May 2006 and October 2009 and enrolled 
men aged ≥ 18 years with confirmed prostate cancer and at least one bone metastasis, from 342 centres 
in 39 countries. However, (academic-in-confidence information has been removed) few patients were 
from the UK (MS). Exclusion criteria included creatinine clearance < 0.5 ml/second, current or previous 
treatment with intravenous BP or oral BP for bone metastases, planned radiation therapy or surgery to 
bone, life expectancy < 6 months, current or previous osteonecrosis or osteomyelitis of the jaw or any 
planned invasive dental procedure during the study. Patients received a subcutaneous injection of 120 mg 
denosumab and an intravenous infusion of placebo or an intravenous infusion of 4 mg zoledronic acid 
and a subcutaneous injection of placebo every 4 weeks. The study was powered to detect both non-
inferiority and superiority with respect to time to first on-study SRE (primary outcome), and time to first 
and subsequent SRE. Follow-up was 41 months for the blinded treatment phase. The study was funded 
by Amgen.
The study by Saad and colleagues117 was undertaken between June 1998 and January 2001 and enrolled 
prostate cancer patients with a documented history of bone metastases, from more than 136 centres 
in the USA, Europe, South America and Australasia. Patients received 4 mg zoledronic acid or placebo 
every 3 weeks (a third arm in which 221 patients were assigned to an initial dose of 8 mg per week was 
not considered to meet our inclusion criteria). All patients also received a 500 mg calcium supplement 
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and 400–500 IU of vitamin D daily. Pain management, including analgesics, radiation therapy, or other 
treatment, was at the discretion of the treating physician. The primary outcome was the proportion of 
patients having at least one SRE. Follow-up was 15 months (with an extension phase to 24 months). The 
study was funded by Novartis.
Quality of the included studies
Table 22 shows the results of the risk of bias assessment for the studies by Fizazi and colleagues29 and Saad 
and colleagues.117
Both studies were good-quality studies with low risk of bias as assessed against the criteria in Table 22. The 
study by Fizazi and colleagues29 employed computer-generated randomisation, with an interactive voice 
response system used to assign patients (1 : 1 ratio) to treatment. Patients, study staff and investigators 
were masked to treatment assignment throughout the primary analysis period. Both primary and 
secondary efficacy end points included all randomised patients, irrespective of administration of study 
treatments (intention to treat), while the safety data set included all patients from the full analysis set who 
received at least one dose of study treatment. There was adequate description of withdrawals and losses 
to follow-up, and all of the prespecified outcomes were reported.
TABLE 21 Characteristics of the studies included in the NMA
Criteria
Fizazi 201129 Saad 2002117
Denosumab Zoledronic acid Zoledronic acid Placebo
Randomised 950 951 214 208
Age (years)a 71 (64–77) 71 (66–77) 71.8 (7.9) 72.2 (8.0)
Ethnicity
White 829 (87%) 810 (85%) 178 (83%) 173 (83%)
Other 121 (13%) 141 (15%) 36 (17%) 35 (17%)
ECOG status 0–1 882 (93%) 886 (93%) 197 (92%) 190 (91%)
Time from diagnosis (months)b
Of prostate cancer 37.5 (18.1–75.4) 41.2 (18.3–82.0) 62.2 ± 43.5 66.6 ± 46.9
Of bone metastases 3.94 (1.22–15.67) 5.19 (1.31–16.10) 23.8 ± 26.1 28.4 ± 30.7
Previous SREs 232 (24%) 231 (24%) 66 (31%) 78 (38%)
a Age. Fizazi29 reported median (interquartile range), Saad117 reported mean (SD).
b Time from diagnosis. Fizazi29 reported median (interquartile range), Saad117 reported mean (SD) and also median; for 
time since diagnosis this was 51.8 months for denosumab and 56.9 months for placebo; for time since first bone 
metastases this was 16.1 months for denosumab and 17.8 months for placebo.
TABLE 22 Results of the risk of bias assessment
Criteria Fizazi 201129 Saad 2002117
Adequate sequence generation Yes Yes
Adequate allocation concealment Yes Yes
Blinding Yes Yes
Incomplete outcome data addressed Yes Yes
Free of selective reporting Yes Yes
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The study by Saad and colleagues117 employed a computer-generated list of randomisation numbers 
to assign patients. Treatment assignments were revealed to study personnel and any other persons 
involved in study conduct or monitoring only after the last patient had completed the last study visit. The 
study was double blind, patients lost to follow-up were described and all of the prespecified outcomes 
were reported.
Assessment of effectiveness
Time to first on-study skeletal-related event
The study by Fizazi and colleagues29 reported a statistically significant difference in favour of denosumab 
compared with zoledronic acid in the median time to first on-study SRE (20.7 vs 17.1 months; HR 0.82; 
95% CI 0.71 to 0.95; p = 0.0002), reducing the risk of this event by 18% compared with zoledronic 
acid. Figure 6 shows the Kaplan–Meier estimates of the time to the first on-study SRE. The MS reported 
that denosumab reduced the risk of a symptomatic SRE (academic-in-confidence information has been 
removed) and reduced the proportion of patients with symptomatic SREs [to 25% (academic-in-confidence 
information has been removed)].
The study by Saad and colleagues118 reported a statistically significant difference in favour of zoledronic 
acid compared with placebo in the median time to first on-study SRE (488 vs 321 days; HR 0.68; 95% CI 
0.51 to 0.91; p = 0.009), reducing the risk of this event by 32% compared with placebo.
Skeletal-related event by type
Neither study reported the time to first SRE for individual SREs.
Table 23 shows the distribution of first on-study SRE by type of SRE in the study by Fizazi and colleagues.29 
The distribution of type of SRE was similar across the treatment groups, with radiation to bone and 
pathological fracture being the most commonly occurring.
Saad and colleagues117 did not report this outcome.
FIGURE 6 Kaplan–Meier (KM) estimates of time to first on-study SRE. Reproduced with permission from Fizazi et al. 
Denosumab vs zoledronic acid for treatment of bone metastases in men with castration resistant prostate cancer: a 
randomised, double-blind study. Lancet 2011;377:813–22.29
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Prior history of skeletal-related events
The MS reported time to first on-study SRE by prior history of SREs for study 103 (Table 24). This showed a 
statistically significant difference in favour of denosumab for those patients with no prior SRE (academic-
in-confidence information has been removed). Covariate analysis showed that patients with a prior SRE 
history had an increased risk (academic-in-confidence information has been removed) compared with 
those without a SRE history.
Saad and colleagues117 reported that the median time to first on-study SRE for those with a previous SRE 
(n = 144) was 361 days for the zoledronic acid group compared with 258 days for the placebo group 
(p = 0.066), whereas for those with no previous SRE (n = 277) it was 499 days for the zoledronic acid 
group and 337 days for the placebo group (p = 0.065).119
TABLE 23 Patients with first on-study SRE by type
SRE
Number of events (%)
Denosumab (n = 950 randomised) Zoledronic acid (n = 951 randomised)
Overall 341 (100%) 386 (100%)
Radiation to bone 177 (51.9%) 203 (52.6%)
Pathological fracture 137 (40.2%) 143 (37.1%)
SCC 26 (7.6%) 36 (9.3%)
Surgery to bone 1 (0.3%) 4 (1.0%)
Source: Fizazi 2011.29
TABLE 24 Time to first on-study SRE by history of SRE
SRE history Denosumab Zoledronic acid
Overall
Number 950 951
HR (95% CI) 0.82 (0.71 to 0.95)
p-value 0.008
No prior SRE
Number 718 720
HR (95% CI) 0.80 (0.67 to 0.95)
p-value 0.011
Prior SRE
Number 232 231
HR (95% CI) 0.88 (0.67 to 1.16)
p-value 0.3675
Covariate effect
Point estimate (95% CI) AiC information has been removed
p-value AiC information has been removed
AiC, academic-in-confidence.
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Risk of first and subsequent on-study skeletal-related events
The study by Fizazi and colleagues29 reported a statistically significant difference in favour of denosumab 
compared with zoledronic acid in the risk of developing first and subsequent on-study SREs (RR 0.82; 
95% CI 0.71 to 0.94; p = 0.004, adjusted for multiplicity p = 0.008). Figure 7 shows the cumulative mean 
number of SREs (multiple-event analysis).
Saad and colleagues117 reported a statistically significant difference in favour of zoledronic acid compared 
with placebo in the risk of developing first and subsequent on-study SREs (RR 0.64; 95% CI not reported; 
p = 0.002).
Skeletal-related event by type
Neither study reported risk of first and subsequent on-study SRE by type of SRE.
The MS reported the distribution of first and subsequent on-study SREs by type of SRE in the denosumab 
RCT (study 103) (Table 25). As for first on-study SRE by type, the distribution of type of SRE was 
similar across the treatment groups, with radiation to bone and pathological fracture again the most 
commonly occurring.
FIGURE 7 Cumulative mean number of SREs (multiple-event analysis). Reproduced with permission from Fizazi et al. 
Denosumab vs zoledronic acid for treatment of bone metastases in men with castration resistant prostate cancer: a 
randomised, double-blind study. Lancet 2011;377:813–22.29
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TABLE 25 Distribution of first and subsequent SRE by type: with 21-day window
SRE Denosumab (n = 950 randomised) Zoledronic acid (n = 951 randomised)
Number of events (%) Number of events (%)
Total confirmed events 494 (100%) 584 (100%)
Radiation to bone AiC information has been removed AiC information has been removed
Pathological fracture AiC information has been removed AiC information has been removed
SCC AiC information has been removed AiC information has been removed
Surgery to bone AiC information has been removed AiC information has been removed
AiC, academic-in-confidence.
Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
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Prior history of skeletal-related events
The MS reported risk of developing first and subsequent on-study SREs by history of SRE for study 103 
(Table 26). (Academic-in-confidence information has been removed.) Covariate analysis as presented in 
the manufacturer’s table showed that patients with a history of SRE had an increased risk (academic-in 
confidence information has been removed) compared with those without a SRE history [although in 
the text the manufacturer reported the covariate effect (academic-in confidence information has been 
removed) and increased risk (academic-in confidence information has been removed)].
Saad and colleagues reported that among the 144 patients with a SRE before study entry, zoledronic acid 
significantly reduced the risk of SREs by 40% compared with placebo (RR 0.60; p = 0.028), and among the 
277 patients without a SRE before study entry, zoledronic acid significantly reduced the overall risk of SREs 
by 33% compared with placebo (RR 0.67; p = 0.027).119
Skeletal morbidity rate
The SMR is defined as the ratio of the number of SREs per patient divided by the patient’s time at risk. 
Information on this outcome for the denosumab RCT was reported in the MS, which stated that for 
the SMR calculations a 21-day event window was used for counting on-study SREs, so that any event 
occurring within 21 days of a previous event was not counted as a separate on-study SRE.
The MS for study 103 compared the annual SMR with denosumab (academic-in-confidence information 
has been removed) with zoledronic acid [0.79 vs 0.83 (academic-in-confidence information has 
been removed)]. Saad and colleagues117 reported that the mean SMR for all SREs combined and for 
each individual type of SRE was lower for patients who received zoledronic acid than for those who 
received placebo.
TABLE 26 Risk of first and subsequent on-study SREs by prior history of SRE
SRE history Denosumab Zoledronic acid
Overall
Number 950 951
Rate ratio (95% CI) 0.82 (0.71 to 0.94)
p-value 0.0044
No prior SRE
Number 718 720
Rate ratio (95% CI) 0.79 (0.67 to 0.94)
p-value 0.0067
Prior SRE
Number 232 231
Rate ratio (95% CI) 0.88 (0.68 to 1.13)
p-value 0.3081
Covariate effect
Point estimate (95% CI) AiC information has been removed
p-value AiC information has been removed
AiC, academic-in-confidence.
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Skeletal-related event by type
The MS did not report SMR by type of SRE.
Table 27 shows the SMR by type of SRE for the study by Saad and colleagues.117
Prior history of skeletal-related event
SMR by history of SRE was not reported for the denosumab RCT.
Saad and colleagues reported that the mean on-study SRE per year, for those patients with a previous SRE 
(n = 144) was 0.8 for zoledronic acid compared with 2.3 for placebo (p = 0.036), whereas for those with 
no previous SRE it was 0.77 for zoledronic acid and 0.98 for placebo (p = 0.06).119
Incidence of skeletal-related events
In the denosumab RCT (study 103) 780 SREs occurred in 1045 patient-years in the denosumab arm and 
943 occurred in 996 patient-years in the zoledronic acid arm, with the number-needed-to-treat analysis 
showing that compared with zoledronic acid, treatment of five patients with denosumab would prevent 
an additional SRE (first or subsequent) per year.124
The MS reported an annualised SRE rate based on the number of SREs observed in each treatment arm 
divided by the number of patient-years for each treatment arm and reported this outcome both with and 
without a 21-day event window.
Table 28 shows the annualised SRE rate both with and without the 21-day window for study 103. The 
MS reported that the primary analysis of annualised SRE rates was based on all SREs reported in each arm 
of the study (calculated without a 21-day window). Subsequently, a post-hoc analysis of the annualised 
SRE rate applying the trial-defined 21-day window for SREs was conducted. Both analyses show that 
the annualised SRE rate was lower in patients receiving denosumab compared with those receiving 
zoledronic acid.
In the study by Saad and colleagues117 statistically significantly fewer patients in the zoledronic acid group 
compared with the placebo group experienced at least one SRE [33.2% (71/214) vs 44.2% (92/208), 
respectively; p = 0.021].
Skeletal-related event by type
Incidence of SREs by type of SRE was not reported for the denosumab RCT.
Table 29 shows the proportions of patients with different types of SRE for the study by Saad and 
colleagues.117 More SREs occurred in the placebo group overall. The most frequently occurring SRE in both 
groups was radiation therapy to bone, followed by pathological fractures.
TABLE 27 Skeletal morbidity rate up to month 15
SRE Zoledronic acid (n = 214) Placebo (n = 208) p-value
All SREs 0.80 (0.57 to 1.03) 1.49 (1.03 to 1.94) 0.006
Pathological fractures 0.21 (0.11 to 0.31) 0.45 (0.27 to 0.63) 0.009
Radiation therapy to bone 0.44 (0.27 to 0.60) 0.88 (0.48 to 1.28) 0.084
Surgery to bone 0.03 (0.00 to 0.07) 0.06 (0.01 to 0.11) 0.509
SCC 0.14 (0.00 to 0.28) 0.23 (0.04 to 0.42) 0.247
Data are mean number of SREs per patient-year (95% CI).
Source: Saad 2002.118 
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Prior history of skeletal-related events
Neither study reported incidence of SRE by history of SREs. However, Saad and colleagues117 reported 
that for those with a previous SRE (n = 144), the proportion of patients with one or more SRE while on 
study was 41% (27/66) for zoledronic acid compared with 51% (40/78) for placebo (p = 0.215), whereas 
for those with no previous SRE (n = 277) this was 37% (54/147) for zoledronic acid compared with 47% 
(61/130) for placebo (p = 0.087).119
Prevention of hypercalcaemia
This was discussed in study 103, (academic-in-confidence information has been removed) (CSR 103).
Saad and colleagues117 did not report hypercalcaemia.
Overall survival
In the denosumab RCT, median overall survival was similar between the groups, with a median overall 
survival of 19.4 months (95% CI 18.1 to 21.7 months) for the denosumab group compared with 
19.8 months (95% CI 18.1 to 20.9 months) for the zoledronic acid group (HR 1.03; 95% CI 0.91 to 1.17; 
p = 0.65).29
In the study by Saad and colleagues,117 median survival was 546 days (around 18.2 months) for the 
zoledronic acid group and 464 days (around 15.5 months) for the placebo group (p = 0.091).
TABLE 28 Annualised SRE rate in study 103
Annualised SRE rate per patient Denosumab (n = 950) Zoledronic acid (n = 951)
Subject years AiC information has been removed AiC information has been removed
Without 21-day window
Number of events AiC information has been removed AiC information has been removed
Annualised rate AiC information has been removed AiC information has been removed
With 21-day window
Number of events AiC information has been removed AiC information has been removed
Annualised rate AiC information has been removed AiC information has been removed
AiC, academic-in-confidence.
Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
TABLE 29 Proportions of patients with SREs up to month 15
SRE Zoledronic acid (n = 214) Placebo (n = 208) p-value
All SREs 71 (33.2) 92 (44.2) 0.021
Pathological fractures 28 (13.1) 46 (22.1) 0.015
Radiation therapy to bone 49 (22.9) 61 (29.3) 0.136
Surgery to bone 5 (2.3) 7 (3.4) 0.514
SCC 9 (4.2) 14 (6.7) 0.256
Source: Saad 2002.117 
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Prior history of skeletal-related events
Neither study reported overall survival by history of SREs.
Pain
The MS stated that the denosumab RCT used the BPI-SF, which captures information on the intensity of 
pain (pain severity) and the degree to which pain interferes with function (pain interference) in patients 
with cancer. The BPI-SF scores range from 0 to 10, with a higher score indicating more severe pain (0 = no 
pain, 1–4 = mild pain, 5–6 = moderate pain and 7–10 = severe pain). Pain analyses included evaluation of 
changes from baseline in BPI-SF worst pain score; evaluations of time to pain worsening, time to moderate 
or severe pain, or time to pain improvement; and the proportions of patients meeting these criteria.
The MS reported that denosumab delayed the time to development of moderate or severe pain in 
patients with no or mild pain at baseline by around 1 month compared with zoledronic acid (median 
5.8 months vs 4.9 months) although the difference was not statistically significant (HR 0.89; 95% CI 0.77 
to 1.04; p = 0.1416) (MS). Denosumab also significantly decreased the proportion of patients with no/
mild pain at base who progressed to moderate or severe pain [relative decrease (academic-in-confidence 
information has been removed) over 73 weeks]. The median time to worsening pain (≥ 2-point increase 
from baseline in BPI-SF worst pain score) was similar in the denosumab and zoledronic acid groups. 
(Academic-in-confidence information has been removed.) There was no significant difference in time to 
pain improvement (≥ 2-point decrease from baseline) between denosumab and zoledronic acid (academic-
in-confidence information has been removed) (MS).
There was no statistically significant difference at study end point or any study time point (19 study time 
points) in the use of strong analgesics.
The study by Saad and colleagues117 also used the BPI instrument, with the pain score a composite of 
four pain scores (worst pain, least pain, average pain of the last 7 days, and pain right now), and was the 
primary efficacy variable for the quality-of-life assessments. Saad and colleagues117 reported that the mean 
pain scores increased from baseline in each group at every 3-month interval, except at 3 months, when 
the zoledronic acid group exhibited a slight decrease from baseline. The mean increase from baseline in 
pain score at 15 months was 0.58 (95% CI 0.29 to 0.87) in the zoledronic acid group compared with 0.88 
(95% CI 0.61 to 1.15) in the placebo group (p = 0.134). Saad and colleagues117 also reported that fewer 
patients in the zoledronic acid group experienced bone pain than in the placebo group [51% (108/214) vs 
61% (127/208), respectively].
Health-related quality of life
Functional Assessment of Cancer Therapy
The Functional Assessment of Cancer Therapy – Prostate (FACT-P) questionnaire consists of the FACT-G 
questionnaire plus additional questions specific to prostate cancer. For each component of the FACT-P 
(FACT-G total score, FACT-P total score, physical well-being domain, functional well-being domain, and 
TOI: a composite of the functional well-being domain, physical well-being domain, and the prostate 
cancer subscale), a higher score indicates better HRQoL.
Table 30 shows the change in FACT scores from baseline to week 73. (Academic-in-confidence information 
has been removed) (CSR 103).
Saad and colleagues117 reported that the total FACT-G score decreased from baseline to the last 
measurement, with no statistically significant differences between the zoledronic acid and placebo groups.
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European Quality of Life-5 Dimensions
For both components of EQ-5D (the health index and the VAS), a higher score indicates a more preferred 
health status. For the health index questions of the EQ-5D, a three-level response was used to assess 
quality of life. (Academic-in-confidence information has been removed) (CSR 103).
Saad and colleagues117 reported that the EQ-5D scores decreased from baseline to the last measurement, 
with no statistically significant differences between the zoledronic acid and placebo groups.
Adverse events related to treatment
Data relating to adverse events were collected primarily from the included RCTs and supplementary data 
were included from observational studies where available.
Hypocalcaemia
The MS reported that hypocalcaemia events were mainly non-serious and transient and either resolved 
spontaneously or with calcium supplementation (MS). More hypocalcaemia adverse events occurred in 
the denosumab group than in the zoledronic acid group [13% (121/943) vs 6% (55/945), respectively], 
a statistically significant difference (p < 0.0001).29 Calcium decreases of grade 3 or higher occurred in 48 
patients (5%) receiving denosumab and 13 patients (1%) receiving zoledronic acid.
In the study by Saad and colleagues,117 1.9% (4/214) of patients in the zoledronic acid group experienced 
grades 3 or 4 hypocalcaemia compared with none in the placebo group.
Osteonecrosis of the jaw
In the denosumab RCT, more patients in the denosumab group than in the zoledronic acid group 
experienced ONJ events [2% (22/943) vs 1% (12/945)], although the difference was not statistically 
significant (p < 0.09).29 Of those, 17 (77%) on denosumab and 10 (83%) on zoledronic acid had a history 
of tooth extraction, poor oral hygiene, or use of a dental appliance. Fizazi and colleagues29 reported 
that, by April 2010, 10 patients (45%) on denosumab had received limited surgical treatment for ONJ 
(debridement, sequestrectomy, or curettage) and two (9%) had undergone bone resection, whereas 
three patients (25%) on zoledronic acid had received limited surgery and one (8%) had undergone 
bone resection. They also reported that, overall, resolution of ONJ, as defined by mucosal coverage, was 
recorded in four patients (18%) on denosumab and one patient (8%) on zoledronic acid.
TABLE 30 Change in FACT scores from baseline to week 73
Denosumab (n = 950) Zoledronic acid (n = 951)
Scale Baseline mean (SD)
Change from 
baseline to week 73 Baseline mean (SD)
Change from 
baseline to week 73
FACT-B/-P total score AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
Physical well-being AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
Functional well-being AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
TOI AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
FACT-G total score AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
AiC, academic-in-confidence.
Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
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Saad and colleagues117 did not report ONJ.
The proportion of patients experiencing ONJ was slightly lower than in observational studies 
(see Appendix 11). Walter and colleagues160 retrospectively studied patients prescribed BPs and found that 
18.6% of patients experienced ONJ (time at risk not reported). However, three other observational studies 
reported a cumulative incidence of 2.2–6.5% over 12–15 months.62,137,144
Renal toxicity
In the denosumab RCT, a similar rate of adverse events potentially associated with renal impairment 
occurred in the denosumab and zoledronic acid groups [15% (139/943) vs 16% (153/945), respectively].29 
The rates of SAEs associated with renal impairment were also similar [5.9% (56/943) vs 5.6% (53/945) 
respectively] (MS). It should be noted that, as zoledronic acid is contraindicated in patients with poor 
renal function, such patients were excluded from the trial. The manufacturer stated that the incidence 
of renal toxicity observed in the denosumab group represented a background rate for patients with 
advanced cancer, as such patients were predisposed to renal dysfunction, for example owing to the use of 
nephrotoxic drugs (MS).
Saad and colleagues117 reported that renal function deterioration occurred in 15.2% of patients who 
received zoledronic acid and 11.5% of those receiving placebo. They stated that Kaplan–Meier estimates of 
time to first renal function deterioration indicated a comparable RR between the groups, so that compared 
with the placebo group the zoledronic acid group had a RR of 1.07 (95% CI 0.46 to 2.47; p = 0.882).117
Observational studies of zoledronic acid reported a higher incidence of renal toxicity. Oh and colleagues152 
found that 23.8% of patients experienced renal toxicity over 10 months while Bonomi and colleagues137 
reported a figure of 6.5%. However, these studies had a broader definition of renal toxicity than the RCTs.
Acute-phase reactions
In the denosumab RCT, during the first 3 days of treatment, fewer patients in the denosumab group than 
in the zoledronic acid group experienced symptoms associated with acute-phase reactions [8% (79/943) vs 
18% (168/945), respectively].29
Saad and colleagues117 did not report this outcome.
Other adverse events
Table 31 shows, for the denosumab RCT, rates of a number of selected other adverse events, including 
those leading to treatment discontinuation, CTCAE grade 3 or 4 events, serious and fatal adverse events. 
The rates for both groups were broadly similar.
Saad and colleagues117 reported that similar proportions of patients who received zoledronic acid (9.8%) 
and placebo (10.1%) discontinued the study drug because of a SAE.
TABLE 31 Selected other adverse events
Adverse event Denosumab (n = 943) Zoledronic acid (n = 945) p-value
AE leading to treatment discontinuation 164 (17%) 138 (15%) 0.10
CTCAE grade 3 or 4 AE 678 (72%) 628 (66%) 0.01
Serious AE 594 (63%) 568 (60%) 0.20
Fatal AE 283 (30%) 276 (29%) 0.72
AE, adverse event, CTCAE was version 3.0.
Source: Fizazi 2011,29 
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In the denosumab group, 337 patients (36%) developed anaemia compared with 341 (36%) in the 
zoledronic acid arm. In the study by Saad and colleagues, a higher proportion of patients in the zoledronic 
acid group than in the placebo group experienced anaemia (26.6% vs 17.8%).117 The clinical significance 
of this is unclear.
For details of all other adverse events extracted from the RCTs meeting the review’s inclusion criteria and 
also adverse events extracted from a number of observational studies identified, see Appendix 11.
Network meta-analysis
The AG and manufacturer performed a NMA for prostate cancer. Both NMAs included only two 
studies.29,117 The definition of SRE differed between the studies. Saad and colleagues117 included change in 
antineoplastic medications. Therefore, the results should be interpreted with caution. Table 32 shows the 
differences between the AG’s NMA and MS’s NMA.
Time to first skeletal-related event
Results from the NMAs for time to first on-study SRE are shown in Table 33.
The NMA results from both the AG and the MS show that time to first SRE favoured denosumab 
compared with zoledronic acid or placebo. The AG’s NMA found these differences to be statistically 
significant in favour of denosumab, (academic-in-confidence information has been removed).
Risk of first and subsequent skeletal-related events
The NMA results for risk of developing first and subsequent on-study SREs are shown in Table 34.
The NMA results show the risk of developing first and subsequent SREs favoured denosumab compared 
with zoledronic acid or placebo. The AG’s NMA found these differences to be statistically significant in 
favour of denosumab, (academic-in-confidence information has been removed).
Skeletal morbidity rate 
The NMA results for SMR are shown in Table 35.
TABLE 32 Assessment group’s NMA compared with the manufacturer’s NMA
Comparison
Time to 
first SRE
Risk of first and 
subsequent SRE SMR
Proportion of patients with on-study SRE
All patients
Subgroup of patients with 
SRE at baseline
Denosumab vs zoledronic 
acid
AG + MS AG + MS AG + MS AG AG
Denosumab vs placebo AG + MS AG + MS AG + MS AG AG
Zoledronic acid vs placebo AG + MS AG + MS AG + MS AG AG
TABLE 33 Time to first on-study SRE
Comparison
AG’s NMA 
HR (95% CI)
MS’s NMA
HR (95% CI)
Denosumab vs zoledronic acid 0.82 (0.71 to 0.95) AiC information has been removed
Denosumab vs placebo 0.56 (0.40 to 0.77) AiC information has been removed
Zoledronic acid vs placebo 0.68 (0.50 to 0.91) AiC information has been removed
AiC, academic-in-confidence.
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The AG’s NMA found a non-significant difference in favour of denosumab compared with zoledronic 
acid and a significant difference in favour of denosumab compared with placebo, whereas there was 
a statistically significant difference in favour of zoledronic acid compared with placebo. (Academic-in-
confidence information has been removed.) 
Proportion of patients with on-study skeletal-related events
The AG compared the proportion of patients with an on-study SRE for individual SREs and with a 
subgroup with a SRE history. This outcome does not differentiate between time on study and, therefore, 
the results should be interpreted with caution. However, it provides an opportunity to indirectly compare 
SRE types and SRE history.
Denosumab non-significantly favoured zoledronic acid and placebo throughout. Owing to the small 
numbers, however, these results should not be used to compare the relative effectiveness of denosumab 
for preventing individual SRE types.
TABLE 34 Risk of first and subsequent on-study SREs
Comparison
AG’s NMA 
RR (95% CI)
MS’s NMA
RR (95% CI)
Denosumab vs zoledronic acid 0.82 (0.71 to 0.94) AiC information has been removed
Denosumab vs placebo 0.53 (0.39 to 0.72) AiC information has been removed
Zoledronic acid vs placebo 0.64 (0.48 to 0.85) AiC information has been removed
AiC, academic-in-confidence.
TABLE 35 Skeletal morbidity rate
Comparison
AG’s NMA 
RR (95% CI)
MS’s NMA
RR (95% CI)
Denosumab vs zoledronic acid 0.95 (0.46 to 1.47) AiC information has been removed
Denosumab vs placebo 0.52 (0.07 to 0.82) AiC information has been removed
Zoledronic acid vs placebo 0.54 (0.11 to 0.83) AiC information has been removed
AiC, academic-in-confidence.
TABLE 36 Proportion of patients with an on-study SRE (odds ratio and 95% CI)
Comparison Any SRE
Pathological 
fracture
Radiation 
to bone
Surgery 
to bone SCC
No prior 
SRE Prior SRE
Denosumab vs 
zoledronic acid
0.81 (0.07 
to 10.40)
0.91 (0.07 to 
12.06)
0.79 (0.06 
to 10.16)
0.58 (0.04 
to 7.34)
0.73 (0.06 
to 9.65)
0.82 (0.06 
to 10.01)
0.81 (0.07 
to 10.27)
Denosumab vs 
placebo
0.53 (0.01 
to 18.80)
0.48 (0.01 to 
18.46)
0.57 (0.02 
to 19.20)
0.39 (0.01 
to 15.95)
0.44 (0.01 
to 16.32)
0.53 (0.01 
to 19.50)
0.53 (0.01 
to 19.57)
Zoledronic acid vs 
placebo
0.64 (0.05 
to 7.51)
0.53 (0.04 to 
7.06)
0.72 (0.06 
to 8.87)
0.68 (0.05 
to 10.20)
0.60 (0.05 
to 7.80)
0.65 (0.05 
to 8.72)
0.65 (0.05 
to 8.29)
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Summary
No studies were identified comparing denosumab with the primary comparator BSC. One study29 
compared denosumab with zoledronic acid. Another study,117 comparing zoledronic acid with placebo, 
contributed data to the indirect comparisons of denosumab versus BSC undertaken by both the AG and 
the MS and therefore was also reported in this chapter. In terms of generalisability, both studies were 
multicentre, international good quality RCTs. The Fizazi study29 was the larger, randomising 1901 patients 
compared with 422 for the Saad study.117 However, in the Fizazi study29 few (academic-in-confidence 
information has been removed) patients were from the UK. All participants in this study were men aged 
≥ 18 years with life expectancy ≥ 6 months, confirmed prostate cancer and at least one bone metastasis. 
The exclusion criteria included patients with severe renal impairment or current or previous BP treatment 
for bone metastases, or current or previous ONJ. The study was powered to detect both non-inferiority 
and superiority with respect to time to first, and time to first and subsequent, on-study SRE.
The study by Fizazi and colleagues29 reported a statistically significant difference in favour of denosumab 
compared with zoledronic acid in both the median time to first on-study SRE (20.7 months vs 
17.1 months), most of which were radiation to bone or pathological fractures, and the risk of developing 
first and subsequent on-study SREs. The annual SMR was also significantly lower in the denosumab group, 
as was the annualised SRE rate.
In the study by Saad and colleagues117 there was a statistically significant difference in time to first 
on-study SRE in favour of zoledronic acid compared with placebo (488 days vs 321 days), a lower SMR 
for the zoledronic acid group and a statistically significant lower incidence in the numbers of patients 
who experienced at least one SRE in the zoledronic acid group (33.2%) compared with the placebo 
group (44.2%).
The denosumab RCT reported on hypercalcaemia. (Academic-in-confidence information has been 
removed.) Saad and colleagues117 did not report this outcome.
In the denosumab study overall survival was similar between the groups (19.4 months for the denosumab 
group compared with 19.8 months for the zoledronic acid group). Saad and colleagues118 reported a 
median survival of 546 days (around 18.2 months) for the zoledronic acid group and 464 days (around 
15.5 months) for the placebo group.
Denosumab delayed the time to development of moderate or severe pain by around 1 month compared 
with zoledronic acid (median 5.8 vs 4.9 months). Saad and colleagues117 reported that the mean increase 
from baseline in pain score at 15 months was 0.58 (95% CI 0.29 to 0.87) for the zoledronic acid group 
compared with 0.88 (95% CI 0.61 to 1.15) for the placebo group.
In terms of quality of life, for FACT-G, (academic-in-confidence information has been removed); Saad 
and colleagues117 reported that the total FACT-G score and the EQ-5D scores decreased from baseline 
to the last measurement, with no statistically significant differences between the zoledronic acid and 
placebo groups.
In terms of adverse events, there were statistically significantly more hypocalcaemia events in the 
denosumab group compared with the zoledronic acid group (13% vs 6%), slightly more ONJ events (2% 
vs 1%) and slightly fewer adverse events potentially associated with renal impairment (15% vs 16%), while 
fewer patients in the denosumab group experienced acute-phase reactions (8% vs 18%). The rates for 
adverse events leading to treatment discontinuation, CTCAE grade 3 or 4, or serious or fatal adverse events 
were broadly similar between the denosumab and zoledronic acid groups.
In the study by Saad and colleagues,117 2% of patients in the zoledronic acid group experienced grade 3 
or 4 hypocalcaemia compared with none in the placebo group, and renal function deterioration occurred 
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in 15.2% of patients who received zoledronic acid compared with 11.5% of those receiving placebo (ONJ 
and acute-phase reactions were not reported). Similar proportions of patients who received zoledronic acid 
(9.8%) and placebo (10.1%) discontinued the study drug because of a SAE.
The AG’s NMA reported statistically significant differences in favour of denosumab compared with 
placebo for time to first on-study SRE, risk of developing first and subsequent SREs and SMR (academic-in-
confidence information has been removed).
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Chapter 6 Results: non-small cell lung cancer
This chapter reports NSCLC alone. As NSCLC alone, OSTs excluding NSCLC and OSTs including NSCLC were reported by the same two studies,30,130 information on the characteristics of the included studies 
and quality of the included studies is reported here and not repeated in Chapter 7 (on OSTs excluding 
NSCLC) or Chapter 8 (on OSTs including NSCLC).
Quantity of research available
See Chapter 4, Quantity of research available.
Number and type of studies included
The flow diagram outlining the screening process for the overall review is shown in Figure 3.
Number and type of studies excluded
See Chapter 4 for information on studies that were excluded from the review and Appendix 5 for a list 
of these studies along with the reasons for their exclusion. These studies were excluded because they 
failed to meet one or more of the inclusion criteria in terms of types of study, participants, intervention or 
outcomes reported.
Characteristics of the included studies
Two trials reported on bone metastases secondary to OSTs (excluding breast cancer and prostate cancer) 
and were included for the indirect comparison.30,130 Both trials included a subgroup of patients with bone 
metastases secondary to NSCLC and reported outcomes for that group of patients. Appendix 8 shows 
the characteristics of the included studies. Table 37 shows summary information for the two studies that 
provided direct evidence for denosumab or were included in the NMA.
TABLE 37 Characteristics of the studies included in the NMA
Henry 201130 Rosen 2003b130
Baseline characteristic Zoledronic acid Denosumab Zoledronic acid Placebo
Randomised 890 886 257 250
Age (years), median (range) 61 (22–87) 60 (18–89) 64 64
Sex (% male) 552 (62%) 588 (66%) 158 (61%) 159 (64%)
ECOG status 1 or below 728 (82%) 748 (84%) 211 (83%) 215 (87%)
Primary tumour type
NSCLC 352 (40%) 350 (39%) 124 (49%) 120 (49%)
Multiple myeloma 93 (10%) 87 (10%) NR NR
Other 455 (50%) 449 (51%) 130 (51%) 130 (51%)
Time from diagnosis of bone metastasis 
(months), median (range)
2 (0–130) 2 (0–152) 3.8 2.5
Previous SREs 446 (50%) 440 (50%) 166 (65%) 179 (73%)
NR, not reported.
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Data from the trial comparing denosumab with zoledronic acid were derived from three sources: (1) 
the peer-reviewed publication by Henry and colleagues,30 which included multiple myeloma, but also 
presented certain outcomes for subgroups; (2) the MS, which included a post-hoc analysis excluding 179 
patients with multiple myeloma (n = 800 denosumab, n = 797 zoledronic acid included for analysis); and 
(3) CSR 244 including multiple myeloma, which was included with the MS.
The study by Henry and colleagues30 was undertaken between June 2006 and May 2008 and enrolled 
patients aged ≥ 18 years with confirmed solid tumours (except breast and prostate) or multiple myeloma 
and at least one bone metastasis or osteolytic lesion (in the case of multiple myeloma), from 321 centres 
worldwide. However, few (academic-in-confidence information has been removed) patients were from the 
UK (MS). Exclusion criteria included creatinine clearance < 30 ml/minute, prior treatment with intravenous 
BPs, planned radiation or surgery to bone, and unhealed dental/oral surgery. Patients received 120 mg 
denosumab subcutaneously (plus intravenous placebo) or 4 mg zoledronic acid intravenously (adjusted for 
renal impairment plus subcutaneous placebo) every 4 weeks. Before the randomisation process, patients 
were stratified by tumour type that included NSCLC, myeloma, or other, previous SRE and systemic 
anticancer therapy at enrolment. The overall study was powered to detect non-inferiority and superiority 
for time to first on-study SRE (primary outcome) and risk of first and subsequent on-study SRE. Study 
duration was median 7 months and length of follow-up was 34 months. The study was funded by Amgen.
The study by Rosen and colleagues130 enrolled patients aged ≥ 18 years with osteolytic, osteoblastic, or 
mixed bone metastases from solid tumours (excluding breast and prostate cancer). Patients received 4 mg 
or 8 mg zoledronic acid intravenously or placebo every 3 weeks for 9 months. Before the randomisation 
process, patients were stratified by tumour type that included NSCLC or OST. The duration of the study 
was 9 months. The primary outcome was the proportion of patients with at least one SRE. During the 
trial there was a study protocol amendment. Patients randomised to the 8 mg zoledronic acid arm were 
changed to 4 mg because of renal toxicity concerns.
The study by Henry and colleagues30 included 40% of patients with NSCLC, 10% with multiple myeloma 
and 50% with other tumours where half of the included participants belonged to ECOG status 1. Similarly, 
the study by Rosen and colleagues130 included 49% of patients with NSCLC and the rest with OSTs 
including SCLC (7–8%), renal cell carcinoma (8–11%), unknown primary (7%), head and neck (2%), thyroid 
(1–2%) and other (24%) where more than 80% of patients had ECOG status 1 or below.
In the study by Henry and colleagues30 reporting on denosumab, 87% to 96% received antineoplastic or 
anticancer treatment. However, none of the patients had received previous intravenous BP treatment. Fifty 
per cent of the included participants had had a previous SRE at baseline while 40% and 46% had received 
radiotherapy and surgery, respectively. More than 80% had received chemotherapy in the trial by Rosen 
and colleagues130 reporting zoledronic acid and 3% had previously received BP treatment, while 68% had 
had a previous SRE at baseline (65% in zoledronic acid and 73% in placebo).
The definition of SRE in both trials included pathological fracture, radiation or surgery to bone, and SCC. In 
addition, Rosen and colleagues130 included hypercalcaemia in the definition of SRE for secondary efficacy 
analysis. A subsequent SRE was defined as an event occurring more than 21 days after the previous SRE in 
both trials by Henry and colleagues30 and Rosen and colleagues.130
The characteristics of the subgroup of patients with bone metastases from NSCLC was reported in the 
manufacturer’s CSR 244 of the denosumab RCT and are shown in Table 38.
Quality of the included studies
Table 39 shows the results of the risk of bias assessment for the studies by Henry and colleagues30 and 
Rosen and colleagues.130
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The study by Henry and colleagues30 was of good quality with low risk of bias as assessed against the 
criteria in Table 39. In the study by Rosen and colleagues130 it was unclear whether or not sequence 
generation and allocation concealment were adequate. The study by Henry and colleagues30 used an 
interactive voice response system to randomly assign patients (1 : 1 ratio) to treatment groups. An 
individual independent of the study team prepared the random assignment schedule. The study was 
double blind and study dose and outcomes were blinded throughout the primary analysis. There was 
adequate description of withdrawals and losses to follow-up and all of the prespecified outcomes were 
reported. Both primary and secondary efficacy end points included all randomised patients (intention-
to-treat analysis).
The study by Rosen and colleagues130 did not state the randomisation process and mentioned only that 
the participants were stratified by tumour type before randomisation. The study was double blind, patients 
lost to follow-up were described and all of the prespecified outcomes were reported; however, not all 
secondary outcomes were fully reported.
Assessment of effectiveness
Time to first on-study skeletal-related event
Henry and colleagues30 reported a HR of 0.84 (95% CI 0.64 to 1.10; p = 0.20) for denosumab compared 
with zoledronic acid for time to first on-study SRE for NSCLC, indicating a non-significant risk reduction 
TABLE 38 Characteristics of the subgroup of patients with NSCLC (denosumab trial) 
Baseline characteristic Denosumab (n=350) Zoledronic acid (n=352)
Mean age (SD) AiC information has been removed AiC information has been removed
Proportion female AiC information has been removed AiC information has been removed
Time from diagnosis to randomisation, median months (range)
Of lung cancer AiC information has been removed AiC information has been removed
Of bone metastases AiC information has been removed AiC information has been removed
Visceral metastases AiC information has been removed AiC information has been removed
ECOG status
0 AiC information has been removed AiC information has been removed
1 AiC information has been removed AiC information has been removed
2 AiC information has been removed AiC information has been removed
AiC, academic-in-confidence.
Source: CSR 244.131
TABLE 39 Results of the risk of bias assessment
Criteria Henry 201130 Rosen 2003b131
Adequate sequence generation Yes Unclear
Adequate allocation concealment Yes Unclear
Blinding Yes Yes
Incomplete outcome data addressed Yes No
Free of selective reporting Yes Yes
NIHR Journals Library www.journalslibrary.nihr.ac.uk
results: nOn-small cell lung cancer
68
for denosumab compared with zoledronic acid. (Academic-in-confidence information has been removed) 
(CSR 244). The study by Rosen and colleagues130 reported longer median time to first on-study SRE in the 
zoledronic acid group compared with the placebo group (171 vs 151 days); however, the difference was 
not significant (p = 0.188).
Neither study reported SRE by type or prior history of SRE for this outcome.
Risk of first and subsequent on-study skeletal-related event
The study by Henry and colleagues30 did not report the risk of developing multiple SREs (first and 
subsequent on-study SREs) for the NSCLC subgroup. (Academic-in-confidence information has been 
removed) (CSR 244). In the study by Rosen and colleagues,130 a 27% risk reduction of multiple SREs by the 
use of zoledronic acid was reported relative to placebo (HR 0.73; p = 0.061). A similar risk reduction was 
reported when HCM was included in the analysis (HR 0.71; p = 0.036).
Neither study reported SRE by type or prior history of SRE for this outcome.
Skeletal morbidity rate
Neither study reported SMR for the NSCLC subgroup.
Incidence of skeletal-related events
(Academic-in-confidence information has been removed) (CSR 244). The study by Rosen and colleagues130 
reported that in the NSCLC group of patients, a similar proportion of patients experienced SREs in the 
zoledronic acid group and in the placebo group (42% vs 45%; p = 0.007).
Neither study reported SRE by type or prior history of SRE for this outcome.
Prevention of hypercalcaemia
Neither study reported hypercalcaemia for the NSCLC subgroup.
Overall survival
An ad hoc analysis for overall survival in a trial by Henry and colleagues30 reported that denosumab 
significantly improved overall survival relative to zoledronic acid by 21% (HR 0.79; 95% CI 0.65 to 0.95).
The study by Rosen and colleagues130 did not report this outcome.
Prior history of skeletal-related events
Neither study reported overall survival by prior history of SRE for those with NSCLC.
Pain
Neither study reported this outcome for those with NSCLC.
Health-related quality of life
Neither study reported this outcome for those with NSCLC.
Adverse events related to treatment
There were no published or unpublished data on adverse events including hypocalcaemia, ONJ, renal 
toxicity, acute-phase reactions or other adverse events reported separately for those with NSCLC. See 
Chapter 8, Adverse events related to treatment for adverse events reported for all OSTs including NSCLC.
Network meta-analysis
The AG group performed a NMA of NSCLC alone, using subgroups from the Henry and Rosen studies.30,130 
The manufacturer did not perform this analysis. Three outcomes were included: time to first on-study SRE 
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(Table 40), risk of first and subsequent SREs (Table 41) and the proportion of patients with an on-study 
SRE (Table 42).
Time to first on-study skeletal-related event
The results for time to first on-study SRE are shown in Table 40. The NMA results favoured 
denosumab compared with zoledronic acid or placebo for time to first on-study SRE but were not 
statistically significant.
Risk of first and subsequent on-study skeletal-related events
The results for the risk of developing first and subsequent on-study SREs are presented below in Table 41. 
The NMA results favoured denosumab compared with zoledronic acid or placebo for risk of developing 
first and subsequent SREs, although only the result compared with placebo was statistically significant.
Proportion of patients with on-study skeletal-related events
Results for the proportion of patients with an on-study SRE are shown below in Table 42. The NMA results 
favoured denosumab compared with zoledronic acid or placebo for the proportion of patients with an 
on-study SRE but were not statistically significant. These results should be interpreted with additional 
caution because this outcome does not differentiate between lengths of study, thereby adding to 
the uncertainty.
Summary
Only one study, by Henry and colleagues,30 was identified that compared denosumab with zoledronic 
acid. Another study comparing zoledronic acid with placebo, by Rosen and colleagues,130 met the 
inclusion criteria for the NMA and so is reported in this chapter. The study by Henry and colleagues30 was 
a good-quality RCT with low risk of bias, whereas the study by Rosen and colleagues130 did not report 
TABLE 40 Time to first on-study SRE
Comparison AG’s NMA, HR (95% CI)
Denosumab vs zoledronic acid 0.84 (0.64 to 1.10)
Denosumab vs placebo 0.68 (0.45 to 1.03)
Zoledronic acid vs placebo 0.81 (0.59 to 1.11)
TABLE 41 Risk of first and subsequent SREs 
Comparison AG’s NMA, RR (95% CI)
Denosumab vs zoledronic acid 0.87 (0.68 to 1.12)
Denosumab vs placebo 0.63 (0.42 to 0.97)
Zoledronic acid vs placebo 0.73 (0.52 to 1.02)
TABLE 42 Proportion of patients with on-study SRE
Comparison AG’s NMA, OR (95% CI)
Denosumab vs zoledronic acid 0.96 (0.08 to 11.7)
Denosumab vs placebo 0.83 (0.02 to 30.6)
Zoledronic acid vs placebo 0.87 (0.07 to 11.2)
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sufficient information on randomisation. In terms of generalisability, the Henry study30 was multicentre and 
international while the Rosen study130 was multicentre. However, in these studies patients with NSCLC did 
not form the whole patient population but rather were a subgroup of a population that included patients 
with bone metastases from a range of OSTs, excluding breast and prostate cancer. The studies reported 
outcomes for all OSTs grouped together, and separately for NSCLC – approximately 40% (n = 702) of 
patients in the Henry study30 and 50% (n = 244) in the Rosen study130 – and OSTs excluding NSCLC. The 
proportion of NSCLC patients from the UK was not reported. In both studies the exclusion criteria included 
severe renal impairment or prior treatment with BPs. Study duration was longer in the Henry trial30 (primary 
analysis at 34 months) compared with the Rosen trial130 (9 months). The Henry study30 was not powered 
to detect either non-inferiority or superiority for time to first on-study SRE or risk of first and subsequent 
on-study SREs for the NSCLC subgroup alone.
For those with bone metastases from NSCLC, a non-significant difference favouring denosumab over 
zoledronic acid in time to first on-study SRE was reported in the study by Henry and colleagues.30 
(Academic-in-confidence information has been removed) (CSR 244). No data were reported on SMR, 
incidence of SRE, hypercalcaemia, pain or quality of life. The study by Henry and colleagues30 reported 
a statistically significant difference in favour of denosumab for overall survival (21% risk reduction with 
denosumab) for patients with NSCLC.
The study by Rosen and colleagues130 reported a non-significant difference favouring zoledronic acid over 
placebo in time to first SRE and time to first and subsequent SREs. A similar proportion of SREs were 
reported in the two groups. No data were reported for SMR, hypercalcaemia, overall survival, pain or 
quality of life. Adverse events were not reported separately for the subgroup of patients with NSCLC.
In the AG’s NMA, there was a statistically significant difference in favour of denosumab compared with 
placebo for risk of developing first and subsequent SREs, while the direction of effect for SMR favoured 
denosumab but was not statistically significant.
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Chapter 7 Results: other solid tumours (excluding 
non-small cell lung cancer)
This chapter reports outcomes for OSTs excluding NSCLC, breast cancer, prostate cancer or multiple myeloma.
Quantity of research available
See Chapter 4, Quantity of research available.
Number and type of studies included
The flow diagram outlining the screening process for the overall review is given in Figure 3.
Number and type of studies excluded
For information on studies that were excluded from the review see Chapter 4, Number and type of studies 
excluded, and see Appendix 5 for a list of these studies along with the reasons for their exclusion. These 
studies were excluded because they failed to meet one or more of the inclusion criteria in terms of types of 
study, participants, interventions or outcomes reported.
Characteristics of the included studies
As these were the same trials that reported the subgroup of patients with lung cancer separately (Henry 
and collagues30 and Rosen and colleagues130), see Chapter 6, Characteristics of the included studies for 
details of the characteristics of the included studies for the overall studies.
Quality of the included studies
As these were the same trials that reported the subgroup of patients with lung cancer separately, see 
Chapter 6, Quality of the included studies for the quality of the included studies for the overall studies.
Assessment of effectiveness
Time to first on-study skeletal-related event
Henry and colleagues30 reported that denosumab reduced the risk of having a first on-study SRE relative to 
zoledronic acid by 21% (HR 0.79; 95% CI 0.62 to 0.99; p = 0.04) for OSTs excluding NSCLC. The CSR 244 
reported median time to first on-study SRE (academic-in-confidence information has been removed) for 
zoledronic acid and (academic-in-confidence information has been removed) for the denosumab group.
The study by Rosen and colleagues130 reported that the median time to developing a first SRE was 
significantly longer in the zoledronic acid group (314 days) than in the placebo group (168 days) 
(p = 0.051).
Neither study reported SRE by type or prior history of SRE for this outcome for the subgroup with OSTs 
excluding NSCLC.
Risk of first and subsequent on-study skeletal-related events
The published paper by Henry and colleagues30 did not report risk of developing first and subsequent 
on-study SREs. (Academic-in-confidence information has been removed) (CSR 244). The study by Rosen 
and colleagues130 reported a 26% reduction in the risk of developing multiple SREs for the zoledronic acid 
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group compared with the placebo group (HR 0.74, CI not reported); however, the difference was non-
significant (p = 0.136).
Neither study reported SRE by type or prior history of SRE for this outcome for the subgroup of patients 
with OSTs excluding NSCLC.
Skeletal morbidity rate
Neither study reported SMR for those with OSTs excluding NSCLC.
Incidence of skeletal-related events
The published study by Henry and colleagues30 did not report incidence of SREs for the subgroup of 
patients with OSTs excluding NSCLC. (Academic-in-confidence information has been removed) (CSR 244).
In the study by Rosen and colleagues,130 the proportion of patients with a SRE was significantly lower in 
the zoledronic acid group (33%) compared with the placebo group (43%) (p = 0.11) for those with OSTs 
(excluding NSCLC).
Neither study reported SRE by type or prior history of SRE for this outcome for the subgroup of patients 
with OSTs excluding NSCLC.
Prevention of hypercalcaemia
Neither study reported prevention of hypercalcaemia for those with OSTs excluding NSCLC.
Overall survival
All patients
An ad hoc analysis by Henry and colleagues30 reported a non-significant difference in overall survival 
between the denosumab and zoledronic acid groups (HR 1.08; 95% CI 0.90 to 1.30).
The study by Rosen and colleagues130 did not report overall survival for those with OSTs excluding NSCLC.
Prior history of skeletal-related events
Neither study reported overall survival by history of SREs for those with OSTs excluding NSCLC.
Pain
Neither study reported the outcome of pain for those with OSTs excluding NSCLC.
Health-related quality of life
Neither study reported quality of life for those with OSTs excluding NSCLC.
Adverse events related to treatment
Adverse events including hypocalcaemia, ONJ, renal toxicity, acute-phase reactions or other adverse events 
were not reported separately for those with OSTs excluding NSCLC. See Chapter 8, Adverse events related 
to treatment, for information on adverse events reported for patients with OSTs including NSCLC.
Network meta-analysis
The AG performed a NMA of OSTs, excluding breast cancer, prostate cancer, multiple myeloma and NSCLC, 
using subgroups from the Henry and Rosen studies.30,130 The manufacturer did not perform this analysis. 
Three outcomes were included: time to first on-study SRE (Table 43), risk of first and subsequent on-study 
SRE (Table 44) and the proportion of patients with an on-study SRE (Table 45).
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Time to first on-study skeletal-related event
The results for time to first on-study SRE are shown in Table 43. There was a statistically significant 
difference in favour of denosumab compared with zoledronic acid or placebo for this outcome.
Risk of first and subsequent on-study skeletal-related events
The NMA results for risk of developing first and subsequent SREs are presented in Table 44. There was a 
statistically significant difference in favour of denosumab compared with placebo for this outcome.
Proportion of patients with an on-study skeletal-related event
The results for the proportion of patients with an on-study SRE are shown in Table 45. The results for 
denosumab compared with zoledronic acid or placebo were not statistically significant although the 
direction of effect favoured denosumab. These results should be interpreted with additional caution 
because this outcome does not differentiate between lengths of study, thereby adding to the uncertainty.
Summary
As these two studies were the same studies that contained the subgroups of NSCLC patients, see also 
Chapter 6, Summary for information on the characteristics, quality and generalisability of the overall 
studies. One further point to note in terms of generalisability is that data from patients with a range of 
different types of solid tumour (excluding breast, prostate or NSCLC) were pooled to provide an overall 
estimate for OSTs. The Henry study30 was not powered to detect non-inferiority or superiority for OSTs 
excluding NSCLC.
For those with bone metastases from OSTs excluding NSCLC, there was a significant risk reduction for 
denosumab compared with zoledronic acid in time to first on-study SRE (21% reduction with denosumab 
TABLE 43 Time to first on-study SRE
Comparison AG’s NMA, HR (95% CI)
Denosumab vs zoledronic acid 0.79 (0.62 to 0.99)
Denosumab vs placebo 0.30 (0.11 to 0.82)
Zoledronic acid vs placebo 0.37 (0.14 to 1.01)
TABLE 44 Risk of first and subsequent SREs
Comparison AG’s NMA, RR (95% CI)
Denosumab vs zoledronic acid 0.83 (0.67 to 1.03)
Denosumab vs placebo 0.61 (0.39 to 0.97)
Zoledronic acid vs placebo 0.74 (0.49 to 1.10)
TABLE 45 Proportion of patients with an on-study SRE
Comparison AG’s NMA, OR (95% CI)
Denosumab vs zoledronic acid 0.68 (0.05 to 8.81)
Denosumab vs placebo 0.44 (0.01 to 17.13)
Zoledronic acid vs placebo 0.65 (0.05 to 8.19)
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in the study by Henry and colleagues30) (academic-in-confidence information has been removed) (CSR 
244). (Academic-in-confidence information has been removed.) In the study by Henry and colleagues,30 
no statistically significant difference was reported for overall survival. No data were reported for SMR, 
hypercalcaemia, pain or quality of life.
The study by Rosen and colleagues130 reported a statistically significant difference between zoledronic acid 
and placebo in time to first on-study SRE (314 days vs 168 days); however, a non-significant difference in 
risk of first and subsequent on-study SREs was reported. Significantly lower incidence of SREs was reported 
for zoledronic acid (33%) compared with placebo (43%) but the difference was not statistically significant 
(p = 0.11). No data were reported for hypercalcaemia, overall survival, pain or quality of life. Adverse 
events were not reported separately for OSTs excluding NSCLC.
In the AG’s NMA, there was a statistically significant difference in favour of denosumab compared with 
zoledronic acid or placebo for time to first on-study SRE and compared with placebo for risk of developing 
first and subsequent SREs, while for the proportion of patients with an on-study SRE there was no 
statistically significant difference, although the direction of effect favoured denosumab.
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Chapter 8 Results: other solid tumours (including 
non-small cell lung cancer)
This chapter reports outcomes for OSTs including NSCLC (but excluding breast cancer or prostate cancer). Data taken from the CSR may include multiple myeloma and this has been highlighted 
where applicable.
Quantity of research available
See Chapter 4, Quantity of research available
Number and type of studies included
The flow diagram outlining the screening process for the overall review is shown in Figure 3.
Number and type of studies excluded
For information on studies that were excluded from the review, see Chapter 4, Number and types of 
studies excluded, and for a list of these studies along with the reasons for their exclusion, see Appendix 5. 
These studies were excluded because they failed to meet one or more of the inclusion criteria in terms of 
types of study, participants, intervention or outcomes reported.
Characteristics of the included studies
As these were the same trials (Henry and colleagues30 and Rosen and colleagues130) that reported the 
subgroup of patients with lung cancer separately, see Chapter 6, Characteristics of the included studies for 
details of the characteristics of the included studies.
Quality of the included studies
As these were the same trials that reported the subgroup of patients with lung cancer separately, see 
Chapter 6, Qualities of the included studies for details of the quality of the included studies.
Assessment of effectiveness
Time to first on-study skeletal-related event
Results for time to first on-study SRE are shown in Table 46. In the MS post-hoc analysis of study 244 of 
OSTs (excluding myeloma), the median time to first on-study SRE was longer for denosumab (academic-
in-confidence information has been removed) compared with zoledronic acid (academic-in-confidence 
information has been removed) with a risk reduction of 19% [HR 0.81; 95% CI 0.68 to 0.96; p = 0.03 
(superiority)]. Some patients in the zoledronic acid group (academic-in-confidence information has been 
removed) and the denosumab group (academic-in-confidence information has been removed) were 
reported to experience a first on-study SRE. The MS (excluding multiple myeloma) further reported that the 
median time to first symptomatic SRE was significantly shorter for denosumab compared with zoledronic 
acid (HR 0.81; 95% CI 0.66 to 0.99; p = 0.0383). The study by Henry and colleagues30 (including multiple 
myeloma) reported a statistically significant difference in favour of denosumab compared with zoledronic 
acid in delaying time to first on-study SRE by 16% (HR 0.84; 95% CI 0.71 to 0.98; p = 0.0007). The median 
time to first on-study SRE was significantly longer for denosumab (20.6 months) than for zoledronic 
acid (16.3 months) (p = 0.03). However, when adjusted for multiple comparisons (using the Hochberg 
procedure) to test for superiority for time to first SRE, the difference was not significant (p = 0.06).
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The study by Rosen and colleagues130 reported significantly longer median time to first SRE for zoledronic 
acid (230 days) compared with placebo (163 days) (p = 0.023). Analysis of median time to first event 
excluding HCM and including death was longer for zoledronic acid (136 days) compared with placebo 
(93 days) (p = 0.039).
Skeletal-related events by type
The time to radiation to the bone was reported in the post-hoc analysis of study 244 (excluding multiple 
myeloma). The median time to radiation to the bone in the zoledronic group and in the denosumab 
group (academic-in-confidence information has been removed), and the risk reduction for denosumab 
(academic-in-confidence information has been removed) (MS) were reported.
In the study by Henry and colleagues30 (including multiple myeloma), denosumab reduced the risk 
of having radiation to bone by 22% compared with zoledronic acid (HR 0.78; 95% CI 0.63 to 0.97; 
p = 0.03).134
(Academic-in-confidence information has been removed) (CSR 244).
Table 47 shows the distribution of first on-study SRE by type of SRE as reported in the MS (post-hoc 
analysis of CSR 244, excluding multiple myeloma). The distribution of type of SRE was similar across the 
treatment groups, with radiation to bone and pathological fracture being the most commonly occurring.
The study by Rosen and colleagues130 reported that the median time was not reached for individual SRE 
except for median time to first pathological fracture, which was longer in the zoledronic acid group 
(238 days) compared with the placebo group (161 days) (p = 0.031). Rosen and colleagues131 further 
reported that the time to first vertebral fracture and time to first radiation therapy were significantly longer 
in the zoledronic acid group (p = 0.05).
Prior history of skeletal-related events
The MS reported time to first on-study SRE by prior history of SREs for post hoc study 244 (excluding 
myeloma) (Table 48). (Academic-in-confidence information has been removed.)
The published study by Henry and colleagues30 did not report time to first on-study SRE by previous history 
of SRE. (Academic-in-confidence information has been removed) (CSR 244).
TABLE 46 Time to first on-study SRE 
Study ID Measures Denosumab Zoledronic acid p-value
Henry 201130 (including multiple 
myeloma)
Number 
randomised
886 890 NA
Median months 20.6 16.3 0.03
HR (95% CI) 0.84 (0.71 to 0.98) 0.0007
Post-hoc analysis CSR 244 (excluding 
multiple myeloma)
Number 
randomised
800 797 NA
Median months 21.4 15.4 NA
HR (95% CI) 0.81 (0.68 to 0.96) 0.03 (superiority)
0.001 (inferiority)
NA, not applicable.
Source: Henry 201130 and MS [Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone 
metastases from solid tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011].
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Rosen and colleagues130 did not report time to first on-study SRE by previous history of SRE.
Risk of first and subsequent on-study skeletal-related events
The MS (post-hoc analysis of study 244 excluding multiple myeloma) reported that denosumab reduced 
the risk of developing first and subsequent SREs compared with zoledronic acid. Using Anderson–Gill 
multiple event analysis (any events occurring at least 21 days apart), the result demonstrated borderline 
statistical significance (RR 0.85; 95% CI 0.72 to 1.00) (Table 49). The cumulative number of on-study SREs 
was lower for denosumab (328) than for zoledronic acid (374) (MS).
TABLE 47 Patients with first on-study SRE by type (post-hoc analysis of CSR 244)
Number of events (%)
SRE Denosumab (n = 800 randomised) Zoledronic acid (n = 797 randomised)
Overall AiC information has been removed AiC information has been removed
Radiation to bone AiC information has been removed AiC information has been removed
Pathological fracture AiC information has been removed AiC information has been removed
SCC AiC information has been removed AiC information has been removed
Surgery to bone AiC information has been removed AiC information has been removed
AiC, academic-in-confidence.
Source: MS [Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011].
TABLE 48 Subgroup analysis by prior SRE history for time to first on-study SRE (post-hoc analysis of CSR 244), 
excluding multiple myeloma
SRE history Denosumab Zoledronic acid
Overall
Number 800 797
HR (95% CI) AiC information has been removed
p-value AiC information has been removed
No prior SRE
Number AiC information has been removed AiC information has been removed
HR (95% CI) AiC information has been removed
p-value AiC information has been removed
Prior SRE
Number AiC information has been removed AiC information has been removed
HR (95% CI) AiC information has been removed
p-value AiC information has been removed
Covariate effect
Point estimate (95% CI) AiC information has been removed
p-value AiC information has been removed
AiC, academic-in-confidence.
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Henry and colleagues30 (when including multiple myeloma) reported a non-significant risk reduction 
for first and subsequent on-study SREs (without the 21-day window) for denosumab compared with 
zoledronic acid (RR 0.90; 95% CI 0.77 to 1.04; p = 0.14).
Rosen and colleagues130 reported that zoledronic acid reduced the risk of multiple SREs by 27% compared 
with placebo (HR 0.732; p = 0.017).
Skeletal-related events by type
Neither study reported multiple event analysis for SRE by type.
In the MS (post-hoc analysis CSR 244), there was no difference reported between denosumab and 
zoledronic acid for the proportion of patients with each type of SRE. The distribution of each type of SRE is 
shown in Table 50. Radiation to bone and pathological fracture were the most commonly occurring SREs, 
whereas surgery to bone and SCC were reported for only a small proportion of patients.
The published studies by Henry and colleagues30 and Rosen and colleagues130 did not report on risk of first 
and subsequent on-study SREs by type of SRE.
Prior history of skeletal-related events
The MS reported risk of first and subsequent on-study SREs by history of SRE for post hoc study 244 
(excluding multiple myeloma) (Table 51). (Academic-in-confidence information has been removed) (MS).
TABLE 49 Risk of first and subsequent on-study SRE 
Study ID Measures
Denosumab
(n = 890)
Zoledronic acid
(n = 886) p-value
Henry 201130 (including multiple myeloma) Number randomised 886 890 NA
Number of events 392 436 NA
Rate ratio (95% CI) 0.90 (0.77 to 1.04) 0.14
Post-hoc analysis CSR 244 (excluding multiple 
myeloma)
Number analysed 800 797 NA
Number of events 328 374 NA
Rate ratio (95% CI) 0.85 (0.72 to 1.00) 0.048
NA, not applicable.
Source: Henry 2011.30 Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases 
from solid tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
TABLE 50 Patients with first and subsequent on-study SRE by type (post-hoc analysis of CSR 244)
Number of events (%)
SRE Denosumab (n = 800 randomised) Zoledronic acid (n = 797 randomised)
Total number of events AiC information has been removed AiC information has been removed
Radiation to bone AiC information has been removed AiC information has been removed
Pathological fracture AiC information has been removed AiC information has been removed
SCC AiC information has been removed AiC information has been removed
Surgery to bone AiC information has been removed AiC information has been removed
AiC, academic-in-confidence.
Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
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(Academic-in-confidence information has been removed) (CSR 244).
The studies by Henry and colleagues30 and Rosen and colleagues130 did not report risk of first and 
subsequent on-study SREs by prior history of SRE.
Skeletal morbidity rate
The published study by Henry and colleagues30 did not report data on SMR. (Academic-in-confidence 
information has been removed) (Table 52).
(Academic-in-confidence information has been removed) (CSR 244). Rosen and colleagues130 reported a 
slightly lower SMR (the number of events per year) for zoledronic acid (2.24; SD 9.12) than for placebo 
(2.52; SD 5.11); however, the difference was non-significant (p = 0.069). When hypercalcaemia was 
included in the analysis, the SMR was statistically significantly lower for zoledronic acid than for placebo 
[2.24 (SD 9.12) vs 2.73 (SD 5.29)].
Skeletal-related events by type
The SMR by type of SRE was not reported for the denosumab RCT.30
Rosen and colleagues130 reported that the SMR for each type of SRE was lower in the zoledronic acid 
treatment groups than in the placebo group except for surgery to bone and SCC; however, no data 
were reported.
Prior history of skeletal-related events
Neither study reported SMR by history of SREs.
TABLE 51 Risk of first and subsequent on-study SREs by prior history of SRE
SRE history Denosumab Zoledronic acid
Overall
Number 800 797
HR (95% CI) AiC information has been removed
p-value AiC information has been removed
No prior SRE
Number AiC information has been removed AiC information has been removed
HR (95% CI) AiC information has been removed
p-value AiC information has been removed
Prior SRE
Number AiC information has been removed AiC information has been removed
HR (95% CI) AiC information has been removed
p-value AiC information has been removed
Covariate effect
Point estimate (95% CI) AiC information has been removed
p-value AiC information has been removed
AiC, academic-in-confidence.
Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
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Incidence of skeletal-related events
The study by Henry and colleagues30 did not report incidence of SREs. In the MS (post-hoc analysis of CSR 
244 excluding multiple myeloma), the annualised SRE rate (number of events per subject years) (academic-
in-confidence information has been removed). The results are shown in Table 52.
(Academic-in-confidence information has been removed) (CSR 244).
The study by Rosen and colleagues130 reported a non-significant difference between zoledronic acid and 
placebo in the proportion of SREs experienced (38% vs 44%; p = 0.127).
Skeletal-related events by type
Incidence of SREs by SRE type was not reported for the denosumab RCT.
Rosen and colleagues130 reported the distribution of SRE type in zoledronic acid compared with placebo 
as shown in Table 53. For each individual SRE, a lower proportion of patients receiving zoledronic acid 
experienced a SRE than those receiving placebo. Radiation to bone and pathological fracture were the 
most frequently occurring SREs while SCC occurred least.
Prior history of skeletal-related events
Neither study reported incidence of SRE by history of SREs.
Prevention of hypercalcaemia
(Academic-in-confidence information has been removed.) (CSR 244).
In the study by Rosen and colleagues130 there was no HCM in the zoledronic group, whereas in the placebo 
group 3% of patients experienced HCM.
Overall survival
Henry and colleagues30 reported no difference between denosumab and zoledronic acid for overall survival 
(HR 0.95; 95% CI 0.83 to 1.08; p = 0.43). In the MS median overall survival was balanced between 
the groups, with median time for survival 10.7 months in the denosumab group and 10.0 months in 
TABLE 52 Annualised SRE rate and SMR in post hoc study CSR 244
Annualised SRE rate per patient Denosumab (n = 800) Zoledronic acid (n = 797)
Subject years AiC information has been removed AiC information has been removed
Without 21-day window
Number of events AiC information has been removed AiC information has been removed
Annualised rate AiC information has been removed AiC information has been removed
With 21-day window
Number of events AiC information has been removed AiC information has been removed
Annualised rate AiC information has been removed AiC information has been removed
Mean annual SMR
Rate AiC information has been removed AiC information has been removed
p-value AiC information has been removed
AiC, academic-in-confidence.
Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
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the zoledronic acid group. The risk reduction for overall survival (excluding multiple myeloma) was not 
statistically significant (0.92; 95% CI 0.81 to 1.05; p = 0.2149).
Rosen and colleagues130 reported time to median death, which was similar in the zoledronic acid group 
(203 days) and the placebo group (183 days) (p = 0.623).
Prior history of skeletal-related events
Neither study reported overall survival by history of SREs.
Pain
The MS reported pain outcomes assessed using BPI-SF. The median time to developing moderate or severe 
worst pain was evaluated in a subgroup of patients with no/mild pain (n = 323 for denosumab; n = 273 
for zoledronic acid). The median time to developing moderate or severe worst pain (worst pain score 
> 4) in this group was longer in the denosumab group (3.7 months) than in the zoledronic acid group 
(2.8 months, HR 0.81; 95% CI 0.66 to 0.99; p = 0.038). The MS further reported that denosumab delayed 
the time to worsening pain (≥ 2-point increase from baseline in BPI-SF worst pain score) compared with 
zoledronic acid (4.7 months vs 3.9 months; p = 0.040). (Academic-in-confidence information has been 
removed.) The study by Henry and colleagues134 reported similar results in those with OSTs and including 
multiple myeloma (169 days vs 143 days; HR 0.85; 95% CI 0.73 to 0.98; p = 0.02).
(Academic-in-confidence information has been removed) (CSR 244). 
There was no statistically significant difference at the study end point in the use of strong analgesics in 
OSTs (post-hoc analysis excluding multiple myeloma). 
(Academic-in-confidence information has been removed) (CSR 244).
The study by Rosen and colleagues130 comparing zoledronic acid with placebo reported an increase in 
pain score from baseline to month 9 for mean BPI composite pain score and mean analgesic score in 
both groups, suggesting increased pain and use of analgesics. This study further reported that the mean 
composite pain score was decreased from baseline to month 9 for zoledronic acid for those who had pain 
at baseline; however, no data were reported.
TABLE 53 Proportion of patients experiencing SRE by type
Number of events (%)
SRE Zoledronic acid (n = 257 randomised) Placebo (n = 250 randomised) p-value
All SRE (excluding HCM) 38% 44% 0.127
Radiation to bone 69 (27%) 81 (32%) NR
Pathological fracture 40 (16%) 53 (21%) NR
Vertebral 20 (8%) 30 (12%)
Non-vertebral 26 (10%) 29 (12%)
Surgery to bone 11 (4%) 9 (4%) NR
SCC 7 (3%) 10 (4%) NR
HCM 0 8 (3%) 0.004
Any SRE (including HCM) 97 (38%) 117 (47%) 0.039
NR, not reported.
Source: Rosen 2003b.130 
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Health-related quality of life
Functional Assessment of Cancer Therapy – General
(Academic-in-confidence information has been removed) (Table 54).
(Academic-in-confidence information has been removed) (CSR 244).
The study by Rosen and colleagues130 stated that there were no statistically significant differences between 
zoledronic acid and placebo with respect to any of these global quality-of-life outcomes and that changes 
in FACT-G scores were also comparable between treatment groups; however, no data were reported.
European Quality of Life-5 Dimensions
(Academic-in-confidence information has been removed) (CSR 244).
Adverse events related to treatment
Hypocalcaemia
Henry and colleagues30 reported that 10.8% of denosumab-treated patients had hypocalcaemia compared 
with 5.8% of zoledronic acid-treated patients. The statistical difference between the groups was not 
reported. Grade 3 or 4 decreases in albumin-adjusted calcium values were reported in nine patients (1.0%) 
receiving zoledronic acid and 20 patients (2.3%) receiving denosumab. Although the number of patients 
reporting hypocalcaemia is small the total number of events is higher for denosumab compared with 
zoledronic acid (academic-in-confidence information has been removed) (CSR 244).
The study by Rosen and colleagues130 did not report hypocalcaemia.
Observational studies reported a higher incidence of hypocalcaemia compared with the RCTs. 
However, the observational studies are likely to have broader criteria for hypocalcaemia. Chennuru and 
colleagues138 reported an incidence of 8.3% over 2 years in patients prescribed zoledronic acid. Zuradelli 
and colleagues161 reported an incidence of 4.6% in patients prescribed zoledronic acid (time at risk 
not reported).
Osteonecrosis of the jaw
Henry and colleagues30 reported that rates of ONJ were similar in the denosumab (1.3%) and zoledronic 
acid (1.1%) groups (p = 1.00). The cumulative incidence rates of ONJ at years 1 and 3 was reported to be 
slightly higher in the zoledronic acid group compared with the denosumab group, which was 0.6% versus 
TABLE 54 Change in FACT scores from baseline to week 45 in post hoc study CSR 244
Scale
Denosumab 120 mg (n = 800) Zoledronic acid 4 mg (n = 797)
Baseline, mean (SD)
Change from baseline 
to week 45, mean (SD) Baseline, mean (SD)
Change from baseline 
to week 45, mean (SD)
Physical 
well-being
AiC information has 
been removed
AiC information has been 
removed
AiC information has 
been removed
AiC information has been 
removed
Functional 
well-being
AiC information has 
been removed
AiC information has been 
removed
AiC information has 
been removed
AiC information has been 
removed
FACT-G 
total score
AiC information has 
been removed
AiC information has been 
removed
AiC information has 
been removed
AiC information has been 
removed
AiC, academic-in-confidence.
Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
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0.5% at year 1 and 1.3% versus 1.1% at year 3 (p = 1.0). At year 2, ONJ events were slightly higher in the 
denosumab group (1.1%) compared with the zoledronic acid group (0.9%).
The study by Rosen and colleagues130 did not report ONJ.
Two large observational studies were found. Hoff and colleagues147 reported an incidence of 0.7% 
(29/3994) over 21.2 months in patients taking zoledronic acid or disodium pamidronate. Vahtsevanos and 
colleagues159 reported an incidence of 4.9% (80/1621) over 20.4 months in patients taking any BP.
Renal toxicity
Henry and colleagues30 reported that renal adverse events occurred more often in the zoledronic acid 
group (10.9%) than in the denosumab group (8.3%). In both treatment groups, renal failure was reported 
to be similar. The MS reported a higher number of patients in the zoledronic acid group compared 
with the denosumab group with serious renal adverse events (34 patients compared with 24 patients). 
(Academic-in-confidence information has been removed) (CSR 244). The small discrepancy in these results 
is unclear.
Rosen and colleagues130 reported that the proportion of patients with decreased renal function was higher 
in the zoledronic acid group than in the placebo group. When zoledronic acid was given as a 5-minute 
infusion, the proportion of patients with decreased renal function was much higher in the zoledronic acid 
group (16.4%) than in the placebo group (5.6%). After the implementation of a 15-minute infusion of 
the given dose, 10.9% in the zoledronic acid group and 6.7% in the placebo group experienced decreased 
renal function.
The largest observational study155 (n = 966) evaluated renal impairment in patients taking any BP and 
found an incidence of 2.9% over 9.6 months.
Acute-phase reactions
Henry and colleagues30 reported that acute-phase reactions occurred more often in the zoledronic acid 
group (14.5%) than in the denosumab group (6.9%). In the MS, SAEs of acute-phase reaction occurred 
within 3 days of first dose. (Academic-in-confidence information has been removed.)
Rosen and colleagues130 did not report this outcome.
Other adverse events
In the study by Henry and colleagues,30 SAEs were reported in 66% of those treated with zoledronic 
acid and in 63% of those treated with denosumab (p = 0.16). Pyrexia and anaemia were reported to be 
significantly higher in the zoledronic acid group than in the denosumab group. Other adverse events were 
similar in both groups.
In the study by Rosen and colleagues,130 a higher proportion in the zoledronic acid group than in the 
placebo group was reported to have nausea (46% vs 34%), vomiting (36% vs 29%) and dyspnoea (33% 
vs 26%). The incidence of bone pain was reported to be higher in the placebo group (59%) than in the 
zoledronic acid group (51%).
There were no other adverse events of note from the observational studies assessed. Anaemia was similar 
between all groups.
For details of all other adverse events extracted from the RCTs meeting the review’s inclusion criteria and 
also adverse events extracted from a number of observational studies identified, see Appendix 12.
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Network meta-analysis
The AG and manufacturer performed a NMA of OSTs excluding breast cancer and prostate cancer 
but including NSCLC. Two studies were included in each NMA (Henry and colleagues30 and Rosen and 
colleagues130). Including a mixture of cancers within a NMA increases heterogeneity significantly. Therefore, 
these results should be interpreted with caution. The AG also performed a NMA of the proportion of 
patients with an on-study SRE.
Time to first on-study skeletal-related event
The results for time to first on-study SRE are shown in Table 55. The AG’s NMA results were statistically 
significant in favour of denosumab compared with zoledronic acid or placebo. (Academic-in-confidence 
information has been removed.)
Risk of first and subsequent on-study skeletal-related events
The results for risk of developing first and subsequent on-study SREs are presented in Table 56. The AG’s 
NMA results were statistically significant in favour of denosumab compared with placebo, whereas the 
result for the comparison with zoledronic acid was not statistically significant, although the direction of 
effect favoured denosumab. (Academic-in-confidence information has been removed.)
Proportion of patients with on-study skeletal-related event
The results for the proportion of patients with an on-study SRE are shown in Table 57.
In the AG’s NMA, the differences between denosumab and zoledronic acid or placebo were not 
statistically significant, although the direction of effect favoured denosumab. This outcome does not 
TABLE 55 Time to first on-study SRE
Comparison AG’s NMA, HR (95% CI) MS’s NMA, HR (95% CI)
Denosumab vs zoledronic acid 0.81 (0.68 to 0.96) AiC information has been removed
Denosumab vs placebo 0.49 (0.30 to 0.78) AiC information has been removed
Zoledronic acid vs placebo 0.60 (0.38 to 0.93) AiC information has been removed
AiC, academic-in-confidence.
TABLE 56 Risk of first and subsequent on-study SREs 
Comparison AG’s NMA, RR (95% CI) MS’s NMA, HR (95% CI)
Denosumab vs zoledronic acid 0.85 (0.72 to 1.00) AiC information has been removed
Denosumab vs placebo 0.62 (0.46 to 0.85) AiC information has been removed
Zoledronic acid vs placebo 0.73 (0.56 to 0.95) AiC information has been removed
AiC, academic-in-confidence.
TABLE 57 Proportion of patients with on-study SRE
Comparison AG’s NMA, OR (95% CI)
Denosumab vs zoledronic acid 0.79 (0.07 to 9.45)
Denosumab vs placebo 0.58 (0.02 to 19.48)
Zoledronic acid vs placebo 0.74 (0.06 to 8.83)
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account for differences in length of study, thereby adding to the uncertainty, and thus these results should 
be interpreted with caution.
Summary
See also Chapter 6, Summary, first paragraph, for information on the characteristics, quality and 
generalisability of the studies. In terms of generalisability, data from patients with a range of different 
types of solid tumour (excluding breast or prostate) were pooled to provide an overall estimate for OSTs. 
The Henry study30 was powered to detect non-inferiority or superiority for OSTs including NSCLC and 
multiple myeloma.
For those with bone metastases from OSTs, the study by Henry and colleagues30 reported a statistically 
significant difference in favour of denosumab compared with zoledronic acid in delaying time to first 
on-study SRE (20.6 months vs 16.3 months with 16% risk reduction by denosumab). However, a non-
significant difference was reported in the risk of developing first and subsequent on-study SREs. The SMR 
and annualised SRE rate were also significantly lower in the denosumab group in the study by Henry 
and colleagues.30
The MS reported (academic-in-confidence information has been removed) on risk reduction for first and 
subsequent on-study SRE (15% reduction for denosumab). (Academic-in-confidence information has been 
removed) (MS). Overall survival was similar for both groups.
In the study by Rosen and colleagues,130 a statistically significant difference in favour of zoledronic acid 
compared with placebo was reported in time to first SRE (230 days vs 163 days) and risk of developing first 
and subsequent SREs (risk reduction by 27% with zoledronic acid). No significant difference between the 
groups was reported for SMR and for incidence of SRE.
The MS reported on hypercalcaemia. (Academic-in-confidence information has been removed.) In the 
study by Henry and colleagues30 no significant difference between denosumab and zoledronic acid in 
overall survival was reported. Delay in worsening clinically significant pain at 45 weeks was reported, which 
favoured denosumab (169 days) compared with zoledronic acid (143 days). The MS reported (academic-
in-confidence information has been removed).
In the study by Rosen and colleagues,130 no hypercalcaemia events were reported in the zoledronic acid 
group whereas these occurred in 3% of patients in the placebo group. No significant differences in 
overall survival and quality of life (changes in FACT-G scores) were reported. No data were reported for 
pain outcomes.
In the study by Henry and colleagues30 there were more hypocalcaemia events in the denosumab group 
(10.8%) compared with the zoledronic acid group (5.8%), fewer renal adverse events (8.3% vs 10.9%) and 
acute-phase reactions (6.9% vs 14.5%), whereas similar events of ONJ (1.3% vs 1.1%) were experienced by 
patients. The incidence of SAEs was similar in both groups (63% vs 66%; p = 0.16).
Rosen and colleagues130 reported that, compared with the placebo group, more patients in the zoledronic 
acid group experienced decreased renal function (10.9% vs 6.7%) and less bone pain (51% vs 59%). No 
data were reported on hypocalcaemia, ONJ or acute-phase reaction.
The AG’s NMA reported a statistically significant difference in favour of denosumab compared with 
placebo for time to first on-study SRE and risk of developing first and subsequent on-study SREs. 
(Academic-in-confidence information has been removed.)
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Chapter 9 Assessment design and results: cost-
effectiveness
This chapter consists of the following main sections: Systematic reviews of cost-effectiveness studies and quality-of-life studies; Critique of the manufacturer's submission; and Independent 
economic assessment.
All costs and prices in this report are in 2010 pounds sterling. Costs in foreign currency amounts are 
converted to pounds sterling at the 5 April exchange rate of the relevant year. Where no year is stated for 
prices, it is assumed to be the year of the publication. Indexation to 2010 prices applies the Hospital and 
Community Health Services (HCHS) index as drawn from the Personal Social Services Research Unit Costs of 
Health and Social Care.167 Original amounts are given in square brackets.
Systematic reviews of cost-effectiveness studies and quality-of-
life studies
Search strategy and quantity of research available
Two separate literature searches were conducted to identify studies considering cost-effectiveness and 
quality of life. First, studies focusing on cost-effectiveness or quality of life in relation to bone metastases 
and SREs were sought; this search identified 468 papers. After having screened the titles and abstracts, 
131 full-text papers were retrieved.
A second search was conducted to identify studies considering cost-effectiveness or quality of life in 
relation to denosumab and BPs. This search identified 2600 papers. After having screened the titles and 
abstracts, 139 full-text papers were retrieved.
The databases searched were MEDLINE (1948 to May Week 3 2011), EMBASE (1980 to 2011 Week 21), 
MEDLINE In-Process & Other Non-Indexed Citations (2 June 2011), NHS Economic Evaluation Database 
(June 2011), Science Citation Index (1970 to June 2011), Social Science Citation Index (1970 to June 
2011), Conference Proceedings Citation Index – Science (1990 to June 2011) and Conference Proceedings 
Citation Index – Social Science & Humanities (1990 to June 2011). Conference proceedings from the 2010 
and 2011 meetings of ASCO were hand-searched. The searches had no date restrictions, but were limited 
to English-language papers.
Full details of the search strategies used and websites consulted are documented in Appendix 1.
Results: cost-effectiveness studies
Full papers
Dranitsaris and Hsu168 estimate the cost-effectiveness of disodium pamidronate compared with BSC 
over a 12-month trial among breast cancer patients with bone metastases. This drew on the findings 
of Hortobagyi and colleagues,22 who report the clinical effectiveness of the then only relevant disodium 
pamidronate trial. Over a mean duration of therapy of 10 months, disodium pamidronate and BSC were 
associated, respectively, with the following events:
 z non-vertebral fractures: 20% vs 30% 
 z radiation to the bone: 19% vs 33% 
 z surgery to the bone: 4 % vs 10% 
 z any SRE: 46% vs 62% 
 z any SRE excluding hypercalcaemia: 43% vs 56%.
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Costs per health state were estimated by chart review, with unit costs being drawn from the Princess 
Margaret Hospital and the Centenary Hospital of Ontario, Canada.
The main aspects of the paper that are of interest are the utility data, which are drawn from a time trade-
off (TTO) exercise among 25 women from the Canadian general public and 25 female health workers. 
There is a lack of detail within the paper, and it seems likely that the health state descriptors include 
elements of both the treatment aspects and the clinical effectiveness for each arm. With this noted, the 
TTO exercise yields the following estimates (Table 58).
The source of the anticipated benefit from disodium pamidronate over placebo when no SRE is 
experienced is unclear and is not specified within the paper. Health worker responses are reasonably 
consistent, with a consistent reduction in quality of life from a SRE of around 50% for both the disodium 
pamidronate and the placebo health states. Results are more mixed within the public responses, with 
SREs causing a similar, approximate 50%, reduction in quality of life in the placebo group, but only a 30% 
reduction in the disodium pamidronate group.
Dranitsaris and Hsu168 estimate that disodium pamidronate results in an additional cost of £1758 
(C$2800). Based on the SRE rates including hypercalcaemia of 46% and 62%, this results in an estimated 
gain from disodium pamidronate of 0.15 quality-adjusted life-years (QALYs), with an associated cost-
effectiveness of £11,740 (C$18,700) per QALY based on public preferences and £10,359 (C$16,500) per 
QALY based on health-care worker preferences. Results are sensitive to the costs of surgery to the bone.
Hillner and colleagues169 estimate the cost-effectiveness of disodium pamidronate compared with BSC 
for breast cancer patients over a 2-year time horizon in the USA. The utility values are taken from expert 
opinion, with fractures at 0.8, radiation at 0.6, surgery at 0.4 and both hypercalcaemia and SCC at 0.2. 
The duration applied to these is not clear from the paper, but it may be 1 month. Disodium pamidronate is 
estimated to result in an additional 1.13 months SRE free with a net cost increase of £3593 (US$3968) for 
chemotherapy patients, resulting in a cost-effectiveness of £97,973 (US$108,200) per QALY. For hormone-
treated patients the correspoding amounts are 0.82 additional months free of SRE at a cost of £6958 
(US$7685) to yield a cost-effectiveness of £276,444 (US$305,300) per QALY.
Ross and colleagues,55 in the 2004 Health Technology Assessment (HTA) monograph reviewing the role of 
BPs in metastatic disease, model the cost per SRE avoided for breast cancer patients with bone metastases. 
This uses a cost-effectiveness Markov model with a monthly cycle. This simulates rates of SREs, with the 
health states also including hypercalcaemia and pain reduction, this latter being distinct from palliative 
radiotherapy. Note that SCC is not considered. The RRs for SREs and hypercalcaemia in the model for BPs 
compared with BSC are not differentiated by BP, but are differentiated by event type:
 z 0.90 for vertebral fracture
 z 0.79 for non-vertebral fracture
 z 0.71 for palliative radiotherapy
TABLE 58 Dranitsaris and Hsu168 TTO exercise results: healthy months equivalent to 1 year with disodium pamidronate/
placebo with or without SREs
Health state Average public % Average health workers %
SRE with disodium pamidronate 5.46 months 46 4.80 months 40
No SRE with disodium pamidronate 7.73 months 64 9.92 months 83
SRE with placebo 3.68 months 31 4.13 months 34
No SRE with placebo 6.76 months 56 7.89 months 66
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Ford et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided 
that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed 
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, 
Southampton SO16 7NS, UK.
DOI: 10.3310/hta17290 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 29
89
 z 0.59 for surgery to the bone
 z 0.51 for hypercalcaemia.
Direct drug and administration costs are based on the cost of disodium pamidronate plus an oncology 
outpatient appointment. The cost per fracture is taken as the average of the relevant inpatient health-
care resource groups (HRGs) within NHS reference costs £2786 (£2017), with surgery to the bone being 
costed at £2813 (£2036), while radiotherapy is based on three radiotherapy sessions in an outpatient 
setting to yield a cost of £978 (£708). Ross and colleagues55 undertook their own bottom-up costing for 
hypercalcaemia to estimate an average cost of £4840 (£3503). Note that this study was undertaken when 
discount rates were differentiated between costs at 6% and benefits at 1%.
The model estimates a 4-year survival of 16%, with patients being treated monthly with disodium 
pamidronate until death or to the end of the fourth year. This results in an average 1.45 SREs being 
averted compared with BSC: 0.54 non-vertebral fractures, 0.16 vertebral fractures, 0.64 courses of 
palliative radiotherapy and 0.12 episodes of surgery to the bone. An additional 0.34 episodes of 
hypercalcaemia are modelled as being prevented together with an average 3.2 months bone pain 
reduction. The total cost of therapy is estimated to be £7235 (£5237), but cost offsets reduce this to 
£613 (£444). Excluding hypercalcaemia, this results in a cost per SRE avoided of £423 (£306). With the 
application of a 0.33 QALY loss per SRE drawn from Dranitsaris and Hsu169 as reviewed above but adjusted 
for an increased SRE duration of 22 months, this translates into a cost-effectiveness estimate of £1851 
(£1340) per QALY gained.
Reed and colleagues170 (supported by Novartis) compare the cost-effectiveness of zoledronic acid with BSC 
for prostate cancer patients with bone metastases, mainly within the context of the USA and Medicare. 
This analyses within-trial SRE rates and resource utilisation data over 15 months to estimate the cost per 
SRE avoided. An additional cost–utility analysis is conducted based on the EQ-5D VAS scores. The average 
number of SREs within the zoledronic acid group is 0.78 compared with 1.24 in the BSC group, resulting 
in incremental cost-effectiveness ratios (ICERs) of £11,137 ($12,300) per SRE avoided and £105,976 
(US$159,200) per QALY.
De Cock and colleagues171 model the cost-effectiveness of oral ibandronate compared with zoledronic 
acid and disodium pamidronate among UK breast cancer patients receiving hormonal therapy. Treatment 
with oral ibandronate is estimated to result in a direct utility gain of 0.02 compared with intravenous 
administration. Discontinuation rates are also assumed to be lower, it being estimated that 96.9% of 
ibandronate patients are treated for an average of 7.2 months out of a total survival of 14.3 months. 
This compares with 71% for zoledronic acid and 73% for disodium pamidronate, although 12% of these 
patients switch to oral ibandronate. Oral ibandronate is estimated to be as effective as zoledronic acid 
for those on therapy in preventing SREs, and both are slightly superior to disodium pamidronate. Given 
this, ibandronate is estimated to yield an additional 0.02 QALYs over both zoledronic acid and disodium 
pamidronate, while saving £390 (£307) and £201 (£158), respectively.
In a parallel paper, De Cock and colleagues172 model the cost-effectiveness of oral ibandronate compared 
with zoledronic acid and disodium pamidronate among UK breast cancer patients receiving chemotherapy. 
This applies the same SRE rates and RRs for those on therapy as those applied in De Cock and 
colleagues,172 with the same discontinuation rates and percentages switching to oral ibandronate. There 
is also the same anticipated average survival of 14.3 months and the same quality-of-life values. There 
is the same average gain from ibandronate of 0.02 QALYs compared with zoledronic acid and disodium 
pamidronate, but the costs savings differ marginally: £490 (£386) compared with zoledronic acid and 
£285 (£224) compared with disodium pamidronate.
Guest and colleagues173 (supported by Mayne Pharma) undertake a cost minimisation analysis of disodium 
pamidronate compared with zoledronic acid for breast cancer patients in the UK, with a 1-year time 
horizon. This draws clinical effectiveness estimates from the literature, distinguishing between those on 
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chemotherapy and those on hormonal therapy. Disodium pamidronate is estimated to be marginally 
superior in preventing any SRE among the chemotherapy group, and slightly inferior to zoledronic acid 
in preventing any SRE among the hormonal therapy group. These rates are then qualified by rates of 
individual SREs, with disodium pamidronate typically resulting in slightly more of all SREs among those 
experiencing a SRE, with the exception of fractures among those receiving hormonal therapy. Disodium 
pamidronate has a higher discontinuation rate, particularly among those being treated with hormonal 
therapy. For chemotherapy treated patients, this results in an average 3.77 SREs for disodium pamidronate 
compared with 2.79 for zoledronic acid. For hormone-treated patients, this resulted in an average 3.44 
SREs for disodium pamidronate compared with 2.93 for zoledronic acid. The authors conclude that there 
is little clinical difference, and that as a consequence cost minimisation is appropriate.
Drug administration times for the base case are estimated as 184 to 214 minutes for disodium 
pamidronate compared with 204 to 232 minutes for zoledronic acid, though this latter includes patients 
waiting 90 minutes for test results. It is unclear quite how this has been costed. Expert opinion supplies 
much of the resource-use estimates (Table 59).
In the light of the above, disodium pamidronate is estimated to be cost-saving compared with zoledronic 
acid: £1130 (£936) for chemotherapy patients and £776 (£643) for hormone-treated patients.
Reed and colleagues170 (supported by Novartis) compare the costs and consequences of zoledronic acid 
with disodium pamidronate among breast cancer patients with bone metastases, again mainly within 
the context of the USA and Medicare. This analyses within-trial SRE rates and resource utilisation data, 
with a mean patient follow-up of 10 months. Zoledronic acid is estimated to have a RR of a SRE of 0.80 
compared with disodium pamidronate. Costs in the zoledronic acid group are estimated to be marginally 
higher: £14,218 (US$15,703) compared with £14,198 (US$15,680) for disodium pamidronate. This was 
not taken through to a cost-effectiveness estimate specific to breast cancer patients.
Botteman and colleagues174 (authorship includes an employee of Novartis) compare the cost-effectiveness 
of zoledronic acid, oral ibandronate, intravenous ibandronate, disodium pamidronate, oral clodronate 
and BSC for breast cancer patients with bone metastases. This uses a cost–utility model from a UK NHS 
perspective, with a monthly cycle over a 10-year time horizon. Patients can discontinue active therapy due 
to non-compliance, which might be because of an adverse event. Fifty per cent of those discontinuing 
move on to another active therapy: oral if previously on intravenous and intravenous if previously on oral. 
Disease progression is also assumed to lead to therapy being stopped.
TABLE 59 UK SRE resource use: Guest and colleagues173
Resource use Hypercalcaemia Vertebral fracture Non-vertebral fracture SCC
Inpatient 31% for 3 days 45% for 10 days 20% for 7 days 31% for 20 days
 z 33% oncology  z 17% oncology  z 70% oncology  z 83% oncology
 z 67% general ward  z 17% orthopaedic  z 15% orthopaedic  z 17% general ward
 z 66% general ward  z 15% general ward
Outpatient 2 oncology OP appt. 2 oncology OP appt. 2 oncology OP appt. 2 oncology OP appt.
Radiotherapy 12% of patients 79% of patients 85% of patients 75% of patients
Surgery 1% of patients 42% of patients 7% of patients 19% of patients
OP appt., outpatient appointment.
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A baseline annual rate of 3.05 SREs is assumed for BSC, with this being multiplied by the relevant HR to 
arrive at the treatment-specific SRE rates: 0.56 for zoledronic acid, 0.62 for oral ibandronate, 0.71 for 
intravenous ibandronate and 0.70 for disodium pamidronate.
Quality-of-life values for without a SRE and with a SRE are drawn from Dranitsaris and Hsu168 on the 
grounds that it was the only published source available. There is some arbitrariness in the estimation 
of benefits, with the oral ibandronate being assumed to be postponed to the 12th week, while oral 
clodronate was assumed to have half the benefits of the other therapies. Survival was unaffected by 
treatment, with a mean survival of 20 months.
Zoledronic acid is estimated to require 11 minutes of physician time, 11 minutes of pharmacy technician 
time and 44 minutes of nurse time, in contrast to 8, 12 and 152 minutes for disodium pamidronate 
and 10, 11 and 98 minutes for intravenous ibandronic acid. This results in staff administration costs of 
£42.17 (£37.42) for zoledronic acid, £88.23 (£78.29) for disodium pamidronate and £65.20 (£57.85) for 
intravenous ibandronic acid.
The SRE costs are averaged across the SREs, with an average inpatient cost of £2272 (£2016) plus an 
additional average of £1826 (£1620) outpatient and care in the community costs. These are stated as 
being based on the Ross and colleagues55 BPs review HTA monograph.
The base-case results are an average 6.11 SREs for BSC, with this being reduced to 3.71 SREs for 
zoledronic acid; 4.41 SREs for disodium pamidronate; 4.46 for intravenous ibandronate; and 4.06 for oral 
ibandronate with this last SRE possibly being the result of the high discontinuation rate and second-line 
intravenous therapy. Given the figure for BSC and the average survival of 2 years, it is not obvious how 
progression was included in the modelling.
Average QALY estimates are surprisingly similar between the BPs – 1.18 QALYs to 1.20 QALYs – and BSC 
– 0.99 QALYs. Total costs are £21,032 (£18,662) for BSC, with disodium pamidronate and intravenous 
ibandronate exceeding this by £127 (£113) and £516 (£458), respectively, to yield cost-effectiveness 
estimates relative to BSC of £658 (£584) per QALY and £2671 (£2370) per QALY. Zoledronic acid and 
oral ibandronate are estimated to save £2554 (£2267) and £2382 (£2114) compared with BSC, and so 
dominate it, with zoledronic acid further dominating oral ibandronate. Across the therapies, zoledronic 
acid is estimated to be the preferred treatment at all values of willingness to pay.
Joshi and colleagues (who include Botteman and a Novartis employee) estimate the cost-effectiveness of 
zoledronic acid compared with BSC for NSCLC patients across five European countries in what appears 
to be an update of the Botteman 2009 abstracts, as summarised below.175–181 This is based on the NSCLC 
subset of the Phase III trial populations, within which the median survivals were not statistically different 
between zoledronic acid, 201 days, and BSC, 157 days. As a consequence, a Weibull distribution is fitted 
to the zoledronic acid arm to yield an estimated average survival of 272 days. This is then multiplied by 
each arm’s SRE-specific SMR to derive the number of SREs: 1.38 for zoledronic acid and 2.17 for BSC, 
though the latter includes some episodes of hypercalcaemia.
The SREs are assumed to be associated with only 1 month loss of quality of life, the baseline NSCLC HRQoL 
of 0.63 being reduced by 6.8% by vertebral fracture, 20% by non-vertebral fracture, 40% by radiation 
therapy, 60% by surgery to the bone and 80% by both SCC and hypercalcaemia, as drawn from Hillner 
and colleagues.169 This results in zoledronic acid being estimated to yield 0.44 QALYs compared with 0.42 
QALYs for BSC.
For the UK, in common with the approach of the 2004 Ross HTA monograph,55 the costs per SRE were 
derived mainly from averaging a range of HRG costs. This yields costs of £138 (€187) for vertebral fracture; 
£4520 (€6105) for non-vertebral fracture; £745 (€1007) for radiation to the bone; £2456 (€3318) for 
surgery to the bone; £3714 (€5017) for SCC; and £3822 (€5163) for hypercalcaemia. Administration 
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costs and supplies for zoledronic acid are based on the micro-costing of DesHarnais and colleagues182 
with 11-minute physician time, 11-minute pharmacist time and 44-minute nurse time to yield a total 
administration cost of £38.82 (€52.43). Total UK costs are reported as £3062 (€4136) for zoledronic acid 
compared with £3086 (€4168), which suggests a small net saving from zoledronic acid of £22 (€32), 
though the paper reports this as a saving of £155 (€209). The 0.79 fewer SREs are estimated to provide 
cost offsets of £1217 (€787), and zoledronic acid is estimated to dominate BSC for NSCLC patients with 
bone metastases.
Carter and colleagues183 (a similar authorship list to Joshi and colleagues’ 2011 NSCLC paper,181 and with 
the support of Novartis) model the cost-effectiveness of zoledronic acid versus BSC for prostate cancer 
patients in France, Germany, Portugal and the Netherlands.183 Quality-of-life data are drawn from the Reed 
and colleagues184 paper through a back calculation using the ICER and the estimated additional costs. 
This suggests an average gain from zoledronic acid over placebo of 0.034 QALYs. Rates of individual SREs 
are estimated solely to inform the drug and SRE costing exercise attached to this estimate of QALY gains. 
The base-case results are that 0.759 SREs are avoided on average, generating savings of between £2094 
(€2396) and £3162 (€3617) per patient. The direct drug and administration costs of zoledronic acid are 
less geographically variable at between £3012 (€3446) and £3269 (€3704), with the resulting increase in 
costs leading to cost-effectiveness estimates ranging from a low of £2124 (€2430) in the Netherlands, to a 
high of £31,476 (€36,007) in France.
Xie and colleagues185 (supported by Novartis) estimate the cost-effectiveness of denosumab compared with 
zoledronic acid for patients with hormone refractory prostate cancer with bone metastases. This uses a 
1-year Markov model with a 13-week cycle. The justification for using a 1-year time horizon rather than a 
3-year time horizon is the anticipation of zoledronic acid being available in generic form from March 2013. 
But the analysis is from a US perspective, and the costs are not particularly relevant. The paper is of interest 
in part because in addition to modelling rates of SREs, the probability of a SRE is dependent on whether 
the patient is progression free or with progression. The likelihood of progression is not differentiated by 
treatment arm, but progression increases the rate of SREs by 2.14 compared with the without-progression 
SRE rate, as drawn from Tchekmedyian and colleagues.186 Among those without progression denosumab 
was estimated to have a RR of first on-study SRE of 0.83 and a HR of 0.82 for subsequent SREs, with these 
estimates probably being carried over to the with-progression patients (Table 60).
These cost-effectiveness results are summarised below (Table 61), within which unless otherwise stated 
the cost-effectiveness estimates are the cost per QALY for the more effective treatment over the less 
effective treatment. 
TABLE 60 Cost-effectiveness in prostate cancer results; Xie and colleagues185
Time horizon Zoledronic acid Denosumab Net
1-year time horizon
Drug and administration £6734 $10,960 £11,815 $19,230 £5081 $8270
Total cost £16,914 $27,528 £21,714 $35,341 £4800 $7813
SREs 0.60 0.49 –0.11
ICER £43,641 $71,027
3-year time horizon
Drug and administration £12,271 $19,972 £21,532 $35,044 £9261 $15,072
Total cost £34,169 $55,612 £42,683 $69,468 £8513 $13,856
SREs 1.46 1.18 –0.28
ICER £31,532 $51,319
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Available only as abstracts
A number of other papers available only as abstracts were identified by the literature review. Few 
details are provided within the abstracts and the results for zoledronic acid compared with BSC, or for 
denosumab versus zoledronic acid, are summarised below for completeness. Note that all these studies 
are supported by Novartis. The AG has also been in contact with John Carter of Pharmerit with a view to 
accessing the full texts of the two cost–utility studies of denosumab versus zoledronic acid. Apparently 
these are ready for full publication and will be made available, but are yet to be received by the AG.
Note that some of the abstracts that were identified, for example Stephens for lung,187 simply report the 
results available in other abstracts, in this case Botteman188 for lung, and are therefore not repeated in 
Table 62.
Results: quality-of-life studies
Clohisy and colleagues195 use the SF-36 to estimate the quality-of-life impacts of surgery for skeletal 
metastases among 52 US patients, of whom 39 completed the preoperative questionnaire and 23 
completed the questionnaire 6 weeks subsequent to surgery, this rate falling to 10 questionnaire 
completions at the 1-year point. The SF-36 scores over time across a range of dimensions are shown in 
Table 63.
These values are not readily translatable into quality-of-life values. The high rate of attrition in the 
rate questionnaire completion rate may also call into question the reliability of extrapolation from the 
preoperative through to the postoperative.
Falicov and colleagues35 also investigate the quality-of-life impacts of surgery for skeletal metastases at 
the same time points as Clohisy and colleagues195 but using the European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire-C30, the Health Utilities Index–3 and the EQ-5D among 
85 Canadian patients with an average age of 58.6 years. Median survival was a little less than 1 year. 
EQ-5D data are available from 77 of these patients and are valued using the UK social tariff to provide a 
histogram of the number of patients in the first postoperative year in 0.1 QALY ranges, from –0.2 to –0.1 
QALYs (one patient) through to near full health 0.9 to 1.0 QALY (two patients).
The resulting distribution is strongly bimodal with peaks at 0.0 to 0.2 QALYs and 0.6 to 0.7 QALYs, with 
an implied global average of 0.26 QALYs. It appears that the lower peak and the implied average first-year 
QALY may be in large part determined by survival. The results are not easily amended for this, though the 
second peak at 0.6 to 0.7 QALYs cannot be entirely discounted. Possibly because of patient numbers these 
results are not further analysed by cancer type.
As summarised in the Matza and colleagues ASCO abstract,196 judging from the authorship list it appears 
that Amgen has commissioned a TTO study among 126 members of the UK general public to estimate the 
disutilities arising from a number of SREs: SCC without paralysis, SCC with paralysis, pathological fracture 
of the rib, pathological fracture of the arm and pathological fracture of the leg, radiation to the bone 
over 2 weeks with 10 administrations, radiation to the bone with only two administrations, and surgery 
to the bone (Table 64). This involves assessing a 2-year lifespan with cancer and bone metastases, with 
subsequent assessment of this health state with the various SREs added to it. The base health state utility 
has a mean estimate of 0.47. The abstract reports the SRE disutilities as QALYs, whereas the electronic 
copy of the model submitted by the manufacturer reported these as utility decrements and reconstructs 
the QALY decrement on the assumption that they apply for 11 months. Note that the Amgen model when 
applying the TTO values also assumes that vertebral fracture has the same disutility as the average across 
pathological fractures to the rib, arm and leg.
Professor John Brazier was involved in the study and has been approached by the AG with a view to 
accessing the full paper. Professor Brazier passed this request to Amgen in mid-September 2011. There 
is little detail on the TTO exercise within the published abstract. It appears that the Amgen modelling 
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may have taken the 2-year QALY loss and broadly have converted it pro rata to an 11-month QALY 
loss. Whether or not this is correct within the context of the TTO exercise is impossible to tell from the 
published abstract.
Miksad and colleagues197 (with some indeterminate support from Pfizer and Merck, possibly institutional) 
estimate the quality-of-life impact from the various stages of ONJ: stage 0 with no evidence of necrotic 
bone, stage 1 with exposed or necrotic bone but no infection, stage 2 with infection, pain and erythema 
and stage 3 with pathological fracture, extra oral fistula or osteolysis (Table 65). Of the 54 cancer patients 
with ONJ contacted by telephone, 34 agreed to undertake questionnaires to assess quality of life by the 
VAS, TTO with a horizon of 48 weeks and EQ-5D over the telephone.
Within a cost–utility analysis of palliative radiotherapy, van den Hout and colleagues198 estimate the 
quality of life among 1157 patients with bone metastases from the primary cancers: 39% breast cancer 
patients, 25% lung cancer patients, 23% prostate cancer patients and 13% patients with other cancers. 
This applies the EQ-5D valued using the UK social tariff. Limited quality-of-life differences are found 
between different methods of delivering radiotherapy, which is the focus of the paper. But for current 
purposes the evolution of the average quality of life may be of more immediate interest (Table 66). Van 
den Hout and colleagues198 provide a graph of the evolution of quality of life before death, with the value 
being relatively constant at around 0.60 in the penultimate year, but declining in a concave fashion over 
the year before death. This is admittedly average across a range of cancers and van den Hout198 does not 
TABLE 63 Clohisy and colleagues195 SF-36 values for surgery to the bone
Dimension Preoperative
6 weeks 
postoperative
3 months 
postoperative
6 months 
postoperative
1 year 
postoperative
Physical functioning 21.7 22.8 25.1 36.9 38.5
Role–physical 2.9 4.7 4.5 9.4 16.3
Bodily pain 20.4 36.4 45.2 47.8 50.6
General health 45.0 44.3 39.7 42.3 50.3
Vitality 27.1 33.0 37.0 42.3 50.0
Social functioning 39.1 48.4 47.7 62.5 68.8
Role–emotional 24.8 29.0 17.4 33.3 16.7
Mental health 54.3 55.7 61.7 62.0 50.4
TABLE 64 Matza196 and Amgen model TTO QALY losses for SREs
SRE Abstract Modela
SCC no paralysis 0.68 0.269
SCC with paralysis 0.44
Vertebral fracture n.a. 0.036
Non-vertebral fracture 0.07 0.036
2 weeks' radiation 0.10 0.038
2 radiation administration 0.05
Surgery to the bone 0.14 0.071
n.a., not applicable.
a Supported by Novartis.
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report the number of questionnaires available for each time point, but it may be an important qualifier to 
any modelling.
Weinfurt and colleagues128 (a named author being employed by Novartis with an additional grant for 
the study being given by Novartis) estimate the quality-of-life impact of the first on-study SRE among 
248 prostate cancer patients who experienced at least one SRE during a zoledronic acid RCT: radiation to 
the bone, pathological fracture and other first on-study SREs (Table 67). Pooling of the SREs other than 
radiation and pathological fracture may have been necessary because of the small sample size. For each 
SRE only patients who experience it as their first on-study SRE are included. The EQ-5D data are valued 
using the UK social tariff. The analysis apparently controls for other patient characteristics, with the pre-SRE 
and post-SRE levels being characterised by assessments up to 100 days before the SRE and 100 days after. 
Before any on-study SRE the baseline average quality of life is 0.70. The first on-study SREs are associated 
with the following decrements at the first HRQoL measurement within 100 days of SRE diagnosis:
 z radiation to the bone –0.07
 z pathological fracture –0.13
 z other SREs pooled –0.02.
TABLE 65 Miksad197 utility decrements from ONJ
Method
ONJ decrements
Stage 0 Stage 1 Stage 2 Stage 3
VAS 0.76 –0.10 –0.33 –0.51
TTO 0.86 –0.05 –0.22 –0.29
EQ-5D 0.82 –0.05 –0.33 –0.61
TABLE 66 van den Hout198 quality-of-life values in last year of life – from graph
Months to death Utility Multiplier
1 0.20 34%
2 0.25 43%
3 0.30 52%
4 0.33 57%
5 0.37 63%
6 0.40 69%
7 0.40 69%
8 0.43 74%
9 0.45 78%
10 0.48 83%
11 0.53 91%
12 0.58 100%
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Results: resource-use studies
Full papers
Resource use: drug and administration costs
DesHarnais Castel and colleagues182 (supported by Novartis) provide a USA-based micro-costing study 
of zoledronic acid and disodium pamidronate among patients with metastatic bone disease. This draws 
data from three outpatient chemotherapy infusion sites, which were also participating in a concurrent 
zoledronic acid trial. For zoledronic acid average staff times for preinfusion, preparation and set up, 
administration and follow-up are estimated as 16 minutes, 6 minutes, 40 minutes and 4 minutes, 
respectively, to give a total of 66 minutes. For disodium pamidronate the times are 16 minutes, 5 minutes, 
148 minutes and 4 minutes, respectively, to give a total time of 173 minutes.
Barrett-Lee and colleagues199 (supported by Roche) provide a UK-based study of the costs of administering 
intravenous BPs among breast cancer patients with bone metastases. This is across three cancer centres, 
with the first 50 administrations from the start of study being analysed through audit forms. Only 71% 
of the completed forms relate to breast cancer patients, and results are only reported for these patients. 
Zoledronic acid provided 67% of administrations, with the vast majority of the remainder being disodium 
pamidronate. Zoledronic acid is reported as taking an average 4-minute preparation time coupled with 
18-minute administration time, though it is not clear whether this is patient time or staff time. Disodium 
pamidronate is reported as requiring 4 minutes and 93 minutes, respectively. Perhaps the most relevant 
statistic is that 77% of the breast cancer patients receiving a BP infusion were making a hospital visit solely 
for this purpose.
Oglesby and colleagues200 (supported by Amgen) undertook a time and motion study of the time and 
costs of administering zoledronic acid among 42 breast cancer patients and 26 prostate cancer patients 
in the USA. This concludes that among patients not receiving chemotherapy the overall mean time per 
administration was 1 hour 9 minutes, whereas among patients receiving chemotherapy it was 3 hours 
1 minute, though this latter includes 1 hour 15 minutes specific to the chemotherapy infusion. The average 
across patients was a little under 2 hours.
Houston and colleagues148 (supported by Roche) within a UK-based study of renal function changes and 
NHS resource use among 189 patients, estimate an average staff time per zoledronic acid administration 
of 28 minutes, compared with 6 minutes for oral ibandronate.148
Resource use: skeletal-related events and adverse events
Malmberg and colleagues201 in a Sweden-based cost-effectiveness study of adding strontium 89 to external 
radiotherapy among prostate cancer patients estimate the average cost per radiotherapy episode as £5382 
(SEK31,011) for those in county, and £8433 (SEK48,585) for those out of county, this latter figure being 
higher due to the higher rate of inpatient admissions.
Groot and colleagues202 estimate the resource use associated with SREs among 28 prostate cancer patients 
in the Netherlands over a 2-year period, during which 61 SREs are experienced (Table 68). The majority of 
SREs are radiotherapy to the bone, most of which are treated as outpatient procedures.
Delea and colleagues203 (supported by Novartis) estimate the costs associated with SREs among 534 US 
lung cancer patients using data from an insurance claims database. The average SRE-related cost over a 
3-year time horizon is estimated as £7974 (US$11,979) with 90% of this occurring within 2 months of the 
first claim.
Delea and colleagues204 (supported by Novartis) in a similar analysis estimate the costs associated with 
SREs among 617 US breast cancer patients with bone metastases through a matched pairs analysis of an 
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insurance claims database, of whom 52% experienced at least one SRE. The average lifetime treatment 
cost of SREs is £8981 (US$13,940). Other costs are also higher in the SRE patient group, by £22,055 
(US$34,233) with the average increase among SRE patients being £31,036 (US$48,173).
Lage and colleagues205 (supported by Amgen) undertake a retrospective analysis of a US insurance claims 
database to estimate the costs of SREs among prostate cancer patients. The average annual costs per 
individual SRE are radiotherapy: £3143 (US$5930); fracture: £1685 (US$3179); surgery to the bone: 
£1176 (US$2218); and SCC: £244 (US$460). The annual average per patient is calculated as £6609 
(US$12,469).
Barlev and colleagues206 (supported by Amgen) estimate the direct inpatient costs arising from pathological 
fracture, surgery to the bone and SCC among multiple myeloma, prostate cancer patients with bone 
metastases and breast cancer patients with bone metastases through a USA Medicare-related database. 
For prostate cancer patients the average inpatient costs for pathological fracture, surgery to the bone and 
SCC are £14,652 (US$22,390), £27,546 (US$42,094) and £39,125 (US$59,788) respectively, while for 
breast cancer patients they are £17,627 (US$26,936), £22,735 (US$34,742) and £39,194 (US$59,894).
Critique of the manufacturer’s submission
Patient groups, indications and comparator treatments
The comparators for each cancer are chosen by the manufacturer partly in the light of NICE’s CGs, but 
current prescribing patterns as identified through a manufacturer-commissioned patient chart review 
coupled with drug use data sourced from the IMS Oncology AnalyzerTM (IMS Health®, PA, USA; URL: 
www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/IMS_Oncology_Analyzer_Fact_
Sheet.pdf) also help to determine these (it appears that the prescribing and treatment data of tables 13 
and 14 of the MS) (Table 69).
For breast cancer, the NICE guideline45 recommends consideration of BPs for patients diagnosed with 
bone metastases. This is reflected in the manufacturer’s prescription data, within which zoledronic acid is 
the most frequently used BP. In the light of this, zoledronic acid is chosen as the primary comparator for 
breast cancer.
TABLE 68 Groot202 SRE resource use in Dutch prostate cancer patients
Outpatient SREs Treatment cost Total cost
External-beam RT 25 £1033 €1187 £1033 €1187
Strontium-89 21 £1579 €1815 £1579 €1815
Inpatient LoS Inpatient cost Treatment Cost Total Cost
External-beam RT 3 12 £3091 €3553 £1033 €1187 £4124 €4740
Pain management and RT 1 22 £5667 €6514 £1033 €1187 £6700 €7701
SCC and RT 4 29 £7534 €8660 £1033 €1187 £8567 €9847
Hip operation 2 14 £3477 €3997 £1074 €1234 £4551 €5231
Hip operation with CC 1 129 £33,231 €38,196 £2394 €2752 £35,625 €40,948
Fixation of femur fracture 1 16 £4121 €4737 £965 €1109 £5086 €5846
Pain management and RT 3 10 £2576 €2961 £2576 €2961
CC, complications and comorbidities; LoS, length of stay; RT, radiotherapy.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment DesIgn anD results: cOst-effectIVeness
102
But note that this does not preclude consideration of patient subgroups: the cost-effectiveness of 
denosumab among patients who are SRE naive at baseline may differ from that for those who are 
SRE experienced at baseline. It may also be appropriate to consider BSC as a comparator for those 
contraindicated to BPs. The manufacturer’s case review concluded that 8% of breast cancer patients with 
bone metastases will probably never be treated with BPs.
For prostate cancer, the NICE guideline46 recommends consideration of BPs for pain relief only when other 
conventional analgesics and palliative radiotherapy have failed. The manufacturer’s case review suggests 
that 49% of prostate cancer patients have received BPs. It is not clear from the submission to what extent 
this BP use is a short course, and to what extent it is ongoing continuous use of BPs. The case review also 
suggests that an additional 19% of patients are likely to receive BPs in the future. Within this, zoledronic 
acid is the main drug, with over 90% market share. The manufacturer uses this to split the analysis into 
SRE-naive patients, for whom the comparator is BSC, and SRE-experienced patients which is used as a 
proxy for uncontrolled pain, for whom the primary comparator is zoledronic acid.
For lung cancer, the NICE guideline48 does not recommend the use of BPs. The metastatic SCC guideline 
provides similar recommendations for breast cancer and for prostate cancer to the cancer-specific 
guidelines summarised above. But it adds to this that BPs should not be used in other cancers to treat 
spinal pain with the intention of preventing metastatic SCC except as part of a RCT. Despite this, the 
manufacturer’s case review suggests that 37% of patients with OSTs have been treated with BPs, with 
another 13% likely to receive them in the future. Again, it is not clear from the submission to what extent 
this BP use is a short course, and to what extent it is ongoing continuous use of BPs. Zoledronic acid is the 
main BP used, with an 80% market share. The manufacturer uses this to split the analysis for OST patients 
into SRE-naive patients, for whom the comparator is BSC, and SRE-experienced patients, for whom the 
primary comparator is zoledronic acid.
Within the manufacturer’s modelling there appears to be no specific consideration of uncontrolled pain 
from bone metastases despite use of conventional analgesics and palliative radiation therapy to the bone. 
This subgroup does not appear to have been defined or analysed within the manufacturer’s analyses, but 
the manufacturer notes that among prostate patients who were SRE experienced at baseline, 80% also 
had painful bone metastases at baseline. The corresponding figure for OST patients is 86%. In the light 
of this, the manufacturer has taken the subgroup of patients who were SRE experienced at baseline as a 
proxy for the likelihood of having uncontrolled pain from bone metastases.
TABLE 69 Manufacturer’s primary comparator treatments
Patient group Breast cancer Prostate cancer OSTs
Bisphosphonate tolerant 
All patients Zoledronic acid Not presented Not presented
SRE naive Not presented BSC BSC
SRE experienced Not presented Zoledronic acida Zoledronic acidb
Bisphosphonate contraindicated
All patients Not presented Not presented Not presented
SRE naive Not presented BSCc BSC
SRE experienced Not presented Zoledronic acid Zoledronic acid
a Of these patients, 80% are reported as having painful bone metastases at baseline in the denosumab trial.
b Of these patients, 86% are reported as having painful bone metastases at baseline in the denosumab trial.
c As neither the manufacturer nor the AG has been able to source clinical estimates specific to those contraindicated 
to BPs, where comparisons have been presented for denosumab vs BSC this can be taken as the best estimate for the 
cost-effectiveness of denosumab among those contraindicated to BPs.
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Given data availability, the additional comparators of disodium pamidronate and ibandronic acid are also 
considered for breast cancer. Similarly, for OSTs, data availability permits the consideration of disodium 
pamidronate as an additional comparator for SRE-experienced patients.
Manufacturer’s model structure summary
The manufacturer separately models three cancer groups: breast cancer, prostate cancer and all OSTs 
including lung cancer. While the parameter inputs to the modelling of the three cancers differ, the model 
structure is essentially the same across the three cancers: a cost–utility Markov model; a 4-week cycle to 
reflect dosing frequency; and a 10-year time horizon for the base case. The AG judges the manufacturer’s 
model to be of good quality and structure, and rebuilds it with some structural additions for its own 
economic analysis. As a consequence, the manufacturer’s model is summarised in detail below.
For a given cancer, all patients within the manufacturer’s model are assumed to have the same survival 
risk. This is derived from a survival analysis (Weibull for breast cancer, gamma for prostate cancer and log-
logistic for OSTs based on the Akaike information criterion: tables 53 and 54 of the MS) of the denosumab 
trial data, pooled across the denosumab and zoledronic acid arms. This is augmented by age-specific 
non-cancer deaths drawn from general population data. The reason for augmenting the survival curve 
estimated from the trial data with age-specific non-cancer deaths is not immediately obvious. It may be to 
help prevent the possible overextrapolation of survival given the survival curves for breast cancer, prostate 
cancer and OSTs in the MS, or it may be to enable sensitivity analyses around the baseline age to be 
examined. (The probabilistic modelling treats the baseline age as being deterministic.)
The key assumption, supported by the clinical trials, is that there is no overall survival difference between 
denosumab and zoledronic acid, with this assumption of no survival differences also being carried over to 
the other comparators where applicable. In other words, survival is not affected by rates of SREs.
The manufacturer’s model divides patients into those who are SRE naive at start of treatment and those 
who are SRE experienced at start of treatment. The baseline rates of SREs are drawn from the zoledronic 
acid arm of the relevant denosumab trial.
 z For the SRE-naive, another time-to-event analysis is undertaken using the time to first on-study 
SRE data from SRE-naive patients in the zoledronic acid arm. The HRs for the other comparators 
are applied to this to estimate the evolution of first SREs among SRE-naive patients for the 
comparator arms.
 z For the SRE-experienced, a constant rate of SREs is assumed. This rate is drawn from all on-study SREs 
among the SRE-experienced at baseline. Note that the manufacturer does not include subsequent 
SREs among those who were initially SRE naive at baseline. The manufacturer justifies this on the 
basis that it would break randomisation. It is not clear to the AG why this applies, and including these 
SREs as a sensitivity analysis may be desirable. RRs are applied to this rate to estimate the rates for the 
comparator arms.
The balance between the different types of SREs is taken from the denosumab trials, pooled across 
the arms.
Individual SREs are associated with a HRQoL loss estimated using EQ-5D data from the denosumab trials. 
These estimates are cancer specific, and are summarised in greater detail in Chapter 9, Clinical data and 
effectiveness. It is assumed that the HRQoL loss associated with a SRE can extend up to 5 months before 
the month of its identification, and up to 5 months subsequent to the month of its identification. This 
yields an overall absolute QALY decrement for each SRE. A utility level is also estimated for SRE-naive 
patients, and for SRE-experienced patients. SRE-naive patients experiencing a SRE have the SRE experienced 
utility applied thereafter.
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Individual SREs are also associated with a cost. The base case estimates these from a manufacturer-
commissioned observational study as summarised in greater detail in Chapter 9, Resource use. The 
manufacturer’s expert opinion suggested that vertebral fracture would be asymptomatic to the degree 
that treatment would be unlikely, and the base case applies no cost to vertebral fractures. (Between 40% 
and 45% of fractures in breast cancer, 50% and 70% of fractures in prostate cancer and 40% and 50% of 
fractures in OSTs including lung were vertebral fractures.)
Rates of the SAEs of ONJ, renal toxicity, hypercalcaemia, hypocalcaemia and skin infections are estimated 
from the clinical trials separately for denosumab and for zoledronic acid. These are also associated with 
discontinuation rates as drawn from the clinical trials. Additional non-SAE-specific discontinuations are 
included in the model, with these being the main source of patients discontinuing active treatment for 
both denosumab and zoledronic acid. The risk of a SRE among those discontinuing is assumed to be equal 
to that for BSC.
The HRQoL impact of an adverse event draws on the same EQ-5D data as those used for estimating the 
HRQoL impact of SREs. Note that a unified overall model is not presented, and the data are analysed 
separately for SREs and for adverse events. The assumed duration of HRQoL impacts is lifetime for ONJ 
and renal toxicity, whereas the duration of HRQoL impacts from hypercalcaemia, hypocalcaemia and skin 
infections is as apparently recorded within the individual patient level data.
Clinical data and effectiveness
Patient characteristics
Baseline patient characteristics are drawn from the relevant denosumab trials (Table 70).
Survival data
On the basis of the Akaike information criterion, the survival analysis of the data pooled across the arms 
of the denosumab trials suggests modelling breast cancer survival using a Weibull, prostate cancer using a 
gamma and OSTs using a log-logistic functional form (Table 71).
The key assumption in the above is that there is no overall survival difference between denosumab and 
zoledronic acid, with this assumption of no survival differences also being carried over to the other 
comparators where applicable. In other words, survival is not affected by rates of SREs. Any frailty 
distribution around multiple SREs in the same patient similarly is assumed to not affect survival. The 
TABLE 70 Baseline patient characteristics
Characteristic Breast cancer Prostate cancer OSTs
Age (years) 57 71 60
Female 99% 0% 36%
SRE naive 59% 74% 49%
TABLE 71 Overall survival fitted curves
Parameter Breast cancer Prostate cancer OSTs
Distribution Weibull Gamma Log-logistic
Intercept 7.2206 6.5823 5.7772
Scale 0.7775 0.9240 0.7154
Shape 0.6243
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survival curves are, for reasons that are not entirely clear, augmented with the age-specific non-solid 
tumour mortality rates as drawn from UK life tables. This results in the following survival percentages 
within the modelling (Table 72).
Balance between types of skeletal-related events
The balance between the different SREs is taken from the denosumab trials, with the data being pooled 
between the arms (Table 73). The balance between the SRE types is time invariant, with the exception that 
once a SRE-naive patient has experienced a first SRE the balance between SREs is that for subsequent SREs 
as applied to SRE-experienced patients.
Rates of skeletal-related events for zoledronic acid
Zoledronic acid is taken as the numéraire against which the other treatments’ HRs and RRs are measured. 
The rates of first SREs and subsequent SREs for the comparator treatments are derived through the 
application of the relevant HRs and RRs. The rates of SREs for zoledronic acid are split into:
 z the time to first on-study SRE for SRE-naive patients
 z the SRE rate per cycle for patients who are SRE experienced at baseline.
Times to first skeletal-related event among skeletal-related event-naive patients
A reasonably standard set of time to event functional forms are fitted to the time to first on-study SRE 
among SRE-naive patients for the zoledronic acid arm of the denosumab trials. This results in the log-
normal form being assessed as best by the Akaike information criterion for prostate cancer and OSTs.
But the gamma function is estimated as being superior for breast cancer patients with an Akaike 
information criterion of 3327 compared with 3330 for the log-normal, which is the next best fit. The 
manufacturer justifies the adoption of a common log-normal form on the basis of the probabilistic model 
often simulating a shape parameter for the gamma distribution of less than 0.08, which is apparently 
problematic. But even if this is the case, it would seem desirable to have applied the fitted gamma function 
within the deterministic modelling to test any sensitivity to this assumption. Unfortunately, the submission 
does not outline the parameterised form of the gamma distribution for breast cancer. If the central 
estimate for this postpones the first SRE beyond that suggested by the fitted log-normal distribution this 
TABLE 72 Modelled survival percentages
Year
Breast cancer Prostate cancer OSTs
Fitted curve
+ general 
mortality Fitted curve
+ general 
mortality Fitted curve
+ general 
mortality
1 83% 83% 68% 66% 46% 46%
2 64% 64% 41% 39% 24% 24%
3 47% 47% 25% 23% 15% 15%
4 34% 33% 15% 14% 11% 11%
5 24% 23% 9% 8% 8% 8%
6 16% 16% 6% 5% 6% 6%
6 16% 10% 6% 3% 6% 5%
7 11% 7% 4% 2% 5% 4%
8 7% 4% 2% 1% 4% 3%
9 5% 3% 2% 1% 4% 3%
10 3% 3% 1% 1% 3% 3%
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may have tended to bias the analysis in favour of denosumab. The parameter estimates are shown in 
Table 74.
Rates of subsequent skeletal-related events among skeletal-related event 
experienced patients
The SRE cycle rate is calculated as the total number of SREs divided by the patient-years of exposure, 
and adjusted to the 28-day cycle length. The base case applies the 21-day window definition of a SRE, 
which results in the following cycle rates. The manufacturer assumes a cycle lasts 4/52nds of 1 year within 
this calculation. This is marginally longer than the true 28/365ths and serves to slightly increase the rate 
of SREs within the zoledronic arm, but this is unlikely to have much, if any, material effect on results 
(Table 75).
Note that the SRE rate per cycle for SRE-experienced patients excludes the data on SREs subsequent to the 
first on-study SRE among the SRE naive at baseline patients. The manufacturer justifies this on the grounds 
that it would break randomisation. This justification is not understood by the AG. It could be argued 
that applying the SRE rate estimated from patients who were SRE experienced at baseline to the patients 
who were SRE naive at baseline but have experienced an on-study SRE is a more serious violation of 
randomisation or stratification within the trials. Note also that the proportions of patients who were SRE 
naive at baseline were 59% for breast cancer, 74% for prostate cancer and 52% for OSTs.
TABLE 73 Balance between SRE types with 21-day window data pooled across the arms
SRE
Breast cancer Prostate cancer OSTs
SRE naive SRE exp. SRE naive SRE experienced SRE naive SRE experienced
Vertebral 
fracture
AiC information 
has been 
removed
AiC 
information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been removed
AiC 
information 
has been 
removed
AiC information 
has been removed
Non-
vertebral 
fracture
AiC information 
has been 
removed
AiC 
information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been removed
AiC 
information 
has been 
removed
AiC information 
has been removed
Radiation 
to the 
bone
AiC information 
has been 
removed
AiC 
information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been removed
AiC 
information 
has been 
removed
AiC information 
has been removed
Surgery 
to the 
bone
AiC information 
has been 
removed
AiC 
information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been removed
AiC 
information 
has been 
removed
AiC information 
has been removed
SCC AiC information 
has been 
removed
AiC 
information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been removed
AiC 
information 
has been 
removed
AiC information 
has been removed
AiC, academic-in-confidence.
TABLE 74 Log-normal parameters for time to first on-study SRE for SRE-naive patients
Parameter Breast cancer Prostate cancer OSTs
Intercept 6.8849 6.3098 6.1074
Scale 1.6315 1.4547 1.5229
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Hazard ratios and relative risks for skeletal-related events for comparator treatments
The MS applies the hazard ratios for time to first on-study SRE and RRs for time to first and subsequent 
SRE as estimated from the denosumab trial data for denosumab versus zoledronic acid (table 24 of the 
MS), and from the NMA for the other comparators (tables 50, 51 and 52 of the MS) with zoledronic acid 
being the numéraire as outlined above. These are summarised in Table 76.
Note that while the submission suggests that the subgroups of SRE-naive and -experienced patients are 
analysed separately, the subgroup-specific HRs and RRs for denosumab versus zoledronic acid are not 
applied. Only pooled results are presented for comparator drugs because owing to a lack of published 
data neither the AG nor the manufacturer was able to undertake a NMA for SRE-experienced or SRE-naive 
patients. The modelling submitted by the manufacturer applies the HRs and RRs pooled across all patients, 
whether modelling SRE-naive patients or SRE-experienced patients. This is likely to have mainly affected the 
cost-effectiveness results presented for prostate cancer and for the OSTs group.
It would seem sensible to apply the SRE-naive- and -experienced-specific HRs and RRs for denosumab 
versus zoledronic acid when analysing these subgroups. The SRE-experienced-subgroup-specific 
central estimates suggest a smaller effect from denosumab compared with the pooled estimates for 
these patients.
Adverse events and discontinuations
The model includes the following SAEs:
 z ONJ
 z renal toxicity
 z hypercalcaemia
 z hypocalcaemia
 z skin infections.
For the main comparators of denosumab and zoledronic acid the rates of these are drawn from the 
denosumab trials. Each of these SAEs is also associated with a treatment-specific discontinuation rate, 
again drawn from the denosumab trials (Table 77). A further treatment-specific general discontinuation 
rate is drawn from the denosumab trials, though it is not clear whether or not the definition of this 
excluded the discontinuations due to SAEs. The key assumption within the handling of adverse events and 
discontinuations is that their rates are constant over the period of the modelling.
The rates of adverse events for the other BPs are drawn from the literature, and are assumed to apply 
equally across the three cancer groups being modelled. Discontinuation rates due to SAEs for the other 
BPs are assumed to be the average across the rates observed for denosumab and zoledronic acid. 
TABLE 75 On-study SRE rates among SRE experienced in zoledronic acid arm with 21-day window
Quantity Breast cancer Prostate cancer OSTs
Patient-years of exposure CiC information has been 
removed
CiC information has been 
removed
CiC information has been 
removed
SREs CiC information has been 
removed
CiC information has been 
removed
CiC information has been 
removed
Cycle rate based no 4/52 CiC information has been 
removed
CiC information has been 
removed
CiC information has been 
removed
Cycle rate based no 28/365 CiC information has been 
removed
CiC information has been 
removed
CiC information has been 
removed
CiC, commercial-in-confidence.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment DesIgn anD results: cOst-effectIVeness
108
TABLE 76 The manufacturer’s HRs and RRs
Submission tables 29, 50, 51 and 52a Breast cancer Prostate cancer OSTs
TTF HR vs zoledronic acid
Pooled across all patients
BSC/placebo AiC information has 
been removed
1.493 1.370
Ibandronic acid AiC information has 
been removed
Disodium pamidronate AiC information has 
been removed
AiC information has 
been removed
Denosumab 0.820 0.820 AiC information has 
been removed
Denosumab SRE naive AiC information has 
been removed
0.800 AiC information has 
been removed
Denosumab SRE experienced AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
RR TTF&Subs vs zoledronic acid
Pooled across all patients
BSC/placebo AiC information has 
been removed
1.563 1.366
Ibandronic acid AiC information has 
been removed
Disodium pamidronate AiC information has 
been removed
AiC information has 
been removed
Denosumab AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
Denosumab SRE naive AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
Denosumab SRE experienced AiC information has 
been removed
AiC information has 
been removed
AiC information has 
been removed
AiC, academic-in-confidence; TTF, time to first; TTF&Subs, time to first and subsequent.
a Source: Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011.
Discontinuation rates for the other BPs not due to SAEs are drawn from another three papers within 
the literature.
Rates of adverse events for BSC are assumed to be zero. This may be unrealistic and may tend to worsen 
the cost-effectiveness estimates for the active treatments relative to BSC. In the main, adverse event rates 
do not appear to be key model drivers as there is sufficient differentiation between active treatments 
and BSC in terms of reducing SRE rates. Sensitivity analyses that compare active treatments with BSC and 
assume minimal differences between them in terms of SRE rates may not be reliable, as the assumption 
of zero adverse events in the BSC arm may have come to the fore of the analysis. But given the cost-
effectiveness estimates for active treatments versus BSC as outlined below this may not be a particular 
concern (it is also, at least in part, addressed in the AG modelling through sensitivity analyses that assume 
zero adverse events for all treatments). Note that those discontinuing denosumab or BP therapy are 
assumed to immediately assume the BSC RR for SREs. There is no waning protective effect from having 
received denosumab or BP therapy.
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Discontinuations also introduce what may appear to be a perversity within the model structure. The model 
estimates both denosumab and zoledronic acid to have a very poor cost-effectiveness when compared 
with BSC. Because of this, a treatment that has a high discontinuation rate sees patients rapidly move off 
active treatment and on to the more cost-effective BSC. As a consequence, a high discontinuation rate 
for an active treatment improves the cost-effectiveness estimate for that treatment. This requires some 
qualification, in that the situation is more complicated if the main sources of discontinuations are SAEs, 
with their associated HRQoL and cost impacts. But as can be seen from the above, for both denosumab 
and zoledronic acid the vast majority of discontinuations are not related to SAEs.
Resource use
The manufacturer undertook a systematic literature review to try to identify the costs associated with SREs 
and adverse events as outlined in the MS. Out of the 150 papers identified by the search, six were found 
to have data relevant to the modelling. From these six papers, only the cost of treating hypercalcaemia 
£4579 (£3791 in 2004) as drawn from the Ross HTA journal publication55 is used.
Drug and administration costs
The list price of denosumab is £309.86 per vial. The manufacturer cites the BNF as the source of the direct 
drug costs of the comparators. The BNF used by the manufacturer may predate the current BNF62, which 
differs slightly from table 72 of the submission, giving the list prices as:
 z £174.17 for a 4-mg vial of Zometa® zoledronic acid
 z £165.00 for a 90-mg vial of generic disodium pamidronate.
This compares with the costs applied by the manufacturer of £183.30 and £167.73 respectively. This 
mainly affects the comparison with zoledronic acid, the manufacturer cost for it being 5% higher 
than BNF62.
To estimate the administration costs associated with the different administration routes the manufacturer 
commissioned a micro-costing study, as summarised in the MS. This study was undertaken in the UK 
among 80 oncology nurses and 20 oncology pharmacists. It is unclear to what extent any of the nursing 
staff would have had actual experience of denosumab, but they would obviously be fully familiar with 
subcutaneous injections. The micro-costing study provided estimates of the staff times involved in 
administering denosumab and BPs, and costed these from a NHS perspective using standard Personal 
Social Services Research Unit staff costs.
Note that the micro-costing study prompted respondents about the administration times associated with 
different infusion durations: ‘Question: It is assumed that an infusion of IV X would typically occur over 
a minimum of X minutes according to the SPC. Is this correct for your centre? If not, please specify the 
infusion time.’ This wording may have framed responses to the question. It also does not appear to ask 
whether or not the duration of the intravenous infusion involved any additional nursing time: 15 minutes 
for zoledronic acid, 15 minutes of intravenous ibandronic acid and 90 minutes for disodium pamidronate. 
These timings were included in the costing.
For the comparison between denosumab and zoledronic acid the main differences in terms of minutes 
of staff time reported by the oncology nurses and as outlined in the MS to the nearest minute are given 
(Table 78).
Owing to the apparently highly skewed nature of replies, the manufacturer has chosen to use the medians 
rather than the means for costing purposes. The requirement to make this adjustment may suggest that 
the micro-costing study is not entirely reliable. (Academic-in-confidence information has been removed.)
The manufacturer estimates that denosumab will result in staff time savings compared with zoledronic 
acid (academic-in-confidence information has been removed) per administration. These arise in part 
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from the preadministration savings (academic-in-confidence information has been removed), but more 
from drug administration savings (academic-in-confidence information has been removed) within which 
avoiding the need for infusion saves (academic-in-confidence information has been removed) staff time.
Taking these elements together with the consumables and fixed costs estimated within the micro-costing 
study yields the total annual direct drug and administration costs (Table 79).
Without the patient access scheme (PAS) the annual denosumab cost of £4467 is around £1102 more 
expensive than zoledronic acid.
The PAS proposed by the manufacturer has recently been approved. (Commercial-in-confidence 
information has been removed.)
(Commercial-in-confidence information has been removed.)
The base case assumes 4-weekly dosing for both denosumab and the BPs. The manufacturer also supplies 
a sensitivity analysis that retains 4-weekly dosing for denosumab, but assumes that a percentage of BP 
patients receive 3-weekly dosing in line with their chemotherapy regimen.
Within the denosumab trials intravenous therapy could be withheld because of elevated creatine. This 
affects the average dose received within the zoledronic acid arm. The CSRs provide the subject incidence 
TABLE 79 Direct drug and administration costs: 4-weekly dosing
Administration 
element Denosumab
Zoledronic 
acid
Disodium 
pamidronate
Intravenous 
ibandronic acid 
Oral ibandronic 
acid
Direct drug costs per administration
Manufacturer BNF £183.30 £167.73 £183.69 £183.69
BNF62 £174.17 £165.00
Without PAS £309.86
With PAS CiC information 
has been removed
Administration
Staff time £33.24 £66.28 £138.49 £66.28 £4.50
Monitoring cost £0.00 £1.41 £1.41 £1.41 £1.41
Consumables £0.44 £7.31 £7.24 £7.31 £0.00
Capital costs £0.06 £0.52 £1.84 £0.52 £0.00
Annual totals as per manufacturer
Without PAS £4466.80 £3364.66 £4117.23 £3369.73 £2464.80
With PAS CiC information 
has been removed
Annual totals BNF62
Without PAS £4466.80 £3245.97 £4081.74 £3369.73 £2464.80
With PAS CiC information 
has been removed
CiC, commercial-in-confidence.
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of intravenous dose withholding, though it is not clear to the AG whether this corresponds to the number 
of patients having their dose withheld or the number of doses withheld. It appears possible that since 
exposure to zoledronic acid could be resumed only once creatine levels had returned to acceptable levels, 
some of these incident patients may have had more than one dose withheld. But on the conservative 
assumption that the incident patient dose withheld data is equivalent to only one dose being withheld the 
figures in Table 80 are implied.
The impact of this has not been included within the direct drug and administration costs calculated by 
the manufacturer.
Skeletal-related event costs
The STARs costing study
The STARs costing study is a manufacturer-commissioned observational study across the USA, Canada, 
the UK, Germany, Italy and Spain. This recruited patients with bone metastases secondary to breast 
cancer, prostate cancer, lung cancer or multiple myeloma who had had a SRE during the previous 90 days. 
Subjects were followed up for an average of around 18 months.
Health-care resource use across a number of different categories was collected: inpatient data, outpatient 
visits, procedures, emergency room visits, nursing home use and home health visits. The attribution of this 
resource use to a SRE was apparently at investigator discretion, with no details of the methods for this 
being reported in the submission.
The health-care resource use drawn from the STARs study for the submission is specific to the (academic-
in-confidence information has been removed) UK patients within the study. The STARs study included 
multiple myeloma patients but, from the data presented in the electronic copy of the manufacturer’s 
model, it appears that the (academic-in-confidence information has been removed) multiple myeloma 
SREs have been excluded from the total (academic-in-confidence information has been removed) observed 
to leave (academic-in-confidence information has been removed) SREs split into (academic-in-confidence 
information has been removed) SREs among breast cancer patients, (academic-in-confidence information 
has been removed), lung cancer patients and (academic-in-confidence information has been removed) 
prostate cancer patients.
TABLE 80 Zoledronic acid withheld during denosumab trials
Numbers and 
percentages withheld Breast cancer Prostate cancer OSTs
n AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
n intravenous zoledronic 
acid withheld
AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
% intravenous 
zoledronic acid withheld
AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
Average zoledronic acid 
doses
AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
Total zoledronic acid 
dose exposure
AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
% zoledronic acid 
withheld
AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
AiC, academic-in-confidence.
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Trim points and manufacturer’s costings
For the derivation of the average inpatient cost per event the manufacturer’s costings include an allowance 
for the excess bed-days within the NHS reference costs. The manufacturer calculates a weighted average 
length of stay across elective inpatients, non-elective long-stay inpatients and non-elective short-stay 
inpatients for the identified HRGs. This average HRG length of stay is taken as the trim point. If the average 
length of stay observed within the STARs study exceeds this, the manufacturer costs this excess at the 
excess bed day rate for the identified HRGs, averaged across elective inpatients and non-elective long-stay 
inpatients (Table 81).
For instance, the average length of stay across the three HRGs identified for non-vertebral fractures treated 
as an inpatient is calculated as 7.93 days. Among those treated as inpatients for non-vertebral fracture, 
the STARs study average length of stay is given (academic-in-confidence information has been removed). 
The manufacturer calculates the excess bed-days (academic-in-confidence information has been removed) 
minus 7.93 days: (academic-in-confidence information has been removed) days are costed at £217 per day 
to yield an excess bed-day cost (academic-in-confidence information has been removed). This is added to 
the weighted average inpatient cost across the three HRGs (academic-in-confidence information has been 
removed) to yield an overall total cost for non-vertebral fractures treated on an inpatient basis (academic-
in-confidence information has been removed).
But the 2010–11 episode trim points for the three identified HRGs (HD39A, HD39B and HD39C) are 
45 days, 21 days and 19 days, respectively. Whereas the average treatment duration within the STARs 
study will encompass a spread of values, it is questionable whether or not any allowance for excess bed-
day costs should have been made by the manufacturer.
These considerations around excess bed-day trim points apply throughout the manufacturer’s costings of 
inpatient stays for the other SREs and AEs.
Radiotherapy to the bone costing
For reasons that are not clear, to cost radiotherapy planning and administration the manufacturer uses 
2008–9 reference costs and indexes these for inflation, rather than using the 2009–10 reference costs 
which are employed for all the other SREs.
For the planning of radiotherapy the manufacturer includes the HRG codes SC01Z through to SC03Z, 
which seems reasonable. It may be more questionable to have included SC04Z relating to planning 
TABLE 81 STARs SRE costing study inpatient data
Inpatient days
Vertebral 
fracture
Non-vertebral 
fracture
Radiation to the 
bone
Surgery to the 
bone SCC
Average inpatient 
stays per patient
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
Average duration 
per stay
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
Of which 
assumed 
within trim 
point
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
Of which 
assumed 
excess bed-
days
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC, academic-in-confidence.
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multiple phases of complex radiotherapy and SC010Z relating to planning ‘other’ radiotherapy. The 
weighted average cost across inpatients, day cases, outpatients and ‘other’ settings is applied to all those 
receiving radiotherapy.
Similarly, for the delivery of radiotherapy the manufacturer includes the HRG codes SC21Z through 
to SC24Z, all of which relate to delivering a single fraction of radiotherapy. Again, it may be more 
questionable to have included SC29Z relating to the delivery of ‘other’ radiotherapy, the unit costs of this 
typically being somewhat higher than that of the HRGs specifically relating to delivering a single fraction 
of radiotherapy. The weighted average cost across inpatients, day cases, outpatients and ‘other’ settings 
is multiplied by the average number of fractions (academic-in-confidence information has been removed) 
drawn from the STARs study.
Base-case skeletal-related event costs
The STARs-based costing results in the following cost estimates (Table 82).
Vertebral fracture is something of an outlier within these costings, with quite significant costs being 
associated with outpatient visits and outpatient procedures. Possibly because of the questionable reliability 
of the resource use around vertebral fractures and the numbers observed (academic-in-confidence 
information has been removed), coupled with expert opinion that vertebral fractures are typically 
asymptomatic to the extent of not being treated, the manufacturer applies no cost for vertebral fractures 
in the base case.
Adverse event costs
As already noted, the cost of treating hypercalcaemia, £4579 (£379; 2004), as drawn from the Ross HTA 
monograph is used for the base case.
For hypocalcaemia the manufacturer assumes that this will require one haematology consultant-led 
outpatient appointment, one intravenous calcium injection, and two follow-up visits. Each visit is 
associated with a blood test, to yield a total cost per event of £443.
TABLE 82 STARs-based costing results
Cost 
element
Vertebral 
fracture
Non-vertebral 
fracture
Radiation to the 
bone
Surgery to the 
bone SCC
n AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
Inpatient 
cost
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
Outpatient 
cost
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
Emergency 
care cost
AiC information 
has been removed
AiC information 
has been removed
Home health 
visits
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
Procedures AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
Total STARs 
cost
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
Base-case 
cost applied
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC, academic-in-confidence.
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For the other adverse events the manufacturer assumes that all will be treated as inpatients and simply 
averages the inpatient cost over a range of HRGs:
 z ONJ HRGs: CZ16 minor maxillofacial procedures, CZ17 intermediate maxillofacial procedures, CZ18 
major maxillofacial procedures, and CZ19 complex maxillofacial procedures, to arrive at an average 
cost of £2465
 z renal toxicity HRGs: all LA07 acute kidney injury and all LA08 chronic kidney disease but not LA09 
general renal disorders, to arrive at an average cost of £1681
 z skin infections HRG: only JD04B minor skin disorders category 3 with Intermediate CC at £1440.
Quality of life
The EQ-5D data were administered during the denosumab trials, and this data set is probably the best 
source of HRQoL data for estimating the impact of SREs on patient quality of life for the purposes of 
economic modelling. For the health index questions of the EQ-5D, a three-level response was used to 
assess quality of life. As explored in greater detail below, the manufacturer has undertaken an involved 
analysis of these data. Prior to exploring the analysis presented by the manufacturer two quite large 
caveats are in order:
 z At the stakeholder-briefing meeting, the manufacturer undertook to supply the full EQ-5D data 
analysis report as an appendix to the NICE submission. This report has not been supplied.
 z The submission and its appendices provide no detail of the functional forms that were tested during 
the EQ-5D data analysis. No statistical justification for the functional form chosen by the manufacturer 
over other candidate functional forms is presented.
The key assumption underlying the functional form chosen by the manufacturer is that only SREs and 
adverse events related to metastatic bone disease and its treatment affect deviations from the baseline 
HRQoL. In the context of the underlying condition(s) being cancer with the possibility of progression, 
the development of metastatic disease in areas other than the bone and the relatively short anticipated 
average survival this appears to be a very strong assumption. Other covariates not included within the 
manufacturer’s model might be anticipated to be significant, and it might also be anticipated that there 
could be a general cancer-specific time trend to the patient HRQoL, such as that within the van den Hout 
and colleagues198 reference summarised in the quality-of-life review above. Not considering progression 
within the modelling of utility is surprising.
The other key assumption is that the most appropriate functional form is to estimate the HRQoL impact of 
a SRE from 5 months before its diagnosis, through diagnosis, and on through to 5 months subsequent to 
its diagnosis: 11 months in total. For fractures, it is not obvious why the extended period of time before 
the fracture being identified is required.
Note that the MS makes the assumption that utility 6 months before the diagnosis of a SRE is at the 
relevant baseline value, whether SRE naive or SRE experienced, and that 6 months subsequent to the 
diagnosis of the SRE it returns to the baseline SRE-experienced level. Given this, the overall QALY impact 
of a SRE is in effect calculated as the area between the curves. To illustrate this within the graphs of the 
calculation of disutility for SRE-naive and -experienced patients in the submission, the manufacturer 
anticipated impacts of radiation to the bone for a breast cancer patient. Figure 8 replicates this for the 
11 months centred on radiation to the bone at T0 for a SRE-experienced breast cancer patient, where the 
vertical axis measures the HRQoL and the horizontal axis is in time in months.
This is perhaps the neatest evolution of HRQoL due to a SRE within the manufacturer’s analysis. It can 
be taken as an argument in favour of estimating the QALY impact of radiation to the bone as the area 
between the SRE-experienced straight line for those not experiencing a SRE and the curve for the evolution 
of HRQoL associated with radiation to the bone of a SRE-experienced patient.
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But not all the curves are quite so tidy, as shown in full in Appendix 13. Cherry-picking to a similar degree 
but in the opposite direction to the manufacturer, the evolution of HRQoL due to vertebral fracture within 
the OSTs group of cancer patients for a SRE-experienced patient is shown in Figure 9.
It is not obvious that the HRQoL impact of the vertebral fracture should be taken as far back as 5 months 
before its diagnosis. The dip at 4 months before diagnosis of vertebral fracture is not maintained and 
might be better discarded as an effect. It is also possibly questionable to include the estimated effects for 
the full 5 months subsequent to the diagnosis of the vertebral fracture. From the above, the argument 
could be made that the HRQoL impact of vertebral fractures is limited to the 2 months subsequent to T0.
These considerations outlined may apply in the opposite direction for the evolution of HRQoL because of 
SCC. While the picture varies across the cancers there is some similarity in terms of a possibly permanent 
effect, as would be anticipated given that a proportion of patients will have some degree of paralysis 
(Figure 10).
FIGURE 8 HRQoL evolution due to radiation to the bone for a breast cancer patient (academic-in-confidence 
information has been removed).
FIGURE 9 HRQoL evolution due to vertebral fracture for a OST cancer patient (academic-in-confidence information has 
been removed).
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In this instance it can be argued that evaluating the QALY impact of SCC for only the 5 months subsequent 
to diagnosis of SCC may have underestimated the HRQoL impact of SCC. The HRQoL decrements estimated 
for the months subsequent to SCC for the SRE-experienced patient are presented in Table 83, together 
with the baseline HRQoL value for SRE-naive and -experienced patients.
The total QALY decrements associated with SREs as presented by the manufacturer are summarised in 
Table 84. For the SRE-naive patient experiencing a SRE there is a permanent loss from the first SRE that is 
experienced. This accounts for much of the difference in the SRE QALY impacts between SRE-naive and 
-experienced patients. It is not clear that the full discounted impact of this is within the numbers below.
In the main, however, based on a fairly crude assessment of the central values derived and the graphs 
of the evolution of HRQoL over time as in Appendix 13, the manufacturer’s analysis of the EQ-5D data 
does not appear to have arrived at unreasonable estimates for the impacts of SREs. But this retains the 
caveat that no detail of the EQ-5D study in terms of the alternative functional forms that were tested has 
been provided by the manufacturer. There is also no provision for other elements of the cancers, such as 
progression, to affect patient quality of life, which may have led to bias.
The manufacturer’s model corrects the SRE utility decrements to avoid projecting any effect priors to the 
start of treatment, i.e. during the first five cycles of the model; for instance, for the third 28-day cycle to 
exclude the impacts of the fifth and fourth months before a SRE.
The manufacturer’s model appears to correctly adjust the post-SRE HRQoL decrements for those dying in 
the 5 months subsequent to an event in order not to project SRE HRQoL impacts beyond death (Table 85).
The HRQoL impact of an adverse event draws on the same EQ-5D data as those used for estimating the 
HRQoL impact of SREs. A unified overall model is not presented and the data are analysed separately for 
SREs and for AEs.
The assumed duration of HRQoL impacts is lifetime for ONJ and renal toxicity, whereas the duration 
of HRQoL impacts from hypercalcaemia, hypocalcaemia and skin infections is as recorded within the 
individual patient level data.
FIGURE 10 HRQoL evolution due to SCC for a prostate cancer patient (academic-in-confidence information has been 
removed).
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TABLE 83 Spinal cord compression HRQoL decrement estimates post diagnosis
SRE experienced Breast cancer Prostate cancer OSTs
SRE-naive baseline HRQoL AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
SRE-experienced baseline HRQoL AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
Permanent loss from first SRE AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
SCC HRQoL decrements
First month post diagnosis AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
Second month post diagnosis AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
Third month post diagnosis AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
Fourth month post diagnosis AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
Mean decrement post diagnosis AiC information has been 
removed
AiC information has been 
removed
AiC information has been 
removed
AiC, academic-in-confidence.
TABLE 84 SRE QALY impacts: SRE-naive and -experienced patients
SRE
Breast cancer Prostate cancer OSTs
SRE naive
SRE 
experienced SRE naive
SRE 
experienced SRE naive
SRE 
experienced
Vertebral 
fracture
AiC information 
has been 
removed 
AiC information 
has been 
removed
AiC information 
has been 
removed 
AiC information 
has been 
removed
AiC information 
has been 
removed 
AiC information 
has been 
removed
Non-
vertebral 
fracture
AiC information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been 
removed 
AiC information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been 
removed
Radiation 
to the 
bone
AiC information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been 
removed
Surgery 
to the 
bone
AiC information 
has been 
removed 
AiC information 
has been 
removed 
AiC information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been 
removed
SCC AiC information 
has been 
removed 
AiC information 
has been 
removed
AiC information 
has been 
removed
AiC information 
has been 
removed 
AiC information 
has been 
removed
AiC information 
has been 
removed 
AiC, academic-in-confidence.
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Manufacturer’s modelling conformity to National Institute for Health and 
Care Excellence reference case
The manufacturer’s model broadly conforms to the NICE reference case as summarised in Table 86.
Manufacturer’s base-case results
What follows are the manufacturer-reported estimates for the cost-effectiveness of denosumab compared 
with the primary comparator, plus additional pairwise comparisons where the NMA provides effectiveness 
estimates for other BPs.
Unfortunately, the manufacturer has not reported results relative to BSC for those contraindicated to BPs.
Breast cancer: all patients
The base-case results (Table 87) are that denosumab prevents on average around 0.21 SREs compared with 
zoledronic acid. Among those contraindicated to BPs, denosumab is anticipated to prevent on average 
around 0.91 SREs compared with BSC. These yield a gain from denosumab of 0.007 QALYs compared 
with zoledronic acid. Excluding the PAS, the net overall cost increase from denosumab is £1483 compared 
with zoledronic acid. Including the PAS, denosumab is estimated to yield cost savings of £483 compared 
with zoledronic acid. This results in the following cost-effectiveness estimates for denosumab within the 
pairwise comparisons (Table 88).
Without the PAS, the cost-effectiveness of denosumab compared with zoledronic acid is estimated as 
£203,387 per QALY. The additional benefit of 0.007 QALYs does not warrant the additional cost of £1483. 
Probabilistic modelling undertaken by the manufacturer results in an identical central estimate of a 0.007 
QALY gain over zoledronic acid for a similar average additional cost of £1490.
With the PAS, denosumab is estimated to be cost saving relative to zoledronic acid. Given the small 
additional QALY gain, this results in denosumab dominating zoledronic acid. Probabilistic modelling 
TABLE 85 Serious adverse event average duration and QALY decrements 
Adverse event 
Breast cancer Prostate cancer OSTs
Average days Decrement Average days Decrement Average days Decrement
ONJ AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
Renal toxicity AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
Hypercalcaemia AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
Hypocalcaemia AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
Skin infection AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC 
information 
has been 
removed
AiC, academic-in-confidence.
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undertaken by the manufacturer results in the same central estimate of QALYs gained with a similar 
average cost saving of £481 from denosumab compared with zoledronic acid.
Prostate cancer: skeletal-related event experienced
The QALY gains anticipated from denosumab over zoledronic acid are slightly smaller than but similar to 
those within breast cancer at 0.006 QALYs with the lower survival limiting the potential for patients’ gains 
(Table 89). Excluding the PAS the incremental cost of denosumab is estimated as £922 versus zoledronic 
acid, but with the PAS denosumab results in cost savings of £281 compared with zoledronic acid. This 
results in the following cost-effectiveness estimates (Table 90).
Without the PAS, the cost-effectiveness of denosumab versus zoledronic acid is estimated as £157,276 per 
QALY. Probabilistic modelling undertaken by the manufacturer suggests the same average gain of 0.006 
QALYs from denosumab over zoledronic acid for a similar average cost of £918. With the PAS, denosumab 
is estimated to result in a cost saving of £281 compared with zoledronic acid and as a consequence, 
given the small gain of 0.006 QALYs, is estimated to dominate zoledronic acid. Probabilistic modelling 
TABLE 87 The manufacturer’s disaggregate base-case results for breast cancer: all patients
Quantity
Breast cancer: all patients
Denosumab Zoledronic acid
Disodium 
pamidronate Ibandronic acid
Life-years (undiscounted) 3.45 3.45 3.45 3.45
Life-years (discounted) 3.16 3.16 3.16 3.16
SREs 2.13 2.34 2.47 2.30
Net SREs vs denosumab 0.00 + 0.21 + 0.34 + 0.17
QALYs 1.912 1.904 1.898 1.907
Net QALYs vs denosumab 0.000 –0.007 –0.013 –0.005
Costs
Treatment
Excluding PAS CiC information has 
been removed
CiC information has 
been removed
CiC information has 
been removed
CiC information has 
been removed
Including PAS CiC information has 
been removed
SREs £2932 £3241 £3435 £3199
AEs £93 £137 £317 £37
Death £4356 £4356 £4356 £4356
Total costs
Excluding PAS CiC information has 
been removed
CiC information has 
been removed
CiC information has 
been removed
CiC information has 
been removed
Including PAS CiC information has 
been removed
Net excluding PAS vs 
denosumab
£0 –£1483 £1487 –£72
Net including PAS vs 
denosumab
£0 £483 £3453 £1895
CiC, commercial-in-confidence. 
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TABLE 88 The manufacturer’s base-case cost-effectiveness results for breast cancer: all patients
Quantity Costs (£) QALYs ∆Costs (£) ∆QALYs ICER
Denosumab CiC information has been removed 1.912
With PAS CiC information has been removed
Zoledronic acid CiC information has been removed 1.904 £1484 0.007 £203,387
With PAS –£483 Denosumab dominant 
Disodium 
pamidronate
CiC information has been removed 1.898 –£1486 0.013 Denosumab dominant 
With PAS –£3453 Denosumab dominant 
Ibandronic acid CiC information has been removed 1.907 £72 0.005 £13,835
With PAS –£1895 Denosumab dominant 
CiC, commercial-in-confidence.
TABLE 89 The manufacturer’s disaggregate base-case results for prostate cancer: SRE experienced
Quantity
SRE-experienced patients (26%)
Denosumab Zoledronic acid
Life-years (undiscounted) 2.17 2.17
Life-years (discounted) 2.04 2.04
SREs 1.98 2.12
Net SREs vs denosumab 0.00 +0.14
QALYs 1.089 1.083
Net QALYs vs denosumab –0.006
Costs
Treatment
Excluding PAS CiC information has been removed CiC information has been removed
Including PAS CiC information has been removed
SREs £2810 £3010
AEs £165 £125
Death £4625 £4625
Total costs
Excluding PAS CiC information has been removed CiC information has been removed
Including PAS CiC information has been removed
Net excluding PAS vs denosumab –£922
Net including PAS vs denosumab £281
CiC, commercial-in-confidence.
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undertaken by the manufacturer indicates the same average gain from denosumab over zoledronic acid of 
0.006 QALYs with an additional average cost saving of £286.
Prostate cancer: skeletal-related event naive
For the SRE-naive patients, who made up 74% of the denosumab trial population, the base-case cost-
effectiveness results are summarised in Table 91.
Without the PAS, denosumab is estimated to have a cost-effectiveness compared with BSC of £102,067 
per QALY. With the PAS, the cost-effectiveness estimate falls but only to £71,320 per QALY, which is also 
well above normal cost-effectiveness thresholds. Probabilistic modelling by the manufacturer is in line 
with this, with denosumab yielding a central estimate of 0.039 QALYs over BSC but at an average net cost 
of £2776.
Other solid tumours: skeletal-related event experienced
The QALY gains anticipated from denosumab are smaller than those estimated for the previous analyses: 
0.004 QALYs compared with zoledronic acid (Table 92). Excluding the PAS the incremental cost of 
denosumab is estimated as £757 versus zoledronic acid but sees cost savings of £2118 versus disodium 
pamidronate. With the PAS, denosumab results in cost savings of £43 compared with zoledronic acid and 
the net saving relative to disodium pamidronate increases to £2918. This results in the following cost-
effectiveness estimates (Table 93).
Without the PAS, the cost-effectiveness of denosumab versus zoledronic acid is estimated as £205,580 per 
QALY. Probabilistic modelling undertaken by the manufacturer paints a similar picture at central estimates, 
with an average gain from denosumab over zoledronic acid of 0.004 QALYs at an average net cost 
of £749.
With the PAS, denosumab is estimated to result in a cost saving of £43 compared with zoledronic acid 
and, given the small gain of 0.004 QALYs, to dominate zoledronic acid. Probabilistic modelling undertaken 
TABLE 90 The manufacturer’s base-case cost-effectiveness results for prostate cancer: SRE experienced
Comparator Costs (£) QALYs ∆Costs (£) ∆QALYs ICER
Denosumab CiC information has been removed 1.089
With PAS CiC information has been removed
Zoledronic acid CiC information has been removed 1.083 £922 0.006 £157,276
With PAS –£281 Denosumab dominant 
CiC, commercial-in-confidence.
TABLE 91 The manufacturer’s base-case cost-effectiveness results for prostate cancer: SRE naive including PAS
Comparator Costs (£) QALYs ∆Costs (£) ∆QALYs ICER
Denosumab CiC information has been removed 1.189
With PAS CiC information has been removed
BSC CiC information has been removed 1.150 £3993 0.039 £102,067
With PAS £2790 £71,320 
CiC, commercial-in-confidence.
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TABLE 92 The manufacturer’s disaggregate base-case results for OSTs: SRE experienced
Quantity
SRE-experienced patients (48%)
Denosumab Zoledronic acid Disodium pamidronate
Life-years (undiscounted) 1.76 1.76 1.76
Life-years (discounted) 1.64 1.64 1.64
SREs 1.37 1.46 1.47
Net SREs vs denosumab 0.00 +0.08 +0.10
QALYs 0.765 0.761 0.759
Net vs denosumab –0.004 –0.006
Costs
Treatment
Excluding PAS CiC information has been 
removed
CiC information has been 
removed
CiC information has been 
removed
Including PAS CiC information has been 
removed
SREs £2556 £2714 £2754
AEs £57 £57 £183
Death £4612 £4612 £4612
Total costs
Excluding PAS CiC information has been 
removed
CiC information has been 
removed
CiC information has been 
removed
Including PAS CiC information has been 
removed
Net excluding PAS vs denosumab –£757 £2118
Net including PAS vs denosumab £43 £2918
CiC, commercial-in-confidence.
TABLE 93 The manufacturer’s base-case cost-effectiveness results for OST cancer: SRE experienced
Comparator Costs (£) QALYs ∆Costs (£) ∆QALYs ICER
Denosumab CiC information has been removed 0.765
With PAS CiC information has been removed
Zoledronic acid CiC information has been removed 0.761 £757 0.004 £205,580
With PAS –£43 Denosumab dominant 
Disodium 
pamidronate
CiC information has been removed 0.759 –£2118 0.006 Denosumab dominant 
With PAS –£2918 Denosumab dominant 
CiC, commercial-in-confidence.
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by the manufacturer again paints a similar picture to the deterministic modelling, with an average gain 
from denosumab over zoledronic acid of 0.004 QALYs with a small cost saving of £45.
Other solid tumours: skeletal-related event naive
For the SRE-naive patients, who made up 52% of the denosumab trial population, the base-case cost-
effectiveness results are summarised in Table 94.
For the primary comparator of BSC, even with the PAS the resulting cost-effectiveness estimate for 
denosumab of £83,763 per QALY is again well above normal cost-effectiveness thresholds. Probabilistic 
modelling is in line with this, with denosumab yielding an average 0.021 QALYs over BSC but at an 
average net cost of £1724.
Manufacturer’s structural and sensitivity analyses
The manufacturer undertakes a range sensitivity analyses that apply:
 z time horizons of 2 and 5 years
 z no 21-day window for the definition of SREs
 z costs to vertebral fracture as estimated from the STARs costing exercise
 z the SRE costs as estimated from NHS reference cost admission rates
 z the manufacturer commissioned TTO utilities and the Weinfurt utilities129
 z starting ages of 50 and 65 years
 z a balance between 3-weekly and 4-weekly dosing for intravenous BP administrations
 z oral administration for ibandronic acid
 z community administration for denosumab
 z no discontinuations and a constant 0.025 discontinuation rate per cycle for all treatments
 z sensitivity analyses around the discount rates.
Many of these sensitivity analyses have relatively little impact on the outcomes of the modelling. The full 
sensitivity analyses presented by the manufacturer for the with-PAS scenario are included in Appendix 14 
of this report.
For the breast cancer modelling across all patients, without the PAS results are reasonably sensitive to:
 z the time horizon adopted, which if only 2 years worsens the ICER for denosumab compared with 
zoledronic acid from £203,000 per QALY to £254,000 per QALY, which provides some of the rationale 
for undertaking the modelling and extrapolation of effects
 z the source of utilities, with the TTO values increasing the net gain from denosumab by around 20% 
with parallel effects on the ICERs, while the Weinfurt utilities decrease the net gain from denosumab 
by a slightly smaller percentage
 z ibandronic acid being administered orally, which worsens the ICER for denosumab compared with it to 
£387,000 per QALY
TABLE 94 The manufacturer’s base-case cost-effectiveness results for OST cancer: SRE naive including PAS
Comparator Costs (£) QALYs ∆Costs (£) ∆QALYs ICER
Denosumab CiC information has been removed 0.803
With PAS CiC information has been removed
BSC CiC information has been removed 0.782 £2530 0.021 £122,499
With PAS £1730 £83,763 
CiC, commercial-in-confidence.
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 z the frequency of dosing for the intravenous BPs, as would be anticipated, reducing the net cost of 
denosumab over zoledronic acid by around 20% and causing the ICER to fall to £161,000 per QALY. 
For the other comparisons, including some 3-weekly, intravenous dosing is sufficient for denosumab 
to be cost saving and so dominant
 z the discontinuation rates assumed, with a zero discontinuation rate increasing the net lifetime costs 
from denosumab use. This mainly affects the comparison with ibandronic acid where the ICER worsens 
per QALY. (Commercial-in-confidence information has been removed.)
With the PAS, similar effects are observed among breast cancer patients in terms of the changes to the net 
QALYs and net costs but the sensitivity analyses still result in denosumab being estimated to be cost saving 
and to confer small QALY gains, and so dominate the other treatments. Only oral ibandronic acid stands 
out with a small net cost from denosumab use (commercial-in-confidence information has been removed), 
resulting in a cost-effectiveness estimate of £387 per QALY.
For SRE-experienced prostate cancer patients, without the PAS, results are reasonably sensitive to:
 z excluding the 21-day window from the identification of SREs, with this improving the ICER for 
denosumab compared with zoledronic acid from £157,000 per QALY to £89,000 per QALY
 z basing the utility estimates on the Weinfurt reference, which worsens the ICER to £384,000 per QALY
 z the frequency of dosing for the intravenous BPs, reducing the net cost of denosumab over zoledronic 
acid and causing the ICER to fall to £125,000 per QALY
 z community administration of denosumab, causing the ICER to fall per QALY. (Commercial-in-
confidence information has been removed.)
With the PAS, as for the breast cancer modelling, similar effects are observed in terms of the changes to 
the net QALYs and net costs but the sensitivity analyses still result in denosumab being estimated to be 
cost saving and to confer small QALY gains, and so dominate zoledronic acid.
For SRE-naive prostate cancer patients, even with the PAS, the sensitivity analyses result in ICERs in the 
range of £50,000 per QALY to £355,000 per QALY, which are outside the range usually considered to be 
cost-effective.
For SRE-experienced patients with OSTs, for the comparison with zoledronic acid the cost-effectiveness of 
denosumab without the PAS is reasonably sensitive to:
 z excluding the 21-day window from the identification of SREs, with this improving the ICER for 
denosumab compared with zoledronic acid from £206,000 per QALY to £144,000 per QALY
 z basing the utility estimates on the Weinfurt reference, which worsens the ICER to £420,000 per QALY
 z the frequency of dosing for the intravenous BPs, reducing the net cost of denosumab over zoledronic 
acid and causing the ICER to fall to £176,000 per QALY
 z community administration of denosumab, causing the ICER to fall per QALY (commercial-in-confidence 
information has been removed) 
 z zero discontinuations across treatments which improves the ICER per QALY. (Commercial-in-confidence 
information has been removed.) 
With the PAS, as for the modelling of prostate cancer and breast cancer, similar effects are observed in 
terms of the changes to the net QALYs and net costs but the sensitivity analyses still result in denosumab 
being estimated to be cost saving and to confer small QALY gains, and so dominate zoledronic acid.
For SRE-naive OST patients, even with the PAS, the sensitivity analyses result in ICERs in the range £70,000 
per QALY to £320,000 per QALY and would not typically be considered cost-effective.
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The assessment group’s critique of the manufacturer’s model and results
The manufacturer’s case is broadly that the average patient benefits from the reduced number of SREs are 
not large. (Commercial-In-confidence information has been removed.)
But for patients for whom zoledronic acid is not indicated, the manufacturer accepts that even with the 
PAS the relatively small patient gains do not justify the additional cost of denosumab. The manufacturer’s 
cost-effectiveness estimates for denosumab compared with BSC are typically closer to £100,000 per QALY 
than £50,000 per QALY, even with the PAS.
There are some concerns around the reasonableness of the manufacturer’s argument that case review 
indicates the majority of patients have had or are likely to have treatment with BPs. These may be short 
courses rather than continuous ongoing treatment, the latter seeming to be the manufacturer’s intention 
in terms of denosumab use.
The estimation of utility decrements from the trials’ EQ-5D data is at first pass impressive, but the 
complete lack of detail about the alternative functional forms that have been tested raises concerns. It also 
seems surprising that other aspects of the underlying cancers were not included as covariates. With this 
caveat and as there is no consideration of progression within the utility data, the general model structure 
employed by the manufacturer appears reasonable. It is also in line with the NICE reference case.
The manufacturer’s implementation of the utility data within the model may have two errors within it. 
If so, these are likely to pull in opposite directions. The model appears to attempt to correct so as not to 
project benefits before the start of therapy. But it appears that this may cut off the patient benefits in 
the 5 months following a SRE occurring in the first cycle of the model, in the 4 months following a SRE 
occurring in the second cycle of the model, etc. Pulling in the opposite direction, it also appears that 
the SRE decrement among SRE-naive patients is measured from the SRE-naive baseline HRQoL for the 
5 months subsequent to a SRE, but the patient is modelled as also stepping down to the SRE-experienced 
HRQoL for this period and beyond. This may double-count the impact of first SREs in the 5 months 
subsequent to their incidence.
Independent economic assessment
Methods
Before any cost-effectiveness modelling, some basic considerations should be borne in mind. Within 
the literature there are two broad strands of cost-effectiveness assessments: the straightforward 
assessments of within-trial costs and benefits and the more complicated modelling of costs and benefits 
with extrapolation to death, this latter also permitting other comparators to be included than just those 
studied within the trial. The more complicated modelling, including that of the Amgen submission 
[Amgen Ltd. Multiple Technology Appraisal: Denosumab for the treatment of bone metastases from solid 
tumours (unpublished report). London: National Institute for Health and Care Evidence; 2011], typically 
treats metastatic bone disease as a chronic condition. This gives rise to a SRE rate in one arm under 
consideration, with comparator treatments affecting this rate. There are additional considerations around 
distinguishing between the time to first SRE for SRE-naive patients compared with the rate of subsequent 
SREs for SRE-experienced patients. Almost by definition, extrapolation beyond the trial is likely to alter the 
patient balance towards SRE-experienced patients as SRE-naive patients experience SREs. Cost-effectiveness 
may differ between SRE-naive patients and SRE-experienced patients.
But even in the light of this, given that the condition is typically modelled as being chronic and stable 
through to death with discontinuations immediately leading to the BSC risk of an event, there is an 
argument for a simple economic assessment of the within-trial outcomes before any more sophisticated 
cost–utility economic modelling and extrapolation.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment DesIgn anD results: cOst-effectIVeness
130
The more simple-minded within-trial assessment trial considers the economic implications of:
 z the average number of treatments in each arm of the trials
 z the average number of SREs per patient in each arm of the trials
 z the average number of SAEs per patient in each arm of the trials
 z the average months on study within each arm and how this may condition the above.
Unfortunately, the AG does not have access to sufficiently disaggregate data to present this analysis for the 
SRE-naive and -experienced subgroups.
Other than the paper by Xie and colleagues,185 the cost-effectiveness literature has not explicitly modelled 
progression or considered any explicit stopping rule. There are three main reasons why disease progression 
may affect cost-effectiveness:
 z The rate of SREs may change at progression.
 z A proportion of patients discontinue therapy at progression, which may differ between treatments.
 z The general patient quality of life and the quality-of-life impacts from SREs may change at progression.
Modelling the above would require the progression-free survival curves for each cancer, which are 
available from the denosumab CSRs. But it would also require the time to first SRE and the rate or time to 
subsequent SREs within the zoledronic acid arm to be split by those without disease progression and those 
with progression. These data are not readily available. There would also be the question of whether or not 
the relative effect for the other comparators would remain constant at progression. The additional concern 
about how to model the quality-of-life impacts of SREs among progression-free patients and patients with 
progression is also not readily addressable given the quality-of-life estimates within the literature and the 
Amgen submission.
The AG views the structure of the manufacturer’s model as a reasonable basis for the estimation of 
cost-effectiveness. There is no suggestion that treatments affect the rate of progression or overall survival. 
If progression changes the rate of SREs, this can be explored by sensitivity analyses that change the 
rate of SREs from a given cycle in the model onwards. Quality of life declining towards the end of life 
can be explored through a structural sensitivity analysis that applies the EQ-5D utilities of van den Hout 
and colleagues.198
In the light of this, the AG has rebuilt the model using the same overall structure as the manufacturer’s 
model, the main adjustments within this being to the treatment of utilities to adjust for not projecting 
benefits to before the start of treatment, and to measure any utility decrements subsequent to a SRE from 
the SRE-experienced baseline utility. In the absence of other data, the average utility decrement for SREs 
within lung cancer has been assumed to be the same as within the OSTs including lung cancer trial.
The base case of the modelling applies the results of the AG’s NM. Additional structural elements added 
to the model are the facility for SCC to have a sustained HRQoL impact beyond 5 months from diagnosis, 
and a decay in quality of life in the final year, as estimated by van den Hout and colleagues.198 These are 
applied as sensitivity analyses only to the base case.
Given the AG’s NMA results, cost-effectiveness results are presented for four cancer groups:
 z breast cancer
 z prostate cancer
 z OSTs including lung cancer
 z lung cancer.
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These are further subdivided into;
 z all patients
 z SRE-naive patients
 z SRE-experienced patients.
The model structure can be presented diagrammatically (Figure 11).
The following analyses are presented (Table 95), and compared with those of the manufacturer.
For the above, the cost–utility analyses that employ the pooled HRs and RRs are presented as the base case. 
A range of univariate sensitivity analyses around these estimates are then presented in summary format.
The AG views the structural sensitivity analyses that employ the SRE-naive- and -experienced-specific HRs 
and RRs as sufficiently important for the full results of their impacts on the base case to be reported. This 
is complicated by the results of the AG’s NMA being pooled across all patients, i.e. not being specific to 
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FIGURE 11 Cost–utility model structure.
TABLE 95 Principal cost–utility analyses presented
SRE RR and HR
Breast cancer Prostate cancer OST + lung cancer Lung cancer
Pooled Specific Pooled Specific Pooled Specific Pooled Specific
Manufacturer
All patients ü û û û û û û û
SRE naive û û ü û ü û û û
SRE experienced û û ü û ü û û û
AG
All patients ü ü ü ü ü ü ü û
SRE naive ü ü ü ü ü ü ü û
SRE experienced ü ü ü ü ü ü ü û
Pooled relates to the HRs and RRs of a SRE being drawn from the trial data pooled across SRE-naive and 
-experienced patients.
Specific relates to the HRs and RRs of a SRE being specific to whether it is a SRE-naive patient or a SRE-experienced 
patient being modelled.
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SRE-naive or SRE-experienced patients. In the light of this and the manufacturer’s summary of subgroup 
by SRE history for time to first and time to first and subsequent on-study SRE, the structural sensitivity 
analyses apply the SRE-specific head-to-head clinical effectiveness estimates for the effectiveness of 
denosumab compared with zoledronic acid, while retaining the results of the AG’s NMA for the other 
comparator(s). This distinction is not available for the modelling of lung cancer.
Clinical parameters and effectiveness data for the modelling
The simplistic analysis of CSR data draws the rates of SREs and SAEs from the CSRs, the manufacturer’s 
model and the MS, with cross checks between the two sources.
The cost–utility modelling draws heavily on the manufacturer’s model.
Hazard ratios and relative risks of skeletal-related events
The base cases apply the results of the AG’s NMA. The results of the manufacturer’s NMA are applied as 
sensitivity analyses. The structural sensitivity analyses applying the SRE-naive and -experienced HRs and RRs 
apply to those summarised in Table 76.
Survival
Overall survival is mainly drawn from the manufacturer’s model and as summarised in Table 71. Overall 
survival for lung cancer is drawn from the estimate for zoledronic acid presented within Joshi and 
colleagues182 using a Weibull extrapolation with survival at a given day being determined by:
S(t) = exp (–0.00181455 × t^1.06762733) (1)
Note that Joshi and colleagues181 do not report any standard errors or significance testing for these Weibull 
parameters, and that as a consequence, in contrast to the other probabilistic modelling, the probabilistic 
modelling of lung cancer treats the overall survival curve deterministically.
Time to first skeletal-related event and rate of subsequent skeletal-related events
Owing to the manufacturer having access to individual patient-level data restricted to the SRE-naive 
patient subgroup, the base cases for breast cancer, prostate cancer and OSTs including lung cancer apply 
the time to first SRE curves presented within the MS and summarised in Table 74. These are not available 
for lung cancer, and the base cases apply the AG estimate for this as summarised in Table 96 and Table 97. 
The additional AG estimates for the time to first SRE for zoledronic acid are applied as sensitivity analyses 
within the modelling.
For similar arguments, the base cases for breast cancer, prostate cancer, and OSTs including lung cancer 
apply a cycle rate of SREs within the zoledronic acid arm as estimated by the manufacturer from trial 
data specific to the SRE-experienced subgroup. For lung cancer the AG has, in the absence of other data, 
TABLE 96 The AG’s time to first SRE for zoledronic acid: mean-square-error estimates
Functional 
form
SRE naive All patients
Breast Prostate Breast Prostate OST + lung Lung
Weibull 0.000249 0.000115 0.000351 0.000148 0.000335 0.000128
Log-logistic 0.000225 0.000106 0.000272 0.000081 0.000380 0.000092
Log-normal 0.000205 0.000114 0.000213 0.000074 0.000383 0.000088
Gamma 0.000242 0.000105 0.000294 0.000083 0.000325 0.000111
Values shown in bold face indicate lowest mean-square-error estimates.
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estimated cycle rates based on the pooled data across all patients; i.e. not specific to the SRE-experienced 
subgroup (Table 98).
Discontinuation rates and serious adverse events
The base case applies those of the manufacturer’s model, as summarised in Table 77. In the absence of 
any other data, the rates for modelling of lung cancer are assumed to be the same as those for the OSTs 
including lung cancer modelling.
TABLE 97 The AG’s time to first SRE for zoledronic acid parameter estimates
Patient type Distribution Intercept Scale Shape
SRE naive
Breast Log-normal 3.62 1.84
Prostate Gamma 3.51 1.28 0.8
All patients
Breast Log-normal 3.33 1.97
Prostate Log-normal 2.85 1.48
OST + lung Gamma 3.55 1.54 0.82
Lung Log-normal 2.62 2.73
TABLE 98 The AG’s subsequent SRE rates for zoledronic acid functional form
Zoledronic arms (with 21-day 
window)
Prior SRE All patients
Breast Prostate OST + lung Lung
Sample size CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
Length of study (months) CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
Length of study (years) CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
Overall survival hazard rate (estimate) CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
Patient-years of exposure CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
Cumulative mean rate at end of study CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
SREs (estimate) CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
SMR CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
Cycle length (days) CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
Cycle rate CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC information 
has been removed
CiC, commercial-in-confidence.
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Quality-of-life values
Despite the lack of detail around their estimation, the AG views the manufacturer’s estimates for the 
quality-of-life impacts from SREs and SAEs as the best that are available. The balance between the SREs 
results in average QALY decrement per SRE as outlined in Table 99.
The lower average SRE QALY decrement in breast cancer patients compared with patients with other 
cancers arises mainly from the lower proportion of SREs, which are either radiation to the bone or SCC. 
The average SRE QALY decrement among SRE-experienced breast cancer patients is further affected by 
non-vertebral fractures being estimated to have a particularly small impact on HRQoL in this group. Note 
that the QALY decrements reported above for the SRE-naive patients do not take into account the step 
change in utility when moving from being SRE naive to SRE experienced and continuing through to death, 
as outlined in Table 83.
Modelling a sustained quality-of-life impact from SCC beyond the 5 months subsequent to the 
compression is implemented by calculating the discounted expected cycles of survival from 5 months 
subsequent to the compression through to the model horizon. This is then multiplied by the per cycle 
QALY decrement associated with SCC. The QALY decrement can be either the average or the maximum 
decrement estimated during the 5 months subsequent to the compression, as outlined in Table 83.
Modelling decay in quality of life in the final year adjusts the total within-cycle QALY by the proportionate 
decline in utility as outlined in Table 66, taking the modelled survival into account. The proportion of 
patients anticipated to survive to 12 months beyond the cycle requires no adjustment to be made to their 
QALY. Working back from this, the proportion anticipated to survive to 11 months beyond the cycle has 
the percentage reduction in utility for being 11 months to death, as drawn from Table 66, applied. This 
is worked back through to the proportion anticipated to survive only 1 month beyond the cycle being 
modelled, which has the proportionate decline in utility for being 1 month to death applied. Summing 
these gives a total overall QALY multiplier to apply to the total within-cycle QALY. For instance, within the 
first cycle of the breast cancer model this gives rise to a multiplier of 0.96, which by the 12th cycle has 
fallen to 0.93.
Health-related quality-of-life values for SAEs are as per Table 85. The manufacturer’s assumption of a 
permanent decrement from ONJ and renal toxicity has been adopted for the base case, with a sensitivity 
analysis limiting this to the average duration observed within the trials.
Resource use
The direct drug and administration costs for the base cases are as per the MS, correcting only the 
zoledronic acid price and the disodium pamidronate price for BNF62. Note that these costings do not 
attempt to correct for doses of zoledronic acid being withheld because of renal toxicity. Given the 
uncertainty around the future price of zoledronic acid as a result of imminent patent expiry, a common set 
of sensitivity analyses are presented that incrementally reduce this price by 5%.
Note that removing the 15-minute nursing time for zoledronic acid infusion that the manufacturer adds 
post hoc to the time and motion survey is equivalent to a reduction in the price of zoledronic acid of 
TABLE 99 Skeletal-related event distribution and average QALY decrements
Breast cancer Prostate cancer OSTs
SRE naive SRE experienced SRE naive SRE experienced SRE naive SRE experienced
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC information 
has been removed
AiC, academic-in-confidence.
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around 7%. In the light of this, sensitivity analyses around zoledronic acid administration costs have not 
been separately presented.
In common with the Ross HTA report55 and the MS, the AG’s costings of events rely to a large extent on 
averaging reference costs, coupled with some expert opinion on the balance between the proportion of 
patients admitted as a result of the event and the proportion treated as either day cases or outpatients. As 
already noted, the manufacturer’s costings include excess bed-days on the basis of the trim point being 
the average length of stay. These have been excluded from the AG costings, with the exception of the SCC 
costing. For SCC, NICE CG75 suggests an average £892 (£844) for patient rehabilitation drawn from CG75. 
Even this may underestimate the full cost of SCC, given that a proportion of patients will be paralysed to a 
greater or lesser extent and require ongoing care.
Costs for SAEs are less in line with those of the manufacturer, mainly because the manufacturer typically 
assumes that all would be treated on an inpatient basis, though this does include a proportion of day 
cases (Table 100). AG expert opinion suggests that an elective or non-elective inpatient admission is 
unlikely for ONJ, skin infections or renal toxicity caused by BP use. In the light of this, ONJ has been costed 
on the basis of 90% being treated as day cases with the remainder being admitted; skin infections on the 
basis of 90% being treated as outpatients with one initial and two follow-up appointments; and renal 
toxicity on the basis of 90% being treated as outpatients with one initial and two follow-up appointments, 
with the remainder being treated as day cases. Sensitivity analyses find these distinctions to have relatively 
little impact.
As in the manufacturer’s base case, the cost of vertebral fractures is set to zero on the basis that most are 
sufficiently asymptomatic to not require treatment. Within the probabilistic modelling the rates of SREs are 
treated probabilistically, but the unit costs are treated deterministically. (In the light of referee comment, 
treating the NHS reference costs underlying the SRE and SAE average costs as being deterministic may 
have slightly understated the degree of uncertainty around the overall resource use associated with SREs 
and SAEs. Distributions could and perhaps should have been placed on the underlying NHS reference 
costs, based on the interquartile ranges reported. But it seems likely that any resulting distributions would 
have to be treated as being independent, which would tend to reduce the overall uncertainty associated 
TABLE 100 Skeletal-related event and SAE event costs
Event AG Manufacturer
SREs
Vertebral fracture £294 AiC information has been removed
Non-vertebral fracture £1581 AiC information has been removed
Radiation to the bone £662 AiC information has been removed
Surgery to the bone £7269 AiC information has been removed
SCC £7311 AiC information has been removed
SAEs
ONJ £1220 £2465
Renal £496 £1681
Hypercalcaemia £4579 £4579
Hypocalcaemia £443 £443
Skin £370 £1440
AiC, academic-in-confidence.
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with the distributions of average costs per SRE and per SAE compared with that of the underlying 
NHS reference costs. The opinion of the AG is that, in the light of the final results, this amendment to 
the modelling would not be expected to have any significant impact on the central estimates of the 
probabilistic modelling. But it is conceded that this omission will have caused some underestimation of the 
degrees of uncertainty around the central estimates within the probabilistic modelling.)
Univariate sensitivity analyses
A range of univariate sensitivity analyses are presented for the lifetime cost–utility modelling (Table 101).
The results of these are presented in full for all patients, for SRE-naive patients and for SRE-experienced 
patients for the comparison of denosumab with zoledronic acid and for the comparison of denosumab 
with BSC. But given the results of the analyses for the comparisons with BSC result in cost-effectiveness 
estimates typically in excess of £100,000 per QALY, even with the PAS, these are generally not reported 
in the main body of the text. For the sake of space, the body of the report presents only the summary of 
these for all patients for breast cancer, and all patients and SRE-experienced patients for the remaining 
analyses. Where the sensitivity analysis results in a cost-effectiveness estimate for denosumab versus BSC of 
less than £50,000 per QALY this is individually reported in the text, and whether this applies to all patients, 
SRE-naive patients or SRE-experienced patients.
In addition to these, as zoledronic acid is shortly coming off patent, the approximate changes in the price 
of zoledronic acid that would be required for the cost-effectiveness of denosumab relative to zoledronic 
acid to be £20,000 per QALY and £30,000 per QALY are reported.
TABLE 101 Univariate sensitivity analyses conducted
Description Abbreviated
Base case Base case
Amgen STARs costing Amgen STARs
Amgen NMA results Amgen NMA
Amgen STARs costings and NMA results Amgen STARs+NMA
No HRQoL step change for naive to experienced No naive util step
SCC permanent utility effect of the average P1–P5 decrement SCC ongoing mean
SCC permanent utility effect of the maximum P1–P5 decrement SCC ongoing max.
No general mortality No gen. mortality
5-year horizon 5-year horizon
2-year horizon 2-year horizon
van den Hout utility multipliers for last year of life vd Hout utility
ONJ and renal toxicity utility impact beyond trial average SAE P1+
Excluding SAEs No SAE 
General discontinuations at the end of the average treatment then constant Gen. discs. EoT
No general discontinuations No gen. discs.
No discontinuations No discs.
AG TTF functional form from naive for breast and prostate TTF form AG naive
AG TTF functional form all patients for breast, prostate and OSTL TTF form AG all
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Presentation of results
For the lifetime cost–utility modelling a common format has been adopted for each of the four cancer 
groups being modelled. The results of the base-case deterministic modelling that apply the AG’s NMA 
results are presented in detail, coupled with the associated cost-effectiveness acceptability frontiers (CEAFs) 
from the probabilistic modelling. The range of univariate sensitive analyses are then tabulated, followed by 
a summary of the main points arising from them and of the impact of reductions in the price of zoledronic 
acid. This is then followed by a detailed presentation of results from the application of the SRE-naive- 
and -experienced-specific HRs and RRs. This latter is as per the base case, only with the SRE-naive- and 
-experienced-specific HRs and RRs for denosumab versus zoledronic acid being applied, as summarised in 
Table 76.
Results
Within-trial data analysis
Using data from the CSRs and the submission permits the average number of doses administered and 
the numbers of SREs to be presented, together with the numbers of SAEs, for each arm. The following 
presents these on the basis of net number of events per patient-year together with their costs, coupled 
with the average number of drug administrations per patient-year and the costs of this.
To cost the SREs and SAEs, and to assess their QALY impact, the individual events can be assessed 
separately. But this may result in the analysis being driven by a very small net difference in costly events 
between the arms. The same average distribution between SREs has been assumed for each arm as has 
been applied within the more involved cost–utility modelling and as reported in Table 73 above. The 
resulting average SRE unit cost and average SRE QALY impact can then be applied to the net difference 
between the arms. This latter will be referred to as average event based, the former as individual event 
based. The average total QALY decrements per event are drawn from the MS as summarised above.
Breast cancer
The direct on-trial drug and administration costs are as shown (Table 102).
This can be further summarised as shown (Table 103).
This analysis is relatively straightforward and sees denosumab increase total costs by between £1101 and 
£1149 compared with zoledronic acid. This suggests crude estimates of the on-trial cost-effectiveness 
excluding the PAS of between £191,000 and £378,000 per QALY compared with zoledronic acid. 
However, with the PAS, denosumab is estimated to be broadly cost neutral, with this ranging between a 
cost saving of £26 and a small additional cost of £23 depending on how the costs of SREs and SAEs are 
summed. This results in denosumab being estimated to range from dominating zoledronic acid to having 
a very acceptable cost-effectiveness ratio of £3783 per QALY. Because of the small QALY gains estimated in 
the above, relatively small changes in the price of zoledronic acid cause quite large changes in the cost-
effectiveness estimates. (CiC information has been removed.)
Prostate cancer
The direct on-trial drug and administration costs are as shown (Table 104).
This can be further summarised (Table 105).
Again, the principal immediate uncertainty may relate to the cost of zoledronic acid.
As for breast cancer, this analysis for prostate cancer is relatively straightforward and sees denosumab 
increase total costs by between £1214 and £1228 compared with zoledronic acid. This suggests crude 
estimates of the on-trial cost-effectiveness excluding the PAS of between £77,000 and £166,000 per QALY 
compared with zoledronic acid. Within this analysis there is a greater absolute QALY discrepancy between 
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the average event-based analysis and the individual event-based analysis. This arises in large part from 
the crude estimate of the impact on the annual incidence of SCC. Whether or not this is an argument for 
assessing the SREs on an individual event basis is a moot point, but it seems conceivable that there may be 
different effects in osteolytic cancers compared with osteoblastic cancers.
With the PAS, denosumab is estimated to result in an average cost increase of between £111 and £126 
per annum. Given the differences in the QALY estimates, this results in cost-effectiveness estimates ranging 
between £7904 per QALY and £15,190 per QALY. Because of the small QALY gains estimated using the 
average event-based method, as for breast cancer, relatively small changes in the price of zoledronic acid 
cause large changes in the cost-effectiveness. With the PAS, a fall in the price of zoledronic acid between 
that in the average event analysis (commercial-in-confidence information has been removed) and that in 
the individual event analysis (commercial-in-confidence information has been removed) would be sufficient 
to make the additional cost of denosumab not justify the relatively small average QALY gains.
Other solid tumours excluding multiple myeloma
Unfortunately, the CSR, the manufacturer’s model and the submission do not provide sufficient detail to 
be able to present this analysis for the patient group of OSTs excluding multiple myeloma.
Cost–utility modelling
Breast cancer base case
The modelling applies the AG’s NMA results in Table 106.
The net gain from denosumab over zoledronic acid of 0.007 QALYs is in line with that estimated by the 
manufacturer. But this remains a relatively small gain, which without the PAS requires an additional £1707, 
resulting in a cost-effectiveness of £245,264 per QALY.
Among those in whom BPs are contraindicated, the cost-effectiveness of denosumab compared with BSC 
is broadly similar. Patient gains are larger at 0.027 QALYs but the net cost rises by a similar amount to 
£6242, resulting in a cost-effectiveness estimate of £229,547 per QALY.
With the PAS, the anticipated cost savings are less than anticipated by the manufacturer, but this appears 
to be broadly in line with the assumed costs of SREs and SAEs. Given the cost saving and the anticipated 
patient gains, denosumab is estimated to dominate zoledronic acid. Probabilistic modelling over 2000 
iterations is broadly in line with this, estimating the same 0.007 QALYs, but a slightly smaller average cost 
saving of £243. The likelihood of denosumab being cost-effective compared with the BPs is estimated 
as 98% for a willingness to pay of £20,000 per QALY and as 100% for a willingness to pay of £30,000 
per QALY.
For those in whom BPs are contraindicated, the cost-effectiveness of denosumab compared with BSC is 
again considerably worse, with a central estimate across all these patients of £157,829 per QALY. Across 
all patients the probabilistic modelling suggests similar central estimates of 0.028 QALYs and a net cost 
of £4269 to yield a cost-effectiveness estimate of £154,944 per QALY. The likelihood of denosumab being 
TABLE 103 Breast cancer trial-based annual cost-effectiveness
Results
Average event assessment Individual event assessment
Costs QALYs ICER Costs QALYs ICER
Results excluding PAS £1098 0.003 £378,487 £1147 0.006 £190,841
Results including PAS –£26 0.003 Dominant £23 0.006 £3783
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cost-effective compared with the BPs and BSC is estimated as 0% for a willingness to pay of £20,000 per 
QALY and as 0% for a willingness to pay of £30,000 per QALY (Figure 12).
Breast cancer sensitivity analyses
The univariate sensitivity analyses for the all-patient modelling for the cost-effectiveness of denosumab 
compared with zoledronic acid are presented in Table 107.
The sensitivity analyses suggest that the AG’s and manufacturer’s estimates are broadly in line. Applying 
the manufacturer’s estimates for costs and effectiveness has little impact, whereas applying the AG’s 
estimates for the functional form for the time to first SRE again has very little impact.
The main sensitivity of results is around the SAEs and the discontinuation rates, given the higher rate 
of renal failure within the zoledronic acid arm, and the assumption that this lasts for longer than that 
measured in the trials affects results. If SAE ONJ and renal failure durations are the average remaining 
cohort survival, the anticipated benefits from denosumab over zoledronic acid increase by up to half, 
with a parallel impact on the cost-effectiveness estimate. Excluding discontinuations also has quite a large 
impact when compared with BSC, although the increase in the net patient gains is broadly mirrored by an 
increase in the net cost, resulting in a relatively static ICER.
A reduction in the price of zoledronic acid (commercial-in-confidence information has been removed) 
results in the cost-effectiveness of denosumab compared with zoledronic acid across all breast cancer 
patients including the PAS worsening to levels that might not be considered cost-effective. Applying the 
head-to-head SRE-naive- and -experienced-specific clinical effectiveness results for denosumab versus 
zoledronic acid, while retaining the remainder of the AG’s NMA, gives the results in Table 108.
For breast cancer, as the subgroup-specific HRs and RRs for denosumab compared with zoledronic acid are 
broadly similar to the estimates pooled across all patients, applying the subgroup-specific HRs and RRs has 
relatively limited impact on results.
Prostate cancer base case
The modelling that applies the AG’s NMA gives the results in Table 109.
Larger patient gains are anticipated for prostate cancer patients. This is partly because of a higher 
proportion of SCC within the overall incidence of SREs. But the analysis is broadly similar to that for breast 
cancer. Without the PAS, the relatively small patient gain of 0.009 QALYs at an additional cost of £1059 
results in a cost-effectiveness compared with zoledronic acid of £111,603 per QALY. However, with the 
PAS, cost savings and dominance over zoledronic acid are anticipated.
The cost-effectiveness is estimated to be slightly worse among the SRE experienced than across the patient 
group as a whole, though this may be partly the result of the step change in HRQoL that is applied when 
SRE-naive patients experience their first SRE. But with the PAS, cost savings are again anticipated, which 
again results in dominance over zoledronic acid. The probabilistic modelling suggests central estimates of 
a gain of 0.009 QALYs and a cost saving of £123 across all patients. The likelihood of denosumab being 
TABLE 105 Prostate cancer trial-based annual cost-effectiveness
Results
Average event assessment Individual event assessment
Costs QALYs ICER Costs QALYs ICER
Results excluding PAS £1214 0.007 £165,881 £1228 0.016 £77,129
Results including PAS £111 0.007 £15,190 £126 0.016 £7904
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FIGURE 12 Breast cancer cost-effectiveness acceptability curves (CEACs) and CEAFs including the PAS. (The CEAF has 
been overlaid on top of the CEACs for reasons of space, but they are presented separately in Appendix 15.) (a) CEAF 
excluding BSC: all patients; (b) CEAF including BSC: all patients; (c) CEAF excluding BSC: SRE-naive patients; (d) CEAF 
including BSC: SRE-naive patients; (e) CEAF excluding BSC: SRE-experienced patients; (f) CEAF including BSC: SRE-
experienced patients.
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FIGURE 12 Breast cancer cost-effectiveness acceptability curves (CEACs) and CEAFs including the PAS. (The CEAF has 
been overlaid on top of the CEACs for reasons of space, but they are presented separately in Appendix 15.) (a) CEAF 
excluding BSC: all patients; (b) CEAF including BSC: all patients; (c) CEAF excluding BSC: SRE-naive patients; (d) CEAF 
including BSC: SRE-naive patients; (e) CEAF excluding BSC: SRE-experienced patients; (f) CEAF including BSC: SRE-
experienced patients. (continued)
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cost-effective compared with the BPs across all patients is estimated as 99% for a willingness to pay of 
£20,000 per QALY and as 100% for a willingness to pay of £30,000 per QALY (Figure 13).
For those in whom BPs are contraindicated, even with the PAS, the cost-effectiveness of denosumab 
compared with BSC is poor, at between £70,000 per QALY and £240,000 per QALY. Across all patients 
the probabilistic modelling suggests similar central estimates of 0.035 QALYs and a net cost of £2764 to 
yield a cost-effectiveness estimate of £78,756 per QALY. The likelihood of denosumab being cost-effective 
compared with the BPs and BSC across all patients is estimated as 0% for a willingness to pay of £20,000 
per QALY and as 0% for a willingness to pay of £30,000 per QALY.
Prostate cancer sensitivity analyses
The univariate sensitivity analyses for the SRE-experienced patient modelling for the cost-effectiveness of 
denosumab are presented in Table 110.
Prostate cancer patient benefits are more sensitive to the assumed duration of the quality-of-life impact 
from SCC than those of breast cancer patients. The anticipated net QALY gain from denosumab compared 
with zoledronic acid increases by up to around 40% depending on whether the mean decrement post 
diagnosis or the maximum decrement post diagnosis is carried forward.
If the average (or maximum) SCC utility decrement is carried forward in the modelling for SRE-naive 
prostate cancer patients, this yields a cost-effectiveness estimate for denosumab with the PAS compared 
with BSC of £56,420 per QALY (or £49,023 per QALY). There are limited data on the rates of paralysis from 
SCC and the cost estimates from averaging reference costs may be too low. CG75 suggests an average 
therapy cost of £14,173 (£13,705). Adding this to the average rehabilitation costs and applying the 
average SCC decrement through to death results in a cost-effectiveness estimate for the with-PAS analysis 
for SRE-naive prostate cancer patients (commercial-in-confidence information has been removed) per QALY 
compared with BSC higher than the (commercial-in-confidence information has been removed) when 
applying the maximum decrement. 
As for the breast cancer modelling, removing treatment discontinuations increases the net gain from 
denosumab over zoledronic acid, though this may be better viewed in effect as fewer patients receiving 
BSC. The net impact on the ICER is quite muted as net costs change roughly in proportion, but note that 
it tends to worsen the cost-effectiveness for the comparison with BSC but improve it for the comparison 
with zoledronic acid.
A reduction in the price of zoledronic acid (commercial-in-confidence information has been removed) 
is sufficient to result in the cost-effectiveness of denosumab compared with zoledronic acid for SRE-
experienced prostate cancer patients including the PAS to worsen to levels that might not be considered 
cost-effective.
Applying the head-to-head SRE-naive- and -experienced-specific clinical effectiveness results for 
denosumab versus zoledronic acid, while retaining the remainder of the AG’s NMA, gives the results in 
Table 111.
Cost-effectiveness results for prostate cancer are more sensitive to the application of the SRE-naive- and 
-experienced-specific HRs and RRs. Note that within the modelling the impact of this on the average 
cost-effectiveness across all patients does not broadly cancel out. This is because over the period of 
extrapolation SRE-naive patients experience SREs and so cross over to the SRE-experienced group. The 
baseline balance between SRE-naive and -experienced patients as drawn from the trial trends towards 
SRE-experienced patients as extrapolation within the model progresses. This also explains why applying 
the SRE-specific estimates worsens the cost-effectiveness estimate among those who were SRE naive 
at baseline.
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FIGURE 13 Prostate cancer CEAFs including the PAS. (a) CEAF excluding BSC: all patients; (b) CEAF including BSC: all 
patients; (c) CEAF excluding BSC: SRE-naive patients; (d) CEAF including BSC: SRE-naive patients; (e) CEAF excluding 
BSC: SRE-experienced patients; (f) CEAF including BSC: SRE-experienced patients.
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FIGURE 13 Prostate cancer CEAFs including the PAS. (a) CEAF excluding BSC: all patients; (b) CEAF including BSC: all 
patients; (c) CEAF excluding BSC: SRE-naive patients; (d) CEAF including BSC: SRE-naive patients; (e) CEAF excluding 
BSC: SRE-experienced patients; (f) CEAF including BSC: SRE-experienced patients. (continued)
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But with the PAS, denosumab is still estimated to be cost saving across the patient groups and so 
dominates zoledronic acid (commercial-in-confidence information has been removed).
Other solid tumours including lung cancer base case
The modelling that applies the AG’s NMA gives the results in Table 112.
For OSTs including lung cancer, possibly because of around 40% having lung cancer with the associated 
poor survival, the additional patient benefits from denosumab over zoledronic acid are muted: between 
0.004 QALYs for SRE-experienced patients and 0.008 QALYs for SRE-naive patients. Without the PAS the 
additional cost of around £840 results in cost-effectiveness estimates of more than £100,000 per QALY.
(Commercial-in-confidence information has been removed.) This results in an additional average cost 
of around £50 and cost-effectiveness estimates of between £5400 per QALY and £15,300 per QALY. 
Probabilistic modelling is again in line with this, an average gain of 0.006 QALYs at an additional 
average cost of £56 resulting in a central estimate of £9391 per QALY across all patients. The likelihood 
of denosumab being cost-effective compared with the BPs across all patients is estimated as 75% for a 
willingness to pay of £20,000 per QALY and as 88% for a willingness to pay of £30,000 per QALY.
As would be anticipated given the preceding analysis, for those in whom BPs are contraindicated, even 
with the PAS denosumab is not estimated to be cost-effective compared with BSC. Across all patients the 
probabilistic modelling suggests similar central estimates of 0.017 QALYs and a net cost of £1771 to yield 
a cost-effectiveness estimate of £102,102 per QALY compared with BSC. The likelihood of denosumab 
being cost-effective compared with the BPs and BSC across all patients is estimated as 0% for a willingness 
to pay of £20,000 per QALY and as 0% for a willingness to pay of £30,000 per QALY (Figure 14).
Other solid tumours including lung cancer sensitivity analyses
The univariate sensitivity analyses for the SRE-experienced patient modelling for the cost-effectiveness of 
denosumab are presented in Table 113.
(Commercial-in-confidence information has been removed.) The slight increase in patient benefits is 
not sufficient to offset the increase in costs within the without-PAS scenario and the cost-effectiveness 
worsens as a consequence. But with the PAS the balance alters and the SRE and SAE effects come to the 
fore and the cost reductions result in cost-effectiveness estimates with the PAS seeing denosumab come 
to dominate zoledronic acid. This is mirrored to a more muted extent by the sensitivity analysis, which 
removes the impact of SAEs, causing the patient benefit to be reduced and cost-effectiveness estimates to 
worsen accordingly.
Assuming discontinuations occur at the end of the average trial duration of therapy, or removing 
discontinuations altogether, tends to worsen the cost-effectiveness for the comparison with BSC but 
improve it for the comparison with zoledronic acid. The latter is mainly due to the higher rate of 
discontinuations in the zoledronic arm than in the denosumab arm, causing more to move on to BSC. 
Given the poor cost-effectiveness of denosumab compared with BSC, this tends to also worsen the 
cost-effectiveness of the denosumab arm compared with the zoledronic acid arm. It can be argued that 
the apparent worsening of the cost-effectiveness of denosumab versus zoledronic acid, when compared 
with the breast cancer and prostate cancer estimates, is the result of the perverse impact of the differential 
discontinuation rates causing more patients in the zoledronic acid arm to discontinue and receive BSC.
A reduction in the price of zoledronic acid (commercial-in-confidence information has been removed) may 
be sufficient to result in the cost-effectiveness of denosumab compared with zoledronic acid for SRE-
experienced patients with OSTs including lung cancer, including the PAS, worsening to levels that might 
not be considered cost-effective.
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FIGURE 14 Other solid tumours + lung cancer CEAFs including the PAS. (a) CEAF excluding BSC: all patients; (b) CEAF 
including BSC: all patients; (c) CEAF excluding BSC: SRE-naive patients; (d) CEAF including BSC: SRE-naive patients; (e) 
CEAF excluding BSC: SRE-experienced patients; (f) CEAF including BSC: SRE-experienced patients.
(a)
0
10
20
30
40
50
60
70
80
90
100
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
 (
%
)
0 10 20 30 40 50
Willingness to pay per QALY (£000)
60 70 80 90 100
Denosumab
Zoledronic acid
Frontier
(b)
0
10
20
30
40
50
60
70
80
90
100
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
 (
%
)
0 10 20 30 40 50
Willingness to pay per QALY (£000)
60 70 80 90 100
Denosumab
Zoledronic acid
BSC
Frontier
(c)
0
10
20
30
40
50
60
70
80
90
100
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
 (
%
)
0 10 20 30 40 50
Willingness to pay per QALY (£000)
60 70 80 90 100
Denosumab
Zoledronic acid
Frontier
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Ford et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided 
that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed 
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, 
Southampton SO16 7NS, UK.
DOI: 10.3310/hta17290 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 29
163
FIGURE 14 Other solid tumours + lung cancer CEAFs including the PAS. (a) CEAF excluding BSC: all patients; (b) CEAF 
including BSC: all patients; (c) CEAF excluding BSC: SRE-naive patients; (d) CEAF including BSC: SRE-naive patients; (e) 
CEAF excluding BSC: SRE-experienced patients; (f) CEAF including BSC: SRE-experienced patients. (continued)
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Applying the head-to-head SRE-naive- and -experienced-specific clinical effectiveness results for 
denosumab versus zoledronic acid, while retaining the remainder of the AG’s NMA, gives the results 
in Table 114.
The SRE subgroup-specific clinical effectiveness estimates have the most dramatic impact on this group 
of cancers. As would be anticipated given the RR among the SRE-experienced subgroup their modelled 
benefits from denosumab over zoledronic acid are very slight and do not justify the additional cost.
Lung cancer base case
The results for lung cancer are broadly similar to the previous analysis (Table 115). For the comparison 
with zoledronic acid patient benefits are muted among SRE-experienced patients: 0.003 QALYs. This may 
be a factor in their short life expectancy, but with the PAS the additional costs of £43 result in a cost-
effectiveness estimate of £12,742. This also applies to the SRE-naive subgroup where larger gains of 0.006 
QALYs are achieved at minimal additional cost once the PAS is included. But the cost-effectiveness for these 
patients compared with BSC remains poor at an estimated £110,671 per QALY.
As for the other analyses, the probabilistic modelling central estimates are broadly in line with those 
of the deterministic analysis. Across all patients the central estimate is of a 0.005 QALY gain compared 
with zoledronic acid and a 0.012 QALY gain compared with BSC. This is at an additional net cost central 
estimate of £32 and £1582, respectively, with the PAS.
The likelihood of denosumab being cost-effective compared with the BPs across all patients is estimated 
as 69% for a willingness to pay of £20,000 per QALY and as 77% for a willingness to pay of £30,000 per 
QALY. The likelihood of denosumab being cost-effective compared with the BPs and BSC across all patients 
is estimated as 0% for a willingness to pay of £20,000 per QALY and as 0% for a willingness to pay of 
£30,000 per QALY (Figure 15).
Lung cancer sensitivity analyses
The univariate sensitivity analyses for the SRE-experienced patient modelling for the cost-effectiveness of 
denosumab compared with zoledronic acid is presented in Table 116.
The sensitivity analyses for lung cancer that remove the discontinuations have a similar impact as within 
the OSTs plus lung cancer modelling, given that in the absence of other data the lung cancer modelling 
assumes the adverse event rates and discontinuations of the OST plus lung cancer modelling. This may 
again argue that the apparent worsening of the cost-effectiveness of denosumab versus zoledronic acid, 
when compared with the breast cancer and prostate cancer estimates, is the result of the perverse impact 
of the differential discontinuation rates causing more patients in the zoledronic acid arm to discontinue 
and receive BSC.
The main sensitivities are in the treatment of utilities, with the removal of the step change going from 
naive to experienced reducing patient benefits by around one-quarter. Given the short life expectancy, the 
application of the van den Hout utility modifiers also has a reasonably large impact.
A reduction in the price of zoledronic acid of (commercial-in-confidence information has been removed) 
results in the cost-effectiveness of denosumab compared with zoledronic acid for SRE-experienced patients 
with OSTs including lung cancer including the PAS, which might not be considered cost-effective.
Sensitivity analyses
The sensitivity analyses are presented in greater detail within each of the cancer-specific modelling 
sections above.
In brief, the results of the AG for breast cancer are broadly in line with those of the manufacturer. There is 
some sensitivity in results to the rates of SAEs because of the higher rate of renal toxicity applied within the 
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FIGURE 15 Lung cancer CEAFs including the PAS. (a) CEAF excluding BSC: all patients; (b) CEAF including BSC: all 
patients; (c) CEAF excluding BSC: SRE-naive patients; (d) CEAF including BSC: SRE-naive patients; (e) CEAF excluding 
BSC: SRE-experienced patients; (f) CEAF including BSC: SRE-experienced patients.
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FIGURE 15 Lung cancer CEAFs including the PAS. (a) CEAF excluding BSC: all patients; (b) CEAF including BSC: all 
patients; (c) CEAF excluding BSC: SRE-naive patients; (d) CEAF including BSC: SRE-naive patients; (e) CEAF excluding 
BSC: SRE-experienced patients; (f) CEAF including BSC: SRE-experienced patients. (continued)
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zoledronic acid arm. Discontinuations tend to increase net costs compared with zoledronic acid broadly in 
line with the net benefits and the cost-effectiveness estimates are reasonably stable. Applying the SRE-
naive- and -experienced-specific HRs and RRs has only a muted impact.
For prostate cancer the AG base-case results are again broadly in line with those of the manufacturer. 
Results show some sensitivity to the utility decrements from SCC being extended to the end of life. 
Applying the SRE-naive- and -experienced-specific HRs and RRs has a more noticeable effect. Among 
the SRE-experienced patients this sees the net impact of denosumab compared with zoledronic acid fall 
from a reduction in SREs of 0.135 to a reduction of only 0.087, with a parallel impact on the anticipated 
patient benefits.
Within the modelling of OSTs including lung cancer, the benefit of denosumab over zoledronic acid is small 
and results become sensitive to the other parameters within the modelling, such as the treatment of SAEs. 
Results for denosumab compared with BSC are more stable as the analysis is driven more by the relative 
rates of SREs, particularly among SRE-naive patients.
Applying the SRE-naive- and -experienced-specific HRs and RRs has a relatively large impact on results 
for the SRE-experienced OSTs including lung cancer modelling. This may in itself be sufficient to render 
denosumab, even with the PAS, non-cost-effective compared with zoledronic acid for this group.
The OSTs plus NSCLC results are broadly mirrored in the modelling of lung cancer.
An aspect that may have an impact beyond that modelled is the treatment of SCC. Extending the average 
quality-of-life decrement measured in the 5 months subsequent to the compression through to death 
improves the estimated cost-effectiveness, particularly among SRE-naive prostate cancer patients. There 
remains uncertainty as to the rate of paralysis from SCC, the long-term quality-of-life impacts from SCC 
and the need for long-term care together with the associated costs.
Where the appropriate comparator is zoledronic acid, there is additional uncertainty concerning its likely 
price when it shortly comes off patent. (Commercial-in-confidence information has been removed.)
Probabilistic modelling suggests that within the usual range of cost-effectiveness thresholds there is 
relatively little uncertainty around the CEAF. The central estimates are also in line with those of the 
deterministic analyses.
Discussion
For ease of reference, the manufacturer’s base-case results, the Evidence Review Group (ERG)’s base-case 
results and the ERG’s structural sensitivity analyses that apply the SRE-naive- and -experienced-specific HRs 
and RRs are summarised for the comparison with zoledronic acid (Table 117) and the comparison with BSC 
(Table 118).
The manufacturer’s case is broadly that while the average patient benefits from the reduced number 
of SREs is not large, with the PAS denosumab will be cost saving compared with zoledronic acid. 
(Commercial-in-confidence information has been removed.) As a consequence, denosumab is estimated to 
dominate zoledronic acid among patients for whom zoledronic acid is indicated when the PAS is included.
But for patients for whom zoledronic acid is not indicated, the manufacturer accepts that even with the 
PAS the relatively small patient gains do not justify the additional cost of denosumab. The manufacturer’s 
cost-effectiveness estimates for denosumab compared with BSC are typically in excess of £100,000 per 
QALY, and even with the PAS are closer to £100,000 per QALY than £50,000 per QALY.
Within-trial analyses by the AG suggest that for breast cancer patients denosumab results in a slightly 
lower average number of SREs than zoledronic acid, and that this will translate into a small average annual 
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TABLE 117 Summary of results: denosumab vs zoledronic acid
Quantity
Breast cancer Prostate cancer OST + lung cancer Lung cancer
Excluding 
PAS
Including 
PAS
Excluding 
PAS
Including 
PAS
Excluding 
PAS
Including 
PAS
Excluding 
PAS
Including 
PAS
Manufacturer: pooled RR and HR
All
∆ cost £1484 –£483
∆ QALY 0.007
ICER £203,387 Dominant
Experienced
∆ cost £922 –£281 £757 –£43
∆ QALY 0.006 0.004
ICER £157,276 Dominant £205,580 Dominant
AG modelling: pooled RR and HR
All
∆ cost £1707 –£243 £1059 –£125 £836 £54 £708 £28
∆ QALY 0.007 0.007 0.009 0.009 0.006 0.006 0.005 0.005
ICER £245,264 Dominant £111,603 Dominant £139,739 £9004 £149,878 £5972
Naive
∆ cost £1747 –£203 £1061 –£123 £823 £41 £693 £13
∆ QALY 0.008 0.008 0.011 0.011 0.008 0.008 0.006 0.006
ICER £209,345 Dominant £99,561 Dominant £106,812 £5337 £112,617 £2135
Experienced
∆ cost £1649 –£301 £1053 –£131 £848 £66 £722 £43
∆ QALY 0.005 0.005 0.006 0.006 0.004 0.004 0.003 0.003
ICER £332,185 Dominant £170,854 Dominant £196,114 £15,282 £215,614 £12,743
AG modelling: SRE-naive- and -experienced-specific HRs and RRs
All
∆ cost £1693 –£258 £1076 –£109 £893 £112 £708 £28
∆ QALY 0.007 0.007 0.009 0.009 0.005 0.005 0.005 0.005
ICER £259,484 Dominant £117,021 Dominant £197,725 £24,686 £149,878 £5972
Naive
∆ cost £1763 –£187 £1064 –£121 £827 £45 £693 £13
∆ QALY 0.007 0.007 0.011 0.011 0.008 0.008 0.006 0.006
ICER £247,591 Dominant £96,209 Dominant £102,773 £5580 £112,617 £2135
Experienced
∆ cost £1592 –£359 £1111 –£74 £957 £176 £722 £43
∆ QALY 0.006 0.006 0.004 0.004 0.001 0.001 0.003 0.003
ICER £280,994 Dominant £285,209 Dominant £846,749 £155,285 £215,614 £12,743
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TABLE 118 Summary of results: denosumab vs BSC
Quantity
Breast cancer Prostate cancer OST + lung cancer Lung cancer
Excluding 
PAS
Including 
PAS
Excluding 
PAS
Including 
PAS
Excluding 
PAS
Including 
PAS
Excluding 
PAS
Including 
PAS
Manufacturer: pooled RR and AR
Naive
∆ cost £3993 £2790 £2530 £1730
∆ QALY 0.039 0.021
ICER £102,067 £71,320 £122,499 £83,763
AG modelling: pooled RR and HR
All
∆ cost £6242 £4292 £3951 £2766 £2548 £1766 £2262 £1583
∆ QALY 0.027 0.027 0.035 0.035 0.017 0.017 0.012 0.012
ICER £229,547 £157,829 £112,415 £78,713 £147,122 £101,986 £191,412 £133,926
Naive
∆ cost £6308 £4358 £3969 £2785 £2473 £1691 £2257 £1578
∆ QALY 0.035 0.035 0.039 0.039 0.024 0.024 0.014 0.014
ICER £181,092 £125,109 £103,003 £72,269 £103,350 £70,679 £158,333 £110,671
Experienced
∆ cost £6146 £4196 £3897 £2713 £2620 £1839 £2268 £1588
∆ QALY 0.016 0.016 0.025 0.025 0.011 0.011 0.009 0.009
ICER £379,539 £259,113 £152,916 £106,446 £238,840 £167,587 £239,211 £167,529
AG modelling: SRE-naive- and -experienced-specific HRs and RRs
All
∆ cost £6227 £4277 £3968 £2783 £2606 £1824 £2262 £1583
∆ QALY 0.027 0.027 0.035 0.035 0.016 0.016 0.012 0.012
ICER £232,756 £159,866 £113,851 £79,865 £164,322 £115,025 £191,412 £133,926
Naive
∆ cost £6323 £4373 £3972 £2788 £2477 £1695 £2257 £1578
∆ QALY 0.034 0.034 0.039 0.039 0.024 0.024 0.014 0.014
ICER £188,162 £130,133 £102,016 £71,597 £102,060 £69,845 £158,333 £110,671
Experienced
∆ cost £6089 £4139 £3955 £2770 £2730 £1948 £2268 £1588
∆ QALY 0.017 0.017 0.023 0.023 0.008 0.008 0.009 0.009
ICER £360,413 £244,979 £170,340 £119,327 £350,937 £250,441 £239,211 £167,529
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gain of perhaps 0.003–0.006 QALYs: roughly equivalent to 1–2 additional days in full health or 2–3 days 
at the SRE-naive average quality of life. Without the PAS, the additional cost of denosumab does not justify 
these relatively minor gains. With the PAS, denosumab is estimated to be broadly cost-neutral to slightly 
cost saving, and so cost-effective compared with zoledronic acid. (Commercial-in-confidence information 
has been removed.)
Within-trial analyses suggest that for prostate cancer patients, denosumab results in a slightly lower 
average number of SREs compared with zoledronic acid. This translates into a slightly larger additional 
average annual gain of perhaps 0.008–0.016 QALYs. The reason for this difference in prostate cancer is 
the greater proportion of SCCs within the overall number of SREs. (Academic-in-confidence information 
has been removed.) This aspect is not considered in either the manufacturer’s model or the AG 
economic model.
Without the PAS the additional cost of denosumab still does not justify the relatively minor estimated 
gains. With the PAS, because of the average annual number of doses, denosumab is estimated to increase 
annual costs by around £100, which translates into cost-effectiveness estimates of between £6545 per 
QALY and £15,272 per QALY. But this AG within-trial analysis does not distinguish between SRE-naive and 
-experienced patients.
Given the slightly larger patient gains estimated for prostate cancer patients from denosumab, its cost-
effectiveness compared with zoledronic acid is not as sensitive to the price of zoledronic acid as it is in 
breast cancer. (Commercial-in-confidence information has been removed.)
For the cost–utility modelling within breast cancer, the lifetime gains across all patients are estimated to 
be around 0.007 QALYs. This is again small, and does not justify the additional cost of £1707 per patient 
compared with zoledronic acid. With the PAS (commercial-in-confidence information has been removed), 
denosumab is estimated to dominate zoledronic acid. But for those in whom BPs are contraindicated the 
cost-effectiveness is poor: even with the PAS the cost-effectiveness is £157,829 per QALY. Applying the 
SRE-naive and -experienced subgroup-specific clinical effectiveness has little impact on the results, as these 
estimates are reasonably close to the pooled all-patient estimates.
For the cost–utility modelling within prostate cancer, across all patients the gain from denosumab over 
zoledronic acid is around 0.009 QALYs, while compared with BSC it is 0.035 QALYs, at net costs without 
the PAS of £1059 and £3951, respectively. Without the PAS, compared with zoledronic acid, this results in 
a cost-effectiveness of £111,603 per QALY. Cost-effectiveness is estimated to be slightly better among the 
SRE-naive patients, at £99,561 per QALY, but the quid pro quo is a worse cost-effectiveness among the 
SRE-experienced patients of £170,854 per QALY. This may arise in large part because of the estimated step 
change in HRQoL arising from a patient’s first SRE.
With the PAS, denosumab is estimated to be cost saving compared with zoledronic acid and so dominate 
it. For those in whom BPs are contraindicated, denosumab is not estimated to be cost-effective compared 
with BSC.
Within the cost–utility modelling of OSTs including lung cancer, the gains from denosumab over zoledronic 
acid are estimated to be less than 0.01 QALYs. Without the PAS, denosumab is not cost-effective, but with 
it the small additional overall costs of around £50 result in cost-effectiveness estimates of between £5400 
per QALY and £15,300 per QALY. The impact of applying the SRE subgroup-specific estimates within this 
group is quite large. While it improves the estimates of cost-effectiveness of denosumab compared with 
BSC for SRE-naive patients, even with the PAS it is not sufficient to render it cost-effective. (Academic-in-
confidence information has been removed.) The cost-effectiveness estimate for denosumab worsens to 
£155,285 per QALY compared with zoledronic acid among these patients.
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For lung cancer, possibly because of the short life expectancy, the patient gains from denosumab over 
zoledronic acid among SRE-experienced patients are estimated to be small: 0.003 QALYs. With the PAS, 
the additional cost of £43 results in a cost-effectiveness of £12,743 per QALY.
Some questions for possible consideration are:
 z To what extent do the available data on SRE-naive patients and SRE-experienced patients reflect the 
likely patient groups for whom zoledronic acid is used? Is the manufacturer’s case review sufficient to 
conclude that most SRE-experienced patients within the cancers reviewed are typically receiving BPs, 
leading to zoledronic acid being the appropriate comparator?
 z Should the base case apply the SRE subgroup-specific clinical effectiveness estimates? This has 
little impact within breast cancer. But it has quite large adverse effects on the cost-effectiveness of 
denosumab for SRE-experienced patients in prostate cancer and OSTs including lung cancer.
 z To what extent should zoledronic acid coming off patent in 2013 be considered? The anticipated 
patient benefits from denosumab over zoledronic acid are small. Only a relatively small drop in the 
price of zoledronic acid would be sufficient to make denosumab not cost-effective when judged by 
conventional thresholds.
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Chapter 10 Assessment of factors relevant to the 
National Health Service and other parties
Any change in the treatment pathway of bone metastases is likely to have an impact on the NHS and other parties. The impact of denosumab depends on whether the patient would otherwise have 
received an intravenous BP, oral BP or BSC.
Factors relevant to the National Health Service
For patients who would have received an intravenous BP, subcutaneous denosumab is advantageous. First, 
subcutaneous administration does not require inpatient administration. Denosumab could be given in 
an outpatient setting, in a general practitioner surgery or even potentially at home by a district nurse or 
other qualified health-care provider. Compared with intravenous injections, subcutaneous administration 
takes less time, is associated with few complications and is technically easier. This is not relevant to those 
patients who would have been prescribed an oral BP or who need to attend hospital for other reasons, 
such as intravenous chemotherapy. Any shift of care from acute hospitals into the community has 
implications for the NHS. Additional resources and training may be needed in the community. Denosumab 
is administered using the standard subcutaneous method. NHS staff need to be aware that in prostate 
cancer and OSTs BPs may be used for treatment of bone pain when conventional analgesics have failed. 
Denosumab is licensed for the prevention of SREs and not for the treatment of bone pain. It is conceivable 
that reduction in pain is a method of preventing the need for radiotherapy. However, evidence for the 
analgesic effects of denosumab is not consistent. Prescribers would also need to be aware of the potential 
adverse events, such as hypocalcaemia and ONJ.
Second, for patients who are prescribed oral BPs, adherence may increase if they are switched 
to denosumab. Oral BPs are inconvenient for patients to take because of adverse effects and the 
required technique. Subcutaneous injection avoids these unpleasant upper gastrointestinal adverse 
effects. However, it should be noted that, according to the Xgeva SPC, diarrhoeal adverse events are 
‘very common’.
For those patients who would have otherwise been treated with BSC, administration of denosumab would 
require additional resources. Denosumab needs to be stored at 2–8 °C in a refrigerator. Most NHS premises 
have facilities to store medicinal products in a refrigerator. However, if any premises did not have these 
facilities or required more space, additional resources may be necessary.
Renal monitoring is required in patients receiving BPs. This has not only resource issues but also safety 
issues. Any medication that requires dose adjustment according to renal function increases the likelihood 
of human error. As denosumab is administered by fixed-dose single injection, the risk of human error is 
substantially reduced. Denosumab may reduce the need for laboratory services. However, patients with 
advanced cancer usually undergo frequent blood sampling, including measure of renal function.
Factors relevant to other parties
Delaying or preventing SREs may result in patients being mobile for longer. It should be noted that mobility 
has not been assessed in the pivotal trials. However, preventing pathological fractures, surgery to bone or 
SCC is likely to result in reduced immobility. In turn, this would reduce the burden on carers.
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Patients who would have otherwise been prescribed an intravenous BP may have reduced need for hospital 
attendance. Administration may be possible in the community. This would reduce travelling time for both 
patients and carers. This is particularly important for patients who have problems with mobility or live in 
rural locations or areas with poor transport links. It may reduce the number of days off work for patients 
who are still employed or for carers who need to take time off to attend hospital appointments. For 
patients who are required to attend hospital, denosumab would shorten the time in hospital. Total time 
for administration of zoledronic acid may be 30–45 minutes depending on the time it takes to establish 
intravenous access, whereas a subcutaneous injection would take only a few minutes.
Subcutaneous administration may also be less unpleasant for many patients compared with intravenous or 
oral BP administration.
For patients who would have previously been treated with BSC alone, the addition of denosumab would 
usually mean additional health-care appointments. This may require the patient and carer travelling to an 
acute hospital or general practitioner surgery.
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Chapter 11 Discussion
Clinical effectiveness
Statement of principal findings
Breast cancer
There was a statistically significant difference in favour of denosumab compared with zoledronic acid 
for the time to first on-study SRE for all patients (HR 0.82; 95% CI 0.71 to 0.95; not reached vs median 
26.4 months) (Table 119). (Academic-in-confidence information has been removed) (Table 119) (academic-
in-confidence information has been removed). For both time to first on-study SRE and risk of developing 
first and subsequent SREs, the distribution of type of SRE was similar across treatment groups, with 
pathological fracture (academic-in-confidence information has been removed) and radiation to bone 
(academic-in-confidence information has been removed) being the most common, while there were 
few occurrences of SCC (academic-in-confidence information has been removed) or surgery to bone. 
(Academic-in-confidence information has been removed.)
For the subgroup of patients with no or mild pain at baseline, denosumab delayed the time to 
development of moderate or severe worst pain (worst pain score of > 4 points) compared with zoledronic 
acid (HR 0.78; 95% CI 0.67 to 0.92; median 9.7 vs 5.8 months; p = 0.0024). The median time to 
worsening pain (≥ 2-point increase from baseline) was longer for denosumab (median 8.5 vs 7.4 months; 
p = 0.0822). In terms of quality of life, overall mean FACT scores remained similar between the groups 
(academic-in-confidence information has been removed).
In terms of adverse events, there were more occurrences of hypocalcaemia in the denosumab group than 
in the zoledronic acid group (5.5% vs 3.4%); rates of ONJ were also higher (2.0% vs 1.4%), but there were 
lower rates of events associated with renal impairment (4.9% vs 8.5%) or acute-phase reactions (10.4% vs 
27.3%) (academic-in-confidence information has been removed). Overall survival was balanced between 
the denosumab and zoledronic acid groups (HR 0.95; 95% CI 0.81 to 1.11). (Academic-in-confidence 
information has been removed.)
In the AG’s NMA, there was a statistically significant difference in favour of denosumab compared with 
zoledronic acid or placebo for time to first on-study SRE and for these comparisons plus denosumab 
versus disodium pamidronate for risk of first and subsequent SREs (Table 120). (Academic-in-confidence 
information has been removed.) 
Prostate cancer
There was a statistically significant difference in favour of denosumab compared with zoledronic acid for 
the time to first on-study SRE for all patients (HR 0.82; 95% CI 0.71 to 0.95; median 20.7 vs 17.1 months) 
(Table 119) and for those with no prior SRE (HR 0.80; 95% CI 0.67 to 0.95) but not for those with a 
prior SRE (HR 0.88; 95% CI 0.67 to 1.16). There was also a statistically significant difference in favour 
of denosumab for reducing the risk of developing first and subsequent SREs for all patients (RR 0.82; 
95% CI 0.71 to 0.94) (Table 119) and for those with no prior SRE (RR 0.79; 95% CI 0.67 to 0.94), but not 
for those with a prior SRE (RR 0.88; 95% CI 0.68 to 1.13). For both time to first on-study SRE, and risk 
of first and subsequent SREs, the distribution of type of SRE was similar across treatment groups, with 
radiation to bone (academic-in-confidence information has been removed) and pathological fracture 
(academic-in-confidence information has been removed) being the most common, whereas there were 
fewer occurrences of SCC (academic-in-confidence information has been removed) or surgery to bone. 
(Academic-in-confidence information has been removed.)
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The time to development of moderate or severe worst pain, in patients with no or mild pain at baseline, 
favoured denosumab compared with zoledronic acid (median 5.8 vs 4.9 months) without being 
statistically significant (HR 0.89; 95% CI 0.77 to 1.04). The median time to worsening pain was similar 
(academic-in-confidence information has been removed). In terms of quality of life, overall mean FACT 
scores remained similar between the groups (academic-in-confidence information has been removed).
In terms of adverse events, there were more occurrences of hypocalcaemia in the denosumab group 
compared with the zoledronic acid group (12.8% vs 5.8%), higher rates of ONJ (2.3% vs 1.3%) (academic-
in-confidence information has been removed), whereas events associated with renal impairment (14.7% 
vs 16.2%) and acute-phase reactions (8.4% vs 17.8%) were lower. Overall survival was similar between the 
treatment groups (HR 1.03; 95% CI 0.91 to 1.17; median 19.4 months vs 19.8 months).
The AG’s NMA reported a statistically significant difference in favour of denosumab compared with 
zoledronic acid or placebo for both time to first on-study SRE and risk of first and subsequent SREs 
(academic-in-confidence information has been removed) (Table 120).
Non-small cell lung cancer 
For time to first on-study SRE for all patients, the difference favoured denosumab without being 
statistically significant [HR 0.84; 95% CI 0.64 to 1.10 (academic-in-confidence information has been 
removed)], (academic-in-confidence information has been removed) (Table 120). There was a statistically 
significant difference in favour of denosumab for overall survival (HR 0.79; 95% CI 0.65 to 0.95). The 
following outcomes were not reported for NSCLC: time to first on-study SRE or risk of first and subsequent 
SRE by history of SRE or type of SRE; pain scores or quality of life; hypercalcaemia; hypocalcaemia; ONJ; 
events associated with renal impairment; or acute-phase reactions.
The MS did not perform a NMA of NSCLC. In the AG’s NMA, the direction of effect of the comparisons 
of denosumab compared with zoledronic acid or placebo favoured denosumab for both time to first 
on-study SRE and risk of first and subsequent SREs but only the comparison with placebo for risk of first 
and subsequent SRE was statistically significant (Table 120).
Other solid tumours (excluding non-small cell lung cancer)
There was a statistically significant difference in favour of denosumab for median time to first on-study SRE 
for all patients [HR 0.79; 95% CI 0.62 to 0.99; (academic-in-confidence information has been removed)] 
(Table 119). Overall survival was similar (HR 1.08; 95% CI 0.90 to 1.30). The following outcomes were 
not reported for OSTs excluding NSCLC: time to first on-study SRE or risk of first and subsequent SREs by 
history of SRE or type of SRE; pain scores or quality of life; hypercalcaemia, hypocalcaemia, ONJ, events 
associated with renal impairment or acute-phase reactions.
The MS did not perform a NMA of OSTs excluding NSCLC. In the AG’s NMA there was a statistically 
significant difference in favour of denosumab compared with zoledronic acid or placebo for time to first 
on-study SRE and compared with placebo for risk of first and subsequent on-study SREs (Table 120).
Other solid tumours (including non-small cell lung cancer)
In the manufacturer’s post-hoc analysis (excluding multiple myeloma) there was a statistically significant 
difference in favour of denosumab for time to first on-study SRE for all patients (HR 0.81; 95% CI 0.68 to 
0.96; 21.4 vs 15.4 months) (Table 119). (Academic-in-confidence information has been removed.) For risk 
of developing first and subsequent SREs, for all patients, the difference was borderline significant in favour 
of denosumab (RR 0.85; 95% CI 0.72 to 1.00) (Table 119). (Academic-in-confidence information has been 
removed.) For both time to first on-study SRE and risk of first and subsequent SREs, the distribution of type 
of SRE was similar across treatment groups, with radiation to bone (academic-in-confidence information 
has been removed) and pathological fracture (academic-in-confidence information has been removed) 
being the most common while there were fewer occurrences of SCC (academic-in-confidence information 
has been removed) or surgery to bone (academic-in-confidence information has been removed).
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Denosumab delayed the time to development of moderate or severe worst pain in patients with no or mild 
pain at baseline compared with zoledronic acid (median 3.7 months vs 2.8 months; p = 0.0369) and also 
the time to worsening pain (academic-in-confidence information has been removed; p = 0.04). In terms 
of quality of life, overall mean FACT scores remained similar between the groups. (Academic-in-confidence 
information has been removed.)
In terms of adverse events, there were more occurrences of hypocalcaemia in the denosumab group than 
in the zoledronic acid group (10.8% vs 5.8%), rates of (academic-in-confidence information has been 
removed). Rates of ONJ (1.3% vs 1.1%) were similar, while there were lower rates of events associated with 
renal impairment (8.3% vs 10.9%) or acute-phase reactions (6.9% vs 14.5%). Overall survival was similar 
[HR 0.92; 95% CI 0.81 to 1.05; median (academic-in-confidence information has been removed)].
The AG’s NMA reported a statistically significant difference in favour of denosumab compared with 
zoledronic acid or placebo for time to first on-study SRE and compared with placebo for risk of first and 
subsequent SREs (academic-in-confidence information has been removed) (Table 120).
Strengths and limitations of the assessment
In terms of strengths, our review focused on RCTs, resulting in a high level of evidence. Where outcome 
data were not available from published reports, we attempted to source such data from the MS and 
CSRs. We undertook a NMA to provide an indirect estimate of the effectiveness of denosumab against 
appropriate comparators that were not considered in the direct evidence. A NMA of NSCLC and OSTs 
(excluding NSCLC) was undertaken which reduced the degree of methodological heterogeneity within 
the analysis. We did not assume a class effect for BPs and instead incorporated different types of BP, as 
appropriate for the type of primary cancer being considered in the NMA.
In terms of limitations, non-English-language studies were excluded from the review because of the tight 
timelines. Fewer outcomes were available for NSCLC and for OSTs excluding NSCLC than were reported for 
breast cancer, prostate cancer or OSTs including NSCLC. Definitions used by the studies of what constituted 
BSC varied both within and across each of the primary tumour types. The study by Saad and colleagues118 
was used in the NMA for BSC. The control arm was randomised to receive placebo. Both groups received 
standard pain management, including analgesics, radiation or ‘other treatment’, at the discretion of the 
clinician. This standard treatment is consistent with the BSA described by the AG clinical expert (RJ).
The strength of a NMA is that all the available and relevant evidence (direct and indirect) can be considered 
in a single consistent analysis. However, a key limitation of the NMA in this assessment is the small number 
of trials included. Furthermore, network meta-analyses are not randomised comparisons but rather 
observational findings across studies and therefore the results are subject to considerable uncertainty and 
should be interpreted with caution.
Uncertainties
External validity of the denosumab randomised controlled trials
The three denosumab RCTs were large, international, multicentre trials. The participants all had advanced 
cancer (breast, prostate, lung or OSTs) with at least one bone metastasis, ECOG status ≤ 2 and a life 
expectancy of ≥ 6 months. Therefore, it is reasonable to expect that the results of the trials would be 
generalisable to patients meeting the above criteria. It is important to note that these results would not be 
generalisable to patients with a life expectancy of < 6 months. (Academic-in-confidence information has 
been removed.) It is unclear to what extent, if any, this might impact on the generalisability of the results 
to a UK setting. Patients with poor renal function (creatinine clearance < 30 ml/minute) were excluded from 
the trials on the basis that they could not be randomised to zoledronic acid because the drug would be 
contraindicated for them. Therefore, the effects of denosumab on patients with advanced cancer with 
bone metastases and poor renal function are unknown. However, it has been estimated that < 2% of 
patients with solid tumours have sufficiently poor renal function to avoid zoledronic acid.207 The RCT for 
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Ford et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided 
that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed 
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, 
Southampton SO16 7NS, UK.
DOI: 10.3310/hta17290 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 29
185
OSTs (excluding breast or prostate cancer) pooled data from patients with a range of different types of 
solid tumour.
In addition, the direct evidence from the trials comparing denosumab with zoledronic acid is generalisable 
only to those patients with advanced cancer and bone metastases for whom clinical guidance advocates 
the use of BPs. For breast cancer, this applies to all patients with advanced breast cancer and newly 
diagnosed bone metastases.45 For prostate cancer, it applies to men with hormone-refractory prostate 
cancer with painful bone metastases for whom other treatments (including analgesics and palliative 
radiotherapy) have failed.46 For lung cancer and OSTs there is no clear guidance on when BPs should be 
administered.48 In the prostate cancer denosumab RCT (and the other two denosumab RCTs), in subgroup 
TABLE 120 The AG’s and manufacturer’s NMA results for time to first on-study SRE and time to first and subsequent 
on-study SRE 
Comparison
Time to first on-study SRE Time to first and subsequent SRE
AG’s NMA, HR 
(95% CI) MS’s NMA, HR (95% CI)
AG’s NMA, RR 
(95% CI) MS’s NMA, RR (95% CI)
Breast cancer
Denosumab vs 
zoledronic acid
0.82 (0.71 to 0.95) AiC information has been 
removed
0.77 (0.66 to 0.89) AiC information has been 
removed
Denosumab 
vs disodium 
pamidronate
0.79 (0.61 to 1.03) AiC information has been 
removed
0.62 (0.48 to 0.80) AiC information has been 
removed
Denosumab vs 
placebo
0.46 (0.29 to 0.72) AiC information has been 
removed
0.45 (0.28 to 0.72) AiC information has been 
removed
Denosumab vs 
ibandronic acid
Not done AiC information has been 
removed
Not done AiC information has been 
removed
Prostate cancer
Denosumab vs 
zoledronic acid
0.82 (0.71 to 0.95) AiC information has been 
removed
0.82 (0.71 to 0.94) AiC information has been 
removed
Denosumab vs 
placebo
0.56 (0.40 to 0.77) AiC information has been 
removed
0.53 (0.39 to 0.72) AiC information has been 
removed
NSCLC
Denosumab vs 
zoledronic acid
0.84 (0.64 to 1.10) Not done 0.87 (0.68 to 1.12) Not done
Denosumab vs 
placebo
0.68 (0.45 to 1.03) Not done 0.63 (0.42 to 0.97) Not done
OST excluding NSCLC
Denosumab vs 
zoledronic acid
0.79 (0.62 to 0.99) Not done 0.83 (0.67 to 1.03) Not done
Denosumab vs 
placebo
0.30 (0.11 to 0.82) Not done 0.61 (0.39 to 0.97) Not done
OST including NSCLC
Denosumab vs 
zoledronic acid
0.81 (0.68 to 0.96) AiC information has been 
removed
0.85 (0.72 to 1.00) AiC information has been 
removed
Denosumab vs 
placebo
0.49 (0.30 to 0.78) AiC information has been 
removed
0.62 (0.46 to 0.85) AiC information has been 
removed
AiC, academic-in-confidence.
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analysis, rather than presenting data on patients with painful bone metastases for whom other treatments 
have failed, the manufacturer presents data on patients with (1) no prior SRE and (2) prior SRE. The results 
would be more generalisable if effectiveness data were presented for patients who had painful bone 
metastases despite conventional analgesics.
Network meta-analysis
There are several uncertainties associated with the NMA. Although caution was exercised when selecting 
trials for inclusion in the NMA, some differences inevitably exist between included studies in terms of 
populations and trial methodologies, and this can lead to uncertainty in any meta-analysis with potential 
for further bias in a NMA. There were primary studies (other than those comparing denosumab) that did 
not report complete results, so some treatment effects used in the NMA (including levels of precision of 
the effects) were estimated and therefore subject to uncertainty although when missing data were treated 
as uncertain parameters the impact on the results was negligible. The small number of trials in each of 
the NMAs add to the uncertainty in the results, particularly as some of the individual trials were small 
themselves and there were no instances (for any comparison between two treatments within a NMA) 
where there was sufficient comparable direct evidence to include more than one trial. Further uncertainty 
may have resulted from the potential for different assumptions to be made when specifying NMA models 
(e.g. in relation to baseline prior distributions) and this could be illustrated by differences between the 
NMA results in this assessment and the manufacturer’s analysis. Although a different approach to the 
manufacturer was taken, many of the results from the manufacturer’s indirect comparisons can be 
accurately replicated, which may mitigate some of the uncertainty associated with the NMA.
Skeletal-related events as a composite end point
Skeletal-related events are composite end points used in research studies and generally defined as 
including pathological fracture, requirement for radiation therapy to bone, surgery to bone, or SCC. These 
end points include both complications of bone metastases (pathological fracture and SCC) and therapeutic 
or preventative measures (radiotherapy and surgery). In the three denosumab RCTs the distribution of 
type of SRE was similar across treatment groups, for both time to first on-study SRE and risk of first and 
subsequent SREs. The vast majority of SREs consisted of pathological fracture or radiation to bone, with far 
fewer occurrences of SCC or surgery to bone. The three RCTs reported a statistically significant difference 
in favour of denosumab for time to first on-study SRE. (Academic-in-confidence information has been 
removed.) Therefore, higher event rates and larger treatment effects that are associated with the less 
important components of a composite end point could result in a misleading impression of the treatment’s 
effectiveness in relation to components that are clinically more important but occur less frequently. This 
could potentially create the impression that the treatment is equally effective for each component of the 
composite end point when in fact this may not be supported by the evidence.
Symptomatic versus non-symptomatic skeletal-related events
The impact on patients of pathological fractures varies from unnoticeable, asymptomatic fractures 
to vertebral fractures associated with SCC that result in paraplegia. Patients in the denosumab RCTs 
underwent radiography before treatment and at 12-weekly intervals during the study to detect the 
occurrence of pathological fractures or SCC. This skeletal survey frequency is unlikely to be the case in 
clinical practice. More frequent tests may have resulted in asymptomatic pathological fractures being 
detected that would have remained undetected in clinical practice. Also, in the RCTs once a SRE had been 
detected and classified as asymptomatic it could not later be reclassified as symptomatic – this could 
potentially lead to a rate of symptomatic SREs detected that was lower than that observed in clinical 
practice, on the basis that in clinical practice asymptomatic fractures would likely remain undetected until 
they had become symptomatic. Trinkaus and colleagues37 compared observational SRE frequency in clinical 
practice with SRE frequency in the intravenous BP trials and reported a higher rate of SREs in the trial 
setting compared with clinical practice.
The MS stated that clinical expert opinion indicated that in clinical practice SCCs were symptomatic. For 
pathological fractures, vertebral fractures were predominantly asymptomatic, whereas non-vertebral 
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fractures were predominantly symptomatic, based on their skeletal locations. In the denosumab RCTs, for 
time to first on-study SRE, and risk of first and subsequent SREs respectively, the percentage of fractures 
that were vertebral were recorded in the breast cancer trial (academic-in-confidence information has been 
removed), in the prostate cancer trial (academic-in-confidence information has been removed) and in the 
OSTs trial (academic-in-confidence information has been removed).
Twenty-one-day window
More than one SRE may occur in relation to a single event. For example, an individual may suffer a 
pathological fracture, which is treated by radiotherapy or surgery (two SREs related to one event). 
Therefore, in order to provide an estimate of the number of SRE events rather than just the overall number 
of SREs, in the denosumab and BP trials a subsequent SRE was counted as a separate SRE only after a 
defined period (usually 21 days). When more than one SRE occurred within a 21-day period, the SRE that 
was taken to represent the event was the first SRE that occurred within the 21-day period.
Overall survival
In the three denosumab RCTs, overall survival was reported as similar. However, a post-hoc analysis of the 
NSCLC subgroup of the OSTs RCT by Henry and colleagues30 reported a statistically significant difference 
in favour of denosumab (HR 0.79; 95% CI 0.65 to 0.95). A recent paper by Scagliotti and colleagues208 
reported this difference as a median 9.5 months for denosumab and 8.1 months for zoledronic acid (HR 
0.78; 95% CI 0.65 to 0.94). Henry and colleagues30 postulated that the difference in survival observed 
in this post-hoc analysis might be a result of differences in prognostic variables at study entry in a highly 
heterogeneous population or of differences in specific antineoplastic treatments while on study. The AG is 
of the opinion that this result should be interpreted with caution until further evidence is available.
Appropriateness of analysing different tumour types together
The denosumab RCT of OSTs (post-hoc study 244) analysed a number of different primary tumour types 
together. The tumour types included NSCLC (44.0%). (Academic-in-confidence information has been 
removed.) Combining tumour types within a trial increases the risk of selection and performance bias. In 
addition, because of the small numbers of each tumour type, it is difficult to conclude if an intervention is 
more effective in one tumour type than another. However, it would not be practical to conduct sufficiently 
powered trials on each tumour type and combining tumour types would be required at some stage.
Bisphosphonates
It was our intention to compare denosumab with zoledronic acid, disodium pamidronate, ibandronic acid 
and sodium clodronate. However, head-to-head evidence was available only for denosumab compared 
with zoledronic acid. In breast cancer, disodium pamidronate was suitable for inclusion in the NMA and 
indirect comparison with denosumab was possible. Owing to lack of evidence, the assessment of the 
effectiveness of denosumab compared with ibandronic acid and sodium clodronate was not possible. In 
addition, it was not possible to compare the different routes of BP treatments because of the inadequacy 
of data for indirect comparison. However, based on advice from clinical experts, zoledronic acid is the most 
widely used BP and should be used as the primary BP comparator.
Other relevant factors
Place of denosumab in the care pathway
There are various points in the care pathway at which the use of denosumab could be considered. 
Current evidence assesses denosumab compared with zoledronic acid as a first-line treatment only for 
the prevention of SREs. Denosumab could also be considered in patients who have had a previous SRE. 
In the denosumab trials, individuals who had previously experienced a SRE at baseline were at higher 
risk than those who had not. Subgroups of patients with and without a history of SRE at baseline were 
reported. Denosumab significantly delayed the time to first SRE in those patients without a history of SRE 
and reduced the risk of first and subsequent SREs compared with zoledronic acid. However, for those 
patients with a history of SRE at baseline there was a significant difference in these outcomes only in 
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those with breast cancer. It should be noted that the trials were not powered to detect differences in 
these subgroups.
Denosumab could also be considered in the care pathway as a second-line agent in those who continue to 
have SREs on current recommended treatment (BPs or BSC) or in patients who are contraindicated to BPs. 
All patients in the pivotal denosumab trials were naive to BPs for bone metastases. Therefore, no evidence 
was found for the use of denosumab in patients previously prescribed a BP. Patients with severe renal 
impairment were excluded from the pivotal trials. Therefore, the effectiveness of denosumab in patients 
with advanced cancer and severe renal impairment is unknown.
Potential for community-based treatment
Denosumab is administered by monthly subcutaneous injection, whereas zoledronic acid is administered 
in hospital by intravenous infusion over at least 15 minutes every 3–4 weeks. Therefore, patients receiving 
denosumab who were not otherwise required to attend hospital could potentially receive community-
based treatment, which they (and their carers) might find more convenient in terms of, for example, 
having less distance to travel.
Physiology of bone metastases between tumour types
Bone metastases result in an imbalance of osteoclast and osteoblast activity. Traditionally it was thought 
that bone metastases could be osteolytic (also known as osteoclastic), osteoblastic or mixed. However, 
current opinion is that a spectrum exists, with no metastasis being purely osteolytic or osteoblastic. 
Prostate cancer generally results in predominantly osteoblastic lesions and breast cancer predominantly 
osteolytic lesions. Theoretically there may be a difference in the efficacy of denosumab depending on 
the predominant type of bone lesion. As denosumab inhibits osteoclasts, one might expect denosumab 
to be more effective in preventing complications associated with osteolytic lesions. However, osteoclasts 
also affect osteoblastic function. A subgroup of the study comparing zoledronic acid and disodium 
pamidronate in breast cancer found that patients with predominantly lytic lesions responded better to 
zoledronic acid.109 The pivotal denosumab studies did not report a subgroup of patients by lesion type.
Bone markers
Despite the clinical benefits of denosumab and BPs, only a proportion of SREs are prevented, and some 
patients may not experience a skeletal event despite the presence of metastatic bone disease. It has been 
suggested that bone markers could be used to stratify risk to individuals with bone metastases.27,28 There 
are several different types of bone markers, including BSAP, osteocalcin and PINP for monitoring bone 
formation and CTX and NTX for monitoring bone resorption. The ASCO guidelines34 currently do not 
recommend the use of bone markers in breast cancer outwith the trial setting.
Ongoing studies
Five ongoing studies of denosumab were reported by the manufacturer. Two studies are open-label 
extensions of the Stopeck trial31 and Fizazi trial.29 One Phase III study is currently evaluating denosumab for 
prolonging bone metastasis-free survival in hormone-refractory prostate cancer. There are also two Phase II 
studies in progress, one investigating the use of denosumab for the treatment of hypercalcaemia and the 
other evaluating the effectiveness of denosumab in giant cell tumour of the bone.
Cost-effectiveness
Statement of principal findings
Within-trial analyses by the AG suggest that for breast cancer patients denosumab results in a slightly 
lower average number of SREs than zoledronic acid, and that this will translate into a small average annual 
gain of perhaps 0.003–0.006 QALYs: roughly equivalent to 1–2 additional days in full health or 2–3 days 
at the SRE-naive quality of life. Without the PAS, the additional cost of denosumab does not justify these 
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relatively minor gains. With the PAS, denosumab is estimated to be broadly cost neutral to slightly cost 
saving, and so cost-effective compared with zoledronic acid.
Within-trial analyses suggest that, for prostate cancer patients, denosumab results in a slightly lower 
average number of SREs than zoledronic acid. This translates into a slightly larger additional average 
annual gain of perhaps 0.008–0.016 QALYs. The reason for this difference for prostate cancer is the 
greater proportion of SCCs within the overall number of SREs. However, there is a suggestion that there 
may be slightly fewer zoledronic acid administrations per annum than denosumab administrations. This 
triangulates with the higher proportion of zoledronic acid patients within the prostate cancer trial having 
doses withheld for creatine clearance. This aspect is not formally considered in either the manufacturer’s or 
the AG’s economic model.
Without the PAS, the additional cost of denosumab still does not justify the relatively minor estimated 
gains. With the PAS (commercial-in-confidence information has been removed), denosumab is estimated 
to increase annual costs by around £100, which translates into cost-effectiveness estimates of between 
£6545 per QALY and £15,272 per QALY. However, this AG within-trial analysis does not distinguish 
between SRE-naive and -experienced patients.
For the cost–utility modelling within breast cancer, the lifetime gains across all patients are estimated to 
be around 0.007 QALYs. This is again small, and does not justify the additional cost of £1707 per patient 
compared with zoledronic acid. With the PAS (commercial-in-confidence information has been removed), 
denosumab is estimated to dominate zoledronic acid. But for those in whom BPs are contraindicated 
the cost-effectiveness is poor: even with the PAS the cost-effectiveness is £157,829 per QALY. Applying 
the SRE-naive and -experienced subgroups, clinical effectiveness has little impact on the results, as these 
estimates are reasonably close to the pooled all-patient estimates.
For the cost–utility modelling within prostate cancer, across all patients the gain from denosumab over 
zoledronic acid is around 0.009 QALY, whereas compared with BSC it is 0.035 QALYs, at net costs without 
the PAS of £1059 and £3951, respectively. Without the PAS, compared with zoledronic acid this results 
in a cost-effectiveness of £111,603 per QALY. Cost-effectiveness is estimated to be slightly better among 
the SRE-naive patients, at £99,561 per QALY, but the quid pro quo is a worse cost-effectiveness among 
the SRE-experienced patients of £170,854 per QALY. This may arise in large part from the estimated step 
change in HRQoL arising from a patient’s first SRE.
With the PAS, denosumab is estimated to be cost saving compared with zoledronic acid and so dominates 
it. For those in whom BPs are contraindicated, denosumab is not estimated to be cost-effective compared 
with BSC. The PAS (commercial-in-confidence information has been removed) results in denosumab being 
estimated to remain dominant over zoledronic acid.
Within the cost–utility modelling of OSTs including lung cancer, the gains from denosumab over zoledronic 
acid are estimated to be less than 0.01 QALYs. Without the PAS, denosumab is not cost-effective, but with 
it the small additional overall costs of around £50 result in cost-effectiveness estimates of between £5400 
per QALY and £15,300 per QALY. The impact of applying the SRE-subgroup-specific estimates within this 
group is quite large. Although it improves the cost-effectiveness estimates of denosumab compared with 
BSC for SRE-naive patients, even with the PAS it is not sufficient to render it cost-effective because of the 
SRE-experienced RRs for SREs. (Academic-in-confidence information has been removed.)
For lung cancer, possibly because of the short life expectancy, the patient gains from denosumab over 
zoledronic acid among SRE-experienced patients are estimated to be small: 0.003 QALYs. With the PAS, 
the additional cost of £43 results in a cost-effectiveness of £12,743 per QALY.
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If the price of zoledronic acid falls by only a reasonably small amount at patent expiry, the cost-
effectiveness of denosumab will change dramatically in comparison owing to the very small estimate for 
patient gains.
Strengths and limitations of the assessment
The AG’s analysis is in part framed by the manufacturer’s analysis in terms of outlook and approach. 
The cost–utility modelling relies on it for the greater part of its input, because of a paucity of other data 
sources for elements such as quality-of-life values. But the broad conclusions of the assessment appear 
relatively insensitive to the approach adopted, as shown by the much simpler within-trial analyses.
Uncertainties
A concern within the modelling is BSC being assumed to have a zero incidence of the modelled SAEs. 
When the benefits from active treatments on SREs are muted, there is the possibility that SAEs come to 
the fore and require more detailed consideration. Sensitivity analyses that completely exclude SAEs from 
the analysis do improve the cost-effectiveness of denosumab compared with BSC, but this in itself is not 
sufficient to render denosumab cost-effective compared with BSC when this is the appropriate comparator.
There remains some structural uncertainty around the reasonableness of the utility estimates applied. In 
particular, the step change estimated between SRE-naive patients and SRE-experienced patients provides 
much of the gain anticipated from SRE-naive patients avoiding their first SRE. Whether or not this estimate 
is picking up the impact of other variables, such as progression, which are not considered in the utility 
estimates is currently an open question.
A key uncertainty is the rate of paralysis associated with SCC and the duration of quality-of-life impact 
from SCC. Extending the average quality-of-life decrement measured in the 5 months subsequent to the 
compression through to death improves the estimated cost-effectiveness, particularly among SRE-naive 
prostate cancer patients. Although not in itself sufficient to render denosumab cost-effective against BSC, 
extending the impacts of SCC does improve the cost-effectiveness. There are also some concerns that the 
ongoing costs of SCC may have been underestimated.
Probabilistic modelling suggests that within the usual range of acceptable cost-effectiveness thresholds 
there is relatively little uncertainty because the treatment with the highest probability of being cost-
effective is also that with the highest probability of being optimal when compared with the alternatives, 
and this treatment does not change over the usual range of acceptable cost-effectiveness thresholds. The 
central estimates are also in line with those of the deterministic analyses.
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Chapter 12 Conclusions
Implications for service provision
Denosumab is effective in delaying the time to first SRE and reducing the risk of developing first and 
subsequent SREs in patients with bone metastases from breast cancer and prostate cancer. For NSCLC, 
for time to first SRE the direction of effect favoured denosumab without being statistically significant. 
(Academic-in-confidence information has been removed.) For OSTs (excluding breast cancer, prostate 
cancer and NSCLC), denosumab was effective in delaying the time to first SRE. (Academic-in-confidence 
information has been removed.) The distribution of type of SRE was similar across treatment groups, with 
the vast majority consisting of pathological fracture or radiation to the bone. (Academic-in-confidence 
information has been removed), whereas there were few occurrences of SCC or surgery to bone.
Denosumab was also shown to be effective in delaying the time to development of moderate or severe 
pain (for the subgroup of patients with no or mild pain at baseline) in patients with breast cancer and 
those with OSTs (including NSCLC), but the difference was smaller for prostate cancer. The median time 
to worsening pain was generally similar for the treatment groups in the three studies. In terms of quality 
of life, across all three RCTs FACT scores remained similar between the groups. (Academic-in-confidence 
information has been removed.) Overall survival was reported to be similar in the studies apart from 
the post-hoc analysis of NSCLC, in which a statistically significant difference was reported in favour 
of denosumab.
In the AG’s NMA, there was a statistically significant difference in favour of denosumab for both time to 
first SRE and risk of first and subsequent SRE for most comparisons. (Academic-in-confidence information 
has been removed.) However, the results of the network meta-analyses are subject to considerable 
uncertainty and should be interpreted with caution.
The effectiveness of denosumab compared with zoledronic acid and BSC in delaying time to first SRE and 
reducing the risk of first and subsequent SREs has been demonstrated. These results have mostly reached 
statistical significance and met the minimally clinically significant change described by clinical experts 
(delay of > 3 months or HR reduction of > 20%). However, the importance of the composite SRE outcome, 
and spectrum of corresponding possible health states, to an individual patient is not clear. Evidence for the 
effectiveness of denosumab compared with zoledronic acid in reducing pain and improving relative quality 
of life is less evident.
The manufacturer’s model, the AG within-trials analyses and the AG cost–utility model all estimate 
denosumab to result in patient benefits from reduced SREs compared with denosumab, and larger 
benefits compared with BSC. But the estimates of the numbers of SREs avoided per patient are small 
when compared with zoledronic acid, typically less than 0.3 SREs over the patient’s lifetime, and often a 
lot less than this. SCC is relatively rare. The QALY gains from the number of SREs avoided compared with 
zoledronic acid are small, typically less than 0.02 QALYs over the patient’s lifetime, and again often quite a 
lot less than this.
(Commercial-in-confidence information has been removed.) Given the small QALY gains, denosumab is 
estimated to dominate or be cost-effective compared with zoledronic acid. But zoledronic acid comes 
off patent quite soon. (Commercial-in-confidence information has been removed.) A price reduction 
(commercial-in-confidence information has been removed) for zoledronic acid is required to result 
in the additional net costs from denosumab rendering it not cost-effective at current thresholds. 
For those patients for whom BPs are not currently recommended or are not used, possibly owing to 
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contraindications, both the manufacturer and the AG conclude that denosumab is not cost-effective 
compared with BSC.
Suggested research priorities
Further research would be helpful in the following areas:
 z the effectiveness of denosumab compared with zoledronic acid in delaying time to first SRE and 
reducing the risk of first and subsequent SREs in patients with hormone-refractory prostate cancer and 
painful bone metastases for whom other treatments, including analgesics and palliative radiotherapy, 
have failed
 z whether or not there is an identifiable subgroup of patients at higher risk of SCC for whom 
denosumab might result in larger QALY gains
 z the safety and efficacy of denosumab in patients with severe renal impairment and advanced cancer 
(breast cancer, prostate cancer, NSCLC and OSTs)
 z the safety and efficacy of denosumab in patients with advanced cancer who have previously been 
exposed to a BP
 z the role of bone markers (including BSAP, PINP, CTX and NTX) to identify subgroups of patients with 
advanced cancer and bone metastases who may be likely to benefit from bone-targeting therapies
 z the effectiveness of denosumab compared with zoledronic acid for overall survival in patients with 
NSCLC and bone metastases.
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Appendix 1 Search strategies
Clinical effectiveness
Ovid MEDLINE 1948 to March week 5 2011
1. exp Diphosphonates/
2. RANK Ligand/
3. (denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*).tw.
4. (radiation or radiotherapy or radionuclide* or hormone therapy or strontium or samarium).ti.
5. or/1-4
6. exp Neoplasms/
7. (solid tumor or solid tumour* or cancer or carcinoma or myeloma).tw.
8. or/6-7
9. 5 and 8
10. exp Bone Neoplasms/
11. (((bone or osteolytic or lytic) adj lesion*) or (bone adj2 metast*)).tw.
12. (skeletal or fracture*).tw.
13. or/10-12
14. 9 and 13
15. randomized controlled trial.pt.
16. 14 and 15
17. limit 16 to english language
Ovid MEDLINE In-Process and Other Non-Indexed Citations 8 April 2011
1. (solid tumor or solid tumour* or cancer or carcinoma or myeloma).ti.
2. (bone adj2 metast*).tw.
3. (skeletal related event* or fracture*).tw.
4. or/2-3
5. 1 and 4
6. random*.tw.
7. randomized controlled trial.pt.
8. or/6-7
9. 5 and 8
Ovid EMBASE 1980 to March week 5 2011
1. exp *DENOSUMAB/
2. *clodronic acid/ or *ibandronic acid/ or *pamidronic acid/ or *zoledronic acid/
3. (denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*).tw.
4. (radiation or radiotherapy or radionuclide* or hormone therapy or strontium or samarium).ti.
5. or/1-4
6. (solid tumor or solid tumour* or cancer or carcinoma or myeloma).tw.
7. 5 and 6
8. exp *bone cancer/
9. ((bone or osteolytic or lytic) adj lesion*).tw.
10. (bone adj2 metast*).tw.
11. (skeletal or fracture*).tw.
12. or/8-11
13. 7 and 12
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14. randomized controlled trial/
15. 13 and 14
16. limit 15 to english language
Cochrane Database of Systematic Reviews Issue 3 of 12, March 2011
Cochrane Central Register of Controlled Trials (CENTRAL) Issue 1 of 4, January 2011
1. (denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*):ti,ab,kw
2. (radiation or radiotherapy or radionuclide* or hormone therapy or strontium or samarium):ti
3. (solid tumor or solid tumour* or cancer or carcinoma or myeloma):ti,ab,kw
4. (#1 OR #2)
5. (#4 AND #3)
6. (bone or skeletal) near/1 metast*:ti,ab,kw
7. (osteoly* or lesion* or lytic) near/3 bone*:ti,ab,kw
8. (#6 OR #7)
9. (#5 AND #8)
Conference Proceedings
American Society of Clinical Oncology 2011 abstracts 
http://abstract.asco.org/
American Urological Association’s Annual Meeting 2011 
http://www.aua2011.org/
Economics or quality of life of bone metastases and skeletal-
related effects
Ovid MEDLINE 1948 to May week 3 2011
1. “Costs and Cost Analysis”/
2. “cost of illness”/
3. exp Economics/
4. (pharmacoeconomic$ or pharmaco-economic$ or economic$ or cost-effective* or cost-benefit).tw.
5. exp Health Status/
6. exp “Quality of Life”/
7. quality-adjusted life years/
8. (health state* or health status).tw.
9. (qaly$ or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36).tw.
10. (markov or time trade off or standard gamble or hrql or hrqol or disabilit$).tw.
11. (quality adj2 life).tw.
12. (decision adj2 model).tw.
13. (utilit* adj3 (cost* or analys* or score* or health or value* or assessment*)).tw.
14. ((utilit* or preference) adj3 (weight* or score*)).tw.
15. or/1-14
16. ((skeletal or fracture or bone) and (malignan* or metastat* or cancer or carcinoma)).tw.
17. (spinal cord compression or hypercalc* or (surgery adj3 bone)).tw.
18. ((radiation or radiotherapy) adj3 bone).tw.
19. or/16-18
20. 15 and 19
21. limit 20 to english language
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EMBASE 1980 to 2011 week 21 
Ovid MEDLINE In-Process and Other Non-Indexed Citations 27 May 2011
(pharmacoeconomic$ or pharmaco-economic$ or economic$).ti.
1. (health state* or health status).tw.
2. (qaly$ or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36).tw.
3. (markov or time trade off or standard gamble or hrql or hrqol or disabilit$).tw.
4. (quality adj2 life).tw.
5. (decision adj2 model).tw.
6. (utilit* adj3 (cost* or analys* or score* or health or value* or assessment*)).tw.
7. ((utilit* or preference) adj3 (weight* or score*)).tw.
8. (cost or costs).m_titl.
9. ((skeletal or fracture or bone) and (malignan* or metastat* or cancer or carcinoma)).ti
10. spinal cord compression or SRE or hypercalc* or (surgery adj3 bone)).ti.
11. ((radiation or radiotherapy) and bone).ti.
12. or/10-12
13. or/1-9
14. 13 and 14
15. limit 15 to english language
Science Citation Index – 1970 to present
Social Sciences Citation Index – 1970 to present 
Conference Proceedings Citation Index – Science – 1990 to present
Conference Proceedings Citation Index – Social Science & Humanities – 
1990 to present
1. Title=((skeletal or fracture or bone) and (malignan* or metastat* or cancer or carcinoma)) AND 
Title=(spinal cord compression or SRE or hypercalc* or surgery or radiation or radiotherapy) 
2. Topic=(Pharmacoeconomic* or pharmaco-economic* or economic* or cost or costs or quality of life 
or health status or health utiliti*) 
3. #1 and #2
4. Title=(Pharmacoeconomic* or pharmaco-economic* or economic* or cost or costs or quality of life or 
health status or health utiliti*) AND Topic=((skeletal or fracture or bone) and (malignan* or metastat* 
or cancer or carcinoma)) AND Topic=(spinal cord compression or SRE or hypercalc* or surgery or 
radiation or radiotherapy) 
5. #3 or #4 Refined by: Languages=( ENGLISH ) 
Economics of denosumab and bisphosphonates
Ovid MEDLINE 1948 to May week 3 2011
1. (denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*).tw.
2. ((skeletal or fracture or bone) and (malignan* or metastat* or cancer or carcinoma)).tw.
3. 1 and 2
4. “Costs and Cost Analysis”/
5. “cost of illness”/
6. exp Economics/
7. (pharmacoeconomic$ or pharmaco-economic$ or economic$ or cost-effective* or cost-benefit).tw.
8. exp Health Status/
9. exp “Quality of Life”/
10. exp quality-adjusted life years/
11. health state* or health status).tw.
12. (qaly$ or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36).tw.
13. (markov or time trade off or standard gamble or hrql or hrqol or disabilit$).tw.
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14. (quality adj2 life).tw.
15. (decision adj2 model).tw.
16. (utilit* adj3 (cost* or analys* or score* or health or value* or assessment*)).tw.
17. ((utilit* or preference) adj3 (weight* or score*)).tw.
18. or/4-17
19. 3 and 18
20. limit 19 to english language
EMBASE 1980 to 2011 week 21
Ovid MEDLINE In-Process and Other Non-Indexed Citations 2 June 2011
1. (denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*).tw.
2. ((skeletal or fracture or bone) and (malignan* or metastat* or cancer or carcinoma)).tw.
3. 1 and 2
4. (pharmacoeconomic$ or pharmaco-economic$ or economic$ or cost-effective* or cost-benefit).tw.
5. (health state* or health status).tw.
6. (qaly$ or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36).tw.
7. (markov or time trade off or standard gamble or hrql or hrqol or disabilit$).tw.
8. (quality adj2 life).tw.
9. (decision adj2 model).tw.
10. (utilit* adj3 (cost* or analys* or score* or health or value* or assessment*)).tw.
11. ((utilit* or preference) adj3 (weight* or score*)).tw.
12. or/4-11 
13. 3 and 12
14. limit 13 to English language
NHS Economic Evaluation Database
Centre for Reviews and Dissemination
URL: http://www.york.ac.uk/inst/crd/
1. denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*:TI
Science Citation Index – 1970 to present
Social Sciences Citation Index – 1970 to present
Conference Proceedings Citation Index – Science – 1990 to present
Conference Proceedings Citation Index – Social Science & Humanities – 
1990 to present
1. Title=(denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*) AND 
Title=(pharmacoeconomic* or pharmaco-economic* or economic* or cost* or quality of life or 
qaly* or EQ5D or EQ-5D or health utilit* or euroqol or euro-qol or SF-36 or SF36) NOT Title=(post-
menopaus* or postmenopaus* or osteopor*)
Conference Proceedings
American Society of Clinical Oncology 2010 and 2011 abstracts 
http://www.asco.org/ascov2/meetings/abstracts
Safety and adverse events
Ovid MEDLINE 1996 to June week 3 2011
1. exp *Diphosphonates/ae [Adverse Effects]
2. exp *RANK Ligand/ae [Adverse Effects]
3. (denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*).ti.
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4. (risk or safety or adverse or harm or pharmacovigilance).ti.
5. (side-effect* or precaution* or warning* or contraindication* or contra-indication* or tolerability or 
toxic* or complication*).ti.
6. (osteonecrosis or ONJ or renal or hypocalc*).ti.
7. or/4-6
8. or/1-2
9. 3 and 8
10. 7 and 9
11. limit 10 to yr=”2000 - 2011”
Ovid MEDLINE In-Process and Other Non-Indexed Citations 28 June 2011
1. (denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*).ti.
2. (risk or safety or adverse or harm or pharmacovigilance).ti.
3. (side-effect* or precaution* or warning* or contraindication* or contra-indication* or tolerability or 
toxic* or complication*).ti.
4. (osteonecrosis or ONJ or renal or hypocalc*).ti.
5. or/2-4
6. 1 and 5
EMBASE 1996 to 2011 week 25
1. exp *denosumab/ae [Adverse Drug Reaction]
2. exp *bisphosphonic acid derivative/ae [Adverse Drug Reaction]
3. (denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*).ti.
4. (risk or safety or adverse or harm or pharmacovigilance).ti
5. (side-effect* or precaution* or warning* or contraindication* or contra-indication* or tolerability or 
toxic* or complication*).ti.
6. (osteonecrosis or ONJ or renal or hypocalc*).ti.
7. or/4-6
8. or/1-2
9. 3 and 8
10. 7 and 9
11. limit 10 to (english language and yr=”2005 - 2011”)
Science Citation Index – 1970 to present
Social Sciences Citation Index – 1970 to present 
Arts & Humanities Citation Index – 1970 to present 
Conference Proceedings Citation Index – Science – 1990 to present
Conference Proceedings Citation Index – Social Science & Humanities – 
1990 to present
1. Title=(denosumab or bisphosphonate* or ibandron* or clodron* or pamidron* or zoledron*) AND 
Title=(osteonecrosis or ONJ or renal or hypocalc* or risk or safety or adverse or side-effect*) AND 
Title=(cancer or carcinoma or metast* or malignant or complication*) 
Refined by: Document Type=( MEETING ABSTRACT ) 
Timespan=2008-2011 – 30 June.
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Systematic reviews of denosumab and bisphosponates for 
bone metastases and skeletal-related events
Ovid MEDLINE 2000 to 11 July 2011
1. (bone and metast*).ti.
2. bisphosphonate*.m_titl.
3. (metast* or cancer).tw.
4. 2 and 3
5. 1 or 4
6. “cochrane database of systematic reviews”.jn.
7. (systematic review or meta-analysis).tw.
8. or/6-7
9. 5 and 8
10. limit 9 to english language
11. limit 10 to yr=”2000 – 2011
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Appendix 2 Data extraction form
Study details
Name of the reviewer
Study details
Name Duration of trial Settings Comparisons
Name and year of the study   Intervention
versus
Comparators
Study aim: 
 
Study design: 
 
Dosing: 
Dose of intervention: 
Dose of control: 
Dose of any other treatments: 
Intervention in both groups:
Definition of SRE:
 
Methods of assessment of SREs during follow-up:
 
Primary outcomes: 
Other outcomes: 
 
Follow-up: 
 
Safety data: 
 
Inclusion criteria: 
 
Exclusion criteria:
 
Previous treatment
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Patient characteristics
No. of patients, n (%) Intervention (n=) Control (n=)
Screened   
Excluded   
Enrolled   
Randomised   
Excluded   
Efficacy analysis   
Safety analysis   
Discontinued   
Primary data analysis cut-off date   
Patient characteristics Intervention (n=) Control (n=)
Total patients, n   
Age (years)   
Sex (M/F), n (%)   
Ethnicity, n (%)   
White   
Other   
ECOG performance status 0–1, n (%)   
Time from diagnosis of prostate cancer to randomisation (months/years)
Time from diagnosis of bone metastases to randomisation (months/years)
Presence of visceral metastases, n (%)   
Recent chemotherapy, n (%)   
Haemoglobin concentration (g/l), mean (SD)   
Creatinine clearance of ≥ 1.5 ml/second, n (%)   
PSA at randomisation (µg/l)   
< 10, n (%)   
≥ 10, n (%)   
Gleason score at diagnosis, n (%)   
2–6   
7   
8–10   
Missing   
Bone turnover markers, median (IQR)   
BSAP (µg/l)   
Urinary N-telopeptide (nmol/mmol)   
Previous SREs, n (%)   
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Quality of the study
Quality of the study Details Yes/No/Unclear
Adequate sequence generation   
Allocation concealment   
Blinding   
Incomplete outcome data addressed   
Free of selective reporting   
Generalisability   
Sample size calculation   
Conflict of interest   
Source of funding   
Outcomes and safety
 Intervention (n=) Control (n=) Difference between groups 
(95% CI)
p-value
Time to first on-study SREs (in months/years)
 Intervention (n=) Control (n=) Difference between groups 
(95% CI)
p-value
Time to first and subsequent on-study SREs 
Number of events     
 Intervention (n=) Control (n=) Difference between groups p-value
Number of patients with first on-study SREs, n (%)
Total confirmed events     
Radiation to bone     
Pathological fracture     
SCC     
Surgery to bone     
 Intervention (n=) Control (n=) Difference between groups p-value
Overall survival rate     
   
 Intervention (n=) Control (n=)
SMR (the ratio of the number of skeletal complications to the time on trial)
 Intervention (n=) Control (n=) Difference between groups p-value
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Time to disease progression
 Intervention (n=) Control (n=) Difference between groups p-value
HRQoL     
 Intervention (n=) Control (n=) Difference between groups p-value
Any adverse events, n (%)     
Acute-phase reactions, n (%)     
Adverse events associated with renal impairments, n (%)
Withdrawals due to adverse 
events, n (%)
    
Reasons for withdrawal     
Death     
Disease progression     
Consent withdrawn     
Adverse events     
Patient request     
Lost to follow-up     
Non-compliance     
Administrative decision     
Protocol deviation     
Ineligibility determined     
Other     
 Intervention (n=) Control (n=) Difference between groups p-value
CTCAE grade 3 or 4 adverse 
events
    
Adverse events occurring with ≥ 20% frequency in either treatment group, n (%)
Back pain     
Pain in extremity     
Bone pain     
Arthralgia     
Asthenia     
Anaemia     
Decreased appetite     
Nausea     
Fatigue     
Constipation     
Peripheral oedema     
Infectious adverse events, n (%)     
Cumulative ONJ (total)     
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Year 1     
Year 2     
Hypocalcaemia     
SAEs     
Fatal adverse events     
New primary malignant disease     
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Appendix 3 The Cochrane collaboration’s tool for 
assessing risk of bias
Domain Support for judgement
Review authors’ 
judgement
Selection bias   
Random sequence 
generation
Describe the method used to generate the allocation 
sequence in sufficient detail to allow an assessment of 
whether it should produce comparable groups
Selection bias (biased 
allocation to interventions) 
due to inadequate 
generation of a randomised 
sequence
Allocation concealment Describe the method used to conceal the allocation 
sequence in sufficient detail to determine whether 
intervention allocations could have been foreseen in 
advance of, or during, enrolment
Selection bias (biased 
allocation to interventions) 
due to inadequate 
concealment of allocations 
prior to assignment
Performance bias   
Blinding of participants 
and personnel Assessments 
should be made for each 
main outcome (or class of 
outcomes) 
Describe all measures used, if any, to blind study 
participants and personnel from knowledge of which 
intervention a participant received. Provide any information 
relating to whether the intended blinding was effective
Performance bias due to 
knowledge of the allocated 
interventions by participants 
and personnel during the 
study
Detection bias   
Blinding of outcome 
assessment Assessments 
should be made for each 
main outcome (or class of 
outcomes)
Describe all measures used, if any, to blind outcome 
assessors from knowledge of which intervention a 
participant received. Provide any information relating to 
whether the intended blinding was effective
Detection bias due to 
knowledge of the allocated 
interventions by outcome 
assessors
Attrition bias   
Incomplete outcome data 
Assessments should be made 
for each main outcome (or 
class of outcomes)
Describe the completeness of outcome data for each 
main outcome, including attrition and exclusions from 
the analysis. State whether attrition and exclusions 
were reported, the numbers in each intervention group 
(compared with total randomised participants), reasons for 
attrition/exclusions where reported, and any re-inclusions in 
analyses performed by the review authors
Attrition bias due to 
amount, nature or handling 
of incomplete outcome 
data
Reporting bias   
Selective reporting State how the possibility of selective outcome reporting was 
examined by the review authors, and what was found
Reporting bias due to 
selective outcome reporting
Other bias   
Other sources of bias State any important concerns about bias not addressed in 
the other domains in the tool
If particular questions/entries were pre-specified in the 
review’s protocol, responses should be provided for each 
question/entry
Bias due to problems not 
covered elsewhere in the 
table
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Appendix 4 List of included studies
Breast cancer
Direct evidence reporting denosumab or contributing data to the network 
meta-analysis
Kohno 2005
Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces 
skeletal complications compared with placebo in Japanese women with bone metastases from breast 
cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314–21.
Lipton 2000
Primary report
Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents 
skeletal complications and is effective palliative treatment in women with breast carcinoma and 
osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 
2000;88:1082–90.
Secondary reports
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in 
reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 
Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785–91.
Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal 
complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study 
Group. J Clin Oncol 1998;16:2038–44.
Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al. Pamidronate reduces skeletal 
morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled 
trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846–54.
Rosen 2003
Primary report
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of 
zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in 
patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, 
comparative trial. Cancer 2003;98:1735–44.
Secondary reports
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate 
in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple 
myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–87.
Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to 
pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic 
lesion. Cancer 2004;100:36–43.
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Stopeck 2010
Primary report
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with 
zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a 
randomized, double-blind study. J Clin Oncol 2010;28:5132–9.
Secondary reports
Kidson S. Clinical Study Report: 20050136. A randomized, double-blind, multicenter study of denosumab 
compared with zoledronic acid (Zometa) in the treatment of bone metastases in subjects with advanced 
breast cancer. Thousand Oaks, CA: Amgen Inc.; 2009 
Fallowfield L, Patrick D, Body JJ, Lipton A, Tonkin KS, Qian Y, et al. The effect of treatment with denosumab 
or zoledronic acid on health-related quality of life in patients with metastatic breast cancer. Proceedings 
of the 33rd Annual San Antiono Breast Cancer Symposium, 8–12 December 2010. URL: www.asco.org/
ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=100&abstractID=60225 (accessed 
September 2011).
Fallowfield L, Patrick D, Body J, Lipton A, Tonkin KS, Qian Y, et al. Effects of denosumab versus zoledronic 
acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: results from a randomized 
phase III trial. J Clin Oncol 2010;28(Suppl. 15):1025. 
Martin M, Steger G, von Moos R, Stopeck A, de Boer R, Bourgeois H, et al. Benefit of denosumab therapy 
in patients with bone metastases from breast cancer: a number-needed-to-treat (NNT) analysis. Breast 
2011;20:S85. 
Stopeck A, Martin M, Ritchie D, Body JJ, Paterson A, Viniegra M, et al. Effect of denosumab versus 
zoledronic acid treatment in patients with breast cancer and bone metastases: Results from the extended 
blinded treatment phase. Cancer Res 2010;70(Suppl. 2):P6-14-01.
Stopeck A, Fallowfield L, Patrick D, Cleeland CS, de Boer RH, Steger GG, et al. Effects of denosumab versus 
zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: results from a phase III clinical 
trial. J Clin Oncol 2010;28(Suppl.):abstract no. 1024.
Stopeck A, Fallowfield L, Patrick D, Cleeland CS, de Boer RH, Steger GG, et al. Pain in patients (pts) 
with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid (ZA). 
Proccedings of the 33rd Annual San Antiono Breast Cancer Symposium, 8–12 December 2010. URL: 
www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=100&abstractID=60225 
(accessed September 2011).
Stopeck A, Lipton AA, Campbell-Baird C, von Moos R, Fan M, Haddock B, et al. Acute-phase reactions 
following treatment with zoledronic acid or denosumab: Results from a randomized, controlled phase 3 
study in patients with breast cancer and bone metastases. Cancer Res 2010;70(Suppl. 2):P6-14-09.
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Reply to V. Fusco et al. J Clin Oncol 
2011;29:e523–4.
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Meeting inclusion criteria but not included in network meta-analysis
Body 2003
Primary report
Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate 
reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann 
Oncol 2003;14:1399–405.
Secondary report
Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Improved quality of life after 
long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to 
breast cancer. Eur J Cancer 2004;40:1704–12.
Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the 
risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two 
randomized, placebo-controlled phase III studies. Br J Cancer 2004;90:1133–7.
Body 2004
Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, et al. Oral ibandronate improves 
bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 
2004;111:306–12.
Secondary report
Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, et al. Oral ibandronate for 
the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, 
double-blind, placebo-controlled trial. Ann Oncol 2004;15:743–50.
Elomaa 1988
Elomaa I, Blomqvist C, Porkka L, Holmström T, Taube T, Lamberg-Allardt C, et al. Clodronate for osteolytic 
metastases due to breast cancer. Biomed Pharmacother 1988;42:111–16.
Heras 2009
Heras P, Kritikos K, Hatzopoulos A, Georgopoulou AP. Efficacy of ibandronate for the treatment of skeletal 
events in patients with metastatic breast cancer. Eur J Cancer Care 2009;18:653–6.
Kristensen 1999
Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer 
patients with bone metastases: a randomized study. J Intern Med 1999;246:67–74.
Paterson 1993
Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral 
clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59–65.
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Prostate cancer
Direct evidence reporting denosumab or contributing data to the network 
meta-analysis
Fizazi 2011
Primary report
Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for 
treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-
blind study. Lancet 2011;377:813–22.
Secondary reports
Brown JE, Cleeland CS, Fallowfield LJ, Patrick DL, Fizazi K, Smith MR, et al. Pain outcomes in patients with 
bone metastases from castrate-resistant prostate cancer: results from a phase 3 trial of denosumab vs. 
zoledronic acid. Eur Urol Suppl 2011;10:336. 
Tadros S. Clinical Study Report: 20050103. A randomized, double-blind, multicenter study of denosumab 
compared with zoledronic acid (Zometa) in the treatment of bone metastases in men with hormone-
refractory prostate. Thousand Oaks, CA: Amgen Inc.; 2010.
Miller K, Fizazi K, Smith M, Moroto JP, Klotz L, Brown J, et al. Benefit of denosumab therapy in patients 
with bone metastases from castrate resistant prostate cancer: a number-needed-to-treat (NNT) analysis. J 
Urol 2011;185:e262.
Patrick D, Cleeland C, Fallowfield L, Smith MR, Trachtenberg J, Chilingirov P, et al. Effects of denosumab 
and zoledronic acid on pain interference with daily functioning in patients with castrate-resistant prostate 
cancer. J Urol 2011;185(Suppl. 4):e286. 
Shore ND, Smith MR, Jievaltas M, Fizazi K, Damiao R, Chin J, et al. Effect of denosumab versus zoledronic 
acid in patients with castrate-resistant prostate cancer and bone metastases: subgroup analyses by prior 
SRE and baseline pain. J Clin Oncol 2011;29(Suppl.):4533. 
Saad 2002
Primary report
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-
controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl 
Cancer Inst 2002;94:1458–68.
Secondary reports
European Medicines Agency. Assessment report for zometa (zoledronic acid). European Medicines Agency; 
2010. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000336/
human_med_001182.jsp&mid=WC0b01ac058001d124# (accessed October 2011).
Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life 
considerations throughout the continuum of care. Eur Urol 2004;46:731–9.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of 
zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory 
prostate cancer. J Natl Cancer Inst 2004;96:879–82.
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Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate 
cancer. Clin Prostate Cancer 2005;4:31–7.
Saad F, Chen YM, Gleason DM, Chin J. Continuing benefit of zoledronic acid in preventing skeletal 
complications in patients with bone metastases. Clin Genitourin Cancer 2007;5:390–6.
Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced 
survival in patients with malignant bone disease. Cancer 2007;110:1860–7.
Saad F, Eastham J. Zoledronic Acid improves clinical outcomes when administered before onset of bone 
pain in patients with prostate cancer. Urology 2010;76:1175–81.
Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with 
bone metastasis in patients with prostate cancer. Ann Oncol 2006;17:986–9.
Meeting inclusion criteria but not included in network meta-analysis
Adami 1989
Primary report
Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. 
Recent Results Cancer Res 1989;116:67–72.
Secondary report
Adami S, Salvagno G, Guarrera G. Dichloromethylene-diphosphonate in patients with prostatic carcinoma 
metastatic to the skeleton. J Urol 1985;134:1152–4.
Buchali 1988
Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of 
89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nuclear Med 1988;14:349–51.
Dearnaley 2003
Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, et al. A double-blind, placebo-
controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J 
Natl Cancer Inst 2003;95:1300–11.
Elomaa 1992
Elomaa I, Kylmala T, Tammela T, Viitanen J, Ottelin J, Ruutu M, et al. Effect of oral clodronate on bone pain. 
A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 1992;24:159–66.
Ernst 2003
Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, et al. Randomized, double-blind, 
controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in 
patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335–42.
Kylmala 1993
Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on 
skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer 
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Kylmala T, Taube T, Tammela TL, Risteli L, Risteli J, Elomaa I. Concomitant i.v. and oral clodronate in the 
relief of bone pain – a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer 
1997;76:939–42.
Nilsson 2005
Nilsson S, Strang P, Ginman C, Zimmermann R, Edgren M, Nordstrom B, et al. Palliation of bone pain in 
prostate cancer using chemotherapy and strontium-89. A randomized phase II study. J Pain Sympt Manag 
2005;29:352–7.
Porter 1993
Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized 
phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation 
in the management of endocrine resistant metastatic prostate cancer. Int J Rad Oncol Biol Physics 
1993;25:805–13.
Quilty 1994
Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative 
effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 
1994;31:33–40.
Small 2003
Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, 
randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men 
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clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. 
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Other solid tumours
Direct evidence reporting denosumab or contributing data to the network 
meta-analysis
Henry 2011
Primary report
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of 
denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer 
(excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125–32.
Secondary reports
O'Neill S. Clinical Study Report: 20050244. A randomized, double-Blind, multicenter study of denosumab 
compared with zoledronic acid (Zometa) in the treatment of bone metastases in subjects with advanced 
cancer excluding breast and prostate Cancer) or multiple myeloma. Thousand Oaks, CA: Amgen Inc.; 2010.
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Primary report
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Secondary reports
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Appendix 6 Characteristics of studies excluded 
from network meta-analysis
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TABLE 125 Risk of bias for NMA studies
Study ID
Q1 Adequate 
sequence 
generation?
Q2 Adequate 
allocation 
concealment? Q3 Blinding?
Q4 Incomplete 
outcome data 
addressed?
Q5 Free of 
selective 
reporting?
Breast cancer
Lipton 2000103 Yes Yes Yes Unclear Unclear
Kohno 2005102 Yes Yes Yes No Yes
Stopeck 201031 Unclear Unclear Yes Yes Yes
Rosen 2003a104 Yes Yes Yes Yes Yes
Prostate cancer
Fizazi 201129 Yes Yes Yes Yes Yes
Saad 2002117 Yes Yes Yes Yes Yes
OSTs
Henry 201130 Yes Yes Yes Yes Yes
Rosen 2003130 Unclear Unclear Yes No Yes
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TABLE 126 Breast cancer adverse events
Adverse event
Study  
CSR Stopeck Rosen 2004109 Lipton 2000103,22
Kohno 2005102 
(only grade 4 
hypocalcaemia) Body 200472
Diel 2004140
Jackson 
2005150 (renal) 
Pecherstorfer 
2006154 
(extension) Paterson 199376
Kirstensen 
199975
Carteni 2006165 
(pooled)
Coleman 2011139 
(AZURE abstract) aHouston 2010148
Intervention D Z Z P P PL Z PL I* PL I** PL C PL C NT Z† Z NT Z I*
Time (years) 1.31 1.32 1.08 1.08 1.65 1.48 114 113 1.5 1.33 1.51 
(0.87)
1.09 
(1.37)
1.17 1.21 1.53 1.5 1.08 3 3 98 91
Number analysis 1013 1020 378 388 367 386 1 1 287 277 154 
(46)
158 
(16)
85 88 49 51 177 1665 1675 NR NR
Adverse event, n (%)
ONJ 20 (2.0) 14 (1.4) 11 (0.7) 0
Renal toxicity 2 (0.2) 15 (1.5) 29 (7.7) 23 (5.9) 0 1 (0.9) 15 
(5.2)
13 
(4.7)
6 (3.9) 7 (4.4) 1 (0.6)  2 (0.1) 1 (0.1) 2 (2.0) 2 (2.2)
Hypercalcaemia 2 (0.2) 11 (1.1) 21 (5.7) 49 
(12.7)
3 
(2.6)
10 (8.8) 28 
(32.0)
52 
(59.1)
5 (10.2) 5 (9.8)
Hypocalcaemia 6 (0.6) 4 (0.4) 3 (0.8) 3 (0.8) 1 
(0.9)
1 (0.9) 27 
(9.4)
14 
(5.1)
13 (26.5) 2 (3.9) 28 
(15.8)
Skin infection 9 (0.9) 5 (0.5) 10 (0.6) 8 (0.5)
Abdominal pain 19 (1.9) 16 (1.6) 19 
(16.7)
8 (7.1) 6 
(2.1)
2 
(0.7)
Alopecia 67 
(17.7)
57 
(14.7)
15 
(13.2)
22 (19.5)
Anaemia 34 (3.4) 39 (3.9) 96 
(25.4)
91 
(23.5)
Arthralgia 90 
(23.8)
76 
(19.6)
24 
(21.1)
18 (15.9)
Asthenia 12 (1.2) 16 (1.6) 77 
(20.4)
64 
(16.5)
8 (4.5)
Bone pain 11 (1.1) 14 (1.4) 228 
(60.3)
223 
(57.5)
36 
(31.6)
51 (45.1) 32 
(18.1)
Constipation 92 
(24.3)
100 
(25.8)
33 
(28.9)
37 (32.7) 4 (4.7) 5 (5.7)
Cough 87 
(23.0)
77 
(19.8)
Dehydration 13 (1.3) 26 (2.5)
Diarrhoea 19 (1.9) 16 (1.6) 89 
(23.5)
94 
(24.2)
29 
(25.4)
29 (25.7) 5 (5.9) 2 (2.3)
Dizziness 17 
(14.9)
25 (22.1)
Dyspepsia 20 
(7.0)
13 
(4.7)
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TABLE 126 Breast cancer adverse events
Adverse event
Study  
CSR Stopeck Rosen 2004109 Lipton 2000103,22
Kohno 2005102 
(only grade 4 
hypocalcaemia) Body 200472
Diel 2004140
Jackson 
2005150 (renal) 
Pecherstorfer 
2006154 
(extension) Paterson 199376
Kirstensen 
199975
Carteni 2006165 
(pooled)
Coleman 2011139 
(AZURE abstract) aHouston 2010148
Intervention D Z Z P P PL Z PL I* PL I** PL C PL C NT Z† Z NT Z I*
Time (years) 1.31 1.32 1.08 1.08 1.65 1.48 114 113 1.5 1.33 1.51 
(0.87)
1.09 
(1.37)
1.17 1.21 1.53 1.5 1.08 3 3 98 91
Number analysis 1013 1020 378 388 367 386 1 1 287 277 154 
(46)
158 
(16)
85 88 49 51 177 1665 1675 NR NR
Adverse event, n (%)
ONJ 20 (2.0) 14 (1.4) 11 (0.7) 0
Renal toxicity 2 (0.2) 15 (1.5) 29 (7.7) 23 (5.9) 0 1 (0.9) 15 
(5.2)
13 
(4.7)
6 (3.9) 7 (4.4) 1 (0.6)  2 (0.1) 1 (0.1) 2 (2.0) 2 (2.2)
Hypercalcaemia 2 (0.2) 11 (1.1) 21 (5.7) 49 
(12.7)
3 
(2.6)
10 (8.8) 28 
(32.0)
52 
(59.1)
5 (10.2) 5 (9.8)
Hypocalcaemia 6 (0.6) 4 (0.4) 3 (0.8) 3 (0.8) 1 
(0.9)
1 (0.9) 27 
(9.4)
14 
(5.1)
13 (26.5) 2 (3.9) 28 
(15.8)
Skin infection 9 (0.9) 5 (0.5) 10 (0.6) 8 (0.5)
Abdominal pain 19 (1.9) 16 (1.6) 19 
(16.7)
8 (7.1) 6 
(2.1)
2 
(0.7)
Alopecia 67 
(17.7)
57 
(14.7)
15 
(13.2)
22 (19.5)
Anaemia 34 (3.4) 39 (3.9) 96 
(25.4)
91 
(23.5)
Arthralgia 90 
(23.8)
76 
(19.6)
24 
(21.1)
18 (15.9)
Asthenia 12 (1.2) 16 (1.6) 77 
(20.4)
64 
(16.5)
8 (4.5)
Bone pain 11 (1.1) 14 (1.4) 228 
(60.3)
223 
(57.5)
36 
(31.6)
51 (45.1) 32 
(18.1)
Constipation 92 
(24.3)
100 
(25.8)
33 
(28.9)
37 (32.7) 4 (4.7) 5 (5.7)
Cough 87 
(23.0)
77 
(19.8)
Dehydration 13 (1.3) 26 (2.5)
Diarrhoea 19 (1.9) 16 (1.6) 89 
(23.5)
94 
(24.2)
29 
(25.4)
29 (25.7) 5 (5.9) 2 (2.3)
Dizziness 17 
(14.9)
25 (22.1)
Dyspepsia 20 
(7.0)
13 
(4.7)
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Adverse event
Study  
CSR Stopeck Rosen 2004109 Lipton 2000103,22
Kohno 2005102 
(only grade 4 
hypocalcaemia) Body 200472
Diel 2004140
Jackson 
2005150 (renal) 
Pecherstorfer 
2006154 
(extension) Paterson 199376
Kirstensen 
199975
Carteni 2006165 
(pooled)
Coleman 2011139 
(AZURE abstract) aHouston 2010148
Dyspnoea 67 (6.6) 47 (4.6) 98 
(25.9)
94 
(24.2)
21 
(18.4)
15 (13.3)
Fatigue 18 (1.8) 5 (0.5) 152 
(40.2)
159 
(41.0)
147 
(40.1)
107 
(27.7)
51 
(44.7)
36 (31.9)
Flu-like symptoms 10 (6.5) 3 (1.9) 4 (4.1) 0
Gastrointestinal 
symptoms
2 (2.4) 1 (1.1) 12 
(12.2)
12 
(13.2)
General 
physical health 
deterioration 
22 (2.2) 16 (1.6)
Headache 16 (1.6) 9 (0.9) 70 
(18.5)
94 
(24.2)
34 
(29.8)
32 (28.3) 6 (13.0) 1 (6.3) 1 (1.2) 0 7 (4.0)
Hepatic failure 32 (3.2) 20 (2.0)
Metastases to liver 23 (2.3) 32 (3.1)
Myalgia 106 
(28.0)
95 
(24.5)
Nausea 26 (2.6) 26 (2.5) 180 
(47.6)
179 
(46.1)
57 
(50.0)
60 (53.1) 10 
(3.5)
4 
(1.4)
18 
(21.2)
19 
(20.5)
9 (5.1)
Neutropenia 18 (1.8) 25 (2.5) 18 
(15.8)
19 (16.8) 8 (0.5) 10 (0.6)
Oedema peripheral 58 
(15.3)
73 
(18.8)
Oesophagitis 6 
(2.1)
2 
(0.7)
Pleural effusion 31 (3.1 32 (3.1)
Pulmonary 
embolism 
11 (1.1) 21 (2.1)
Pyrexia 22 (2.2) 20 (2.9) 118 
(31.2)
103 
(26.5)
51 
(13.9)
19 
(4.9)
63 
(55.3)
37 (32.7) 67 
(37.9)
 4 (0.2) 3 (0.2)
Respiratory failure 24 (2.4) 20 (2.0)
Thrombocytopenia 14 (1.4) 15 (1.5)
Vomiting 40 (3.9) 36 (3.5) 119 
(31.5)
120 
(30.9)
37 
(32.5)
44 (38.9) 7 (8.2) 10 
(11.4)
10 (5.6)
C*, 1.6 g daily; D, denosumab 120 mg 4-weekly; I*, ibandronic acid 50 mg orally; I**, ibandronic acid 6 mg intravenously; 
NR, not reported; NT, no treatment; PL, placebo; Z, zoledronic acid 4 mg 4-weekly; Z†, 4 mg and 3 mg combined.
a Observational study.
TABLE 126 Breast cancer adverse events (continued)
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Adverse event
Study  
CSR Stopeck Rosen 2004109 Lipton 2000103,22
Kohno 2005102 
(only grade 4 
hypocalcaemia) Body 200472
Diel 2004140
Jackson 
2005150 (renal) 
Pecherstorfer 
2006154 
(extension) Paterson 199376
Kirstensen 
199975
Carteni 2006165 
(pooled)
Coleman 2011139 
(AZURE abstract) aHouston 2010148
Dyspnoea 67 (6.6) 47 (4.6) 98 
(25.9)
94 
(24.2)
21 
(18.4)
15 (13.3)
Fatigue 18 (1.8) 5 (0.5) 152 
(40.2)
159 
(41.0)
147 
(40.1)
107 
(27.7)
51 
(44.7)
36 (31.9)
Flu-like symptoms 10 (6.5) 3 (1.9) 4 (4.1) 0
Gastrointestinal 
symptoms
2 (2.4) 1 (1.1) 12 
(12.2)
12 
(13.2)
General 
physical health 
deterioration 
22 (2.2) 16 (1.6)
Headache 16 (1.6) 9 (0.9) 70 
(18.5)
94 
(24.2)
34 
(29.8)
32 (28.3) 6 (13.0) 1 (6.3) 1 (1.2) 0 7 (4.0)
Hepatic failure 32 (3.2) 20 (2.0)
Metastases to liver 23 (2.3) 32 (3.1)
Myalgia 106 
(28.0)
95 
(24.5)
Nausea 26 (2.6) 26 (2.5) 180 
(47.6)
179 
(46.1)
57 
(50.0)
60 (53.1) 10 
(3.5)
4 
(1.4)
18 
(21.2)
19 
(20.5)
9 (5.1)
Neutropenia 18 (1.8) 25 (2.5) 18 
(15.8)
19 (16.8) 8 (0.5) 10 (0.6)
Oedema peripheral 58 
(15.3)
73 
(18.8)
Oesophagitis 6 
(2.1)
2 
(0.7)
Pleural effusion 31 (3.1 32 (3.1)
Pulmonary 
embolism 
11 (1.1) 21 (2.1)
Pyrexia 22 (2.2) 20 (2.9) 118 
(31.2)
103 
(26.5)
51 
(13.9)
19 
(4.9)
63 
(55.3)
37 (32.7) 67 
(37.9)
 4 (0.2) 3 (0.2)
Respiratory failure 24 (2.4) 20 (2.0)
Thrombocytopenia 14 (1.4) 15 (1.5)
Vomiting 40 (3.9) 36 (3.5) 119 
(31.5)
120 
(30.9)
37 
(32.5)
44 (38.9) 7 (8.2) 10 
(11.4)
10 (5.6)
C*, 1.6 g daily; D, denosumab 120 mg 4-weekly; I*, ibandronic acid 50 mg orally; I**, ibandronic acid 6 mg intravenously; 
NR, not reported; NT, no treatment; PL, placebo; Z, zoledronic acid 4 mg 4-weekly; Z†, 4 mg and 3 mg combined.
a Observational study.
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Appendix 11 Prostate cancer adverse events
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Appendix 13 European Quality of Life-5 
Dimensions health-related quality-of-life estimates 
presented by the manufacturer
A cademic-in-confidence information has been removed. 
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TABLE 131 Prostate cancer, pain and history of a prior SRE with PAS
Description
Incremental costs 
for denosumab 
with comparator (£)
Incremental QALYs 
for denosumab with 
comparator
ICERs for denosumab 
with comparator  
[∆ cost (£)/∆ QALY]
Zoledronic acid Zoledronic acid Zoledronic acid
Base case –281 0.006 Denosumab dominant
Time horizon
Time = 2 years –240 0.005 Denosumab dominant
Time = 5 years –279 0.006 Denosumab dominant
21-day window
Without 21-day window –350 0.010 Denosumab dominant
Asymptomatic events
Include costs for trial-defined 
asymptomatic events 
–307 0.006 Denosumab dominant
SRE costs
Based on NHS reference costs –215 0.006 Denosumab dominant
SRE utilities
SRE utilities based on TTO –281 0.006 Denosumab dominant
SRE utilities based on Weinfurt et al. 
2005a
–281 0.002 Denosumab dominant
AE utilities
Normal model –281 0.006 Denosumab dominant
Starting age
Starting age = 50 years –288 0.006 Denosumab dominant
Starting age = 80 years –269 0.006 Denosumab dominant
Intravenous dosing frequency
Based on UK treatment patterns of 3- to 
4-weekly dosing
–469 0.006 Denosumab dominant
Denosumab setting
Community (district nurse) –412 0.006 Denosumab dominant
Discontinuation
Zero for all treatments –561 0.011 Denosumab dominant
0.025 per cycle for all treatments –334 0.007 Denosumab dominant
Discounting
0% for costs and benefits –292 0.006 Denosumab dominant
0% for costs and 6% benefits –292 0.006 Denosumab dominant
AE, adverse event.
a Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning G.A, et al. The significance of skeletal-related events for 
the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 2005;16: 579–584.
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TABLE 132 Prostate cancer, no pain or pain and no history of a prior SRE with PAS
Description
Incremental costs 
for denosumab with 
comparator (£)
Incremental QALYs 
for denosumab 
with comparator
ICERs for denosumab 
with comparator  
[∆ cost (£)/∆ QALY]
BSC BSC BSC
Base case 2790 0.039 71,320
Time horizon
Time = 2 years 2562 0.030 84,079
Time = 5 years 2788 0.038 72,496
21-day window
Without 21-day window 2584 0.051 51,153
Asymptomatic events
Include costs for trial-defined 
asymptomatic events 
2693 0.039 68,826
SRE costs
Based on NHS reference costs 3044 0.039 77,796
SRE utilities
Based on TTO 2790 0.023 120,262
Based on Weinfurt et al. 2005a 2790 0.008 355,201
AE utilities
Normal model 2790 0.039 71,415
Starting age
Starting age = 50 years 2838 0.040 70,233
Starting age = 80 years 2702 0.037 73,343
Denosumab setting
Community (district nurse) 2660 0.039 67,988
Discontinuation
Zero for all treatments 5296 0.069 76,777
0.025 per cycle for all treatments 3408 0.047 72,572
Discounting
0% for costs and benefits 2874 0.041 69,835
0% for costs and 6% benefits 2874 0.038 75,997
AE, adverse event.
a Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning G.A, et al. The significance of skeletal-related events for 
the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 2005;16: 579–584. 
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TABLE 133 Other solid tumours, pain and history of a prior SRE with PAS
Description
Incremental costs 
for denosumab with 
comparator (£)
Incremental QALYs 
for denosumab with 
comparator
ICERs for denosumab  
with comparator  
[∆ cost (£)/∆ QALY]
Zoledronic 
acid
Disodium 
pamidronate
Zoledronic 
acid
Disodium 
pamidronate
Zoledronic 
acid
Disodium 
pamidronate
Base case –43 –2918 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
Time horizon
Time = 2 years –63 –2002 0.003 0.006 Denosumab 
dominant
Denosumab 
dominant
Time = 5 years –44 –2726 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
21-day window
Without 21-day 
window
–78 –2961 0.005 0.007 Denosumab 
dominant
Denosumab 
dominant
Asymptomatic events
Include costs 
for trial-defined 
asymptomatic 
events 
–56 –2934 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
SRE costs
Based on NHS 
reference costs
–8 –2874 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
SRE utilities
Based on TTO –43 –2918 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
Based on Weinfurt 
et al. 2005a
–43 –2918 0.002 0.003 Denosumab 
dominant
Denosumab 
dominant
AE utilities
Normal model –43 –2918 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
Starting age
Starting 
age = 50 years
–43 –2935 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
Starting 
age = 70 years
–44 –2863 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
Intravenous dosing 
frequency
Based on UK 
treatment patterns 
of 3- to 4-weekly 
dosing
–157 –3176 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
Denosumab setting
Community (district 
nurse)
–130 –3004 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
Disodium pamidronate 
efficacy
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Description
Incremental costs 
for denosumab with 
comparator (£)
Incremental QALYs 
for denosumab with 
comparator
ICERs for denosumab  
with comparator  
[∆ cost (£)/∆ QALY]
Zoledronic 
acid
Disodium 
pamidronate
Zoledronic 
acid
Disodium 
pamidronate
Zoledronic 
acid
Disodium 
pamidronate
No efficacy (placebo 
treatment effect)
–43 –3181 0.004 0.011 Denosumab 
dominant
Denosumab 
dominant
Discontinuation
Zero for all 
treatments
–469 –2274 0.008 0.018 Denosumab 
dominant
Denosumab 
dominant
0.025 per cycle for 
all treatments
–282 –1385 0.005 0.011 Denosumab 
dominant
Denosumab 
dominant
Discounting
0% for costs and 
benefits
–40 –3112 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
0% for costs and 
6% benefits
–40 –3112 0.004 0.006 Denosumab 
dominant
Denosumab 
dominant
AE, adverse event.
a Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning G.A, et al. The significance of skeletal-related events for 
the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 2005;16: 579–584. 
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TABLE 134 Other solid tumours, no pain or pain and no history of a prior SRE with PAS
Description
Incremental costs 
for denosumab 
with comparator (£)
Incremental QALYs 
for denosumab 
with comparator
ICERs for denosumab 
with comparator  
[∆ cost (£)/∆ QALY]
BSC BSC BSC
Base case
Time horizon 1730 0.021 83,763
Time = 2 years 1683 0.018 93,698
Time = 5 years 1735 0.020 85,522
21-day window
Without 21-day window 1642 0.024 68,020
Asymptomatic events
Include costs for trial-defined 
asymptomatic events
1683 0.021 81,497
SRE costs
Based on NHS reference costs 1859 0.021 90,036
SRE utilities
Based on TTO 1730 0.013 128,757
Based on Weinfurt et al. 2005a 1730 0.005 319,401
AE utilities
Normal model 1730 0.021 83,439
Starting age
Starting age = 50 years 1732 0.021 83,606
Starting age = 70 years 1721 0.020 84,263
Denosumab setting
Community (district nurse) 1643 0.021 79,565
Discontinuation
Zero for all treatments 4109 0.042 97,505
0.025 per cycle for all treatments 2538 0.029 87,963
Discounting
0% for costs and benefits 1765 0.021 82,207
0% for costs and 6% benefits 1765 0.020 87,728
AE, adverse event.
a Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning G.A, et al. The significance of skeletal-related events for 
the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 2005;16: 579–584. 
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Appendix 15 Univariate and probabilistic 
sensitivity analyses
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A range of univariate sensitivity analyses have been explored 
Sensitivity 
analyses Description Abbreviated
SA01 Base case Base case
SA02 Amgen STARs costing Amgen STARs
SA03 Amgen NMA results Amgen NMA
SA04 Amgen STARs costings and NMA results Amgen STARs+NMA
SA05 No HRQoL step change for naive to experienced No naive util step
SA06 SCC permanent utility effect of the average P1–P5 decrement SCC ongoing mean
SA07 SCC permanent utility effect of the maximum P1–P5 decrement SCC ongoing max.
SA08 No general mortality No gen. mortality
SA09 5-year horizon 5-year horizon
SA10 2-year horizon 2-year horizon
SA11 vdHOUT utility multipliers vd Hout utility
SA12 QoL impact SAEs ONJ and renal cohort average survival, not the measured trial 
duration
SAE P1+
SA13 Excluding SAEs No SAE 
SA14 No general discontinuations No gen. discs.
SA15 No discontinuations No discs.
SA16 AG TTF functional form from NAIVE for breast and prostate TTF form AG naive
SA17 AG TTF functional form all patients for breast, prostate and OSTL TTF form AG all 
patients
These are presented for the four cancer groupings: breast, prostate and OST including lung (OSTL). 
They are also presented for the three patient groups of all, naive and experienced, coupled with the split 
between applying the pooled HRs and RRs and the SRE-specific HRs and RRs for breast prostate and OSTL. 
The summaries that follow all show the net impact of denosumab on total amounts. The costs reported 
are the total costs including SRE costs and SAE costs; for example, the cost associated with BSC excluding 
PAS is the additional cost of using denosumab compared with BSC. These sensitivity analyses are presented 
only for the analyses that apply the pooled HRs and RRs. The parallel sensitivity analyses that present them 
for the analyses that apply the SRE experience subgroup-specific HRs and RRs are available on demand 
from the AG.
The probabilistic analyses were run over 2000 iterations. As a cross-check the ALL PATIENT probabilistic 
modelling was re-run with 10,000 iterations, with results being near identical to those of the run with 
2000 iterations.
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Probabilistic modelling
Breast cancer: all patients
QALY £ total ∆ QALY ∆ Cost ICER
BSC 1.822 CiC information has been removed 0.028 £4269 £154,944
Zoledronic acid 1.842 CiC information has been removed 0.007 –£243 Dominant
Denosumab 1.849 CiC information has been removed – – –
Disodium 
pamidronate 
1.840 CiC information has been removed 0.010 –£3246 Dominant
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid Disodium pamidronate 
£0 92% 8% 0%
£20,000 98% 2% 0%
£30,000 100% 0% 0%
£40,000 100% 0% 0%
£100,000 100% 0% 0%
WTP/QALY Denosumab Zoledronic acid
Disodium 
pamidronate BSC
£0 0% 0% 0% 100%
£20,000 0% 0% 0% 100%
£30,000 0% 0% 0% 100%
£40,000 0% 0% 0% 100%
£100,000 13% 0% 0% 87%
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FIGURE 16 Breast cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs 
including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 16 Breast cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs 
including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Prostate cancer: all patients
QALY £ total ∆ QALY ∆ Cost ICER
BSC 1.065 CiC information has been removed 0.035 £2764 £78,756
Zoledronic acid 1.091 CiC information has been removed 0.009 –£123 Dominant
Denosumab 1.100 CiC information has been removed – – –
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid
£0 88% 12%
£20,000 99% 1%
£30,000 100% 0%
£40,000 100% 0%
£100,000 100% 0%
WTP/QALY Denosumab Zoledronic acid BSC
£0 0% 0% 100%
£20,000 0% 0% 100%
£30,000 0% 0% 100%
£40,000 2% 0% 98%
£100,000 73% 0% 27%
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FIGURE 17 Prostate cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs 
including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 17 Prostate cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs 
including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Other solid tumours plus non-small cell lung cancer: all patients
QALY £ total ∆ QALY ∆ Cost ICER
BSC 0.701 CiC information has been removed 0.017 £1771 £102,102
Zoledronic acid 0.713 CiC information has been removed 0.006 £56 £9391
Denosumab 0.719 CiC information has been removed – – –
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid
£0 26% 75%
£20,000 75% 25%
£30,000 88% 12%
£40,000 93% 7%
£100,000 99% 1%
WTP/QALY Denosumab Zoledronic acid BSC
£0 0% 0% 100%
£20,000 0% 0% 100%
£30,000 0% 0% 100%
£40,000 1% 0% 99%
£100,000 44% 0% 56%
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FIGURE 18 Other solid tumour plus NSCLC: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding 
BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 18 Other solid tumour plus NSCLC: all patients. (a) Cost-effectiveness acceptability curves (CEACs excluding 
BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Non-small cell lung cancer: all patients
QALY £ total ∆ QALY ∆ Cost ICER
BSC 0.439 CiC information has been removed 0.012 £1582 £132,177
Zoledronic acid 0.446 CiC information has been removed 0.005 £32 £6967
Denosumab 0.451 CiC information has been removed – – –
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid
£0 35% 65%
£20,000 69% 31%
£30,000 77% 23%
£40,000 82% 18%
£100,000 91% 9%
WTP/QALY Denosumab Zoledronic acid BSC
£0 0% 0% 100%
£20,000 0% 0% 100%
£30,000 0% 0% 100%
£40,000 1% 0% 99%
£100,000 27% 1% 73%
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FIGURE 19 Non-small cell lung cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; 
(b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 19 Non-small cell lung cancer: all patients. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; 
(b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Breast cancer: skeletal-related event naive
QALY £ total ∆ QALY ∆ Cost ICER
BSC 1.848 CiC information has been removed 0.035 £4340 £124,461
Zoledronic acid 1.875 CiC information has been removed 0.008 –£204 Dominant
Denosumab 1.883 CiC information has been removed – – –
Disodium 
pamidronate
1.873 CiC information has been removed 0.009 -£3109 Dominant
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid Disodium pamidronate
£0 88% 12% 0%
£20,000 98% 2% 0%
£30,000 99% 1% 0%
£40,000 99% 1% 0%
£100,000 100% 0% 0%
WTP/QALY Denosumab Zoledronic acid
Disodium 
pamidronate BSC
£0 0% 0% 0% 100%
£20,000 0% 0% 0% 100%
£30,000 0% 0% 0% 100%
£40,000 1% 0% 0% 99%
£100,000 26% 0% 0% 74%
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FIGURE 20 Breast cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs 
including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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Prostate cancer: skeletal-related event naive
QALY £ total ∆ QALY ∆ Cost ICER
BSC 1.088 CiC information has been removed 0.039 £2786 £71,920
Zoledronic acid 1.116 CiC information has been removed 0.011 –£121 Dominant
Denosumab 1.126 CiC information has been removed – – –
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid
£0 86% 14%
£20,000 99% 1%
£30,000 99% 1%
£40,000 99% 1%
£100,000 100% 0%
WTP/QALY Denosumab Zoledronic acid BSC
£0 0% 0% 100%
£20,000 0% 0% 100%
£30,000 0% 0% 100%
£40,000 3% 0% 97%
£100,000 81% 0% 19%
FIGURE 20 Breast cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs 
including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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FIGURE 21 Prostate cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs 
including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 21 Prostate cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) CEACs 
including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Other solid tumours plus non-small cell lung cancer: skeletal-related event naive
QALY £ total ∆ QALY ∆ Cost ICER
BSC 0.715 CiC information has been removed 0.024 £1702 £71,883
Zoledronic acid 0.731 CiC information has been removed 0.008 £45 £5848
Denosumab 0.739 CiC information has been removed – – –
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid
£0 31% 69%
£20,000 84% 16%
£30,000 93% 7%
£40,000 96% 4%
£100,000 99% 1%
WTP/QALY Denosumab Zoledronic acid BSC
£0 0% 0% 100%
£20,000 0% 0% 100%
£30,000 1% 0% 99%
£40,000 6% 0% 94%
£100,000 76% 0% 24%
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Ford et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided 
that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed 
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, 
Southampton SO16 7NS, UK.
DOI: 10.3310/hta17290 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 29
363
FIGURE 22 Other solid tumour plus NSCLC: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding 
BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 22 Other solid tumour plus NSCLC: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding 
BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Non-small cell lung cancer: skeletal-related event naive
QALY £ total ∆ QALY ∆ Cost ICER
BSC 0.453 CiC information has been removed 0.014 £1578 £109,934
Zoledronic acid 0.461 CiC information has been removed 0.006 £16 £2620
Denosumab 0.467 CiC information has been removed – – –
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid
£0 44% 56%
£20,000 75% 25%
£30,000 80% 20%
£40,000 83% 17%
£100,000 90% 10%
WTP/QALY DEN ZOL BSC
£0 0% 0% 100%
£20,000 0% 0% 100%
£30,000 0% 0% 100%
£40,000 2% 0% 98%
£100,000 42% 1% 57%
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FIGURE 23 Non-small cell lung cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) 
CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 23 Non-small cell lung cancer: SRE naive. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) 
CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Breast cancer: skeletal-related event experienced
QALY £ total ∆ QALY ∆ Cost ICER
BSC 1.778 CiC information has been removed 0.017 £4146 £241,181
Zoledronic acid 1.790 CiC information has been removed 0.005 –£298 Dominant
Denosumab 1.795 CiC information has been removed – – –
Disodium 
pamidronate
1.785 CiC information has been removed 0.010 –£3470 Dominant
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid Disodium pamidronate
£0 94% 6% 0%
£20,000 98% 2% 0%
£30,000 99% 1% 0%
£40,000 99% 1% 0%
£100,000 100% 0% 0%
WTP/QALY Denosumab Zoledronic acid
Disodium 
pamidronate BSC
£0 0% 0% 0% 100%
£20,000 0% 0% 0% 100%
£30,000 0% 0% 0% 100%
£40,000 1% 0% 0% 99%
£100,000 7% 0% 0% 94%
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FIGURE 24 Breast cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) 
CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 24 Breast cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) 
CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Prostate cancer: skeletal-related event experienced
QALY £ total ∆ QALY ∆ Cost ICER
BSC 0.996 CiC information has been removed 0.027 £2695 £101,216
Zoledronic acid 1.017 CiC information has been removed 0.006 –£132 Dominant
Denosumab 1.023 CiC information has been removed – – –
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid
£0 86% 14%
£20,000 97% 3%
£30,000 98% 2%
£40,000 99% 1%
£100,000 99% 1%
WTP/QALY Denosumab Zoledronic acid BSC
£0 0% 0% 100%
£20,000 0% 0% 100%
£30,000 1% 0% 100%
£40,000 2% 0% 98%
£100,000 44% 1% 56%
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FIGURE 25 Prostate cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) 
CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 25 Prostate cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) 
CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Other solid tumours plus non-small cell lung cancer: skeletal-related event 
experienced
QALY £ total ∆ QALY ∆ Cost ICER
BSC 0.689 CiC information has been removed 0.011 £1825 £159,757
Zoledronic acid 0.696 CiC information has been removed 0.004 £63 £14,373
Denosumab 0.700 CiC information has been removed – – –
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid
£0 26% 74%
£20,000 59% 41%
£30,000 71% 29%
£40,000 80% 20%
£100,000 94% 6%
WTP/QALY Denosumab Zoledronic acid BSC
£0 0% 0% 100%
£20,000 0% 0% 100%
£30,000 0% 0% 100%
£40,000 0% 0% 100%
£100,000 14% 0% 86%
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FIGURE 26 Other solid tumour: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) 
CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 26 Other solid tumour: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding BSC; (b) 
CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Non-small cell lung cancer: skeletal-related event experienced
QALY £ total ∆ QALY ∆ Cost ICER
BSC 0.425 CiC information has been removed 0.010 £1572 £157,231
Zoledronic acid 0.432 CiC information has been removed 0.003 £41 £12,415
Denosumab 0.435 CiC information has been removed – – –
CiC, commercial-in-confidence.
WTP/QALY Denosumab Zoledronic acid
£0 33% 67%
£20,000 59% 41%
£30,000 66% 34%
£40,000 72% 28%
£100,000 84% 16%
WTP/QALY Denosumab Zoledronic acid BSC
£0 0% 0% 100%
£20,000 0% 0% 100%
£30,000 0% 0% 100%
£40,000 1% 0% 99%
£100,000 20% 1% 79%
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FIGURE 27 Non-small cell lung cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding 
BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. 
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FIGURE 27 Non-small cell lung cancer: SRE experienced. (a) Cost-effectiveness acceptability curves (CEACs) excluding 
BSC; (b) CEACs including BSC; (c) CEAF excluding BSC; and (d) CEAF including BSC. (continued)
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Appendix 16  Protocol
Technology Assessment Report commissioned by the NIHR HTA 
Programme on behalf of the National Institute for Health and 
Care Excellence
07/04/2011
NB. This protocol may evolve in the course of the review.
Title of the project
Denosumab for the treatment of bone metastases from solid tumours and multiple myeloma.
Name of Technology Assessment Report team and lead 
Institutional Lead:
Professor Phil Hannaford
NHS Grampian Chair of Primary Care and Head of Division of Applied Health Sciences
University of Aberdeen
Foresterhill Health Centre
Aberdeen AB25 2AY
p.hannaford@abdn.ac.uk
Tel: 01224 551278
Contact person:
Dr Pamela Royle
Research Fellow
Division of Applied Health Sciences
University of Aberdeen
Aberdeen AB25 2ZD
p.royle@abdn.ac.uk
Tel: 01224 555172
Fax: 01224 550925
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Plain English Summary
Cancer can spread from the part of the body where it started (primary site) to other parts of the body; 
when this happens it is called metastatic disease. For example, when breast cancer spreads to bone it 
may be called metastatic breast cancer or breast cancer with bone metastasis. The location and extent of 
metastasis depends on the primary site and the aggressiveness of the cancer.
The bones are a common site of spread in many solid cancers, but especially ones that start in the 
prostate, breast and lung. Multiple myeloma is another type of cancer affecting the white blood cells 
and starts in the bone marrow. Specific areas of the bone can be affected, causing similar symptoms to 
bone metastasis.
Bone metastasis can cause a number of problems. These include:
 z Pain: this may be constant or intermittent
 z Fractures: long bones with cancer in them may break with minimal or no force
 z Compression of the spinal cord: this may happen if a cancer spreads to the bones of the back, if this 
results in squeezing of the spinal cord. If this happens, it may cause weakness or numbness in the legs 
or problems with passing urine or bowel opening
 z High calcium in the blood stream: cancer in the bone may cause calcium to be released into the 
bloodstream. High levels of calcium in the bloodstream may cause an individual to become non-
specifically unwell, and if left untreated can eventually lead to coma and death.
Therefore, if a cancer spreads to the bones, the quality of life and life expectancy of a patient may be 
greatly reduced.
Currently the problems caused by bone metastases and multiple myeloma may be treated with a 
bisphosphonate, such as zoledronic acid, ibandronic acid, disodium pamidronate, or sodium clodronate. 
They may also be treated with supportive care treatments, including painkillers, radiotherapy and 
occasionally surgery. The specific place of the bisphosphonates and supportive care treatments for patients 
with lung cancer, prostate cancer, metastatic spinal cord compression and advanced breast cancer are 
recommended by NICE in their Clinical Guidelines CG 24, 58, 75 and 81, respectively.
Bisphosphonates are unfortunately not suitable for all patients with bone metastasis. They are associated 
with renal toxicity and require routine monitoring of serum creatinine and other biochemical parameters 
and dose adjustments. They are not recommended in patients with severe renal impairment.
The mode of administration of bisphosphonates may also be problematic in clinical use. Zoledronic acid 
and disodium pamidronate must be administered by intravenous infusion, ibandronic acid can be given 
either orally or intravenously, and sodium clodronate can be given orally.
Decision problem
Denosumab is a new drug that has been tested in bone metastases and multiple myeloma. It is currently 
licensed for treatment of thin bones in postmenopausal women and bone loss caused by treatment of 
prostate cancer (hormone ablation treatment).
Denosumab offers an alternative therapy to bisphosphonates for the prevention of skeletal-related events 
(SRE). It is not associated with renal toxicity, and can be used in patients taking concomitant nephrotoxic 
drugs, for whom bisphosphonates cannot be prescribed. Denosumab is also administered as a simple 
subcutaneous injection, which may allow it to be given in general practitioner surgeries, in hospices, or at 
the patient’s home.
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The purpose of this review will be to appraise the clinical effectiveness and cost-effectiveness of 
denosumab, within its licensed indication, for the treatment of bone metastases from solid tumours and 
bone disease in multiple myeloma.
We note that there has been no technology appraisal by NICE of the bisphosphonates. We will not review 
the clinical effectiveness and cost-effectiveness of bisphosphonates relative to best supportive care.
The intervention
The intervention is denosumab, administered every 4 weeks at a dose of 120 mg as a subcutaneous 
injection in the upper arm, upper thigh or abdomen.
One issue is the place of the denosumab in the treatment pathway. We anticipate this varying depending 
on the type of cancer, but some possibilities could be:
1. As primary prevention of SREs in patients newly diagnosed with solid malignancies with bone 
metastases or with multiple myeloma
2. For secondary prevention of further SREs in patients with solid malignancies or those with multiple 
myeloma who have already suffered a SRE
3. For the active treatment of SREs, including treatment of bone-induced pain and hypercalcaemia
4. As a second-line therapy for SREs in patients for whom best supportive care has not proved adequate 
or have failed
5. As an alternative treatment in patients unable to tolerate intravenous bisphosphonates, or for whom 
they are contraindicated.
The comparators
The relevant comparators are: (1) bisphosphonates, and (2) best supportive care.
The bisphosphonates
The bisphosphonates are synthetic analogues of pyrophosphates, the natural regulator of bone mineral 
precipitation and dissolution. They inhibit normal and pathological osteoclast-mediated bone resorption. 
Over the past two decades bisphosphonates have established themselves as an important treatment for 
bone metastases in solid cancers and for multiple myeloma. While denosumab also inhibits osteoclasts, it 
is thought to be through a different pathway to that of bisphosphonates.
There are currently four bisphosphonates licensed in the UK for bone metastasis or multiple myeloma;
(a) Zoledronic acid (Zometa™, Novartis) is licensed for the reduction of bone damage in advanced 
malignancies involving bone. It is administered by intravenous infusion over at least 15 minutes at a 
dose of 4 mg every 3–4 weeks.
(b) Disodium pamidronate (Aredia®, Novartis) is licensed for osteolytic lesions and bone pain in bone 
metastases associated with breast cancer or multiple myeloma. It is administered by slow intravenous 
infusion (at least over 2 hours) at a dose of 90 mg every 4 weeks.
(c) Sodium clodronate (Bonefos™, Bayer Schering; Clasteon™, Beacon; Loron 520™, Roche) is licensed for 
osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with 
breast cancer or multiple myeloma. It is administered by mouth at a dose of 1.6–3.2 g daily.
(d) Ibandronic acid (Bondronate™, Roche) is licensed for the reduction of bone damage in bone 
metastases in breast cancer. It is administered either by mouth (50 mg daily) or intravenous infusion 
(6 mg every 3–4 weeks).
Therefore, only zoledronic acid is licensed in the UK for the reduction of bone damage in all advanced 
malignancies involving bone.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
appenDIx 16
378
Unfortunately bisphosphonates are not uniformly effective in reducing skeletal-related events in all types 
of cancer. There are inconsistencies in the evidence relating to their effectiveness, depending on the site or 
type of cancer and the bisphosphonate used.
Some patients are contraindicated to bisphosphonates or their use is inappropriate. There is wide variation 
currently in the use of bisphosphonates for the management of patients with bone metastases in the UK. 
Patterns of use depend no adoption of local and national guidelines and physician and patient preferences.
Only zoledronic acid and disodium pamidronate are licensed by the US Food and Drug Administration for 
treatment of bone metastases in the USA.
Zoledronic acid (Zometa) is a very frequently used bisphosphonate in the UK, and is recommended by 
many clinicians as the bisphosphonate of choice.
Best supportive care 
Best supportive care (BSC) will also be considered as a comparator where bisphosphonates are not 
considered appropriate.
The patient groups included will be adults with bone metastases from solid tumours and adults with 
myeloma bone disease. The report will separately consider patient groups, based on location or type of 
primary cancer.
The key aspects that will be addressed will be the clinical effectiveness and cost-effectiveness of 
denosumab relative to bisphosphonates and/or best supportive care.
Any adverse effects of the treatment will also be addressed.
Identifying comparators
As the guidelines indicate that the place of bisphosphonates in the care pathway differs for each primary 
tumour type, each type will be treated separately (where data exist). In tumour types where no guidelines 
exist, we will seek expert opinion as to the place of bisphosphonates in the care pathway.
Breast cancer
As NICE CG81 recommends use of a bisphosphonate in patients with advanced breast cancer newly 
diagnosed with bone metastases, we will not use BSC as a comparator.
We know from our scoping searches that there are no published Phase III trials of denosumab against 
comparators other than zoledronate.
We will not assume a class effect for the bisphosphonates. If no high-quality systematic reviews that meet 
our inclusion criteria exist, we will perform an indirect comparison (as shown in Figure 1) to determine the 
most effective bisphosphonate to compare with denosumab.
Other solid tumours or multiple myeloma
As the NICE guidelines for prostate and lung cancer recommend BSC, before giving a bisphosphonate, 
then for these patient groups (where data exist) we will include BSC as a comparator.
For other solid tumours and multiple myeloma, where no relevant NICE guidelines exist, we will seek expert 
opinion as to the place of bisphosphonates in the clinical pathway. If it emerges that bisphosphonates are 
recommended as first-line therapy for any of these patient groups, then the network diagram will be as in 
Figure 1.
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Otherwise we will look for trials against the various comparators to compare with denosumab in an 
indirect comparison as indicated in the network diagram in Figure 2.
Report methods for synthesis of evidence of clinical effectiveness
The assessment report will include a systematic review of the evidence for clinical effectiveness of 
denosumab for bone metastases from solid tumours and multiple myeloma. A review of the evidence for 
clinical effectiveness will be undertaken systematically following the principles in the Centre for Reviews 
& Dissemination (CRD):CRD’s guidance for undertaking reviews in health care: Systematic Reviews (3rd 
Edition), 2008 and the Cochrane Handbook for Systematic Reviews of Interventions.
Criteria for considering studies for the review
Types of studies
Only systematic reviews and randomised controlled trials will be considered for clinical effectiveness. There 
will be no size restriction on the number of patients in trials, because those with inadequate numbers and 
hence power, might be useful when combined in a meta-analysis.
FIGURE 1 Network meta-analysis for those with bone metastases from breast cancer.
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BPs other than
zoledronic acid
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FIGURE 2 Network meta-analysis for those with bone metastases from prostate, lung cancer and other solid tumour.
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If there are any high-quality existing systematic reviews that meet our inclusion we will not repeat them, 
but update them with more recent randomised controlled trials identified from our searches.
We will seek selected clinical study reports from the manufacturer.
Observational studies may be used (in addition to randomised controlled trials) for data on safety.
Types of participants
These will be patients with confirmed carcinoma of any of the below:
 z breast
 z prostate
 z lung
 z other solid tumours
 z multiple myeloma
plus, evidence of at least one bone metastasis or myeloma bone lesion.
Types of interventions
The intervention is denosumab, given as a subcutaneous injection at dose of 120 mg every 4 weeks. 
Denosumab does not yet have a marketing authorisation in the UK for the treatment of bone metastases 
from solid tumours and multiple myeloma. However, it does have a UK marketing authorisation for the 
treatment of osteoporosis in postmenopausal women and for the treatment of bone loss associated with 
hormone ablation in men with prostate cancer.
We will exclude studies (such as pharmacokinetic or drug tolerability studies) where patients are only given 
a single dose of a drug. Also, in studies that have arms with more than one dose of a licensed comparator 
drug, we will only extract data from the arm that includes the licensed dose of the drug.
Types of comparators
Bisphosphonates
These are: sodium clodronate, disodium pamidronate, ibandronic acid and zoledronic acid. We initially 
considered including etidronate as an unlicensed (for this purpose) comparator, because of its much lower 
cost. However, clinical advice is that it is infrequently used because of its gastrointestinal toxicity.
Currently, zoledronic acid has UK marketing authorisation for use in all cancers, disodium pamidronate 
and sodium clodronate are licensed for breast cancer and multiple myeloma, and ibandronic acid is only 
licensed for breast cancer. However, we will also include trials of these bisphosphonates when used outside 
their licensed indications.
Best supportive care (excluding bisphosphonates)
This varies depending on the type of cancer. The relevant NICE Clinical Guidelines are: CG58 for prostate 
cancer and CG24 for lung cancer. The UK Myeloma Forum has issued a guideline for the diagnosis and 
management of multiple myeloma. All these guidelines recommend radiotherapy and analgesics as best 
supportive care. Other supportive care for bone metastasis, also recommended, includes surgical fixation in 
breast cancer and multiple myeloma, strontium-89 in prostate cancer and nerve blocks in lung cancer.
Outcomes
Outcome measures will include
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 z Time to first on-study skeletal adverse events. These will be defined as: pathological fracture, 
requirement for radiation therapy to bone, surgery to bone, or spinal cord compression (information 
on all events will be sought from the manufacturer)
 z time to subsequent skeletal adverse events
 z incidence of skeletal-related events
 z prevention of hypercalcaemia
 z overall survival rate
 z pain
 z health-related quality of life
 z adverse events related to treatment (including hypocalcaemia, osteonecrosis of the jaw, renal toxicity).
Search strategy
We will search the following sources:
 z MEDLINE
 z EMBASE
 z The Cochrane Library (all sections)
 z Science Citation Index Expanded (SCI expanded) and Conference Proceedings Citation Index- Science 
(CPCI-S)
 z Contact with experts in the field
 z Search of ASCO meeting abstracts
 z Scrutiny of bibliographies of retrieved papers.
Searches will be limited to those published in the English language.
Only studies published as full text will be data extracted and used to assess clinical effectiveness. Meeting 
abstracts will be searched for and tabulated for use in the Discussion to indicate ongoing research (for 
recent abstracts), or possible sources of publication bias (for older abstracts not subsequently published 
in full).
Study selection
Study selection will be made independently by two reviewers. Discrepancies will be resolved by discussion, 
with involvement of a third reviewer when necessary.
Data extraction strategy
Data will be extracted from the included studies by one reviewer, using a standardised data extraction form 
and checked by a second. Discrepancies will be resolved by discussion, with involvement of a third reviewer 
when necessary.
Quality assessment
The quality of the individual studies will be assessed by one reviewer, and independently checked for 
agreement by a second reviewer. Any disagreements will be resolved by consensus, and if necessary a third 
reviewer will be consulted.
The quality of the randomised controlled trials will be assessed by using methods for assessing Cochrane 
risk of bias and include:
 z adequate sequence generation
 z allocation concealment
 z blinding
 z incomplete outcome data addressed
 z free of selective reporting
 z generalisability
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 z sample size calculation.
The quality of the systematic reviews will be assessed using quality assessment criteria:
 z inclusion criteria described
 z details of literature search given
 z study selection described
 z data extraction described
 z study quality assessment described
 z study flow shown
 z study characteristics of individual studies described
 z quality of individual studies given
 z results of individual studies shown
 z statistical analysis appropriate.
Methods for estimating qualify of life
Quality-of-life data, as reported within the studies identified, the clinical systematic review, the denosumab 
clinical study reports, and the manufacturer’s submission, will be reviewed.
A further systematic review of the effects no quality of life of SREs arising from metastatic bone disease 
and from myeloma bone disease will be undertaken. There may also be a requirement to review mapping 
functions from disease-specific quality-of-life functions and/or disease-specific pain scores to generic 
quality-of-life functions and/or index values.
Economic modelling may require additional quality-of-life values for health states within the underlying 
cancer(s). The default will be to source these from previous NICE clinical guidelines as outlined above, and 
only if these are insufficient, to undertake further literature search and review.
Summary statistics as reported within the denosumab clinical study reports and the manufacturer’s 
submission may lead the Technology Assessment Report team to request patient-level data from the 
manufacturer in order to cross check and possibly separately identify HRQoL values for use within any 
economic model(s).
Methods of analysis/synthesis
Initially we will look for head-to-head trials of denosumab versus bisphosphonates or BSC. Our initial 
scoping searches indicate that at present there are only three published Phase III trials of denosumab 
which include our relevant population, and these all use zoledronic acid as a comparator. The three 
patient groups included in the three trials are respectively: (1) advanced breast cancer, (2) castration-
resistant prostate cancer, and (3) patients with advanced cancer (excluding breast and prostate cancer) or 
multiple myeloma.
Therefore, in order to be able to compare denosumab to bisphosphonates other than zoledronate, or to 
BSC, we will need to look for trials including these comparators, either head-to-head or against placebo.
Trials that fit our inclusion criteria will be assessed for heterogeneity. The studies will be examined 
for comparability with respect to methods, baseline characteristics of the intervention groups and 
measurement of outcome.
If trials are considered sufficiently homogeneous, a mixed treatment comparison of denosumab versus BSC 
will be carried out. This will pool direct and indirect evidence from randomised trials in a single analysis.
Patient groups will be analysed separately based on location or type of primary cancer. If sufficient data 
are available, subgroup analyses will be performed to examine the effect of treatment depending on: the 
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type of SRE, history of SREs, prior use of bisphosphonate, prior type of BSC, different adjuvant therapies, 
different routes of administration of the bisphosphonates, and the location of the metastases.
Report methods for synthesising evidence of cost-effectiveness
A systematic review of cost-effectiveness studies of denosumab for the treatment of bone metastases from 
solid tumours and multiple myeloma will be undertaken.
If the economics of the manufacturer’s submission are insufficient, the modelling underlying this 
submission may be adapted by the Technology Assessment Report teams or the Technology Assessment 
Report team may develop a de novo model.
If de novo modelling is required, the NICE reference case will be adopted by the Technology Assessment 
Report team, including probabilistic modelling. Modelling will adopt a lifetime horizon.
For primary tumours where bisphosphonates are recommended, among those who tolerate 
bisphosphonates it will be assumed that bisphosphonates are cost-effective and the cost-effectiveness of 
bisphosphonates relative to BSC will not be reviewed. Should there be a significant proportion of patients 
who do not tolerate bisphosphonates it may be desirable to undertake a review of effectiveness, as per 
Figure 2. But there is unlikely to be the network of evidence to support this in the patient group under 
consideration. In these circumstances, a second-best solution may be to identify which other cancer being 
reviewed that has BSC as a comparator best mirrors the ideal network of evidence for this patient group, 
and apply the clinical effectiveness estimates from this comparison for this patient group.
For primary tumours where bisphosphonates are not recommended, BSC will be the comparator, with the 
clinical effectiveness estimates being drawn from a network of evidence as described in Figure 2.
Modelling will limit itself to consideration of the impacts no patient quality of life and treatment costs of:
 z SRE rates differentiated by type and time, these potentially also having some survival effect
 z morbidity with possibly particular attention being paid to pain scores
 z hypercalcaemia
 z adverse events.
Any significant non-bone activity will be assumed to be reflected in overall survival estimates. Where there 
is evidence of an overall survival effect, the extent to which this is likely to be due to non-bone activity 
will be reviewed. If there is not good evidence of a survival effect arising from non-bone activity, the 
progression of the primary tumour will be assumed to be the same between the arms.
For patient groups in which bisphosphonates are recommended, the review will start by identifying the 
most effective bisphosphonate. If one bisphosphonate appears to be more effective than the rest, it will be 
used as the main comparator.
Zoledronic acid goes off patent in March 2013. In the comparisons of denosumab with the 
bisphosphonates, threshold analyses around the bisphosphonate price will be undertaken for 
willingness-to-pay values of £20,000 per QALY and £30,000 per QALY, with this also referencing the cost 
of etidronate.
Costs will be obtained from standard reference costs. A sensitivity analysis of administration costs will use 
two assumptions about costs in primary care: standard costs, and an enhanced service payment.
Since different cancers behave differently, we will need to review the evidence on clinical effectiveness 
and cost-effectiveness separately for the main cancers: breast, prostate and lung cancers, and 
multiple myeloma.
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For a primary cancer with an insufficient network of evidence to enable firm conclusions to be drawn 
about the effectiveness of denosumab relative to the appropriate comparator, it may be possible to assume 
clinical effects as drawn from the review of denosumab compared to that comparator as estimated within 
another cancer. These clinical effectiveness estimates could then be applied to the survival estimates for the 
primary cancer with an insufficient network of evidence. In other words, the only analysis possible will in 
effect be a sensitivity analysis around patient survival, with some additional variation in the quality-of-life 
values and costs being applied to health states for the underlying cancer. The credibility of the clinical 
assumptions necessary for this, and any resultant estimates of cost-effectiveness, will be reviewed in 
conjunction with expert clinical opinion.
Handling the company submission(s)
All data submitted by the manufacturers/sponsors may be considered if received by the Technology 
Assessment Report team no later than 22 July 2011. Data arriving after this date will not be considered. 
If the data meet the inclusion criteria for the review they may be extracted and quality assessed in 
accordance with the procedures outlined in this protocol. Any economic evaluations included in the 
company submission, provided they comply with NICE’s advice on presentation and length, will be 
assessed for clinical validity, reasonableness of assumptions and appropriateness of the data used in the 
economic model. If the Technology Assessment Report team judge that the existing economic evidence is 
not robust, then further work will be undertaken, either by adapting what already exists or developing a de 
novo model.
Any commercial-in-confidence data taken from a company submission, and specified as confidential in 
the check list, will be replaced in the assessment report with the statement: commercial-in-confidence 
information has been removed.
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